

BIOTECHGAZINE

生物科技誌

SEPTEMBER 2023

BIOHK2023

香港國際生物科技論壇暨展覽

SEPTEMBER 九月13-16

HONG KONG CONVENTION AND EXHIBITION CENTRE

香港會議展覽中心

BIOHK2023
主辦單位:



AUSVIC
Capital

BayHelix
GROUP



中国生物工程学会
Chinese Society of Biotechnology



中国科学院微生物研究所
INSTITUTE OF MICROBIOLOGY
CHINESE ACADEMY OF SCIENCES

編輯委員會 Editorial Committee

總編輯 Chief Editor

于常海教授 PhD, JP
Prof. Albert Cheung-Hoi YU, PhD, JP



客座主編 Guest Chief Editor

彭俊圖
Chris PANG



學生大使（編輯）Editorial Student Ambassadors

宮煒貽
Juliet Wei Yi KOUNG



許鈞傑
Jack Kit Hui KWAN



美術顧問 Creative Consultant and AI Cover Artist

楊綺鈴
Elaine Young, Yi Ling YANG STUDIOPHORIA



出版社 Publisher

海康生命出版社有限公司 H.K. Life Publishing Limited

電話 Tel: (852) 2111 2123

傳真 Fax: (852) 2111 9762

電郵 Email: editorial@biotechgazine.com

廣告查詢 Advertising

電郵 Email: info@biotechgazine.com

出版日期 Publishing Date 2023年9月 September 2023

定價 Price HK \$100

ISBN 2959-6963

版權所有，未經本會及作者同意，不得翻印

All reproduction requests are subject to the approval of HKBIO and authors




Table of Contents

About The Convention

BIOHK2023 Foreword	5
Welcome message from President	7
BIOHK2023 Governance	9
BIOHK2023 Organizing Committee	13
Program Schedule	17

Day 1 Convention Information


• Keynote Address and Speaker Biographies	23
• BIOHK Auditorium Program Rundown and Speaker Biographies	30
• Innovation Galleria Program Rundown and Speaker Biographies	40
• Technology Hall Program Rundown and Speaker Biographies	52
• Loci Square Program Rundown and Speaker Biographies	62

Day 2 Convention Information

• Keynote Address and Speaker Biographies	68
• BIOHK Auditorium Program Rundown and Speaker Biographies	75
• Innovation Galleria Program Rundown and Speaker Biographies	88
• Technology Hall Program Rundown and Speaker Biographies	106
• Loci Square Program Rundown and Speaker Biographies	116

Day 3 Convention Information

• Keynote Address and Speaker Biographies	123
• BIOHK Auditorium Program Rundown and Speaker Biographies	127
• Innovation Galleria Program Rundown and Speaker Biographies	140
• Technology Hall Program Rundown and Speaker Biographies	155
• Loci Square Program Rundown and Speaker Biographies	169




Day 4 Convention Information

• Keynote Address and Speaker Biographies	173
• BIOHK Auditorium Program Rundown and Speaker Biographies	179
• Innovation Galleria Program Rundown and Speaker Biographies	187
• Technology Hall Program Rundown and Speaker Biographies	187

Acknowledgments & Resources

Acknowledgments	196
Supporting Organizations	197
BIOHK2023 Recap	200
Exhibitor Guide	210
Convention Floor Guide	213
Speaker Index	214
Sponsor & Exhibitor Index	218



BIOHK2023 Foreword

今年會議的主題是「生物技術萬花筒」。與會者可以期待多元化和多方面的體驗。我們旨在展示廣泛的生物技術應用和創新，讓與會者從不同角度探索生物技術。您將遇到各種各樣的生物技術主題包括衰老與長壽、癌症、神經科學、傳染病、中醫、人工智能、合成生物學、精準醫學、RNA醫學、再生醫學、細胞和基因療法等關鍵技術，以及如何在生物科技市場和國際新創企業的創新生態系統中蓬勃發展，讓您全面了解生物技術的現狀和未來前景。

今年我們很榮幸能邀請到頂級的演講嘉賓陣容，其中包括頂尖科學家、產業專家、倫理學家和政策制定者。諾貝爾獎得主Bruce Beutler博士的參與預計會帶給我們靈感。他將為他的開創性研究和發現提供寶貴的見解，啟發與會者了解衰老領域的最新發展。此外，受邀演講和分享專業知識的其他「重量級」嘉賓將進一步提升大會的學術交流和社交網絡層面，為與會者提供向知名專業人士學習和互動的獨特機會。

因此，我們非常高興歡迎您來香港參加2023年香港國際生物科技論壇暨展覽（BIOHK2023）。當我們聚集在這個充滿活力的城市，這個融合了新舊、東方和西方的城市時，讓我們準備好審視生物科技對我們全球社會的深遠影響。歡迎來到BIOHK2023！

The theme of this year's conference is "Biotechnology Kaleidoscope". Participants may expect a diverse and multifaceted experience. We aim to showcase the vast spectrum of biotechnology applications and innovations, allowing attendees to explore the field from different angles. You will encounter a wide range of topics, including ageing and longevity, cancer, neurosciences, infectious diseases, Chinese medicine, key technologies like artificial intelligence, synthetic biology, precision medicine, RNA medicine, regenerative medicine, and cell and gene therapy, as well as perspectives such as how to thrive in the biotech market and innovative ecosystems for international start-ups, giving you a comprehensive overview of the current state and future prospects of biotechnology.

We are privileged to host an impressive line-up of speakers this year, featuring leading scientists, industry experts, ethicists, and policymakers. The participation of Dr. Bruce Beutler, the Nobel laureate, is expected to convey his lasting impacts on all of us. Dr. Beutler's presence will provide valuable insights into his groundbreaking research and discoveries, inspiring and educating attendees about the latest developments in the field of ageing. In addition, other "heavyweight" guests invited to speak and share their expertise will further enhance the educational and networking aspects of the event, offering unique opportunities for attendees to learn from and interact with renowned professionals.

It therefore gives us great pleasure to welcome you to Hong Kong for the 2023 BIOHK International Biotechnology Conference (BIOHK2023). As we get together in this vibrant city, which is a mix of old and new, East and West, let us be poised to examine the profound impact of biotechnology on our global community. Welcome to BIOHK2023!



ZEIN BIOTECHNOLOGY CO.,LTD.

**WITH MAH AS
THE CORE ,
FOCUSING ON
THE FULL
LIFECYCLE
SERVICE
OF DRUGS**

Zein Biotechnology Co., Ltd., founded in 2001, is a national high-tech enterprise engaged in the construction of the full-life cycle management service system of pharmaceuticals, with the capability of compliance management and key technology services for the whole process of drug development, manufacturing, transaction promotion and post-marketing research. We have been approved to establish "Chongqing Chiral Drug Engineering Technology Research Center," "Chongqing New Drug Design Engineering Technology Research Center," and "Chongqing Postdoctoral Research Workstation." At present, the industrial achievements include 33 new drug certificates, 51 production approvals, 11 foreign invention patents (including 2 in the United States, 2 in Europe, 1 in Japan, 2 in South Korea, and 1 in India), and 36 domestic invention patents.



Address: Zhibo Center Podium, No. 38 Yingbin Avenue, Jiulongpo District, Chongqing
Website: www.zein.bio.com

Business docking: Luo Liping 13636361651;

Wang Zhanghong 15730333828

Welcome Message

Dear Biotechnology Enthusiasts,

Hong Kong has re-opened its borders to the world! Alongside the Hong Kong government's 'Hello Hong Kong!' campaign to spearhead its efforts for economic recovery, we are excited to welcome you to the next chapter of Hong Kong Biotech – BIOHK2023 International Convention – to be held from the 13th – 16th September at the Hong Kong Convention and Exhibition Center.

As one of Asia's top financial centers, Hong Kong utilized the power of biotechnology to resist pandemic-induced economic decline. Significant demographic shifts are spurring Hong Kong's emergence as a new player in innovative healthcare. As a city with a rich history in industrial development and innovation, and one that is frequently lauded as "Asia's World City", there is no better place to bring together biotech companies from both East and West. Welcome back to Hong Kong! We look forward to catching up with you all about the latest industry innovations and trends across the international biotechnology industry.

Supported by the Central Government's dedication to establish Hong Kong as an international innovation and technology hub, the Hong Kong Government has devoted tremendous efforts to promote biotech development. The scale of biotech fundraising in Hong Kong is the second largest in the world, with 53 pre-revenue companies raising close to HKD116 billion as of end-October 2022. A new listing regime under Chapter 18C of the Listing Rules has recently been introduced to further increase accessibility for innovative technology enterprises with high growth potential that seek to list on the Hong Kong stock exchange.

Hong Kong is considered 'the gateway to China' due to its unique status as a special administrative region, which offers a rich source of opportunities for overseas investors looking to capitalize on the continued growth of the Greater Bay Area (GBA). This scheme is an initiative by the Chinese government to link Hong Kong, Macau and 9 other cities along the Pearl River Estuary to form an international technology and innovation center rivalling that of Silicon Valley. With its international reputation for heightened exposure and integration, Hong Kong has long been the go-to stepping stone for Chinese companies looking to expand abroad. As such, owing to its geopolitical advantage, the presence of world-class universities, and its reputation as the No.1 biotech IPO market in Asia, Hong Kong is a safe harbor for global investors to capitalize on prime

conditions for growth and innovation at the epicenter of Asia's biotech revolution. Our goal is to establish BIOHK on the annual biotech convention calendar, and foster the GBA as a vibrant and dynamic biotech research and innovation epicenter in Asia.

Hong Kong's position in the GBA enables companies to tap into vast pools of talent and funding in mainland China. COVID-19 accelerated the growth and development of the biotechnology industry. Biotech's essential role and impact on solving humanity's biggest health problems and combating future threats became glaringly evident. From AI-assisted drug developments to emerging state-of-the-art biotechnologies, enormous advances were made during the pandemic period. For example, the introduction of mRNA vaccines demonstrated the essential role of biotech for the future of humanity. It is our mission to harness the energy of these advancements to further foster collaboration at BIOHK2023.

BIOHK aims to bring you a world-class biotech convention. Our Vice Presidents are from diverse disciplines across biotech spanning years of expertise from academia to venture capital. Business opportunities are best made face to face and BIOHK2023 will continue to offer large-scale networking opportunities in September 2023.

I hope you will join us at BIOHK2023. Whether you want to expand your global network, explore new markets, attract government and/or private funding or to invest in the next biotech unicorn, BIOHK2023 is a forum for the convergence of intentions and actions towards better health futures for all.

Enjoy BIOHK2023 and the world-class program we have built for you.

Yours sincerely,

Presidents of BIOHK2023



Professor Albert Cheung-hoi YU, PhD, JP,
President, BIOHK2023



Dr. Guoliang YU, Co-president, BIOHK2023;
Chairman & CEO, Apollomics Inc.



Mr. Ping CHEN, Co-president, BIOHK2023;
Main founder, AusvicCapital

BIOHK2023 Governance

Co-Presidents

Prof. YU Cheung-Hoi, Albert	President, BIOHK2023 海康科技有限公司
Dr. YU Guoliang	Co-president, BIOHK2023; Chairman & CEO, Apollomics Inc.
Mr. CHEN Ping	Co-president, BIOHK2023; Main founder, AusvicCapital

Vice Presidents

CHAN Russell	CTO, Gense Technologies Ltd Biomedical Engineering
CHEN Chrank	Partner, Ausvic Capital Limited
CHEN Gordon	Chief Executive Officer, Cameron Pace China Limited
HU Charles	Founder & CEO, Ryoden Medical & Transformation Biotechnology Entrepreneur
LEUNG Chuen Yan	Hai Kang Life Corporation Limited
LI Benjamin	Chairman & CEO, Zhaoke Ophthalmology Limited
WAN Mu Maki	Past President, Rotary Club Kowloon Golden Mile
WONG Yu Ngai Alister	Associate, Philip K.H. Wong, Kennedy Y.H. Wong & CoLegal and Business
YU Ben	Commercial Director, Qianhai Holdings Limited

Advisor Convenor

WONG Kennedy	National Committee Member, Chinese People's Political Consultative Conference
--------------	--

Vice Advisor Convenor

CHAN Yung	Deputy, the 12 & 13th National People's Congress of the People's Republic of China
-----------	---

International Advisor

HARA George	Chairman & CEO, DEFTA Partners
-------------	--------------------------------

Advisors

CHAN Pui-leung	Member, Legislative Council General Manager, China Taiping Insurance (HK) Co Ltd
CHAN Siu-hung	Member, Legislative Council
GUO Yike	Provost, The Hong Kong University of Science and Technology

BIOHK2023

Governance

Advisors

HO Shun Man	President, The Hang Seng University of Hong Kong
HONG Wendy	Member, Legislative Council
HU Herman	Deputy, the 12th & 13th National People's Congress of the People's Republic of China
HUNG Witman	Deputy, the 13th National People's Congress of the People's Republic of China
IP LAU Suk-ye	Convenor, the Non-Official Members of the Executive Council Legislative Council Member New People's Party Chair
JIANG Jasper	Founding Partner, Tiger Jade Capital
KAN Carmen	Legislative Council Member Solicitor/General Counsel
KOON Peter Douglas	Legislative Council Member Clergy
LAM Chun Sing	Member of Legislative Council, The Federation of Hong Kong and Kowloon Labour Unions – Chairman
LAM Dennis	Founder, Chairman and Chief Executive Officer, CMER Medical
LAM Lung On	Deputy, the 13th National People's Congress of the People's Republic of China
LAM San-keung	Legislative Legal Functional Constituency – Member of Legislative Council
LEE Chun-keung	Member, Legislative Council
LEE Kwan Ho	Deputy, the 13th National People Congress of the People's Republic of China
LEE Simon	Member, Legislative Council
LEUNG Andrew	President, Legislative Council Business and Professionals Alliance for Hong Kong
LEUNG Dennis	Legislative Council Member Community Officer
LEUNG Siu Fai	Dir of Agri., Fisheries & Conservation, Dir of Marketing, Regr of Co-op. Soc., Regr of Credit Unions
LIU Da	Managing Director, CR CP Life Science Fund
LEE Kwan Ho	Deputy, the 13th National People Congress of the People's Republic of China
LEE Simon	Member, Legislative Council

BIOHK2023

Governance

Advisors

LIU Zhiming	Former First Class Inspector, the Department of International Cooperation, Ministry of Science and Technology of China (MOST)
LUK Bension	Member, Legislative Council
Ma Fung-kwok	Member, Legislative Council
NG Jimmy	Functional Constituency – Industrial (Second)
QUAT Elizabeth	Member, Legislative Council
JUNGJOHANN-OTT Rainer	Member of AHK, German Chamber, Hong Kong
SHANG Hai Long	Managing Director, SenseTime Hong Kong
SHI Allen	President, the Chinese Manufacturers' Association of Hong Kong
SIT Wing-hang	Former Secretary for Innovation and Technology
SO Chi-ki	Executive Director, Hong Kong New Generation Cultural Association
TAN Henry	Hong Kong Deputy, National People's Congress, PRC
TANG Fei	Member, Legislative Council
TING Bernie	Chairman, PRD Council
TUAN Rocky S.	Vice-Chancellor and President, The Chinese University of Hong Kong
WONG Stephen	Legislative Council Member, Our Hong Kong Foundation, Senior Vice President & Executive Director of Public Policy Institute
YANG Michael	Vice-President (Research and Technology), City University of Hong Kong
YUNG Hoi-yan	Legislative Council Member, Barrister-at-law

Legal Advisors

DE Theresa	Managing Partner, Jun He Law Offices
UNG Monin	Legal Advisor, Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance
WONG Yu Ngai	Assistant Solicitor, Philip K.H. Wong, Kennedy Y.H. Wong & Coember of AHK, German Chamber, Hong Kong

BIOHK2023 Governance

Accounting Advisors

LAU Franklin

CEO, Reanda International Accounting Network

Art Advisor

TANG Tat-Chi, William

CEO, Reanda International Accounting Network

Brand Director

LEUNG Fungyi, Joey

Founder and CEO, AIFA TECH LIMITED

Ambassadors

CHAN John

Head of Strategic Development, Ample Capital Limited

CHAN Paul

Chairman, Wellink International Accounting Group

CHOW Joseph

Funding Partner of Wellington Legal

JAGETIYA Avinash

Managing Director, Sun Management Group (Reanda UAE)

JAGETIYA Sunil

Chairman and Founder, Sun Management Group (Reanda UAE)

KOONG Lin Loong

Managing Partner, Reanda LLKG International Chartered Accountants

LAU Franklin

CEO, Reanda International Accounting Network

LIAO Cecilia

MCIARB DPA, PGDBA, B.A. (Hons) UK

PAN Bella

Deputy International Business Director of Reanda International Accounting Network

PANG Karen

Founder & CEO of Meheal Healthcare Co., Ltd.

POLGAR J Peter

Executive Chairman, Reanda Australia Pty Ltd.

YEUNG Francis

Founding Member, Supreme Life Science Ltd.

Names and affiliations were provided by members. If there are any mistakes, please contact HKBIO.

Email: info@bio-hk.com or **Telephone:** +852 2799 7688

BIOHK2023

Organizing Committee

Committee Members

BA Su Juan	President and CEO, National Foundation for Cancer Research
CAO Jing Hua	Executive Director, ANSO Secretariat, Alliance of International Science Organizations (ANSO)
CHAO Wilton	Chairman, Pan Asia Venture Development Platform (PAVD)
CHEAH Kathryn	Chair Professor of Biochemistry, School of Biomedical Sciences, The University of Hong Kong
CHEN Michelle	Chief Business Officer, Insilico Medicine
CHEN Xin Lorna	Asia Regional Managing Partner and Head of Greater China, Shearman & Sterling
CHENG Gordon	Chief Executive Officer, Cameron Pace China Limited
CHOW Ralph	CEO, Chinese Manufacturers' Association of Hong Kong (CMA)
CHOW Yiu Ming	Chief Financial Officer, Lee's Pharmaceutical Holdings Limited
CHUNG John	Former Superintendent, Hong Kong Police Force
GU Mark	Co-founder, Ying Sen Health Technology
HSIAO Wendy	Professor, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology
HSU Hoi Shan	Director, Beijing-Hong Kong Academic Exchange Center,
HUANG Dennis	Executive Director, Youth Committee for Sustainable Development
HUANG Yuan	Technology Transfer Director of Hong Kong Quantum AI Lab
JE Simon	Board Chairman, Great Treasure International / Galaxy Treasure Group
JIANG Claire	CEO, Queens (Shenzhen) Biotechnology Co., Ltd.
JIANG Gina	Managing Director, Hong Kong Institute of Biotechnology (HKIB)
JIANG Ru Hong	Chairman, CEO and President of ASC Therapeutics Inc.

BIOHK2023

Organizing Committee

Committee Members

LAM Stephen	Director, Clinical Genetics Service, Hong Kong Sanatorium & Hospital
LAW Phillip	Lead Partner, Venture Capital & Private Equity, Deloitte
LEE Tin Lap	Associate Professor, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
LEUNG Lydia	CEO of Belun Technology, Chairman of Hong Kong Medical and Healthcare Device Industries Association
LEUNG Thomas	Lo Ka Chung Charitable Foundation Professor in Pharmaceutical Sciences Professor and DoULS
LI Yifan	Managing Director, Beijing ITAI Technology
LIN Mindin	CEO & Editor in Chief, Global Bio & Investment Monthly
LIU Andy	President, Healthcare Division, BaseBit Technologies
LO Kitty	Chairman and CEO, Finet Group Ltd
LU Minghua	Founding Partner, eChinaHealth
LYU Aiping	Dean and Chair Professor, School of Chinese Medicine, Hong Kong Baptist University
MONTELIUS Lars	Director General, International Iberian Nanotechnology Laboratory
NEARING A. Kimberly	Venture Partner, BVCF Management, Ltd
QIAN Peiyuan	Head and Chair Professor, Department of Ocean Science, Hong Kong University of Science and Technology
QIN Jason	Scientific Director, Beijing ITAI Technology
SEGERBLOM Bjorn	Honorary Chaiman and Hong Kong Representative, International Iberian Nanotechnology Laboratory
SUN Fei	Assistant Professor, Chemical and Biological Engineering, The Hong Kong University of Science and Technology
SUN Nan	Deputy Inspector, Shenzhen Association for Science and Technology
TAM Paul	Director, Dr. Li Dak-Sum Research Centre
Tang C. Mark	Managing Director, Good Health Capital (New York)
TIAN Yaolin	CEO, ShenZhen Govita Medical Laboratory
TSUI Victor	COO, Powder Pharmaceuticals Incorporated

BIOHK2023

Organizing Committee

Committee Members

WANG Jiguang	Assistant Professor, Division of Life Science, The Hong Kong University of Science and Technology
WANG Jing	Center for Advanced Measurement Science, National Institute of Metrology, China
WANG Yitao	Director, Institute of Chinese Medical Sciences, University of Macau
WANG Binglou	Adjunct Professor, Department of Biochemistry, Chinese University of Hong Kong
WONG Vivian	Hon Professor, School of Chinese Medicine, The University of Hong Kong
WU George	Corporate partner, DLA Piper Hong Kong
XIE Jiasheng	Director & Executive President, Guangdong Medical Valley (GDMV)
YANG Haiding	Executive Director and Founding Team Leader, Healthcare sector of Cathay Capital
YANG Ling	Managing Director, The Carlyle Group
YANG Ray	COO, Powder Pharmaceuticals Incorporated
YAO Michael	Board Co Chairman, China Biotech Services Holdings Limited
YAU Edmond	Founder & CEO, Koln 3D Technology (Medical) Limited
YIP Raymond	Chief Representative, Hainan International Economic Development Bureau HK Office
YU Duncan	President, MGI
ZHANG Jimmy	Founding member, Former Chairman of BayHelix Group
ZHENG Peter	Founding and Managing Partner, 東立創新基金
ZHOU Grace	President, Shenzhen International Institute for Biomedical Research
ZUO Joan	Vice-president, The Society of Hong Kong Scholars
KANG Kai	CEO & Founder, Xiyou Health

The GSK logo is rendered in a bold, orange, sans-serif font. The letters 'G', 'S', and 'K' are connected, with the 'S' having a unique, angular design. The background of the entire page features a stylized DNA double helix in shades of purple and blue, overlaid with a network of orange lines and dots, suggesting a molecular or technological theme.

Ahead Together

We unite science, technology
and talent to get ahead of
disease together.

BIOHK2023 GOLD SPONSOR

PROGRAM DAY 1

WEDNESDAY SEP 13

08:30	EVENT REGISTRATION				
	BIOHK AUDITORIUM				
09:00 - 09:30	OPENING CEREMONY				
09:30 - 09:50	KEYNOTE SESSION : MR. CY LEUNG 梁振英 (VICE CHAIRMAN, CPPCC)				
09:50 - 12:10	KEYNOTE SESSION: PROF. BRUCE BEUTLER (NOBEL LAUREATE, CO-FOUNDER OF LONGEVITY X)				
	KEYNOTE SESSION: AMBASSADOR GEORGE HARA (GROUP CHAIRMAN AND CEO, DEFTA PARTNERS)				
	KEYNOTE SESSION: PROF. JISHENG HAN 韩济生 (ACADEMICIAN, THE CHINESE ACADEMY OF SCIENCES)**				
	KEYNOTE SESSION: PROF. YI RAO 饶毅 (PRESIDENT, CAPITAL MEDICAL UNIVERSITY)				
	KEYNOTE SESSION: SIR JONATHAN SYMONDS (CHAIR, GSK PLC)				
	BIOHK AUDITORIUM	INNOVATION GALLERIA	TECHNOLOGY HALL	LOCI SQUARE	VIP ROOM
12:10 - 13:00	<p>SPONSOR: HK LONGEVITY MEDICAL CENTER</p> <p>HEALTHY AGING AND LONGEVITY FORUM</p> <p>Chair: Dr. Christine Huang (HK Longevity Medical Center)</p> <p>Opening: Mr. Amir Latif (CG Israel)</p> <p>Aging Biology and Personalized Medicine Dr. Alexey Moskalev (Komi Scientific Center, Russian Academy of Science) Prof. Xin Wang (Chinese University of Hong Kong)</p>	<p>SPONSOR: SCMP</p> <p>THRIVE IN THE BIOTECH MARKET: INVESTING IN LIFE SCIENCE IN HK</p> <p>Moderator: Ms. Elizabeth Cheung (SCMP)</p> <p>Panelists</p> <p>Sir Jonathan Symonds (GSK) Mr. Conrad Tsang (Strategic Year Holdings) Mr. Aaron Finley (Deloitte) Mr. Frank Yang (BOCG)</p>	<p>ETHICS IN THE BIOTECH INDUSTRY</p> <p>Moderator: Ms. Monin Ung (Mung Legal)</p> <p>Panelists</p> <p>Prof. Yi Rao (Capital Medical University) Prof. Dong Dong (Chinese University of Hong Kong) Ms. Yolanda Wang (Eagle IP)</p>	<p>SPONSOR: SHANGHAI HEALTHCARE CAPITAL</p> <p>HONG KONG'S TECHNOLOGY INNOVATION TRANSFORMATION</p> <p>Moderator: Mr. Samuel Guo (Shanghai Healthcare Capital)</p> <p>Mr. Cho Man (SPH-Inno) Prof. Yuk Lam Lo (HKBMIA) Prof. Michael Yang (City University of Hong Kong) Dr. Pengcheng Zhu (ATLTL)</p>	
13:00 - 14:00	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK		
14:00 - 15:30	<p>Prof. Zhongjun Zhou (The University of Hong Kong) Dr. Dajun Chai (Fujian Medical University) Mr. Raj Bhatti (GSK)</p> <p>Reproductive Aging Prof. Jaron Rabinovici (Sheba Medical Center) Dr. Arthur Yang Zhang (Westlake Medical Sci. Ltd.)</p> <p>Evidence-based Aging Medicine Dr. Zhonglong Gu (Greater Bay Area Institute of Precision Medicine) Prof. Hidekazu Yamada (Japanese Society of Anti-Aging Medicine) Dr. Yoko Masuda (Japanese Society of Stem Cell Supernatant for Clinical Medicine) Dr. Mark Tang (Good Health Capital) Dr. Juliane Hitzel (CellFull)</p>	<p>POLICY FOUNDATIONS FOR A LIFE SCIENCE ECOSYSTEM IN HK AND GBA</p> <p>Chair: Dr. Joe Fang (One Country Two System Research Institute)</p> <p>Mr. Vincent Ma (Hong Kong-Shenzhen Innovation & Technology Park) Mr. Arthur Tsang (Our Hong Kong Foundation)</p> <p>Panel Discussion Moderator: Dr. Hon Yuen-shan Wong (Chief Executive's Policy Unit) Dr. Sabrina Chan (HKAPI) Prof. Yuk Lam Lo (HKBMIA) Mr. Tao Song (Dongguan Biotech Industry Development) Mr. Raymond Yip (Nansha New Area) Dr. Guoliang Yu (BayHelix Group)</p>	<p>SPONSOR: SIRNAOMICS</p> <p>RNA MEDICINE: THERAPEUTICS, VACCINES AND BEYOND</p> <p>Dr. Xiaochang Dai (Sirnaomics) Dr. Patrick Lu (Sirnaomics) Dr. Francois Lebel (Sirnaomics) Dr. Dong Shen (RNAimmune) Dr. Edward Wang (Sirnaomics)</p> <p>Coffee Break</p> <p>RNA Investment Panel Dr. Min Wu (Therorna) Dr. Da Liu (CR-CP Life Science Fund) Prof. Nancy Man (The University of Hong Kong) Mr. Christopher Kennedy (EDIRNA)</p>	<p>REPROGRAMMING FOR REGENERATIVE MEDICINE</p> <p>Chair: Prof. Kathryn Cheah (School of Biomedical Science, HKU)</p> <p>Prof. Ting Xie (Hong Kong University of Science and Technology) Prof. Gong Chen (Jinan University, NeuExcell Therapeutics) Mr. Wayne Tan (Hong Kong University of Science and Technology) Dr. Hongmei Li (Beijing University of Chinese Medicine) Dr. Fang Liu (The University of Hong Kong)</p>	
15:30 - 16:00		<p>HKEX LISTING</p> <p>Keynote: Prof. Shusong Ba (HKEX) Moderator: Ms. Winnie Han (HKEX)</p> <p>Ms. Lynne Wu (LongevityX) Ms. Mengyang Yang (CICC) Mr. Andrew Ng (VMS Group) Dr. Chang Liu (ASK Health)</p>			
16:00 - 17:00	<p>Longevity Investment Panel</p> <p>Mr. Thian Chew (Polar Ventures) Mr. Phil Newman (Longevity Technology) Dr. Hank Wuh (Longevity X) Mr. Sergey Jakimov (LongVC)</p>	<p>HAINAN LIFE SCIENCE DEVELOPMENT</p> <p>Mr. Raymond Yip (Hainan Provincial Bureau)</p>	<p>Dr. Yuling Li (Innoforce Pharmaceuticals Co., Ltd.) Mr. Michael Zhang (Guangzhou Ribo Biotechnology) Dr. Richard Welch (Sirnaomics)</p>	<p>SPONSOR: BEIJING ITAI TECHNOLOGY</p> <p>SPECIAL EVENT</p> <p>ASIAN LIFE SCIENCES AND HEALTHCARE INDUSTRY FINANCIAL FORUM</p>	
17:00 - 17:30					
17:30 - 18:00					

ONEZONE PARTNERING

BOAO
FORUMNOBLE
SUSTAINABILITY
TRUST <-> AUSVIC

**COULD NOT ATTEND DUE TO UNFORESEEN CIRCUMSTANCES

PROGRAM

DAY 2

THURSDAY SEP 14

08:30	EVENT REGISTRATION			
	BIOHK AUDITORIUM			
09:00 - 09:30	KEYNOTE SESSION: PROF. YU WANG (CHINESE FOUNDATION FOR HEPATITIS PREVENTION AND CONTROL)			
09:30 - 09:40	KEYNOTE SESSION: MS. LILLIAN CHEONG (INNOVATION, TECHNOLOGY AND INDUSTRY BUREAU)			
09:40 - 10:10	KEYNOTE SESSION: MS. NISA LEUNG (QIMING VENTURES)			
10:10 - 10:35	KEYNOTE SESSION: PROF. AKIHIKO KONDO (KOBE UNIVERSITY)			
10:35 - 11:00	KEYNOTE SESSION: PROF. RAJU KUCHERLAPATI (HARVARD UNIVERSITY)			
	BIOHK AUDITORIUM	INNOVATION GALLERIA	TECHNOLOGY HALL	LOCI SQUARE
11:00 - 12:00	SPONSOR: AFCR INNOVATIONS IN CANCER RESEARCH & IMMUNOTHERAPIES Opening: Dr. Sujuan Ba (AFCR) New Frontiers for Cancer Research Chair: Dr. Da Liu (CR-CP Life Science Fund) Prof. Haruo Sugiyama (Osaka University) Prof. Moshe Szyf (HKG epiTherapeutics Limited) Prof. Bruce Johnson (Dana Farber) Prof. Lei Zheng (Johns Hopkins University) Prof. Ming Kuang (Sun Yat-sen University) Prof. Ava Kwong (The University of Hong Kong)	POTENTIAL OF SYNTHETIC BIOLOGY IN HEALTHCARE Chair: Prof. Fei Sun (HKUST) Prof. Jian-Dong Huang (The University of Hong Kong) Prof. Jiang Xia (The Chinese University of Hong Kong) Dr. Lei Dai (Shenzhen Institute of Advanced Technology)	UNDERSTAND YOUR MICROBE GARDEN Chair: Prof. Stephen Tsui (The Chinese University of Hong Kong) Dr. Juncal Ma (IMCAS) Dr. Joo Ann Ewe (Nano and Advanced Materials Institute)	SPONSOR: NEW HORIZON HEALTH IVD CANCER SCREENING Mr. Yeqing Zhu (New Horizon Health) Dr. Rita Shih (New Horizon Health)
12:00 - 13:00		REWRITE "HEALTH" WITH CELL/GENE THERAPY Chair: Dr. Shengjiang Liu (Avirmax Biopharma) Chair: Prof. Xumu Zhang (Southern University of Sci & Tech) Dr. Wai Po Chong (Hong Kong Baptist University) Dr. Darren Ji (Elpiscience Biopharma) Dr. Howard Wu (Full Circles Therapeutics)	SPONSOR: ZEIN BIOTECHNOLOGY EXPLORE CUTTING EDGE APPROACHES TO DISEASE TREATMENT Chair: Dr. Zhongmin Ma (Revivalon Biopharmaceutical) Dr. Jinan Li (Talengen Institute of Life Sciences) Dr. Robert Lee (Zhejiang Haichang Biotech) Prof. Guangrui Huang (Beijing University of Chinese Medicine) Dr. Hongming Hu (ImmuXell) Dr. Chi Ming Wong (The Hong Kong Polytechnic University)	INNOVATIVE HEALTHCARE Chair: Prof. Cong Yan (Beijing University of Chinese Medicine) Mr. Kin Ming Lam (Sramek Insight) Mr. Yuxing Zuo (Tongee Medical) Dr. Qiao Jiang (LeaderMed) Ms. Klaudia Kozusznik (A4BEE) Dr. Xudong Yuan (ACON Pharmaceuticals Inc.)
13:00 - 14:00	LUNCH BREAK			
14:00 - 14:30	BRACE Awards Chair: Prof. Raju Kucherlapati (Harvard University) Dr. Lily Zou (Degron Therapeutics) Dr. Tony Wong (Arbele Ltd) Dr. Ignacio Asial (DotBio)	CHINESE PHARMA GOING INTERNATIONAL Chair: Dr. Yuxin Men (Haichang Biotech) Dr. Ning Li (Junshi Biosciences) Dr. Ruyi He (RemeGen) Dr. Tao Du (Evergreen Therapeutics) Dr. Yuzhi Hu (Sidley Austin) Dr. Shen Xiao (3D Medicines) Dr. Changqing Li (Evergreen Therapeutics) Dr. Xiaobin Zhao (Haichang Biotech) Dr. Zhang Mingdong (Suzhou SINUS MedTech) Dr. Xueming Qian (Transcenta)	CHINESE MEDICINE SPECIAL PROGRAM: FROM FARM TO PHARM Chair: Prof. Wendy Hsiao (Macau University of Science and Technology) Keynote: Prof. Clara Lau (Chinese University of Hong Kong) Prof. Wendy Hsiao (Macau University of Science and Technology) Prof. Aiping Lyu (Hong Kong Baptist University) Dr. Erik Ko (Nano and Advanced Materials Institute)	PITCHING STRATEGIES FOR BIOMEDICAL COMPANIES Mr. James Zhang (Porda Hovas International Finance Communications Group)
14:30 - 15:00		Panel Discussion Dr. Jimmy Wei (Chime Biologics) Mr. Ming Tang (Yunnan Baiyao) Ms. Shouqun Wang (China Commercial Lam Lee Lai Lawyers) Mr. Yongheng Huang (Guangdong Association for Standardization) Ms. Huifang Wang (Shenzhen Biotech & Industry Cleaning Association)		PITCHING ACON PHARMACEUTICALS ALPHAFIBRO SSS VITROLOGY NAF PHARMA LOGISTICS LTD ENAND HEALTH CPD-IN HEALTH SCIENCE 中大中华中医脉诊仪 INCANDO THERAPEUTICS SSBC INTRALINKS JSBIO 健顺生物科技 (南通) 有限公司 云舟生物科技 (广州) 股份有限公司 VECTOR BUILDER TEGENT TECHNOLOGY LTD./LYO INNOVATION BIOTECH 深圳生命科学行业协会/深圳市北科生物科技有限公司 MAPPIE PHARMACEUTICALS HERBS 萃姬 MEAT THE NEXT GENEDIT BIO GENESENSE WVCCPA
15:00 - 15:30	Emerging Oncology Companies Chair: Dr. Mark Tang (Good Health Capital) Ms. Rose Wang (AIM-HI Accelerator Fund) Dr. Shane Burgess (Treadwell Therapeutics) Dr. Dajun Yang (Ascentage Pharma) Dr. Guoliang Yu (Apolomics) Dr. Zane Yang (ABM Therapeutics)			
15:30 - 16:00				
16:00 - 16:30				
16:30 - 17:30				

ONEZONE PARTNERING

PROGRAM DAY 3

FRIDAY SEP 15

08:30	EVENT REGISTRATION			
	BIOHK AUDITORIUM			
09:00 - 09:30	KEYNOTE SESSION: PROF. HIDEYUKI OKANO 岡野栄之 (KEIO UNIVERSITY SCHOOL OF MEDICINE)			
09:30 - 10:00	KEYNOTE SESSION: PROF. TAK WAH MAK 麥德華 (THE HONG KONG UNIVERSITY, INNOHK)			
	BIOHK AUDITORIUM	INNOVATION GALLERIA	TECHNOLOGY HALL	LOCI SQUARE
10:00 - 11:00	SPONSOR: PHARMABOARDROOM CAR-T THERAPY Moderator: Ms. Diana Viola (PharmaBoardroom) Dr. Azucena Gonzalez (Hospital Clinic de Barcelona) Dr. Lin Yang (PersonGen BioTherapeutics) Dr. Stephen Liu (ST PHI Therapeutics)	SPONSOR: HUAWEI CLOUD ARTIFICIAL INTELLIGENCE IN HEALTHCARE Keynote: Mr. Wei Sang (Huawei Cloud) Mr. John Yue Jun Jiang (CP Group) Dr. Christopher Morton (ELEM Biotech SL) Dr. Frank Pun (Insilico Medicine) Dr. Echo Chen (LUCA Healthcare)	SEARCHING FOR THE NEXT LIFE SCIENCE UNICORN Chair: Mr. Da Liu (CR-CP Life Sciences Fund) Mr. Nigel Yip (Sirnaomics) Mr. Francis Cao (InxMed) Mr. Simon Hua (China Finances Strategies Investment Holdings Ltd.) Mr. Martin Law (MIRXES Hong Kong)	SPONSOR: ASTRAZENECA BUILDING INNOVATIVE ECOSYSTEM FOR INTERNATIONAL STARTUPS Ms. Shan Wu (AstraZeneca) Ms. Rongrong Guo (CICC) Ms. Carol Liu (Hong Kong Science & Technology Parks, HKSTP) Ms. Michelle Kam (Hong Kong Shenzhen Innovation & Technology Park, HSTIP)
11:00 - 11:30	EXPLORING THE MARVELS OF THE BRAIN Chair: Dr. Charles Hu (Ryoden Medical Holdings Ltd.) Keynote: Prof. Wise Young (Rutgers, State University of New Jersey) Prof. Wei Chen (Tiantan Hospital) Prof. Xuejun Song (Southern University of Science and Technology) Mr. Coach Wei (Neural Galaxy) Mr. Lei Peng (NeuroXess) Dr. Peng Cao (Genlight) Dr. Percy Luu (Incando Therapeutics)	INNOVATIVE BIOPHARMACEUTICAL PRODUCTION Dr. Tao Kang (Medium Biomedicine) Dr. Cole Cheng (VectorBuilder)	ADVANCES IN MEDICAL BIOTECHNOLOGY Chair: Prof. Dan Zhang (Jiangsu Hillgene Biopharma) Dr. Hongzhi Zou (Creative Biosciences) Dr. Jiangshan Zhan (Hai Kang Life Corporation) Dr. Kathy He (Cargene Biopharma) Dr. Taejoon Kang (Korea Advanced Institute of Science and Technology) Dr. Jinhai Shi (Bing Biotech) Dr. Zhaoyu Hu (Rhegen Bio) Dr. Jijun Yuan (Abogen Biosciences)	"TOP 5 TO WATCH" PITCHING COMPETITION INCANDO THERAPEUTICS NEOX BIOTECH (HK) LIMITED 北京星九原生物科技 有限公司 JIANGSU HILLGENE BIOPHARMA CO., LTD. 江苏道新生物 医药有限公司 ABOE ALLERROW BIOTECH LTD 十度生物科技有限公司 CIMPLE BIOTECHNOLOGY LIMITED CITY UNIVERSITY OF HONG KONG CREATIVE BIOSCIENCES (HONGKONG) 广州康立明 ENANO HEALTH FLUX MEDTECH LIMITED GOVITA GREATER BAY BIOTECHNOLOGY LIMITED
11:30 - 12:15				
12:15 - 13:00				
13:00 - 14:00	LUNCH BREAK			
14:00 - 14:30	BIOTECH BATTLE AGAINST INFECTIOUS VIRUSES Chair: Prof. Margaret Ip (Chinese University of Hong Kong) Keynote: Prof. Pei-Jer Chen (National Taiwan University and Hospital) Dr. Ricky Chiu (PHASE Scientific) Dr. Dexing Zhang (Chinese University of Hong Kong) Dr. Qingpeng Zhang (University of Hong Kong) Dr. Jiasheng Song (Difference Biological Tech) Prof. Hongzhou Lu (Shenzhen Third People's Hospital)	SPONSOR: JUN HE FROM LAB TO IPO: NEW TOPICS & CHALLENGES Moderator: Ms. Zhijin Zhang (Jun He) Ms. Lihua De (Jun He) Mr. Xudong Tao (Jun He)	KEY REGULATORS IN INFLAMMATORY DISEASES AS TARGET FOR DRUG DISCOVERY Chair: Prof. Xinyuan Fu (West China Hospital) Dr. Hongtao Lu (Elpisience Biopharma) Dr. Xiao Ding (Insilico Medicine) Dr. Tony Zhang (Tyligand Bioscience)	"TOP 5 TO WATCH" PITCHING COMPETITION LUCY BIOTECH INSIGHTA LIMITED TCRCURE BIOPHARMA TECHNOLOGY JUPITER NEUROSCIENCES, INC. LABWARE SINGAPORE PTE. LTD META PHARMACEUTICALS NEUROPIX PROVECTUS THERAPEUTICS RAPAFUSYN PHARMACEUTICALS AXBIO TALENGEN INSTITUTE OF LIFE SCIENCES 瑞健生命科学研究院 ROMEGA 挪威鱼肝油 TROMSD NUTRITION TECHNOLOGIES TUNECT CRO SYNGULAR ZENXTAG TECHNOLOGY DIFFERENCE BIOLOGICAL TECHNOLOGY CO., LTD 浙江迪福润丝生物科技有限公司 CARGENE BIOPHARMA BEIJING TSINKE BIOTECH CO., LTD. 北京攀科生物科技股份有限公司 株式会社ENKILABS MOCE - 希毅医学
14:30 - 15:00				
15:00 - 15:30				
15:30 - 16:00		BIOTECH CAPITAL MARKETS IN HK AND GBA Moderator: Mr. Vijay Karwal (AffaMed Therapeutics) Mr. Samuel Thong (Goldman Sachs) Mr. Andrew Ng (Private Equity at VMS Group) Mr. Sammi Wong (HKSTP Capital) Ms. Helen Chen (LEK) Dr. Dong Li (Hong Kong APX Capital)	THE PRECISION MEDICINE ERA Chair: Dr. Desmond Hau (Pangenla) Moderator: Dr. Jay Dong (UltraDx) Keynote: Prof. Allen Chan (Center for Novostics) Dr. Mao Mao (Seekin Inc.) Dr. Vince Gao (Govita Tech Ltd.) All Speaker Panel Discussion	
16:00 - 16:30		THE STATE OF EMERGING BIOTECHS Moderator: Mr. Yuyao Peng (China Renaissance Securities) Mr. Mikio Tanji (Delta Partners) Mr. Greg Zuo (Genecast Biotech) Mr. Adrian Lam (Bloworld Ventures) Mr. Jielun Zhu (Fapon Group) Dr. Charles Hu (Ryoden Medical Holdings; Incando Therapeutics) Ms. Viva He (AZ-CICC Venture Investment Fund)		
16:30 - 17:00				

ONE2ONE PARTNERING

PROGRAM

DAY 4

SATURDAY SEP 16

08:30	EVENT REGISTRATION			
	BIOHK AUDITORIUM			
09:00 - 09:30	KEYNOTE SESSION: PROF. FU GAO 高福 (ACADEMICIAN, CHINESE ACADEMY OF SCIENCES)**			
09:30 - 10:00	KEYNOTE SESSION: PROF. TONY MOK 莫樹錦 (CHINESE UNIVERSITY OF HONG KONG)			
10:00 - 10:30	KEYNOTE SESSION: PROF. FAN NGAI HUNG 孔繁毅 (THE UNIVERSITY OF HONG KONG)			
	BIOHK AUDITORIUM	INNOVATION GALLERIA	TECHNOLOGY HALL	LOCI SQUARE
10:30 - 11:30	<p>SPONSOR: CSBT & IMCAS</p> <p>MICROBIOLOGY & BIOSAFETY</p> <p>Dr. Lianpan Dai (IMCAS)</p> <p>Dr. Bian Wu (IMCAS)</p> <p>Dr. Longchao Liu (IMCAS)</p>	<p>HEALTH BENEFITS OF PROBIOTICS</p> <p>Moderator: Mr. Edmond Lau (HK Business Angel Network)</p> <p>Dr. Matey Yordanov (The Matrix Cube)</p> <p>Dr. Mikhail Bychov (Vim Vitae)</p>	<p>GET PUBLISHED IN NATURE</p> <p>Ms. Mimmi Mononen (Nature Journal)</p>	<p>KNOW YOUR STRESS LEVEL WITH A SIMPLE TEST</p> <p>eNano Health</p>
11:30 - 12:00	<p>DISCOVER NEW DRUGS AND REPURPOSE OLD DRUGS</p> <p>Dr. Tien Lee (Aardvark Therapeutics)</p> <p>Prof. Billy Wai-Lung Ng (Chinese University of Hong Kong)</p> <p>Dr. Yu Wai Chen (Hong Kong Polytechnic University)</p> <p>Dr. Fan Liu (neoX Biotech)</p>	<p>STEM EDUCATION AND BIOTECHNOLOGY</p> <p>Prof. Fei Sun (HKUST)</p> <p>Prof. Jiguang Wang (HKUST)</p> <p>Dr. Zhaoshi Bao (Capital Medical University)</p> <p>Mr. Dason Cheung (Cheuk Sui International Group)</p>	<p>VOICES OF GBA SCHOLARS</p> <p>Prof. Hai Rao (Southern University of Science and Technology)</p> <p>Prof. Wenjing Zhao (Sun Yat-sen University [Shenzhen])</p> <p>Dr. Guanyu Wang (The Chinese University of Hong Kong [Shenzhen])</p> <p>Dr. Lin Deng (Shenzhen Bay Laboratory)</p> <p>Dr. Shaohua Ma (Tsinghua Shenzhen International Graduate School)</p>	<p>SELENIUM FOR IMPROVED IMMUNITY: HEALTHY EGG ROLLS</p> <p>Phoenix Bakery</p>
12:00 - 13:00		<p>NEW TECHNOLOGY: ONE MINUTE TO CHECK YOUR RETINA</p> <p>AirDoc</p>		<p>CAN DIABETES BE CURED?</p> <p>Dr. Ma Zhongmin (Revallion Biopharmaceutical)</p>
13:00 - 14:00	LUNCH BREAK			
14:00 - 14:30	<p>SPONSOR: CAIR-HKISI-CAS</p> <p>AI & ROBOTICS IN HEALTHCARE</p>	<p>FOCUS ON THE LOOP (PART 2)</p>		
14:30 - 15:00	<p>Chair: Prof. Hongbin Liu (CAIR-HKISI, Chinese Academy of Sciences)</p> <p>Keynote: Dr. Danny Chan (Chinese University of Hong Kong)</p>	<p>Prof. Albert Yu (HKBIO)</p>		
15:00 - 15:30	<p>Dr. Hongliang Ren (Chinese University of Hong Kong)</p> <p>Dr. Zhongkai Zhang (CAIR-HKISI, Chinese Academy of Sciences)</p>	<p>Prof. Yuk Lam Lo (HKBMIA)</p>		
15:30 - 16:00	<p>Dr. Qingpeng Zhang (The University of Hong Kong)</p> <p>Dr. Kar Hang Henry Chu (The Hong Kong Polytechnic University)</p>	<p>Dr. Sabrina Chan (HKAPI)</p>		

ONEZONE PARTNERING

**COULD NOT ATTEND DUE TO UNFORESEEN CIRCUMSTANCES

What science can do

We push the boundaries of science to deliver life changing medicines



HK-5958 25/8/2023

BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS
POTENTIAL OF HONG KONG'S
BIOTECH ECOSYSTEM

CONFERENCE

DAY ONE

Wednesday September 13

KEYNOTE ADDRESS

Wednesday, September 13 | 09:00 AM - 12:10 PM (GMT+8)

08:45 - 09:30	OPENING CEREMONY
09:30 - 9:50	KEYNOTE SESSION : MR. CY LEUNG 梁振英, VICE CHAIRMAN, CPPCC The Loop Again - Positive Developments
09:50 - 10:20	KEYNOTE SESSION: PROF. BRUCE BEUTLER, NOBEL LAUREATE, CO-FOUNDER OF LONGEVITY X Automated Meiotic Mapping for the Discovery of Protective Mutations for Disease Resistance to Cancer and the Fragility of Aging
10:20 - 10:40	KEYNOTE SESSION: MR. GEORGE HARA, GROUP CHAIRMAN AND CEO, DEFTA PARTNERS To Create Technology Industries by Public Interest Capitalism
10:40 - 11:10	KEYNOTE SESSION: PROF. JISHENG HAN 韩济生, ACADEMICIAN OF THE CHINESE ACADEMY OF SCIENCES ** Application of Acupuncture-related Techniques in Assisted Reproductive Medicine
11:10 - 11:40	KEYNOTE SESSION: PROF. YI RAO 饶毅, PRESIDENT, CAPITAL MEDICAL UNIVERSITY 中国生物医药产业的起飞
11:40 - 12:10	KEYNOTE SESSION: SIR JONATHAN SYMONDS, CHAIR, GSK PLC Building a Data-led Science Eco-system to Support the Health Needs of Today

**COULD NOT ATTEND DUE TO UNFORESEEN CIRCUMSTANCES

BIOHK2023 DIAMOND SPONSOR



盈信泰資本介紹

网站: <https://www.ausviccapital.com/en/>

盈信泰資本成立於2018年，由擁有眾多股權投資背景的專業人士發起建立的前沿科技投資管理機構。創始人陳平先生擁有豐富的高科技領域風險投資及企業管理經驗，並創造了驕人的業績。我們投資全球優秀項目，重點投資領域包括：生物科技、人工智能與大數據、雲計算及數字經濟。同時，盈信泰資本與世界知名家族基金和頂尖大學有著深度合作關係



Bruce Beutler

Nobel Prize Laureate

Winner of the 2011 Nobel Prize in Physiology or Medicine

Bruce Beutler, MD, discovered an important family of receptors that allow mammals to sense infections when they occur, triggering a powerful inflammatory response. For this work he received the 2011 Nobel Prize in Physiology or Medicine.

Beutler received his undergraduate degree from the University of California at San Diego in 1976, and his MD degree from the University of Chicago in 1981. After two years of residency at the University of Texas Southwestern Medical Center, he became a postdoctoral fellow and then an Assistant Professor at the Rockefeller University (1983-1986), where he isolated mouse tumor necrosis factor (TNF), and was the first to recognize TNF as a key executor of the inflammatory response. Returning to Dallas in 1986 as an HHMI investigator, he designed recombinant inhibitors of TNF that are widely used in the treatment of rheumatoid arthritis and other inflammatory diseases. He also used TNF as a biological endpoint in order to identify the receptor for bacterial lipopolysaccharide (LPS). This he achieved by positionally cloning the Lps mutation of mice, known to prevent all biological responses to LPS, including TNF production. He thus concluded that Toll-like receptor 4 (TLR4) acts as the signaling core of the LPS receptor and proposed that other TLRs might also recognize conserved molecular signatures of infection.

Moving in 2000 to the Scripps Research Institute, Beutler developed the largest mouse mutagenesis program in the world, and applied a forward genetic approach to decipher the signaling pathways activated by TLRs. He also identified many other molecules with non-redundant function in the immune response. Returning to UT Southwestern in 2011, he developed a means of instantly identifying mutations responsible for both quantitative and qualitative phenotypes. This allowed rapid discovery of many new components of the immune system.

Beutler is currently a Regental Professor and Director of the Center for Genetics of Host Defense at the University of Texas Southwestern Medical Center. He also holds the Raymond and Ellen Willie Distinguished Chair in Cancer Research in honor of Laverne and Raymond Willie, Sr. Before he received the Nobel Prize, his work was recognized by the Shaw Prize (2011), the Albany Medical Center Prize in Medicine and Biomedical Research (2009), election to the National Academy of Sciences and Institute of Medicine (2008), the Frederik B. Bang Award (2008), the Balzan Prize (2007), the Gran Prix Charles-Leopold-Mayer (2006), the William B. Coley Award (2005), the Robert-Koch-Prize (2004), and other honors.



George Hara 原丈人

**Group Chairman and CEO
DEFTA Partners**

Mr. George Hara is an archaeologist, tech entrepreneur, and venture capitalist.

In Japan, Ambassador Hara served as Senior Advisor to the Ministry of Finance, the Prime Minister's Special Commissioner on the Government Tax Panel, as an advisor to the Ministry of Internal Affairs and Communications, and as a member of various government committees, including Japan's Industrial Structure Council of the Ministry of Economy, Trade and Industry. In these capacities, Ambassador Hara's efforts are aimed at lowering tax rates while increasing tax revenues in order to enable the Japanese government to establish fiscal discipline.

In the private sector, Mr. Hara founded DEFTA Partners in 1984 and became a Partner at Accel Partners in 1990. He was considered one of the most prominent Silicon Valley venture capitalists in ICT in the 1990s and has led more than twenty companies – including Borland, PictureTel, SCO, Tradex, and Unify – to success. Since 2000, Mr. Hara has served as chairman of the board or helped to manage a number of U.S., Israeli and UK companies including Oplus Technologies (Merged with Intel in 2005), Broadware (merged with Cisco in 2007), Transitive Tech (merged with IBM in 2008) and Fortinet (NASDAQ IPO in 2009).

DEFTA Partners has long-term relationship with top universities and research institutes worldwide to commercialize the R&D achievements and to create new industry. Mr. Hara founded DEFTA Partners Hong Kong Office, to invest and to foster next generation of entrepreneurs, to promote collaboration between Hong Kong and Japan, and to make Hong Kong China's international innovation and technology hub. His vision is to make the new technologies and treatments accessible to patients, and thus create a thick layer of healthy and well-educated middle class all over the world.

Mr. Hara currently serves as Chairman of the Alliance Forum Foundation (AFF), a 501(c)3 non-profit organisation in Special Consulting Status with the UN Economic and Social Council. AFF is comprised of a number of divisions, notably the Alliance Forum Development Programme (AFDP) and the Public Interest Capitalism Research Institute (AFPIC). AFDP implements the organisation's international development activities focused on (1) eradicating malnutrition, (2) improving education and health care, and (3) promoting economic self-reliance and empowerment in developing nations. AFPIC, on the other hand, works to conduct research and define models for post-financial capitalism to replace the prevailing shareholder-centric model of capitalism which lies at the root of global financial crises. He has also previously served on the boards of the San Francisco Opera, University of San Francisco, Tokyo Foundation, Japan Society and the Hara Research Foundation.

Mr. Hara was born in Osaka, Japan, in 1952. After graduating from Keio University's Faculty of Law, he became involved in archaeological research in Central America until the age of 27. Following this, he enrolled in the Stanford MBA Programme in California and received a Master of Science degree from the Stanford University Graduate School of Engineering after a period serving as a UN Fellow.

He is also the author of numerous articles and publications, including a Japanese best-seller entitled 21 Seiki no Kokufuron (An Inquiry into the Nature and Causes of the Wealth of Nations in the 21st Century), published by Heibonsha in 2007, and Atarashii Shihonshugi (New Capitalism) published by PHP Institute in 2009. He is a Global Agenda Council Member and a Meta Council Member of Inclusive Growth of the World Economic Forum (Davos Forum), and serves on International Advisory Council of SALK Institute.



Jisheng Han 韩济生

Academician

Chinese Academy of Sciences

Han Jisheng has been studying the principle of acupuncture analgesia from the perspective of central neurochemistry for half a century. He first clarified the time and space distribution rules of acupuncture on human acupoints for analgesia. He found that acupuncture can activate the body's endogenous analgesic system and release He produces opioid peptides, monoamine neurotransmitters and other substances, and is a global leader in the research on the principles of traditional Chinese medicine and acupuncture.

After more than 30 years of clinical practice, he developed a "neuromodulator" that uses transcutaneous electrical acupoint stimulation (TEAS) to treat pain and various other diseases. Under his promotion, the Neuroscience Center of Beijing Medical University was established and developed into the Key Laboratory of Neuroscience of the Ministry of Education and the Key Laboratory of Neuroscience of the Ministry of Health. In addition, he also founded the Pain Branch of the Chinese Medical Association, Beijing Neuroscience Society, China Branch of the International Neuropeptide Association and the Chinese Journal of Pain Medicine.

Since 1979, Academician Han Jisheng has been invited to give 206 lectures at more than 100 universities and research institutions in 27 countries and regions, teaching the principles of traditional Chinese medicine and acupuncture. He served as a scientific advisor to the World Health Organization (WHO) from 1990 to 2002, and a consultant to the US National Institutes of Health (NIH) from 1991 to 2002. He was elected as an international academician of the Royal Academy of Sciences in Lund, Sweden, and the Education Committee of the International Society of Pain (IASP). Member (1991-1995). In 2022, Academician Han Jisheng won the second Sheikh Zayed International Award for Traditional Medicine (TACM2022 International Award).



Rao Yi 饶毅

President
Capital Medical University

Yi Rao is the President of Capital Medical University, a Chair Professor and the Founding Director of the PKU-IDG/McGovern Institute for Brain Research at Peking University, the Founding Director of PKU-Tsinghua Center for Life Sciences, and the Founding Director of the Chinese Institute for Brain Research at Beijing.

Rao received medical and graduate training in China from 1978 to 1985. He obtained his PhD from the University of California at San Francisco in 1991 with a thesis on molecular and genetic analysis of cellular communication in *Drosophila* neural development. He was a postdoctoral fellow at Harvard working on molecular mechanisms of neural development in amphibians. He was on the faculty of Washington University School of Medicine from 1994 to 2004 and Northwestern University School of Medicine from 2004 to 2007, where his lab worked on molecular and cellular basis of neural development, revealing the origin of two eyes in a single morphogenetic field, discovering the chemorepellent function of the Slit proteins in axon guidance and neuronal migration, and dissecting signal transduction mechanisms of the chemorepellent Slit and chemoattractant Netrin. His lab has found conserved guidance mechanisms between neurons and leukocytes. In 2007, he returned to China as the Dean of the School of Life Sciences at Peking University. His lab currently investigates molecular and cellular mechanisms underlying behavior and cognition. Rao has proposed the concept of chemoconnectome (CCT) as the entire set of neurotransmitters, neuromodulators, neuropeptides and their receptors underlying chemical transmission in an animal. The Rao lab has invented the generally applicable chemoconnectomics approach and generated new genetic resources to study the functional roles of genes and cells in the CCT, to manipulate chemical transmission and to map neural circuits. In humans, they use genetics, genomics and functional magnetic resonance imaging (fMRI) to investigate genes and brain regions important in cognition. The Rao lab has carried out research with flies, frogs, mice, rats, monkeys and humans to understand fundamental mechanisms both those conserved among animals and those unique for humans.

Rao is instrumental in reforming and establishing several leading institutions of science and higher education in China. He assisted the establishment of the Institute of Neuroscience (ION) of the Chinese Academy of Sciences in Shanghai (1999) and participated in establishment of the National Institute for Biological Sciences (NIBS) in Beijing (2004). He was a co-founder or founder of the Shanghai Institute for Advanced Studies (2002), the Peking-Tsinghua Center for Life Sciences (2011), the PKU-IDG/McGovern Institute for Brain Research (2012) and the Chinese Institute for Brain Research, Beijing (2018). He is a co-founder of the Westlake University. He is a founding member of Scientific Committee of the Future Science Prize of China (2016), and a co-founder of the Xplorer Prize for Science and Technology of China (2018). He joined the Medical Advisory Board of the Canada Gairdner International Award in 2018.

Rao has taught courses in neurobiology, genetics, developmental biology, molecular biology, cell biology and pharmacology. He has continuously taught the course Concepts and Approaches in Biology (CAB) since 2008, focusing on classic experiments in genetics from Mendel (1866), Miescher (1871), Morgan (1910), Griffith (1928), to Avery, MacLeod and McCarty (1944), in developmental biology from Roux (1888), Spemann and Mangold (1924), Lewis (1978) to Nusslein-Volhard and Wieschaus (1980), in neurochemistry from Bernard (1857), Langley (1901), Elliot (1905) to Dale (1910) and Loewi (1921), in electrophysiology from Adrian (1912), Hodgkin and Huxley (1939), Katz (1952), to Hubel and Wiesel (1962), and in immunology from Behring and Kitasato (1890), Ehrlich (1900), Owen (1945) to Burnet (1959).



Jonathan Symonds

Chair
GSK Plc

Sir Jonathan Symonds has extensive international financial, life sciences and governance experience. In July 2021, Sir Symonds co-chaired with Professor Sir John Bell the preparation of the UK Life Science Vision, which sets out a strategy for UK life sciences in the post-Covid world and seeks to capitalise on many of the UK's scientific successes through the pandemic.

In financial services, Sir Symonds served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc from April 2014 to July 2018 and oversaw the formation of the ring-fence bank HSBC UK plc. He was also a partner and managing director at Goldman Sachs between July 2007 and September 2009.

Sir Symonds was Chief Financial Officer of Novartis AG from September 2009 to January 2014 and Chief Financial Officer of AstraZeneca plc from October 1997 and July 2007, a period which included the negotiation and completion of the merger with Astra. As a CFO, Sir Symonds chaired the 100 Group of Finance Directors, co-chaired the HMRC business tax committee and co-founded the Centre for Business Taxation at the Said Business School.

Prior to joining Zeneca in 1997, Sir Symonds was a Partner at KPMG, specialising in large scale business transformation in the chemicals and pharmaceuticals industries. His additional governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc; Non-Executive Chair of Proteus Digital Health Inc; Non-Executive Director, Rubius Therapeutics Inc.

至善·创新·健康

以患者为中心，追求更高标准的社会价值输出

COMPANY PROFILE

企业简介

康诺亚生物医药有限公司(2162. HK)立足创新、专注研发，致力于为患者提供更多高质量、可负担的创新疗法，解决亟待满足的临床需求。

CORE AREAS

核心领域

聚焦自身免疫及肿瘤领域 康诺亚搭建起具国际竞争力的产品管线
高效推进多项多元化、差异化的创新产品临床研究



CORE PRODUCTS

核心产品

CM310

IL-4Rα 抗体

- 获 CDE 突破性治疗药物认定
- 即将递交用于成人中重度特应性皮炎治疗的上市申请

CMG901

Claudin 18.2 ADC药物

- 获 CDE 突破性治疗药物认定、FDA 快速通道及孤儿药资格认定
- 已与阿斯利康达成全球独家授权协议

BIOHK AUDITORIUM | BIOHK 會堂

Healthy Aging and Longevity

Wednesday, September 13 | 12:10 PM - 17:30 PM (GMT+8)

12:10 - 12:20	Sponsor: HK Longevity Medical Center Chair: Dr. Christine Huang, HK Longevity Medical Center Opening Speech: Mr. Amir Lati, CG Israel
Session One: Aging Biology and Personalised Medicine	
12:20 - 12:40	Biomarkers of Human Aging and Geroprotectors Dr. Alexey Moskalev, Komi Scientific Center, Russian Academy of Science
12:40 - 13:00	Dissecting the Heterogeneity of Aging Acceleration in Breast Cancer Prof. Wang Xin, Chinese University of Hong Kong
13:00 - 14:00	Lunch Break
14:00 - 14:15	Critical Pathways for Life Extension and Healthy Aging Prof. Zhongjun Zhou, The University of Hong Kong
14:15 - 14:30	Cardiovascular disease in aging: Rehabilitation of elderly patients with ST-segment elevation myocardial infarction (STEMI) Dr. Dajun Chai, Fujian Medical University
14:30 - 14:45	Healthy Ageing and Longevity – Prevention-based Healthcare Mr. Raj Bhatti, GSK plc*
Session Two: Reproductive Aging	
14:45 - 14:55	The Importance of Female Hormones for Health and Healthy Longevity Prof. Jaron Rabinovici, Sheba Medical Center
14:55 - 15:05	Micro Devices for Aging-related Diseases Dr. Arthur Yang Zhang, Westlake Medical Sci. Ltd.
Session Three: Evidence-based Longevity Medicine	
15:05 - 15:15	Mitochondrial DNA Mutation and Disease: Young and Old Dr. Zhenglong Gu, Cornell University
15:15 - 15:25	DNAm Clocks and Reversing Biological age Prof. Hidekazu Yamada, Japanese Society of Anti-Aging Medicine
15:25 - 15:35	Practice of Longevity Medicine in Japan Prof. Yoko Masuda, Japanese Society of Stem Cell Supernatant for Clinic
15:35 - 15:45	The Art and Science of Super Longevity: Top Tips for Bioentrepreneurs to Extend Lifespan and Health span to 120 Years Old while Enhancing Productivity and Peak Performance Dr. Mark Tang, Good Health Capital
15:45 - 15:55	NAD+ Biosensors in Aging Intervention Dr. Juliane Hitzel, CelFull
16:00 - 17:30	Panel Discussion: Longevity Investment Panelists: Dr. Hank Wuh, Longevity X Mr. Phil Newman, Longevity Technology Mr. Chew Thian, Polar Ventures Mr. Sergey Jakimov, LongeVC

*No biography or information was provided before September 11, 2023.

Sponsored by HK Longevity Medical Center

Partner with healthcare industry leaders?

As an integrated solutions provider?

To improve the quality of care across Asia?

Beijing

Shanghai

Macau Hong Kong

Philippines

Thailand

Malaysia / Brunei

Singapore

Indonesia

Our Expertise. Your leading healthcare partner in Asia

Auriga is an Asian-based integrated market services provider specialising in healthcare. We aim to connect the world's leading healthcare and life sciences companies to care providers and patients across Asia with a comprehensive range of responsible and effective market management solutions.

For over 50 years, we've helped our partners bring essential pharmaceutical and life science offerings to Asia with

ethical integrity, partnership and transparency. Offering both commercial, logistics and state of the art cold chain solutions, Auriga has operations in Hong Kong, Macau, mainland China, Singapore, Thailand, Indonesia, Brunei, Malaysia, Vietnam, and the Philippines. In alignment with our mission to enrich lives with quality care, we distribute more than 500 brands at over 10,000 points of sale.



Christine Yuan Huang 黄园

**Founder and Managing Director
HK Longevity Medical Center**

As a serial MedTech / biotech entrepreneur with a medical background, Dr. Christine Yuan Huang has devoted herself to bringing cutting-edge technology from the laboratory to clinical use and further commercialization, to help more people facing life-threatening illnesses.

Dr. Christine Huang Yuan was selected as one of Forbes China 2020 "30s Under 30 (Healthcare and Science)". Dr. Huang has vast experience in the biotechnology field and shares her professional insights as a biomedicine investment consultant for China Internet Investment Finance Holding Limited (stock code: 0810. HK). She is also a Fellow of The Royal Society of Medicine(UK). She is also a member of the Advisory Board of Wing Wah Charity Foundation Hong Kong.

In May 2021, Christine, together with other international experts, developed and recorded the "Introduction to Longevity Medicine for Physicians course in Chinese", which has a concise three-hour curriculum designed to familiarize busy medical professionals with the latest advances in aging research (focusing on biomarkers of aging and longevity).



Amir Lati 藍天銘

**Consul General of Israel
Consulate General of Israel**

Mr. Amir Lati has been Consul General of the State of Israel in Hong Kong SAR and Macao SAR since September 2021. A graduate of B. A. in Economics and East Asian Studies at the Hebrew University, Jerusalem, Mr. Lati pursued his interest in Chinese Studies at Beijing University under a Chinese Government Scholarship. His further studies included MA in Democratic studies at the Open University of Israel as well as an MBA in Finance and Organizational Behavior at Tel Aviv University. Since joining Israel's Ministry of Foreign Affairs in 1999, Mr. Lati served at the Embassy of Israel in Abuja, Nigeria (2001) and Canberra, Australia (2003); at the Ministry of Foreign Affairs headquarters in Jerusalem (MFA) as Deputy Director of West and South Africa, African Division (2005-2006); Deputy Consul General of Israel in Shanghai (2006-2010) and Consul General in Chengdu (2014-2018). From 2019 till his arrival in Hong Kong, Mr. Lati was the Director, the North East Asia department, Asia and Pacific division in Israel's MFA. He speaks Hebrew, English, Proficient Chinese and basic Korean.



Alexey Moskalev

Director

Institute of biogerontology of Nizhny Novgorod University

Alexey Moskalev is a Corresponding Member of the Russian Academy of Sciences, Doctor of Biology and the Head of the Laboratory of Geroprotective and Radioprotective Technologies in the Institute of Biology at the Federal Research Center Komi Scientific Centre of the Russian Academy of Sciences.

Alexey is the author of more than 200 publications on the genetics of ageing, longevity and radiation genetics. He focuses on the effects of low-dose ionising radiation on lifespan and ageing of *Drosophila* strains with defects in apoptosis, DNA repair and defence genes. He also studies ageing, longevity and stress resistance mechanisms in animals. He also contributed to creating a database of biomarkers of ageing called the Digital Ageing Atlas and databases of anti-ageing drugs Geroprotectors.org and DrugAge.

He is a member of the editorial boards of Ageing Research Reviews, Aging, Biogerontology, Frontiers in Genetics of Aging, Aging and Disease, Gerontology and Advances in Gerontology. He established the international symposium series "Genetics of Ageing and Longevity," "Biomedical Innovation For Healthy Longevity," "Interventions to Extend Healthspan and Lifespan," and "Longevity Interventions 2020".

Alex is the Head of the Komi branch of the Vavilov Society of Genetics and Breeders, a Member of the Central Council of the Society, and Vice President of the Gerontological Society of the Russian Academy of Sciences and the Head of the Department of Ecology of the Syktyvkar State University.



Xin Wang 王鑫

Associate Professor

Department of Surgery, The Chinese University of Hong Kong

Prof. Xin Wang obtained his PhD in 2014 from the University of Cambridge Department of Oncology and Cancer Research UK Cambridge Institute. From 2013 to 2015, he did his postdoctoral research at the Department of Biomedical Informatics, Harvard Medical School. He is currently an Associate Professor at the Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong. He also serves as a consultant for Shanghai Artificial Intelligence Laboratory, and an academic committee member of Guangdong Key Laboratory of Human Disease Genomics. Prof. Wang's group has been focusing on mechanistic and translational research in major human diseases through large-scale data mining using novel methodologies integrating bioinformatics, systems biology, machine learning, and artificial intelligence. Prof. Wang published > 90 peer-reviewed papers in journals such as Nature Medicine, Gastroenterology, Hepatology, Molecular Cancer, and Annals of Surgery. His research is currently funded by Research Grants Council of Hong Kong, Shenzhen City and Guangdong Province.



***Zhongjun Zhou* 周中軍**

Professor

School of Biomedical Sciences, The University of Hong Kong

Zhongjun Zhou is currently a professor at the department of Biochemistry, The University of Hong Kong. He graduated from Xiamen University with a BSc in Biochemistry. He obtained Master of Science in Biochemistry and PhD in Pathophysiology from Peking Union Medical College. He also obtained a PhD degree in Medical Biochemistry from Karolinska Institute, Sweden. After postdoctoral training in Karolinska Institute, he joined the department as a Research Assistant Professor in 2002 and became Associate Professor in 2005. He has published more than 40 original papers, reviews and book chapter. He is the co-founding Chair of Asian Association of Aging Research.



***Dajun Chai* 柴大军**

Vice President

First Clinical College of Fujian Medical University

Chai Dajun, born in 1975, doctor of medicine, chief physician, professor, doctoral supervisor, vice president of the First Clinical College of Fujian Medical University, visiting scholar of the Berlin Heart Center in Germany, expert member of the American College of Cardiology (FACC), Fujian Provincial Health System academic technology leader, technical director of the Chest Pain Center (National Demonstration Center) of the First Affiliated Hospital of Fujian Medical University, director of the Atrial Fibrillation Center; communication review expert of the National Natural Science Foundation of China, coronary interventional diagnosis and treatment training instructor of the National Health Commission, "Chinese Heart Editorial board member of "Journal of Vascular Diseases" and "Chinese Journal of Hypertension"; national youth committee member of the Cardiovascular Disease Branch of the Chinese Medical Association, deputy director of the Fujian Cardiovascular Branch of the Chinese Medical Doctor Association, and standing member of the Fujian Cardiovascular Branch of the Chinese Medical Association. Executive Vice Chairman of the Youth Committee of the Fujian Cardiovascular Branch of the Chinese Medical Association, Standing Member of the Fujian Cardiovascular Branch of the Society of Integrated Traditional Chinese and Western Medicine, Executive Deputy Chairman of the Youth Committee of the Fujian Cardiovascular Branch of the Society of Integrated Traditional Chinese and Western Medicine, Cardiac Rehabilitation Branch of the Society of Integrated Traditional Chinese and Western Medicine Standing committee member. Specializes in interventional therapy of complex high-risk coronary artery disease and treatment of critically ill patients.



Jaron Rabinovici

**Associate Professor Deputy Chairman, Dpt. Obstet&Gynecol
Sheba Medical Center**

Prof. Rabinovici is an experienced MD Professor in Obstetrics Gynecology and Infertility with a demonstrated history of Clinical Care as well as work in the higher education industry. Prof. Rabinovici is a highly-trained specialist, who provides medical treatment for women and couples with infertility, and performs pregnancy (including at-risk pregnancies) surveillance. Prof. Rabinovici specializes in diagnoses and treatment of fertility problems in women and men. He has extensive experience in IVF (IVF), egg donation, ovulation, insemination, uterine imaging, and recurrent miscarriage treatment. He is an expert in non-invasive conservative treatment of uterine fibroids. He is the head of the Department and Vice-Chairman of the Division of Obstetrics and Gynecology at the Chaim Sheba Medical Center, Israel. He is also a professor at Sackler School of Medicine, Tel Aviv University, Israel.

Prof. Rabinovici authored more than eighty original scientific papers in leading Medical Journals. He has been invited to many lectures around the world. Involved with Biotech and Biomed Companies as Counselor, Board member and Investor.



Yang Zhang 张杨

**CEO
Westlake Medical Sci. Ltd**

Arthur Yang Zhang, PhD MBA: Dr. Zhang is a MedTech entrepreneur and the founder of Westlake Medical Sci. Ltd. The series B startup focuses on MEMS technology applications in medical treatments. Dr. Zhang invented world's first μ RFthera system for Overactive Bladder (OAB) that has been adopted by over 15 leading public hospitals. Over 450 severe OAB patients received this procedure with over 75% of efficacy in reducing episodes to normal situations. The microRF technology also has profound impact in antiaging purposes. Dr. Zhang is the author of over 20 articles on international journals, and the inventor of over 40 international patents on micro devices. Prior to his entrepreneurial effort, Arthur served as Partner of Plug and Play Tech Center, technical director of Calit2 Irvine as well as Postdoc Researcher at the Integrated Nanosystems Research Facility. Dr. Zhang's Ph.D. work at UC Irvine and UCLA Large Plasma Device was supported by a Regents' Fellowship and a Department of Energy grant. Arthur also received an MBA from UCLA Anderson School of Management, with a concentration on entrepreneurship.



Zhenglong Gu 顾正龙

Director

Mitochondrial Genetics and Health Research Center

Zhenglong Gu, Ph. D., obtained his Ph.D. from the University of Chicago, USA, in 2003 and Bachelor from Beijing University, China, in 1998. He did his postdoc training at Stanford University before he setup his own lab at Cornell University in 2006. He obtained his tenure and full professorship in 2012 and 2018, respectively. Currently his major goal in research is to understand the role of mitochondrial DNA mutation in diseases. He started at Cornell investigating the evolution of aerobic fermentation in yeasts and became interested in mitochondrial genetics purely because he was fascinated by the metabolic similarity between yeast evolution and tumorigenesis (the emergence of Warburg Effect). Recently, his lab has been working on several issues that are critical to demonstrate the important role of mitochondrial DNA (mtDNA) mutations in diseases, including inventing various sequencing methods to reveal mtDNA mutation pattern during aging and in age-related diseases, developing tools for mtDNA genetic manipulation so mechanic studies can be conducted directly upon mtDNA mutations, and investigating mechanisms underlying mutated mtDNA purging.



Hidekazu Yamada 山田秀和

President

The Japanese Society of Anti-Aging Medicine

A leading expert in anti-aging research, serving as the president of the Japanese Society of Anti-Aging Medicine. Currently, he is focusing not only on researching "appearance", but also investigating the mechanism of epigenetics, which controls the function of genes. In 2025, he will also serve as a member of the Osaka Pavilion Promotion Committee and Director of Healthcare Advanced Preventive Medicine at the Osaka/Kansai Expo.



Yoko Masuda 増田曜子

Japanese Society of Stem Cell Supernatant for Clinical Medicine

Yoko Masuda graduated from Hamamatsu University School of Medicine in 2012, completed a research fellowship at the Riordan Clinic in the United States in 2020, and has been working as a functional medicine and anti-aging practitioner since returning to Japan. She has accumulated experience in various areas of regenerative medicine including stem cell therapy, hormone therapy, peptide therapy, and nutritional infusion therapy. Currently she serves on the Clinical society of Menstrual Blood Mesenchymal Stem Cells and Japanese Society of Stem Cell Culture Supernatant for Clinical Medicine.



Mark Tang

Managing Director
Good Health Capital (New York)

Dr. Mark Tang has followed and invested in the life sciences biotech industry for over a decade. He has been a senior biotechnology analyst, venture capitalist, wealth management advisor, and Publisher of Bio/Medical Technology Stock Newsletter. Dr Tang has also worked for several investment banks including UBS PaineWebber and Morgan Stanley Dean Witter in New York, and currently heads a healthcare life sciences venture investment firm in the United States.



Juliane Hitzel

CEO
CELLFULL (USA) Inc.

Dr. Juliane Hitzel holds a Ph.D. in Biochemistry from the Goethe University Frankfurt and is the CEO of CELFULL (USA). She has published research papers in top international journals. CELFULL is a biotechnology company focusing on AI multi-target aging intervention. CELFULL aims to conquer mitochondrial anti-aging scientific and technological topics with its Institute of Mitochondrial Medicine and its various anti-aging research platforms. The mitochondrial research projects of CELFULL aim to unlock the human anti-aging mystery, to help promote the scientific developments in this field, and to provide personalized solutions for aging intervention.



Thian Chew

Adjunct Associate Professor
The Hong Kong University of Science and Technology

Professor Chew holds the position of Executive Chairman & Chief Executive Officer for Invion Ltd. and Chairman of Chronic Airway Therapeutics. He is also Managing Partner at Polar Ventures Ltd. He received an MBA from The Wharton School of the University of Pennsylvania, a graduate degree from Joseph H Lauder Institute of Management & International, and an undergraduate degree from Monash University.



Phil Newman

Editor-in-Chief
Longevity Technology

Phil Newman is Founder and CEO of www.Longevity.Technology the leading media and investment platform targeting the longevity megatrend.

In his career he has held multiple c-level management positions; applying his marketing and business development expertise into: longevity, IoT, bionics, medical devices, biopharma, 3D manufacturing, smartgrid and sustainability.

In 2018 he saw an opportunity in the emerging longevity field to create a media platform that addressed science, business and investment activity. Launched in 2019, www.longevity.technology rapidly became the leading news service with unparalleled domain authority enabling the company to expand its reach into investment, education and commerce.



Hank Wuh

Co-Founder of Longevity X
Board Trustee
University of Hawaii Foundation

Hank Wuh, MD, MPH is an orthopedic surgeon, inventor, and serial entrepreneur. He has led the development of over twenty biomedical and consumer healthcare products from inception to market. Dr. Wuh nurtures entrepreneurs to transform ingenious, "unthinkable" ideas into disruptive innovations and high growth companies with global impact that makes the world a better place.

Dr. Wuh received his BA from Johns Hopkins, MPH from Harvard, MD from the Johns Hopkins School of Medicine, and orthopedic surgery residency at Stanford. He speaks fluent Mandarin and is an avid musician and traveler. An accomplished public speaker on the transformative power of ideas, Dr. Wuh was selected 100 of the most intriguing entrepreneurs in the world in 2016 by Goldman Sachs, and has served as a keynote speaker and Technology Pioneer at the World Economic Forum in Davos.



Sergey Jakimov

Managing Partner
LongeVC

Sergey is a serial entrepreneur, having co-founded 3 deep-tech ventures (including Koatum and Vortex Oil Engineering) and raised more than \$50 million in venture funding. He has advised several other startups in the therapeutics space on fundraising, IP protection, and clinical trial strategies. He is also a Visiting Lecturer to several universities on venture capital and intellectual property rights and co-authored a master's program in Technology Law for the Riga Graduate School of Law.

Since 2018, he has led medical tech startup Longgenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. Sergey holds a BSc in International Affairs from Rīga Stradiņš University and two MSc in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named as a Forbes Latvia 30 Under 30 in technology and healthcare in 2020.



BOOTH NO. 3E-A23

BIOHK2023 SILVER SPONSOR

招商永隆銀行

服務香港90年



「一點通」



招商永隆銀行網站

查詢熱線：230 95555 網址：www.cmbwinglungbank.com 關注官方微信：cmbwinglungbank

服務及優惠受有關條款及細則約束

招商永隆銀行有限公司


招商永隆銀行
 CMB WING LUNG BANK

因您而變 成就無限

INNOVATION GALLERIA | 創新廊

Thrive in the Biotech Market

Wednesday, September 13 | 12:10 PM - 17:30 PM (GMT+8)

Thrive in the Biotech Market: Investing in Life Science in HK (Sponsored by SCMP)	
12:10 - 13:00	<p>Chair: Ms. Elizabeth Cheung, South China Morning Post (SCMP)</p> <p>Panelists: Sir. Jonathon Symonds, GSK (See biography on p.28) Mr. Conrad Tsang, Hong Kong Venture Capital and Private Equity Association (HKVCA) Mr. Aaron Finley, Deloitte Mr. Frank Yang, Bank of China Group Insurance (BOCG)</p>
13:00 - 14:00	Lunch Break
Policy Foundations for a Life Science Ecosystem in Hong Kong and GBA	
	Chair: Dr. Joe Fang, One Country Two System Research Institute
14:00 - 14:15	<p>Policy Updates: What has been done and still needs to be done? Mr. Arthur Tsang, Hong Kong Biotechnology Organization (HKBIO)</p>
14:15 - 14:30	Mr. Vincent Ma, Hong Kong-Shenzhen Innovation & Technology Park (HSTIP)
14:30 - 15:30	<p>Panel Discussion</p> <p>Moderator: Dr. Hon Yuen-shan Wong, Chief Executive's Policy Unit **</p> <p>Panelists: Prof. Yuk Lam Lo, HK Bio-Med Innotech Association (HKBMIA) Dr. Sabrina Chan, HKAPI Mr. Tao Song, Dongguan Biotech Industry Development* Mr. Raymond Yip, Nansha New Area Dr. Yu Guoliang, Bay Helix Group</p>
HKEX Special Program	
15:30 - 17:00	<p>Keynote: Dr. Shusong Ba, HKEX Moderator: Ms. Winnie Han, HKEX</p> <p>Panelists: Ms. Lynne Wu, LongevityX Ms. Mengyang Wang, China International Capital Corporation (CICC) Mr. Andrew Ng, VMS Group Dr. Chang Liu, ASK Health</p>
Hainan Live science Development	
17:00 - 17:30	Mr. Raymond Yip, Hainan Provincial Bureau (See biography on p.47)

*No biography or information was provided before September 11, 2023.

** Replaced by Ms. Jacqueline Hui, Chief Executive's Policy Unit

Sponsored by



South China Morning Post



上海生物医药基金

BIOHK2023 GOLD SPONSOR

上海生物医药基金是经上海市政府批准，由上实集团发起设立，目标规模人民币500亿元的创新投资平台，基金坚持“立足沪港、联动长三角、面向全球”，并将在香港发起专注于香港及大湾区生物科技产业的早期创新基金，助推生物科技产业成为香港经济增长的新引擎。



HONG KONG-SHENZHEN
INNOVATION AND
TECHNOLOGY PARK
港深創新及科技園

A PLACE WHERE CROSS BORDER COLLABORATIVE INNOVATION IS REDEFINED

Boasting its unprecedented strategic location in Lok Ma Chau Loop, Hong Kong-Shenzhen Innovation and Technology Park (HSITP) is the one-of-a-kind I&T park conjointly tied to Shenzhen. Harnessing the expertise and talents from both cities, HSITP takes advantage of the unique synergistic development of "One Zone, Two Parks" equipped with supportive government policies, state-of-the-art infrastructure, and pioneering research facilities.

HSITP is the destination offering infinite opportunities for business growth & success.

Join us NOW !



The information contained herein is for information only and does not constitute any warranty or guarantee. All information contained herein is subject to the approval of the relevant Government authorities. All data stated herein are subject to final survey. Hong Kong-Shenzhen Innovation and Technology Park Limited reserves the right to alter the specification, design and layout of the development as referred to herein without prior notice.

 www.hsitp.org

 leasing@hsitp.org

 2629-6822

For more information,
please visit HSITP website





Elizabeth Cheung

Correspondent
South China Morning Post

Elizabeth is currently a correspondent covering Hong Kong healthcare news at the South China Morning Post. A seasoned journalist with over 10 years of experience in newspaper and television, Ms. Cheung has been writing about healthcare news, from policies to scientific research, since 2014. During the Covid-19 pandemic, she was one of the journalists leading the Covid-19 coverage at the Post, breaking news of the latest government measures and writing long-form analyses. Elizabeth is a graduate of the Chinese University of Hong Kong's School of Journalism and Communication, and has a Master's in development studies from the London School of Economics and Political Science.



Conrad Tsang

Founder and Chairman
Strategic Year Holdings

Mr Tsang has been in the private equity and venture capital industry for over 20 years. Mr Tsang's industry experience includes: environmental technologies, healthcare, education and professional services, TMT, financial services, retail and consumer products/services, advanced manufacturing, automotive, ecommerce/logistics, energy and alternative energy, real estate, natural resources/mining etc. The companies he has been involved with include Noah Education Holdings Limited, Minsheng Education Group (1569.HK), Galloping Horse Media Group Limited, Kangda International Environmental Protection Holding Limited (6136.HK), Pansoft Group Limited, Ambow Education, Hidili Industry International Development Limited (1393.HK), Launch Tech Co Ltd (2488.HK), Great Wall Auto (2333.HK, 601633.CN), Nord Anglia Education, China Mini-Storage, Teky Holdings, Carsome, Cakap, Sayurbox, Halodoc, Haus!, Buyandship, AMPD Energy. Prior to founding Strategic Year Holdings Limited, he spent 13 years at Baring Private Equity Asia ("Baring Asia"), where he was Managing Director. He was the Founding Partner of Baring Asia's Beijing office. Prior to that, he was with Merrill Lynch Asia Pacific doing equity research, focusing on media and retail sectors. Since 2016, he became Founder and Chairman of Strategic Year Holdings Limited.

Mr Tsang is currently President and Director of the Hong Kong Venture Capital and Private Equity Association (HKVCA). Previously, he was Hong Kong Venture Capital and Private Equity Association's Chairman of the Board (2013-2015). He was voted one of "The 50 Best Venture Capitalists in China" by Forbes China Magazine (2008, 2009). Mr Tsang is a Member of Oxford Investment Opportunity Network (OION), Member of Imperial College Investor Network, and Member of Hong Kong Cyberport Investor Network (CIN). He was also invited to serve as Asia Senior Advisor of Apollo Education Group/Apollo Global, a global higher-education company.

Mr Tsang obtained a Master's Degree in Management Studies at University of Oxford, United Kingdom; and a Bachelor's Degree in Electrical and Electronic Engineering (First Class Honors) at Imperial College of Science and Technology, London, United Kingdom. He also completed an executive program on Private Equity and Venture Capital at Harvard Business School, US.



Aaron Finley

Director
Deloitte China

Aaron is a Director in Deloitte's South China Business Development team based in the Guangzhou office. With a diverse network and broad experience in international business, Aaron helps his clients in developing best practices for international business, accounting, taxation, as well as seek investment and development opportunities. Aaron is also supporting the Deloitte's Greater Bay Area (GBA) Initiative and is leading the development of a hospital collaboration platform so that hospitals around the GBA can better coordinate best practices. Aaron is a licensed CPA in California and has obtained a Masters in Business Taxation from the University of Southern California. Aaron is a Part-Time Lecturer on International Taxation and PhD Student at the Macau University of Science & Technology. Aaron is a member of the Board of Governors of AmCham South China and is a member of the board of the European Chamber of Commerce South China Chapter. He is an Advisor to the Guangdong Investment Promotion Association, an expert of the Guangzhou Capital Market Pool, and a contributor to the Guangzhou City Business Environment Study.



Frank Yang 楊鋒

Founding Partner and CEO
Blue Ocean Capital Group

Mr. Yang is the founding partner and CEO of Blue Ocean Capital Group ("BOCG"). He has over 20 years of experience in venture capital and private equity investment with US\$ 1 billion proven track records. He led a symbolic US\$ 250 million cross-border healthcare M&A which won him distinguished awards including "the Top 10 Private Equity Investments in China" and "the Best M&A Financing Award" of the year.

Before Mr. Yang founded BOCG, he served as the managing director of China Construction Bank International ("CCBI"), in charge of healthcare investment with dual currency funds. Prior to that, as head and managing director of PPF Group, a leading financial institution in Central and Eastern Europe, Mr. Yang was responsible for strategic investment in Asia and contributed to the establishment of HomeCredit China. Mr. Yang's finance career started in 2001 when he served as a founding member and vice president of the venture capital investment arm of Xiangcai Securities, where he succeeded in raising fund and achieving a 6X return on investment.

Mr. Yang Feng is committed to the transformation of scientific research achievements of biotechnology with a focus on promoting transformation of R&D and cooperation in Asia and globally. Mr. Yang has been promoting corporate governance in the pharmaceutical industry in both practices and theoretical level, and had published numerous research papers in both Chinese and English and made speeches. With Mr. Yang's initial, BOCG joined the Responsible Investment Organization supported by the United Nations ("UN PRI"), among the first batch of signing investment institutions in China to promote ESG and sustainable development.

Recent healthcare investments led by Mr. Yang including Hightide Therapeutics, Ribo Life Science, Boan Biotech, CureGenetics, Koko Life Science, Signet Therapeutics, InterHill MED and Recovery Plus etc. Mr. Yang sits on the board of HK Bio-Med Innovation Association ("HKBMIA"), Chinese Financial Association in Hong Kong ("HCFA"), PRC Committee of Hong Kong Venture Capital and Private Equity Association ("HKVCA"), and the advisory board of HKUST MBA Business School.

Mr. Yang is a PhD candidate of CUHK and holds the MBA degree from HKUST with exchange experience in Columbia University in New York and HHL Business School in Leipzig.



Joe Fang 方舟

Chief Research Officer

One Country Two Systems Research Institute

Dr. Joe Z. Fang is the Chief Research Officer of the One Country Two Systems Research Institute. He has rich research experiences in industrial policy, international relations, urban planning, and regional economic development of Hong Kong and mainland China. Dr. Fang actively participates in various public services. He is the Convener of the Trade Facilitation Committee of the HKSAR Consultative Committee on Economic and Trade Co-operation between Hong Kong and the Mainland. He is also a member of Lantau Development Advisory Committee, Shenzhen Internationalization Advisory Committee, Shenzhen People's Consultative Committee, and Advisory Committee of Qianhai Authority.



Stephen Wong 黄元山

Head

Chief Executive's Policy Units

Dr. Stephen Wong received his Bachelor of Arts (Phi Beta Kappa) in Economics from the University of Chicago and took his Master of Arts in East Asian Studies (Whitney and Betty MacMillan Center for International and Area Studies) from Yale University and earned his Doctorate degree in Public Administration (DPA) from The University of Hong Kong.

Dr. Stephen Wong began his career as an investment banker; he was in managerial roles with several global financial institutions, including as Executive Director at UBS (London) and Managing Director at RBS. He joined Our Hong Kong Foundation (OHKF) as Senior Consultant in May 2015 and was appointed Deputy Executive Director cum Head of Public Policy in November the same year. He was Senior Vice President & Executive Director of Public Policy Institute. He was appointed as the Head of Chief Executive's Policy Units on 27 December.

Mr. Wong's public service also includes various advisory roles appointed by the Hong Kong Government, including Board Member of the Financial Services Development Council, Board Member of the Urban Renewal Authority, Member of the Investment Committee of the Beat Drugs Fund, Member of Investment Sub-Committee of the Housing Authority, Member of Feasibility Study Working Group of "Special Needs Public Trust", Co-opted Member of Social Innovation & Entrepreneurship Development Fund Task Force of Commission on Poverty, Non-official Member of the Assessment Panel of the "Innovation and Technology Fund for Application in Elderly and Rehabilitation Care" of the Social Welfare Department, and ex-Member of Task Force on Land Supply, etc.

Mr. Wong is also active in community service. He is Chairman of the Clean Air Network, Vice Chairman of the Admissions, Budgets & Allocations Committee and Investment Sub-Committee Member of the Community Chest, and Executive Committee Member & Chairman of the Advisory Committee of Social Enterprise and Innovation Platform of the Hong Kong Council of Social Service. Mr. Wong is also an Adjunct Associate Professor at the Hong Kong University SPACE for the Institute for China Business.



Vincent Ma

CEO

Hong Kong-Shenzhen Innovation and Technology Park Limited

Mr. Vincent Ma Wai-shin has over 30 years of extensive experience in the Information and Communication Technology (ICT) industry. He has led and managed sizable technology groups and drove the continuous and comprehensive growth of the groups' business. From 2006 to 2019, Mr. Ma served as the President and then the Chief Executive Officer of WTT Hong Kong Limited. Before joining HSITPL, Mr. Ma served as the Chief Digital Officer of Sun Hung Kai Properties.

Mr. Ma holds a Bachelor's Degree in Computing Studies from the Hong Kong Polytechnic University.



Arthur Tsang

Researcher

Our Hong Kong foundation

Arthur oversees a wide range of research topics in tech innovation, and has recently co-authored research reports on biotechnology and gerontechnology. His research projects were commissioned by the UNESCAP, PRC Ministry of Science and Technology, CPC Shenzhen Municipal Committee, Hong Kong SAR Government, Alibaba Entrepreneurs Fund, and he has collaborated with the UN Population Fund China, China National Committee on Ageing, China Center for International Economic Exchanges, China Development Institute (Shenzhen), Hong Kong Science and Technology Parks Corporation, and Hong Kong Council of Social Service, etc.

He has presented at Revive Tech Asia and BIOHK and served as a discussant at the GBA Talent Forum of the Hong Kong Science and Technology Parks Corporation and the Shenzhen-Hong Kong Expert Forum by Baolong District, Shenzhen. He was also invited by Legislative Councillors, the Hong Kong Police Force and Hong Kong CPPCC Youth Association to deliver sharing. His articles frequently appear on major newspapers, with dedicated pages on Ta Kung Pao, HK Economic Times, South China Morning Post, and China Daily.

He is also a research committee member of the Hong Kong PropTech Association and serves in district positions. He holds a bachelor's degree from the University of Hong Kong and a master's degree from the London School of Economics, and has represented OHKF to complete courses with the National Academy of Governance.



Sabrina Chan

Senior Executive Director
Hong Kong Association of Pharmaceutical Industries

Sabrina is the Senior Executive Director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI); member of the High Level Steering Committee on Antimicrobial Resistance; member of Business Facilitation Advisory Committee; Chair of Advisory Board of the HKU Bachelor of Pharmacy Program, Adjunct Assistant Professor of CUHK School of Pharmacy; and member of APEC Biopharmaceutical Working Group on Business Ethics.

Prior to joining the pharmaceutical industry, she was with the External Affairs Department of i-CABLE Communications Ltd. and was responsible for government relations, regulatory issues, corporate affairs, and the promotion of the company's core products and services. She co-founded the Telecommunications Research Project under Centre of Asia Studies (HKU), and was a journalist at various print and electronic media outlets. Sabrina studied Communications in Hong Kong when she began her tertiary education. She holds a graduate degree in International Studies from the University of Sheffield (UK), as well as law degrees from the CUHK and University of Tsinghua (China).



Yuk Lam Lo 盧毓琳

Chairman
Food and Environmental Hygiene, Food and Health Bureau, Government Secretariat HKSAR

Yuk Lam Lo is a highly accomplished individual with a multitude of roles and affiliations. He serves as the Chairman of Food and Environmental Hygiene within the Food and Health Bureau of the Hong Kong Special Administrative Region (HKSAR) Government Secretariat. Additionally, he holds the position of President at the HK Bio-Med Innotech Association, where he spearheads initiatives to promote innovation in the biotechnology and medical fields in Hong Kong.

Yuk Lam Lo's expertise extends to the corporate sector, as he serves as an Independent Director for several prominent companies. He holds this role at Sinovac Biotech Ltd., a leading biopharmaceutical company listed on the NASDAQ stock exchange. He also serves as an Independent Director for CSPC Pharmaceutical Group Limited and Luye Pharma Group Limited, both of which are renowned pharmaceutical companies listed on the Hong Kong Stock Exchange.

Furthermore, Yuk Lam Lo takes on the responsibility of Chairman at GT Healthcare Capital Partners, contributing his expertise to the company's healthcare investment and capital management endeavors. He is recognized as the Honorary Chairman of the Hong Kong Biotechnology Organization, highlighting his influential contributions to the biotechnology sector in Hong Kong.

In recognition of his outstanding achievements, Yuk Lam Lo has been appointed as an Honorary Fellow by the Hong Kong University of Science and Technology. Additionally, he holds a Council Member position in the Chinese People's Political Consultative Conference, representing Jilin Province.

Yuk Lam Lo's diverse roles and accomplishments across government, academia, and the corporate world demonstrate his exceptional leadership and expertise in the fields of public health, biotechnology, and pharmaceuticals.



Raymond Yip 叶泽恩

Chief Liaison Officer, Guangzhou Nansha Service Centre in Hong Kong
Chief Representative, Hainan International Economic Development
Bureau HK Office

Since July 2022, Mr. Yip serves as the Chief Representative and Chief Liaison Officer for Hainan International Economic Development Bureau and Nansha New Area respectively in Hong Kong. He is also EVC of Dashun Foundation and VC of Belt and Road Global Development Alliance since 2019. He retired from the Hong Kong Trade Development Council as Deputy Executive Director, spearheading promotions for the Belt and Road and Greater Bay Area Initiatives, among other marketing duties, in the same year. He was Part-time Lecturer on BRI and GBA opportunities in the CUHK MBA programme during 2019/20. He is a Director of Hong Kong Japan Society since 2019.

Graduating with BBA degree from the Chinese University of HK, he holds a Post Graduate Diploma in E-Business from Michigan State University. He attended the Columbia Senior Executive Program in 2003. He is a Fellow of the Chartered Institute of Marketing and the Institute of Directors of the UK.



Guoliang Yu 余国良

Chairman
BayHelix

Dr. Guo-Liang Yu is the Chairman and CEO of Apollomics Inc., an innovative therapeutics company devoted to curing cancer by combining immunology and other cancer fighting methods. Before Apollomics, Dr. Yu was the Executive Chairman of Crown Bioscience Inc., a publically-listed personalized oncology platform company with ~600 employees globally. Crown Bioscience was recently acquired by JSR for \$400 million. He co-founded Epitomics Inc., an antibody biotechnology company, and served as Chairman and CEO for 10 years prior to its acquisition by Abcam for \$170 million. During his tenure at Epitomics, spun-off Apexigen Inc., an immune-oncology therapeutics company. He was also a venture partner at OrbiMed Venture LLC during 2013-2019.

Dr. Yu's success is driven by his scientific curiosity and passion for translating scientific discovery to real products. After graduating from Fudan University in Shanghai, China, he came to the United States in 1984 to pursue advanced studies. He obtained his Ph.D. from UC Berkeley, where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburn's lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery.

Dr. Yu later joined Dr. Frederick Ausubel's lab at Harvard University to pursue the question of how plants defend themselves against pathogens without an immune system, and identified the plant disease resistance gene. In 1993, when genomics was still in its infancy, Dr. Yu joined Human Genome Sciences Inc. as one of the first few senior scientists, identifying human gene targets for drug discovery. Among several important drug targets he studied was BLys, the first successfully genomic target for the development of a lupus antibody drug Benlysta, which was approved by FDA in 2010.

In 1998, Dr. Yu was attracted to identifying plant genes with economic value in agriculture and in bio-energy. He was Senior Vice President of R&D at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors, and ultimately identified several valuable traits such as enhanced crop yield, disease resistance, and drought tolerance. Dr. Yu has co-authored 44 peer-reviewed scientific articles that have been referenced by the scientific community over 10,000 times. He is a co-inventor of more than 400 patents.

Dr. Yu currently the Chairman of Bayhelix, a leadership organization in biotech industry. Dr. Yu was the Founding President of the Chinese Biopharmaceutical Association (CBA) and serves on the boards of several professional organizations in the United States and China, including Chinese-American Bio/Pharmaceutical Society (CABS), National Foundation of Cancer Research, Ray Wu Memorial Foundation, and University of Pacific.

科研權威實證

BOOTH NO. 3D-B10

【NMN+靈芝】比單一配方 NMN 更抗衰老更優勝

常說「生老病死」是人生必經階段，但人為甚麼會老呢？

最簡單的解釋是人體的細胞及 DNA 隨著「年齡增長」、「氧化」、「受損」而衰老，繼而影響身體各個機能。是否沒有方法可延緩細胞衰老的速度？

NMN 是甚麼？

NMN 是 β -煙酰胺單核苷酸，與細胞輔酶 NAD⁺（諾加因子）關係密切。NAD⁺ 主宰身體多種化學作用，包括新陳代謝、DNA 修復及能量製造等等，但隨著年齡增長 NAD⁺ 水平不斷下降，這時候便需要攝取 NMN，讓 NMN 轉化成 NAD⁺，藉此增加體內 NAD⁺ 水平以達致抗衰老效果。




報告關鍵：【NMN+靈芝】88%亞洲人細胞因抗氧化而變得年輕*

細胞衰老的一大元兇就是氧化，科學園生物科技團隊曾進行為期半年的首次針對亞洲人細胞及 DNA 研究，報告發現【NMN+靈芝】的配方組合產生人體細胞抗衰老協同效應，能使 88%亞洲人細胞因抗氧化而變得年輕，比單一 NMN 配方更為優勝

報告關鍵：【NMN+靈芝】80%亞洲人細胞內的 DNA 形成保護*

DNA 的損害是人體無法避免的事，無論是體內正常代謝、日常紫外線還是輻射等等，都會破壞 DNA、令 DNA 老化。



不少文獻顯示，NMN 有助修復 DNA，而科學園的科研亦說明，加入靈芝的 NMN 配方能有效地發揮協同作用，令高達 80%的細胞能避免受到氧化劑破壞，

繼而對細胞內的 DNA 形成保護，達致修復 DNA 的作用。



NMN 內修復、靈芝外屏障 抗衰老雙管齊下

抗衰老與「自由基」及「抗氧化」等關鍵詞息息相關，要有效消除令細胞變老的自由基，便需要具備優秀抗氧化功能的物質。當中，靈芝蘊含抗氧化物靈芝醣等等，有效啟動細胞抗氧屏障、消除有害自由基，令身體回復年輕。【NMN+靈芝】組合，這組合能達致內修復、外屏障的雙重抗衰老長壽作用。

單一配方 NMN 其修復細胞的速度未必能夠抵銷細胞損毀速度，而具備極高抗氧化能力的靈芝，則可以於細胞表面形成保護層，有助抵擋及反彈外來侵襲，當靈芝配合 NMN 就能大大降低細胞及 DNA 的受損速度，達致真正的抗老逆齡效果。



郭致因 (Gammy Kwok)

- 草姬國際有限公司創辦人
- 中文大學EMBA
- 加拿大卑斯大學護理學學士
- 加拿大自然療法醫師
- 報章雜誌健康及管理專欄作家
- 畫家及文字創作者

*草姬科學園生物科研團隊 2022 研究數據



Shusong Ba

**Managing Director, Chief China Economist
HKEX**

Professor Ba Shusong is Managing Director, Chief China Economist of Hong Kong Exchanges and Clearing Limited (HKEX), Chief Economist of the China Banking Association (CBA) and Executive Director of the HSBC Financial Research Institute at Peking University. He is also Vice President of the China Society of Macroeconomics, a member of Ministry of Commerce's Economic and Trade Policy Advisory Committee, a member of China Banking and Insurance Regulatory Commission's Expert Guidance Committee for the banking industry's implementation of the new Basel capital accord, a member of China Securities Regulatory Commission's M&A Specialists Committee, a member of China's "13th Five-Year Plan" National Development and Planning Specialists Committee, and Director-General of Peikang Chang Research Foundation of Development Economics.

Professor Ba is a fellow of experts who receive the State Council's special allowance. He was previously Deputy General Manager of the Bank of China Hangzhou Branch, Assistant General Manager of Bank of China (Hong Kong), Director-General of the Strategy and Development Committee of the Securities Association of China, and Deputy Director-General of the Financial Research Institute of the State Council's Development Research Centre. He was engaged in post-doctoral research in the China Center for Economic Research at Peking University and was a senior visiting scholar at Columbia Business School. He also served as the chief expert in the basic research field of "International Economic and Financial Structure" in Development Research Center of the State Council. Professor Ba was awarded by China's Social Science Assessment in 2017 as the Chinese scholar with the highest citation frequency in Chinese literature on economics from 2006 to 2015.

Professor Ba had participated in a large number of seminars and forums held by policy-makers in the financial fields as a financial specialist, and lectured to members of the Political Bureau of the CPC Central Committee in China as the main speaker. He had held management positions in a wide range of financial institutions including commercial banks, securities companies, public funds and trust companies. As an expert who is familiar with the actual practice of China's financial operations and policy-making process as well as well versed in financial theory research, he possesses rich practical experience and research achievements in the fields of the Basel capital accord and risk management, asset management (has published an annual report on China's asset management industry development in 11 consecutive years), banking development and bankers survey (has led the conduction and publication of the annual bankers survey reports in Chinese and English for 8 years), etc. His publications (in Chinese) include "Research on New Basel Capital Accord", "Basel II in Financial Crisis: Challenges and Improvements", "Study on Basel Capital Accord III", "Basel III and Financial Regulatory Reform", "Annual report of China Asset Management Industry Development". Professor Ba received the Global Youth Leader Award from the World Economic Forum in 2009.



Winnie Han

**Senior Vice President
HKEX**

Ms. Winnie Han is the Head of China Issuer Services and Senior Vice President of Global Issuer Services in HKEX. Her key focus is to lead the China team to promote HKEX as the top listing venue for Greater China companies. She has extensive coverage and works closely with potential issuers, investors, governments, associations and intermediaries. She is a familiar face on many New Economy, Advanced Technology or Healthcare Forums/Summits/Conferences promoting Hong Kong as the Go-To IPO destination.

Prior to her current role, Ms. Han had over 15 years of experiences in China A-share investment banking at UBS and Credit Suisse. Before joining HKEX, she was the Co-Head of ECM at Credit Suisse Founder Securities. She holds China A-share Sponsor Representatives Qualification and Certified Public Accountant Qualification of China (non-practicing).

Ms. Han received her Master's degree from Peking University and Bachelor's degree from Xiamen University.



Mengyang Yang 杨孟洋

Executive Director
CICC Capital

Ms. Mengyang Yang is an Executive Director and Head of Hong Kong PE Business of CICC Capital, the PE arm of China International Capital Corporation Limited ("CICC"). Ms. Yang initially joined CICC in 2015 working on investments in mid-cap PE funds in the US and Europe and co-investments. Upon re-joining CICC in 2022, she is responsible for all aspects of the business of CICC Capital in Hong Kong and leads CICC Capital's expansion into international markets.

Ms. Yang received her BA in finance and LLB from the University of International Business and Economics, and her LLM from the London School of Economics and Political Science.



Andrew Ng 伍兆威

Managing Director and Head of Healthcare
VMS Group

Andrew Ng is a Managing Director and Head of Healthcare of VMS Group and an Investment Partner of Panacea Venture. He has over 13 years of experience in the healthcare industry across Asia and the US. Andrew has established the healthcare practice of VMS Group in 2017 and led multiple growth-stage investments for VMS across the therapeutics, diagnostics, medical device and CRO/CDMO verticals. He has also served as an Investment Partner of Panacea Venture, a global healthcare venture capital firm, since 2021.

Prior to that, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.

Andrew has been on the board of multiple companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and CXO industries. These companies include New Horizon Health, Chime Biologics, Jade Biomedical, SyMap Medical, Yizun Biomedicine and Profusa. Andrew received an MBA from INSEAD, a M.Eng. degree and a BS degree in Operations Research & Engineering from Cornell University.



Liu Chang

CEO & Founder
ASK Health Asia

Dr. Chang LIU is the CEO and founder of ASK Health Asia. ASK Health Asia is a catalyst for health systems transformation in Asia. Through in-depth research, consultancy, platform creation, solution co-creation and resource connection, the company works closely with leading industry leaders to provide innovative solutions to jointly promote new tangible health policies and capture growth opportunities within a global emerging economy.

Prior to establishing ASK Health Asia, Dr. Liu was a Regional Director at ACCESS Health International, Inc., a global non-profit organization, overseeing the business development in both China and Singapore for over seven years. As the work developed and matured across both regions, Dr. Liu formally spun off the ACCESS Health China entity into a ASK Health Asia, to fully accelerate the company's work and impact across Asia.

TECHNOLOGY HALL | 科技廳

Bioethics and RNA Medicine

Wednesday, September 13 | 12:10 PM - 17:30 PM (GMT+8)

Ethics In The Biotech Industry	
12:10 - 13:00	Moderator: Ms. Monin Ung, Mung Legal Panelists: Prof. Yi Rao, Capital Medical University (see biography on p.27) Dr. Dong Dong, The Chinese University of Hong Kong Ms. Yolanda Wang, Eagle IP*
13:00 - 14:00	Lunch Break
RNA Medicine: Therapeutics, Vaccine and Beyond (Sponsored by Sirnaomics)	
14:00 - 14:10	Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area Prof. Xiaochang Dai, Sirnaomics
14:10 - 14:30	Advancing Delivery Technology for Innovative RNAi Therapeutics, from Benchtops to Bedsides Dr. Patrick Lu Sirnaomics
14:30 - 14:50	Clinical Development for PNP-based and GalNAc-based RNAi Therapeutic Products Dr. Francois Lebel Sirnaomics
14:50 - 15:10	Unlocking the Future: Exploring mRNA's Boundless Potential in the Post-COVID Landscape Dr. Dong Shen RNA immune
15:10 - 15:30	Building Commercial Scale Manufacturing Facility for RNA Medicine Products, from Guangzhou to Hong Kong Dr. Edward Wang Sirnaomics
15:30 - 15:50	Coffee Break
15:50 - 16:30	Biopharma - Academic Partnerships Panel: Exploring the Future of RNA Investment & Collaborations Moderator: Xiao Chang Dai, PhD, Executive Director and Chief Strategy Officer, Sirnaomics Panelists: Min Wu, PhD Chief Business Officer at Therorna Da Liu, Managing Director, CR-CP Life Science Fund Christopher Kennedy, CEO, EDIRNA Nancy Man, PhD, MD, Chair Professor, Hong Kong University
16:30 - 16:45	Key considerations for development and commercialization of mRNA vaccine and therapeutics Yuling Li, PhD, President, Zhejiang Innoforce Pharmaceuticals Co., Ltd.
16:45 - 17:00	Focusing Oligonucleotide Product Manufacturing, Providing High-Quality Drug Product for RNA Medicine. Michael Zhang, MBA, Vice President, Guangzhou Ribo Biotechnology
17:00 - 17:20	Lessons Learned in Developing and Scaling Novel Platforms for RNA Medicine Products Richard Welch, PhD, Vice President, CMC, Sirnaomics
17:20 - 17:30	Patrick Lu, PhD Closing Remarks + Photoshoot

*No biography or information was provided before September 11, 2023.

Sponsored by





sirnaomics
Advancing RNAi Therapeutics

應用小核酸技術創製新藥的開拓者

A Leading RNAi Therapeutic Company
with Significant Presence in Both China & USA

創新引領 • 全球視野 • 關注病患

Innovation, Global Vision, Patient-centered

抗腫瘤、醫學美容及抗凝治療等

多項臨床研究已在美國及亞洲地區展開



聖諾醫藥官網



sirnaomics
Advancing RNAi Therapeutics



聖諾醫藥公眾號



聖諾醫藥(美國)
Sirnaomics, Inc

Sirnaomics, 廣州

Sirnaomics, 蘇州

Sirnaomics, 香港



Monin Ung 黃夢瑩

Legal Advisor

Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance

Ms. Ung serves as a director at Adluux AI Group Limited operated out of Germany since November 2019. Ms. Ung is the legal adviser to the Greater Bay Area Biotech Alliance since June 2020 and she founded the Oxford Futurists group for futuristic forum discussions. Ms. Ung founded Mung7Art in January 2021, which is an art collective of digital artists across the world. Ms. Ung established the boutique legal practice of MUNG (黃夢瑩律師事務所) in July 2018 and has been serving as the managing partner since then. Prior to that, Ms. Ung held several positions in U.K. and U.S. international law firms where she advised clients on corporate finance and private equity transactions and intellectual property disputes. Ms. Ung received a bachelor's degree of law (LL.B.) from Brunel University in the U.K. in July 1991, a master's degree of law (LL.M.) in Chinese and Comparative Law from the City University of Hong Kong in November 2001, and has been on the executive master's degree of business administration (EMBA) from Said Business School at the University of Oxford since January 2017. Ms. Ung became an advocate and solicitor in Singapore in May 1994, and a solicitor in Hong Kong in May 1997. She is also a recipient of the Hong Kong Chief Executive's Commendation for Community Service Award in July 2015.



Dong Dong 董咚

Assistant Professor

JC School of Public Health and Primary Care, The Chinese University of Hong Kong

Dr. Dong Dong joined the JC School of Public Health and Primary Care as a Research Assistant Professor in 2018. She obtained her doctoral degree in Mass Communication (with a minor in Epidemiology) from the University of Minnesota, Twin Cities. Most of Dr. Dong's research are cross-disciplinary in nature and focus on issues not only related to health communication and medical sociology but also to health equity and social justice. She has been the Principle Investigator of several extramural research grants, including the Hong Kong RGC-GRF on the use of prenatal genetic testing technologies in mainland China. She is also the co-Investigator of several research grants from Hong Kong and mainland China on issues related to community health, health inequity, and healthcare services.

In addition, Dr. Dong is collaborating with several national patient organizations in China to investigate, trace and record the medical, social, and economic status of the Chinese people affected by different types of rare diseases. She is currently leading a research lab in the Shenzhen Research Institute of CUHK on developing a patient-centered real-world database for studying people with rare diseases in China. She has published more than a dozen white paper reports on the topic and served as a board member for three national rare disease patient organizations.



***Xiaochang Dai* 戴晓畅**

**Executive Director / Scientific and Strategic Director
Sirnaomics**

Dr. Dai Xiaochang has over 20 years of experience in biotech technology. Prior to joining Sirnaomics, Dr. Dai served as the chairman of Yunnan Walvax Biopharmaceutical Co., Ltd., the predecessor of Walvax Biotechnology Co., Ltd. a company listed on Shenzhen Stock Exchange, the managing director of Kunming Baker Norton Pharmaceutical Co., Ltd. in 2005, and the president of Kunyao Group Co., Ltd. a company listed on Shanghai Stock Exchange.

Dr. Dai participates in the formulation of the general corporate business plans, strategies and major decisions of Sirnaomics through the Board. Dr. Dai currently serves as a professor at the School of Chemical Science and Engineering, Yunnan University since 2000, the executive director of Value Measure Investments Limited since January 2011 and the executive director of Trinity Power Limited since March 2012, respectively. Dr. Dai also serves as a director of Shenzhen Yunda Technology Industry Co., Ltd. since August 2001.

Dr. Dai obtained a master's degree in biochemistry in Shanghai Institute of Biochemistry, Chinese Academy of Sciences in the PRC. During this period, he and his team developed the sixth type of plant hormone, "Yunda-120". They later became a widely used plant growth regulator. Dr. Dai finished his doctoral degree in chemistry from The Scripps Research Institute in San Diego, California, U.S., and he also conducted postdoctoral research in the laboratory of John N. Ablelson, Division of Biology and Biological Engineering, California Institute of Technology in the U.S. from November 1998 to December 1999. At that time, his main research project was the development of nucleases for biotherapeutic use using in vitro evolutionary techniques.



***Patrick Lu* 陸陽**

**Founder, President and CEO
Sirnaomics**

Dr. Lu started his biopharmaceutical industry career in 1993 as a lab head in Novartis and was the co-founder and Executive VP of Intradigm Corporation (2001-2006). Patrick has authored more than 50 scientific papers, review articles and book chapters, and is an inventor for more than 50 issued and pending patents. He has been an invited speaker in many international conferences throughout the world and received a number of Government grants. Under his leadership, Sirnaomics has raised more than US\$170 million dollars and has developed a series of "first-in-class" siRNA therapeutic candidates at different phases of clinical studies, for treatment of cancer and fibrosis diseases, in both USA and China.



Francois Lebel

**Senior Vice President for Preclinical and Clinical Development
Sirnaomics**

Dr. Lebel is a strategic leader with broad drug development experience including immuno-oncology and nucleic acid therapeutics. Throughout his 30-year biopharma career at companies such as GSK, Pfizer, Baxter Healthcare, MedImmune, and Chiron Corporation, Dr. Lebel has designed and managed international research and development programs to successfully achieve multiple product marketing approvals. His recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer at Spectrum Pharmaceuticals (a Nasdaq-listed company; stock code: SPPI), where he was responsible for preclinical and clinical development, regulatory affairs and pharmacovigilance/drug safety, and successfully secured a novel drug marketing authorization at the U.S. Food and Drug Administration (FDA) in 2022. After joining Sirnaomics as Senior Vice President for preclinical and clinical development, Dr. Lebel will take a leading role in the Group's late-stage product development of innovative RNAi drug candidates.



Dong Shen

**Vice President and Professor
RNAimmune**

Dr. Shen graduated with PhD degree from Johns Hopkins University School of Medicine and MD degree from Shanghai Jiao Tong University School of Medicine. Dr. Shen has extensive drug development experience in AstraZeneca and Johnson and Johnson, having led projects across multiple therapeutic areas with high unmet medical need. He has held leadership across early and late programs in the areas of infectious disease, oncology and rare disease. Dr. Shen received numerous awards in the past. He was the recipient of Johnson & Johnson leadership award in 2018 and innovation award in 2017. All his manuscripts have been published at the most influential journals, such as Science and Nature. The total number of his publication citations is over 16,400.



Edward Wang 王永祥

**Chief Production Officer
Sirnaomics**

Dr. Wang is an internationally recognized expert in large-to-commercial scale manufacturing of biopharmaceutical and vaccine products, with specialization in aseptic processes and GMP compliance. He has more than 25 years of experience in the biopharmaceutical industry and at NGOs, including serving as the vice president of technical operations at Wuxi Biological Base of WuXi AppTec Co., Ltd.; the director of vaccine production at Newlink Genetics Inc.; the deputy director of engineering at a non-profit organization affiliated with the Bill & Melinda Gates Foundation; the technology consultant of Parexel International at Ben Venue Laboratory of Boehringer Ingelheim; and the senior scientist and manager in the Biopharmaceutical development program at the U.S. National Cancer Institute. Dr. Wang received his bachelor's degree of biophysics at the University of Science and Technology of China, a master's degree of biochemistry at the Tokyo Institute of Technology in Japan, and a doctoral degree at the Helsinki University of Technology in Finland.



Min Wu

**Chief Business Officer
Theron Inc.**

Min has more than 15 years of pharmaceutical and biotech R&D and business development experience. Currently served as CBO of Theron Inc. Before joining Theron, Min worked as the Managing Director of Fosun Health Fund. Before that, Min served as Executive Director of the Asia Pacific Innovation Hub of MSD, responsible for R&D business development in various therapeutic areas covering Greater China region and South Korea. Prior to MSD, she was the Head of External R&D and Licensing for Amgen Asia R&D Center, responsible for the center's scientific outreach and alliance management of the external strategic partnerships. She was also in charge of Search & Evaluation for Amgen's Global Business Development for the JPAC region. Min worked in different functions at Roche including Partnering, Alliance and Portfolio Management. Min obtained her Ph.D. in computational biology and chemistry from New York University, conducted post-doctoral research at Pfizer La Jolla site and subsequently worked as Principle Scientist at GlaxoSmithKline in North Carolina, US. Min has an MBA from University of Manchester, UK.



Da Liu 柳達

**Managing Director
CR CP Life Science Fund**

Mr. Liu is now the Managing Director of the CR CP Life Science Fund, whose shareholders, CR Group and CP Group are on the Fortune Global 500 List. Before that, Mr. Liu was the Business Director of the Strategic Management Department at CR Group, responsible for strategic research and project investment in life science and technology; and as Senior Director of China Resources Pharmaceutical Group Co., Ltd. (HK: 03320), responsible for business development and international cooperation. He has also served as the Senior Director of China Resources Pharmaceutical Business Group, the General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., the Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and the COO of Zhoulin Bio-spectrum Technology Co., Ltd. Prior to 2004, Mr. Liu was a pharmacy manager at CVS Group in the United States, and worked at the New York Healthcare Group as a clinical pharmacist.



Nancy Man 萬鈞

**Chair Professor of Transplant Oncology and Immunology
The University of Hong Kong, LKS Faculty of Medicine**



Dr. Nancy K MAN main research focus is in the area of liver graft injury and cancer recurrence after transplantation utilizing an integrated basic, clinical and translational approach. She has developed a series of novel animal models to mimic liver graft injury and cancer recurrence. She is also the first to establish a rat orthotopic liver transplantation model using small-for-size grafts in Hong Kong. These models have been extensively introduced into the investigation of liver transplantation. She is the first to report the significance of small-for-size liver graft injury on tumor recurrence after transplantation in the world and further to explore the molecular mechanisms of inflammatory response in the acute phase and tumour invasiveness in the late phase.



商務印書館(香港)
THE COMMERCIAL PRESS (HK)

獨具慧眼迎商機 創新出版知趨勢

BOOTH NO. 3D-C34, 3D-D33





香港中文大學
The Chinese University of Hong Kong

BOOTH NO. 3D-A19,
3D-A17, 3D-A15

ABOUT ORKTS 研究及知識轉移服務處



研究及知識轉移服務處
Office of Research and
Knowledge Transfer Services

中大研轉處為學人提供多方面支援，包括提供研究資金、產研合作、研究合約、知識產權的開發與授權、倫理政策、知識轉移等各方面的支援，以及推動創新創業活動。研轉處希望匯聚豐碩學研成果，鞏固中大創新創業圈的獨特優勢，將更多「知識解鎖」，惠及各個社群。

The Office of Research and Knowledge Transfer Services (ORKTS) supports researchers with research grants, industry-university collaborations, research contracts, IP development and licensing, research ethics policies and other knowledge transfer services, with a view to "unlocking" knowledge for promoting CUHK's research excellence and innovation, and their translation into social impacts and benefits.

ORKTS provides one-stop services! 研轉處提供一站式服務



Co-Working Space
共創空間



Mentorship & Incubation Programs
指導及孵化計劃



Funding & Investment Opportunities
資助及投資機會



Marketing & Publicity Channels
宣傳及推廣頻道



IP & Legal Consultation Services
知識產權諮詢服務



Workshops, Seminars & Talks
工作坊、研討會和講座



Event Venue & Facilities
活動場地及配套設施



Check out
ORKTS Website
查看研轉處網站



Christopher Kennedy

CEO, EDIRNA

Over 20 years of executive, commercial, and operational leadership in the life sciences industry. Accelerating innovation and growth at all stages of company development.

Christopher W. Kennedy is an award-winning healthcare leader. He has spent the last two decades in executive leadership roles within the Healthcare Provider, Biotechnology, and Medical Device sectors. His efforts in making Patient Experience a measurable outcome have been featured by The Beryl Institute, The Wharton School, a PBS TV Special, and a 2019 Ted Talk presentation. He actively serves on multiple industry advisory boards including MOBIO, URAC, NASP, and The Kauffman Foundation's Skilled KC initiative.



Yuling Li 李玉玲

President

Zhejiang Innoforce Pharmaceuticals Co., Ltd.

Dr. Yuling Li is the co-founder and President of Innoforce Pharmaceuticals, a company established in 2018 at Hangzhou, China with the focus of building CDMO capabilities for innovative drug development including nucleic acid products (plasmid DNA and RNA), viral vector and cell therapy and monoclonal antibody products. Prior to Innoforce, Dr. Li was the Sr. Vice President of Process Development and Manufacturing of Apollomics (Foster City, CA and Hangzhou), the R&D Fellow/Director in BioPharmaceutical Development at MedImmune/AstraZeneca (Gaithersburg, MD), the Senior Director in BioPharmaceutical Development at Human Genome Sciences Inc. (now part of GSK, Rockville, MD) and an Associate Scientist at Hoffmann-La Roche Inc. in Nutley, New Jersey. In the past 30 years, Dr. Li led CMC activities for 3 BLA submissions and contributed to 9 approved products plus 30+ biopharmaceuticals through various clinical stages of CMC development.

During the course of her career, Dr. Li published 40+ peer-reviewed articles and book chapters and is the inventor for five issued patents. In 2014, Dr. Li received the Rising Star Award from the Healthcare Businesswomen Association. Dr. Li served as the President (2007-2008), Board of Directors, member of the Advisory Board for the Chinese Biopharmaceutical Association-USA (CBA, www.CBA-USA.org), a non-profit professional organization. Dr. Li also co-founded the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) in 2008. She is a BayHelix member.



Michael Zhang

Vice President
Guangzhou Ribo Biotechnology

Michael Zhang is the Vice President of Project Development at Guangzhou RiboBio, where he leads project management of the CDMO sector for global clients. He also heads the operations team and oversees Ribobio's industry collaboration portfolios. Michael has a background in management and business and is a graduate of Columbia University. RiboBio is a forerunner in oligonucleotide services and products in Asia, providing a one-stop solution for clients seeking oligonucleotide manufacturing at all stages.



Richard Welch

Vice President
CMC, Sirnaomics

Richard Welch is an experienced professional with a career spanning over 26 years. Throughout his journey, he has worked in various roles and industries, showcasing his adaptability and breadth of expertise. Currently serving as the Vice President CMC at Sirnaomics, Inc., Richard has been dedicated to this position for 730 days. Prior to his current role, he held key leadership positions at Emergent BioSolutions, including Vice President Development Services, CDMO Business Unit, Vice President Process and Analytical Development, and Senior Director Process and Analytical Development, where he contributed significantly to the company's growth and success. Richard's experience also extends to other notable companies, such as Lonza Inc., Chesapeake PERL, Claragen, and North American Vaccine (now part of Baxter). He holds a Doctor of Philosophy (Ph.D.) from Rice University and a Bachelor of Science (BS) from the University of Illinois at Urbana-Champaign. With his extensive background in CMC, process development, analytical development, and manufacturing, Richard Welch is a valuable candidate for roles in the biotechnology and pharmaceutical industries.

LOCI SQUARE | 基因位點廣場

Regenerative Medicine & Sponsored Events

Wednesday, September 13 | 12:10 PM - 17:00 PM (GMT+8)

Hong Kong's Technology Innovation Transformation (Sponsored By Shanghai Healthcare Capital)	
12:10 - 13:00	Moderator: Mr. Qiushan Guo, Shanghai Healthcare Capital* Panelists: Mr. Cho Man, SPJ-Inno* Dr. Pengcheng Zhu, ATLATL* Prof. Michael Yang, City University of Hong Kong Prof. Lo Yuk Lam, HKBMIA (see biography on p.46)
13:00 - 14:00	Lunch Break
Reprogramming for Regenerative Medicine	
14:00 - 14:20	Progenitors and Lineage-directed in vitro Differentiation of Nucleus Pulposus Cells Relevant For Intervertebral Disc Degeneration Chair: Prof. Kathryn Cheah, The University of Hong Kong
14:20 - 14:40	From Basic Stem Cell Biology to Potential Stem Cell Therapy Prof. Ting Xie, Hong Kong University of Science and Technology
14:40 - 15:00	原位神经再生疗法引领神经制药新赛道 Prof. Gong Cheng, Jinan University
14:40 - 15:00	HKUST turning breakthrough technology of CGT and CNS regeneration for global unmet needs Mr. Wayne Tan, The Hong Kong University of Science and Technology*
15:00 - 15:20	Exploration and practice of regenerative medicine from the perspective of Traditional Chinese Medicine 中医再生医学的探索与实践 Dr. Hongmei Li, Beijing University of Chinese Medicine
15:20 - 15:40	Research and Application of Expanded Potential Stem Cell in Centre for Translational Research Biology Dr. Fang Liu, The University of Hong Kong*
16:00 - 17:00	Sponsored Event Asian Life sciences and Healthcare Industry Financial Forum (Beijing ITAI Technology)

*No biography or information was provided before September 11, 2023.

Science

BIOHK2023 SILVER SPONSOR

Science Magazine, published by the American Association for the Advancement of Science (AAAS), is a renowned global publication at the forefront of scientific research and discovery. With a rich history and reputation spanning over a century, Science Magazine delivers cutting-edge scientific articles, news, and expert analysis across various disciplines. It serves as a trusted source of information for scientists, researchers, and enthusiasts worldwide, providing comprehensive coverage of groundbreaking discoveries, technological advancements, and critical issues shaping the scientific community. Through its online and print platforms, Science Magazine continues to inspire and inform readers, fostering curiosity and advancing the frontiers of knowledge.

由美國科學促進會（AAAS）出版的《科學》雜誌是全球知名的學術期刊，在科學研究和發現方面處於前沿。《科學》雜誌擁有一個多世紀的歷史和聲譽，以提供高水平的科學文章、新聞和專家分析，以涵蓋各種學科。它是全球科學家、研究人員和愛好者可信賴的信息來源，全面報導了重大發現、技術進步和科學界塑造的重要問題。通過其在線和印刷平台，《科學》雜誌繼續鼓勵和通知讀者，激發他們的好奇心，推動他們向第一線的知識領域邁進。

TrAnsform[®]

健康在乎你取態

**NMN
Water**

**Alkaline
Water**



逆齡抗衰老



修復受損DNA



激活長壽蛋白

**全球首創
新一代提升
NAD+ 飲料**



pH9

軟水

植物
礦物質

BOOTH NO. 3D-D26

Booth No : 3D-D26

Whatsapp
+852 6588 8183



全新網站
歡迎訂購





Michael Yang

Professor
City University of Hong Kong

Professor Michael Yang Mengsu is currently Senior Vice-President (Innovation and Enterprise), Yeung Kin Man Chair Professor in the Department of Biomedical Sciences, and Director of both the Tung Biomedical Sciences Centre and Shenzhen Biotechnology and Health Centre of City University of Hong Kong (CityU). He is responsible for "HK Tech 300", the largest university-based entrepreneurship programme in Asia. He received a Bachelor's Degree of Science from Xiamen University, China, a Doctor of Philosophy (PhD) from the University of Toronto, Canada, and postdoctoral training from The Scripps Research Institute, the United States. Professor Yang serves on the Hong Kong's Research Grants Council, the Health and Medical Research Fund, and the Innovation and Technology Fund. His research interests focus on studying cancer biology and developing biochips and nanotechnology for diagnostics and therapeutic applications.



Kathryn Cheah 謝賞恩

Chair Professor, Department of Biochemistry
The University of Hong Kong

Prof. Kathryn Cheah is Chair Professor of Biochemistry at HKU and an internationally renowned expert on understanding gene regulation and function and how mutations cause disease, with an emphasis on the skeletal system and the inner ear. She has contributed insights into the regulation and function of genes in vivo and the molecular pathogenesis of disease by generating transgenic mice and mouse models and by studying human degenerative skeletal disorders especially degenerative intervertebral disk disease (DDD). The driving motivation of her research is the realisation that, with an ageing population worldwide, genomic and regenerative medicine will play critical roles in helping to preserve healthy growth and quality of life. She uses human and mouse embryonic stem cells and genetically modified mice as models to study development and disease and develop therapeutic approaches for disorders of cartilage (e.g. osteoarthritis) and low bone mass (e.g. osteoporosis) and intervertebral disc degeneration. In HKU she has served as Jimmy and Emily Tang Professor in Molecular Genetics, Chair Professor of Biochemistry, School of Biomedical Sciences, The University of Hong Kong. She was awarded a Croucher Foundation Senior Fellowship (2000) and is an elected Fellow of the global academy for the advancement of science in developing countries, The World Academy of Sciences (TWAS). In 2021 she was elected as Member of the Hong Kong Academy of Sciences. She was awarded the British Society for Matrix Biology Medal Lecture 2022 for her contributions to matrix biology.



Xie Ting 解亭

Head and Chair Professor
Division of Life Science, The Hong Kong University of Science and Technology

Prof. Ting Xie is Kerry Holdings Professor of Science, Chair Professor, and the head of the Division of Life Science at Hong Kong University of Science and Technology. Before moving to Hong Kong, he was an investigator at the Stowers Institute for Medical Research and a professor at the University of Kansas Medical Center. He obtained his Ph.D. in Molecular Biology and Biochemistry from Rutgers University and did his postdoctoral training at Howard Hughes Medical Institute/Carnegie Institution of Science. His main research areas include stem cell biology and eye degenerative diseases. He is one of the leaders and pioneers in studying stem cell niches. Prof. Xie has published over 70 articles in high-profile journals, including Science, Nature, and Cell. He has been serving on the scientific advisory board of the Glaucoma Foundation and the Y-LOT Foundation and on the editorial board of Cell Research, Development, and ten other scientific journals.



Gong Chen 陈功

Director

Brain Repair Center, Guangdong-Hong Kong-Macau Institute of CNS Regeneration (GHMICR) of Jinan University

Professor Chen Gong is a nationally appointed expert and Director of GHMICR at Jinan University. He graduated from Fudan University and has a PhD in Neurobiology from Shanghai Institute of Physiology, Chinese Academy of Sciences. He is a postdoctoral fellow at Yale University and Stanford University. He was a tenured professor and Endowed Chair Professor at Pennsylvania State University. Dr. Gong Chen's team reported the first landmark work of efficiently converting endogenous astrocytes into functional neurons in situ with the neurotranscription factor NeuroD1, which was named the best paper of the year in 2014 by the journal Cell Stem Cell and opened up a new neuroregenerative therapeutic approach for brain repair.

Prof. Chen Gong is the scientific founder of NeuExcell, a company dedicated to the use of neuroregenerative therapies for the treatment of neurological injuries and degenerative diseases. NeuExcell was selected as one of the top 5 promising startups in Asia by GEN, a leading biotech magazine.



Hongmei Li

Associate Researcher

Beijing University of Chinese Medicine

Li Hongmei, associate researcher at Beijing University of Chinese Medicine and a joint doctorate trained by Yale University in the United States. She is committed to the intersection of traditional Chinese medicine and regenerative medicine under the integration model of clinical scientific research. In 2019, the "Young Talent Promotion Project" of the China Association of Traditional Chinese Medicine was selected as the third batch of young truth-seeking scholars of traditional Chinese medicine. They are members of the excellent talent pool cell and youth editorial board of the "Chinese Journal of Traditional Chinese Medicine". She concurrently serves as a youth member of the Cardiovascular Disease Branch of the China Association of Traditional Chinese Medicine, a member of the Science and Engineering Technology Standards Technical Committee, a member of the Research Methods Professional Group of the Cardiovascular Disease Clinical Committee, and a member of the Aromatherapy Group of the Cardiovascular Drug Research Professional Committee of the China Association of Traditional Chinese Medicine. Hosted 6 scientific research projects of various types including the National Natural Science Foundation of China, won 1 second prize of the Natural Science Award of the China Association of Traditional Chinese Medicine, and published more than 30 academic papers for the first project/author correspondence in STTT, MedComm and other publications, and was authorized to invent. 1 patent, co-edited 2 books.

We've been at this for **10 years**

BIOHK2023 SILVER SPONSOR

Pioneering mRNA for over a decade

Moderna has been advancing its mRNA platform and pipeline of medicines for more than 10 years

New medicines on the horizon

Currently, **Moderna has 48 mRNA programs in its pipeline** and 35 development candidates in active clinical trials

Empowering scientists

mRNA access, a global program launched by Moderna, helps to build a community of scientists who can access our mRNA technology in order to develop new medicines and vaccines

BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS
POTENTIAL OF HONG KONG'S
BIOTECH ECOSYSTEM

CONFERENCE

DAY TWO

Thursday September 14

KEYNOTE ADDRESS

Thursday, September 14 | 09:00 AM - 11:00 AM (GMT+8)

09:00 - 09:30	KEYNOTE SESSION : PROF. YU WANG, CHINESE FOUNDATION FOR HEPATITIS PREVENTION AND CONTROL The Disease Burden and the Strategy of Early Diagnosis of HCC in China
09:30 - 09:40	KEYNOTE SESSION: MS. LILLIAN CHEONG, INNOVATION, TECHNOLOGY AND INDUSTRY BUREAU 香港創科發展新機遇 New opportunities for Hong Kong's innovation and technology development
09:40 - 10:10	KEYNOTE SESSION: MS. NISA LEUNG, QIMING VENTURES The Role of China's Biotech Sector in Global Healthcare Innovation
10:10 - 10:35	KEYNOTE SESSION : PROF. AKIHIKO KONDO, VICE PRESIDENT, KOBE UNIVERSITY Innovations in Biotechnology and Biomanufacturing Through Engineering Biology
10:35 - 11:00	KEYNOTE SESSION: PROF. RAJU KUCHERLAPTI, PAUL C. CABOT PROFESSOR GENETICS, HARVARD UNIVERSITY Genetics and Genomics in Cancer Drug Development

BIOHK2023 GOLD SPONSOR



鸿坤产业
HONGKUN
BUSINESS PARK

鸿坤产业集团

鸿坤产业投资发展集团（以下简称“鸿坤产业”），致力成为中国领先的创新产业园区运营商。作为鸿坤控股旗下面向未来战略的重要业务集团，鸿坤产业秉持“打造产业生态，提升城市价值”的发展理念，以产业园开发、产业投资和产业运营三大业务板块全面构筑产业生态创新发展。聚焦“科技创新、创意创新、孵化创新”三大产业方向，鸿坤产业积极布局国家战略性新兴产业、文化创意产业、现代服务业等重点产业，并围绕国家战略重点区域，夯实巩固首都核心区，积极布局京津冀，开拓辐射长三角、珠三角、成渝、武汉等区域；先后成功开发建设、运营投资鸿坤·金融谷、鸿坤·云时代、亦庄鸿坤·智谷、马驹桥鸿坤·智谷、西红门·鸿坤智谷等产业园项目。目前，产业园区资产规模已达 300 万平方米。



未来，鸿坤产业将延续“创新驱动、共享开放”的价值理念，以构建“产业+基金+园区”的驱动模式和完善“企业发展服务生态体系”，培育特色产业集群在城市中的发展，在推动企业发展的同时，实现产业转型升级，促进区域经济增长，激发城市活力。



KOLN3D

科能三維技術(醫療)有限公司

人工骨 | 手術導板 | 訂製器具

- ✓ 骨癌治療方案
- ✓ 創傷治療方案
- ✓ 醫工合作，一站式訂製生產
- ✓ 增材製造，環保高效

獨家註冊金屬粉材

KOLN3DCobaltChrome (鈷鉻合金)

KOLN3D316LM (316不銹鋼)

KOLN3D Ti-6Al-4V Grade 23 (鈦合金)

- ✓ 生產廠房具有 ISO 13485:2016 認證
- ✓ 金屬粉材通過 ISO 10993-4,5,6 認證
- ✓ 產品及技術已獲中、日、韓、德等多國專利

Hong Kong innovator steps
into Central Asia

香港創新者步入中亞



香港創新者步入中亞



阿拉木圖
09.2022

一帶一路跨國合作: 哈薩克斯坦

骨癌治療 - 盆骨置換手術



- ✓ 科能、港大、哈薩克
三方攜手合作完成
- ✓ 手術時間縮短6成
- ✓ 患者9個月內
恢復全負重行走
(Full weight-bearing walk)



2013年，成立於香港科學園

至今累積超過 **100** 宗成功手術個案



負載藥物骨板

DRUG CARRYING BONE PLATE (DCBP)

內建微導流滲藥系統

- ✓ 直接於傷口釋放藥物
- ✓ 有助調配最適度劑量
- ✓ 高效舒緩術後痛楚

DIPLOME



榮獲2023年度日內瓦發明展金獎

medical.koln3d-tech.com



OFFICE:
Koln 3D Technology (Medical) Limited
Room 322, 3/F Core Building 2,
1W Hong Kong Science Park, Shatin, Hong Kong

WORKSHOP:
Koln 3D Medical Manufacture Limited
Unit 402, 4/F, MARS Centre, 2 Dai Wang Street,
Tai Po, N.T., Hong Kong

EU BRANCH:
Koln 3D Technology SA
Rue de la Pierre-à-Mazel 39,
2000 Neuchâtel, Switzerland



***Yu Wang* 王宇**

Chairman

Chinese Foundation for Hepatitis Prevention and Control

Dr. WANG Yu graduated from Beijing Medical University in 1982. He continued onto his graduate study at the Institute of Hepatology, Beijing Medical University from 1983 to 1989 and received his Master's and Doctorate of Medicine during this period. From 1991 to 1993, he studied at the Jichi Medical School in Japan and received a Ph.D. degree in Preventive Medicine. In 1999, He completed Master of Business Economics program from the Chinese Academy of Social Sciences. Starting in 1985, he had been an assistant professor, associate professor, professor, deputy director and director of the Institute of Hepatology in Beijing Medical University, specializing on hepatology and viral molecular biology.

Dr. Wang had participated in and chaired a number of national scientific and technological projects and programs, such as the Natural Science Foundation of China. He served as a committee member of the Chinese Medical Association and vice chairman of the Medical Virology Branch of the Chinese Medical Association. Since 1996, he had served as the Executive Vice-Director and Director of the Office of Scientific Research in Beijing Medical University, and Deputy Dean, School of Medicine, Peking University. From 2000 to 2003, he was appointed Deputy Director of the Center for Biological Engineering and Development, China Ministry of Science and Technology. From 2003 to 2004, he was Deputy Director of the Office of Rural and Social Development at the Ministry of Science and Technology. During June 2004 to August 2017, he was appointed as the Director of Chinese Center for Disease Control and Prevention under the Ministry of Health, China.



***Lillian Cheong* 張曼莉**

Under Secretary

Innovation, Technology and Industry Bureau

Ms. Cheong joined the Government in 2017 as Political Assistant to the Secretary for Innovation and Technology and was appointed as Under Secretary for Innovation, Technology and Industry in July, 2022.

Before joining the Government, Ms. Cheong served as Assistant to Executive Director and Joint General Manager at a listed company, and had experience in operation and management of real estate development, cross-boundary retail, technology investment, business development and restructuring, digital transformation, investor relations, etc. In addition to profound knowledge in the business sector, Ms. Cheong has extensive public service experience including serving as a co-opted member of the Community Building Committee of the Wan Chai District Council, adviser to a think tank, etc.



Nisa Leung

Managing Partner
Qiming Venture Partners

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 530 portfolio companies.

She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others. Her other investments include Gan & Lee (SSE:603087), Venus MedTech (HKSE:2500), New Horizon Health (HKSE:6606), Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed Medical, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Vision Pro, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), SinoUnited Health, Schrödinger (NASDAQ:SDGR), Recursion (NASDAQ:RXRX), Insilico Medicine, Structure Therapeutics (NASDAQ:GPCR), Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife among others.

Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.

Nisa has been recognized by the Forbes Midas List for five consecutive years in 2019, 2020, 2021, 2022 and 2023, and named Best Women VCs List by Forbes China (#1 in 2022, #2 in 2021) and Most Powerful Women in Business by Fortune China in 2022.

Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited ("HKEX"), Board Member of Hong Kong Palace Museum, Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA.



Akihiko Kondo 近藤昭彦

**Vice President and Professor
Kobe University**

Akihiko Kondo received his Ph.D. from Kyoto University in Chemical Engineering (1988). He has started his faculty career in 1988 in Department of Applied Chemistry at Kyushu Institute of Technology. He was appointed as full professor of Kobe University in Department of Chemical Science and Engineering in 2003 and also appointed as a team leader at RIKEN Center for Sustainable Resource Sciences (CSRS) in 2012. He was appointed a dean of Graduate School of Science, Technology and Innovation at Kobe University in 2016. He became a member of Science Council Japan in 2017 and deputy director of RIKEN CSRS in 2020 and Vice President of Kobe University in 2021.

A. Kondo has developed various platform technologies such as cell surface display systems, metabolic pathway design tools, metabolic analysis technologies, genome editing and long chain DNA synthesis technologies. He also has applied these platform technologies for construction of various microbial cell factories for production of biofuels and various chemicals from biomass, and cyanobacteria and microalgae for production of oil and chemicals from CO₂. He is the scientific founder of several companies including BioPalette (genome editing), Synprogen (genome synthesis), AlgaeNexus (microalgae) and Bacchus Bio innovation (Biofundry).

He has published more than 750 peer reviewed international papers.



Raju Kucherlapati

**Paul C. Cabot Professor of Genetics & Professor of Medicine
Harvard Medical School**

Since 2001 Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG).

Dr. Kucherlapati received his Ph.D. from the University of Illinois at Urbana and did his post-doctoral work at Yale University. He was assistant professor in the Department of Biochemical Sciences at Princeton University, and then became professor in the Department of Genetics at the University of Illinois College of Medicine. In 1989 Dr. Kucherlapati went to the Albert Einstein College of Medicine where he was the Lola and Saul Kramer Professor of Molecular Genetics and University Chairman of the Department of Molecular Genetics, a position he held for eleven years.

Dr. Kucherlapati contributed to several different areas of research. These include gene targeting and homologous recombination, human gene mapping, and generation of physical maps of the human genome with special emphasis on human chromosome 12, development of techniques to modify genes in mammalian cells and in cloning many human disease genes. He was a member and Chair of several review committees at the NIH, was a member of the National Advisory Council for Human Genome Research at the National Human Genomics Research Institute, and was a co-chair of the steering committee for the National Cancer Institute's Mouse Models for Human Cancer Consortium. He served on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics. He is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. Dr. Kucherlapati was a member of the Presidential Commission for the Study of Bioethical Issues during the Obama administration.

Dr. Kucherlapati was a Founder of several biotechnology companies including Cell Genesys, Abgenix (acquired by AMGEN) and Millennium (acquired by Takeda). He serves on the Boards of several privately held biotechnology companies and is a Board member of a publicly traded company called Puretech Health that trades on the London Stock Exchange. He has been active in promoting Precision Medicine in China and is the co-Chair of the International Cancer Precision Medicine Conference that just held its fourth annual meeting in Chongqing.

BIOHK AUDITORIUM | BIOHK 會堂

Cancer Research and Drug Development

Thursday, September 14 | 11:00 AM - 17:30 PM (GMT+8)

11:00 - 12:00	Opening: Dr. Sujuan Ba, Asian Fund For Cancer Research Moderator: Dr. Da Liu, CR-CP Life Science Fund (see biography on p.57)
	WT1 Cancer Vaccine for Treatment and Prevention Prof. Haruo Sugiyama, Osaka University
	DNA Methylation in Health and Disease; Implications for Early Prediction, Prevention and Intervention Prof. Moshe Szyf, HKG Epitherapeutics Inc.
12:00 - 13:00	Expanding the Reach of Precision Medicine in Lung Cancer Moderator: Prof. Bruce Johnson, Dana-Farber Cancer Institute
	Cancer therapeutic development: Hope for the Hopeless Prof. Lei Zheng, Johns Hopkins University
	Precise Medicine-driven management for Primary Liver Cancer Prof. Ming Kuang, Sun Yat-Sen University
13:00 - 13:15	Cancer Genetics and Precision Oncology Is Good Prof. Ava Kwong, The University of Hong Kong
13:15 - 14:00	Lunch Break
Session Two: BRACE Award Presentations	
	Chair: Dr. Raju Kucherlapati, Harvard University (see biography on p.74)
14:00 - 15:30	Molecular Glue Degradar Drugs for Undruggable Disease Targets, Discovered by Degron's Novel Glue Discovery Platform BRACE Awardee 2023: Dr. Lily Zou, Degron Therapeutics
	Circulating CDH17 Marker Made Early Screening of Colorectal Cancers and Polyps Possible Dr. Tony Wong, Arbele Ltd
	High throughput prediction of the best multi-functional molecules to develop in the clinic through preclinical data analysis BRACE Awardee 2019: Dr. Ignacio Asial, DotBio Pte. Ltd.
Session 3: Emerging Oncology Companies	
15:30 - 17:30	Moderator: Dr. Mark Tang, Good Health Capital (see biography on p.37)
	Empower Patients Participation in Clinical Cancer Research Ms. Rose Wang, AIM-HI Accelerator Fund
	Dr. Shane Burgess, Treadwell Therapeutics Inc.
	Developing Global Innovative Anti-Cancer Drugs in China: Challenges and Future Perspective Dr. Dajun Yang, Ascentage Pharma
	Targeting Difficult to Treat Cancers Dr. Guoliang Yu, Apollomics (see biography on p.47)
	一种新型BRAF抑制剂ABM-1310的1期多中心开放标签研究 BRAF突变实体瘤的成年患者 Dr. Zane Yang, ABM Therapeutics

Sponsored by



**ASIAN FUND FOR CANCER
RESEARCH LIMITED**
亞洲癌症研究基金會有限公司



CRRT智慧解决方案 SMARTCRR7 信息化软件

BIOHK2023 SILVER SPONSOR

武汉聚智惠仁信息技术有限公司

武汉聚智惠仁信息技术有限公司成立于2019年。是一家专注赋能医疗行业智能、智慧解决方案的专业新锐信息化公司。公司由国内顶级医学专家团队，行业资深市场团队和极富持续创新创业经验的管理团队共同组建。

使命

我们将通过新一代信息技术的智慧支撑与仁心妙术的专业学术体系深度融合，聚时代之智，惠天下以仁！

愿景

我们立志成为智慧医疗信息化在CRRT(CCBP)治疗领域行业标准创建者和领路人！

力争在未来为1000家重点医院，每年约100万重症患者提供优质服务！



智慧诊疗

智能辅助治疗，智能助手，预警平台；移动办公，帮助医生时刻守护患者生命。



智慧护理

全面掌握患者信息，AI数据采集，减轻工作负担，规范工作流程，改进工作质量。



智慧管理

基于优秀实践，帮助科室妥善解决质控、设备效能、绩效等管理问题。



智慧科研

完整数据链采集，全设备接入，形成CRRT专科病种数据库，提供数据即席



本次盛会免费注册





***Sujuan Ba* 巴素娟**

President and CEO
National Foundation for Cancer Research

Dr. Sujuan Ba has served as the President & CEO of the National Foundation for Cancer Research since 2019 and the founder & CEO of the Asian Fund for Cancer Research since 2005. Dr. Ba is a co-founder and a founding board member of the Global Coalition for Adaptive Research (GCAR), a non-profit organization pioneering the groundbreaking adaptive clinical trial platforms to deliver innovative therapies to patients faster. Dr. Sujuan Ba is also CEO & Co-founder of the AIM-HI Accelerator Fund, a non-profit organization focused on advancing oncology start-ups through venture and impact investments. She serves as a scientific advisor and a board member for more than half a dozen oncology start-ups.

Dr. Ba has served on the Women in Science Committee of CRS (Control Release Society) since 2017. She is also a Member of Springboard's Life Science Council, a group of experts worldwide in biotech, pharma, medical devices, and health IT who invest their "human capital" in Springboard's pipeline of high-growth, women-led companies. She is the former President of the Chinese Biopharmaceutical Association (2010-2011) and a lifetime member of BayHelix, an invitation-only organization of leaders of Chinese origin involved globally in life sciences and health.

Dr. Ba has led the establishment of NFCR's annual Szent-Györgyi Prize for Progress in Cancer Research, an international prize recognizing outstanding scientific achievement in the war against cancer. She has served continuously as co-chair of the Prize Selection Committee since 2006. The prize has now grown into one of the premier cancer research awards in the world.

Dr. Ba has also led the establishment of AIM-HI Women's Venture Competition in 2020, a first-of-its-kind program that provides investment, coaching, and networking opportunities to women-led oncology start-ups. More than 150 women-led oncology start-ups have gone through the rigorous review and judging process of the Women's Venture Competition platform.

Dr. Ba was awarded one of the "20 Most Inspiring Women Leaders 2022" by The Women Leaders Magazine. Dr. Ba received NBC4 WORKING 4 THE COMMUNITY Award in 2019, recognizing her outstanding achievements as a scientist, leader, and role model in the STEM fields. Dr. Ba also received the inaugural Outstanding Achievement Award from Society for Neuro-Oncology of the Chinese Medical Doctor Association for our outstanding contribution to international cooperation in 2017. She was named one of the "Top 300 Women Leaders in Global Health" in 2015 by the Graduate Institute of International and Development Studies' Global Health Programme. She was also awarded the Public Service Award in 2014 from the Chinese Biopharmaceutical Association-USA for her long-term devotion and distinguished service to the global biopharmaceutical community. She was selected to receive the CRS WOMEN IN SCIENCES Award in 2011.

Dr. Ba received her BS in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.



Haruo Sugiyama 杉山治夫

Professor

Graduate School of Medicine, Osaka University

Haruo Sugiyama graduated from Osaka University School of Medicine (M.D.) and received Ph.D. degree from Osaka University in tumor virology in 1979. Then, he moved to internal medicine and specialized in immunology and hematology. He was appointed Professor, Osaka University Graduate School of Medicine in 1995 and he is now appointed Specially Appointed Professor, Osaka University Graduate School of Medicine. He discovered that Wilms' tumor gene 1 (WT1) overexpressed in almost all leukemia, and he invented WT1 mRNA assay, a clinical test that made it possible to detect only one leukemic cell in 100,000 peripheral blood mononuclear cells in 1994. This WT1 mRNA assay was covered by Japanese national health insurance for acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome (MDS), and by Chinese national health insurance for MDS. He was honored by Princess Takamatsu Cancer Research Fund Prize 2011 by the achievement of this invention. Furthermore, he discovered that WT1 overexpressed in not only leukemia but also almost all kinds of solid tumors, and he discovered that WT1 protein was a ubiquitous tumor-associated antigen (TAA) for leukemia and almost all kinds of solid tumors. And he invented WT1 peptide cancer vaccine, and he began for the first time (First - in - Human) a phase I clinical study of WT1 peptide cancer vaccine in 2002. National Cancer Institute, USA evaluated 75 popular tumor-associated antigens (TAAs) for the clinical utility, and ranked WT1 antigen as the top among the 75 TAAs in 2009. He and pharmaceutical companies are conducting many clinical studies of WT1 cancer vaccine to obtain the pharmaceutical affairs approval. Until today, over 14,000 patients with leukemia or many kinds of solid tumors were treated with WT1 cancer vaccine, including WT1 peptide vaccine and WT1 dendritic cell vaccine. Importantly, there is no WT1 vaccine-related death, and therefore, WT1 cancer vaccine is very safe. He is also trying to develop the WT1 cancer prevention vaccine for the hereditary cancer such as hereditary breast and ovary cancer syndrome and familial adenomatous polyposis caused by the mutation of tumor suppressor genes, BRCA1/2 and APC, respectively. He was honored by IAAM Innovation Award 2022 by the achievement of the development of WT1 cancer vaccine.



Moshe Szyf

**McGill Professor, Department of Pharmacology and Therapeutics
McGill University**

Dr Moshe Szyf is a professor of pharmacology and held a Glaxo Smith Kline and James McGill Chair in Pharmacology at McGill University in Montreal Canada and is a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences. Szyf has pioneered research in DNA methylation for the last three decades and published more than 300 papers on the biological role of DNA methylation that span a broad spectrum from basic mechanisms to cancer diagnostics and therapeutics, as well as behavior, chronic pain and addiction. Szyf pioneered epigenetic pharmacology in cancer and as well as the field of behavioral epigenetics. Szyf studies provide a molecular link between environment and genes and between nurture and nature that had a wide impact on the social sciences and psychiatry. Szyf founded the first Pharma in the world dedicated to developing DNA methylation drugs Methylgene Inc. Szyf founded HKG epitherapeutics which develops a novel class of epigenetic diagnostic markers for early detection of cancer and other diseases.



Bruce Johnson

**Professor of Medicine and Institute Physician
Dana-Farber Cancer Institute and Harvard Medical School**

Bruce E. Johnson, MD, is the Co-Director of the Center for Cancer Genomics at the Dana-Farber Cancer Institute and Co-leader of the Dana-Farber/Harvard Cancer Center Lung Cancer Program. He is a Professor of Medicine at Harvard Medical School, an Institute physician at the Dana-Farber Cancer Institute, and a Senior Advisor to the President and CEO of the Dana-Farber Cancer Institute. Dr Johnson served on the American Society for Clinical Oncology (ASCO) Board of Directors from 2008 to 2011, received their Cancer Foundation's Translational Research Professorship in 2008, and was selected as an ASCO fellow in 2012. He was elected president of ASCO for the 2017-2018 term.

Dr Johnson was one of the investigators who discovered the link between mutations of the epidermal growth factor receptor (EGFR) and sensitivity to EGFR- tyrosine kinase inhibitors and is one of the patent holders for EGFR mutation testing. He has published more than 290 research articles on a variety of topics, including the molecular basis of lung cancers and the development of targeted therapies for patients with specific genomic alterations in lung cancer.



Lei Zheng 郑雷

**Professor
Johns Hopkins University School of Medicine**

Lei Zheng, M.D., Ph.D. is Professor of Oncology and Surgery at the Johns Hopkins University School of Medicine. He is the Cancer Center and the Department of Oncology's Assistant Director for Translational Research and Associate Cancer Center Director for Precision Medicine. He co-leads the precision medicine research and practice at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology. He is Director for a new Multidisciplinary Gastrointestinal Cancer Laboratories Program at the Johns Hopkins Cancer Center. He is also Director of the Pancreatic Cancer Precision Medicine Center of Excellence at Johns Hopkins. His clinical work is focused on multidisciplinary management for pancreatic cancer, bile duct cancer, colorectal cancer liver metastases, and gastric cancer. He is affiliated with the Tumor Immunology Program as a laboratory investigator. His primary laboratory research focus is on the identification of new targets and strategy for pancreatic cancer immunotherapies by dissecting tumor microenvironment of pancreatic cancer. He is considered to be one of world's leading pancreatic cancer oncologists and researchers and one of leading experts in preclinical and clinical development of cancer immunotherapy.

He is the founding Editor-in-Chief of Annals of Pancreatic Cancer. In 2021, he was elected into the American Society of Clinical Investigation. He served or is serving as a Councilor for Pancreatic Disorders (PAN) section of the American Gastroenterological Association Institute Council, a Member of the American Society of Clinical Oncology Grant Selection Committee and Education Committee, and a Member of the American Association for Cancer Research (AACR) Program Committee. He is also chairing the China Regional Advisory Group for the AACR International Affair Committee. He is Vice Chair of the World Association of Chinese Oncologists, is currently the Secretary General of the Committee of Oversea Experts of the Chinese Society of Clinical Oncology (CSCO), and is the Immediate Past President of the Chinese American Hematologist and Oncologist Network (CAHON). Dr. Zheng received his M.D. from Peking Union Medical College and his Ph.D. from University of Texas Health Science Center at San Antonio. He did his internal medicine training at the Long Island Jewish Medical Center (now Northwell Health and the Zucker School of Medicine at Hofstra/Northwell). He did his medical oncology fellowship training at Johns Hopkins.



HKG epi THERAPEUTICS Ltd.
Harnessing the epigenome

DNA METHYLATION 專利技術

• HKG EPITHERAPEUTICS LTD於2016年由加拿大麥吉爾大學MOSHE SZYF教授創辦，實驗室持有美國病理學家學會（CAP）及美國臨床實驗室改進案修正案（CLIA）雙重認證。
• MOSHE SZYF教授及其研究團隊在表觀遺傳學領域擁有近40年的經驗，專注於研究表觀遺傳學中的DNA甲基化標記。我們運用表觀遺傳學研發檢測，著重於常見疾病（如癌症）的檢測、預防及促進老年的健康生活。

• FOUNDED IN 2016 BY PROFESSOR MOSHE SZYF AT MCGILL UNIVERSITY, HKG EPITHERAPEUTICS LTD HOLDS DUAL CERTIFICATIONS FROM THE COLLEGE OF AMERICAN PATHOLOGISTS (CAP) AND THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA). • WITH NEARLY 40 YEARS OF EXPERIENCE IN THE FIELD OF EPIGENETICS, PROFESSOR MOSHE SZYF AND HIS RESEARCH TEAM HAVE FOCUSED ON STUDYING DNA METHYLATION MARKS WITHIN EPIGENETICS. USING EPIGENETICS, WE DEVELOP TESTS WITH A FOCUS ON DETECTING, PREVENTING, AND PROMOTING HEALTHY AGING FOR COMMON DISEASES LIKE CANCER.



癌症早期檢測
EARLY CANCER DETECTION



生物年齡檢測
BIO-AGE DETECTION

BOOTH NO. 3D-B23





Ming Kuang

Vice President

The First Affiliated Hospital, Sun Yet-sen University

Dr. Ming Kuang is professor in hepatobiliary surgery and interventional ultrasound, and Chief of Cancer center in First Affiliated Hospital, Sun Yat-sen University. In clinical work, Dr. Kuang majors in minimally invasive treatments for liver cancer such as laparoscopic surgery, robotic surgery and image-guided tumor ablation, and he is an expert in tumor ablation with world reputation. In the field of basic research, he is interested in the mechanism, prevention and treatment of liver cancer recurrence and metastases, and precision cancer research such as immunotherapy. He has published more than 60 SCI papers in world-famous journals such as Hepatology, Cancer Letters, Radiology, Clinical Cancer Research etc. Dr. Kuang has got 7 major grants from the government, such as National Natural Science Foundation of China and Natural Science Foundation of Guangdong Province. He is vice chairman of Interventional ultrasound and Tumor Ablation Cooperation Committee in Chinese Medical Doctor Association, and chairman of Precision Medicine and Molecular Diagnosis Branch of Guangdong Medical Association.



Ava Kwong 鄺靄慧

Chief of the Breast Surgery Division

Queen Mary Hospital, The University of Hong Kong

Dr. Ava Kwong is the Chief of Breast Surgery Division, Clinical Professor at the University of Hong Kong Medical Centre, Director of the Tung Wah Hospital Breast Centre and Director of Breast Center of University of Hong Kong - Shenzhen Hospital. She is the Assistant Dean (Faculty Advancement and Knowledge Exchange) of Faculty of Medicine, The University of Hong Kong. She is Honorary Consultant in Breast Surgery at Hong Kong Sanatorium and Hospital. She had also held the position of Visiting Associate Professor, Division of Oncology, at the Stanford University, USA from 2006- 2013. She has been appointed to be the co-leader of Cancer Work Group in the development of Cancer Services planning of Hong Kong West Cluster, Hospital Authority in 2012 being responsible in the planning of cancer services for the new development plan of Queen Mary Hospital and cluster. In 2013 she was elected to be the Deputy Chief and Committee Member of the Shenzhen Breast and Endocrine Cancer Society, The People's Republic of China. Aside from her clinical and academic work, she also contributes to the governmental bodies and she has also been appointed to be a member of the Cancer Coordinating Committee of the Food and Health Bureau, Government Secretariat, The Government of the Hong Kong Special Administrative Region, The People's Republic of China in August 2014. During her surgical career, she has gained multiple awards including the Hong Kong International Cancer Congress "Young Investigator Award" in 2006 and 2008 on her research work on breast cancer genetics in Chinese and Asian population, the Breast Surgery International Best Paper Prize, at the International Society of Surgery International Surgical Week meeting in 2007, and a scholarship for undertaking a research fellowship in Breast Cancer Genetics at the Stanford University School of Medicine in 2005.



Lily Zou

**CEO and Co-Founder
Degron Therapeutics**

Lily Zou is the Co-founder and CEO of Degron Therapeutics. She is a seasoned executive with comprehensive scientific knowledge in drug discovery and development and extensive business and commercial expertise. Prior to joining Degron, Dr. Zou served as CEO of Fosun Pharma USA, Vice President of Fosun Pharma Group, Healthcare Partner of Fosun Pharma, and Chairman of the Board or Board member of four companies invested by Fosun Pharma. Dr. Zou built and grew Fosun Pharma's US business and founded Fosun Pharma's incubator named Fusion Bioventures based in Boston, which invests and incubates early stage innovative biotech companies. Dr. Zou also built a sales and marketing team in the USA for Fosun Pharma drugs and diagnostics, and launched Fosun Pharma's first products in 2019. Before Fosun, Dr. Zou worked in top management consulting firm (Bain), large pharmas (Novartis/Sandoz, Wyeth, Millennium), and small biotechs (ArQule, Coley).

Dr. Zou received a BS from Beijing University, a PhD in Microbiology and Immunology from Cornell University, and a MBA from MIT Sloan School of Management.



Tony Wong

**Chief Scientific Officer
Arbele Ltd.**

Dr. Wong received his PhD in surgical oncology from the University of Hong Kong and postdoc in liver cancer at the Cancer Science Institute and National University of Singapore. He has published over 30 original research articles, including Nature Genetics and the New England Journal of Medicine. Prior joining Arbele, he led discovery oncology and immunology research at Roche and Janssen Pharmaceuticals in Shanghai, China. Dr. Wong is responsible for discovery science in bispecific antibodies, ADC, and CAR-NK/T programs from drug discovery to IND enabling.



Ignacio Asial

**Founder and CEO
DotBio Pte. Ltd.**

Dr. Ignacio Asial is the CEO and Founder of DotBio, a Singapore-born biopharma company specialized in next-generation antibody therapies. He is also an Adjunct Assistant Professor at Nanyang Technological University.

Prior to launching DotBio, Dr. Asial held diverse scientific positions. He worked in academia in institutions such as NTU, UCSF, and Centre National de la Recherche Scientifique, as well as in the private sector at Ambrilia Biopharma and Genentech.

Dr. Asial obtained a M. Eng. in Biotechnology from Ecole Supérieure d'Ingénieurs de Luminy / Polytech Marseille, a M.Sc. in Biochemistry, Structural Biology, Bioinformatics and Genomics from Aix-Marseille University, and a Ph.D. in Biological Sciences from NTU. He specializes in technology development, in particular in the fields of antibody engineering and directed evolution.

tibtech.
a subsidiary of Arbele Limited

ARBELE

TIBTECH DIAGNOSTICS


DEVELOPING COMPREHENSIVE IVD SOLUTIONS FOR PATIENTS WITH GI DISEASE

TibTech IVD Pipelines

TIB-17C (CDx) TIB-17S (IVD) TIB-01B (Blood) TIB-03P (POCT)



BLOOD DX



*RUO Test Only, Not for Diagnostics Purpose

>300 Clinical colon samples tested

90% Detects 90% of high-risk polyps

>70% With >70% specificity

First-in-class molecule
Exclusive worldwide in-
license of CDH17 from
HKU

Blood Diagnostics

Proprietary CDH17 non-
invasive blood test for
CRC screening

Tissue Diagnostics

Automated AI-integrated
system for standardized,
high-throughput CDH17
IHC assay



TISSUE DX

>400 GI Tissues have
been validated

48 Fast TAT <48 hrs

Strong correlation between
NMPA and FDA IHC platforms

TIB-17C is used to pre-screen CDH17
GI cancer patients in ARB202 Phase 1a



High benefit/cost effectiveness

Highly sensitive CRC
screening test offered
at pocket-friendly price

Quality Assurance

ISO 9001:2015
accredited diagnostic
tests

Ref: 1 Ng L et al. JCO 2023 41:16 suppl. e14651
2 Ng L et al. JCO 2023 41:16 suppl. 3058

Collaborating Partners

瑪麗醫院
Queen Mary Hospital

中山大學
腫瘤防治中心

伊利沙伯醫院
QUEEN ELIZABETH HOSPITAL

中山醫院
CHANG HONG HOSPITAL

HKSTP

Tiberias Technology (HK) Limited

Contact Us 3956 8616
IVD@tiberiastech.com

Visit our
website to
learn more



CityU
香港城市大學
City University of Hong Kong

HK
TECH
300



Noninvasive Cardiovascular Screening 無創進階心臟全功能檢測



Cardiac Home

The Cardiac Home incorporates with the TEBCO technology that allows us to monitor our cardiovascular health noninvasively at home.

- AI analysis of the user's cardiac parameters demonstrated on the software app.
- Recognise the user's lifestyle to achieve a personalized cardiovascular health analysis.
- Operates on a cloud-based platform that connects to numerous healthcare organizations for individualized health plans to precisely achieve optimal cardiovascular health.

Cardiac Home 運用胸腔生物電阻抗技術 (TEBCO)，讓我們能夠在家中無創地監測心血管健康。

- 在軟件應用程序上展示用戶心臟參數及人工智能(AI)分析。
- 識別用戶的生活方式，實現個性化的心血管健康分析及建議。
- 基於雲端技術，與眾多醫療服務機構連接，以制定個性化的健康計劃，精確實現最佳的心血管健康。


Cardiac Skin

The Cardiac Skin comprises a thin graphene film and NCCOM3 technology to measure circulatory conditions and hemodynamic status at the same time.

- An ultra-small, wearable device that monitors cardiovascular health noninvasively, continuously, and remotely.
- Can be used clinically for hypertension management and post-surgical health states.
- Achieve an optimal clinical outcome and individualized drug prescription and health plan.

Cardiac Skin結合石墨烯傳感技術和無創連續心輸出量監測技術(NCCOM3)，可同時測量身體循環和血流動力學狀態。

- 超小型可穿戴設備，可無創、連續和遠程監測心血管健康。
- 可在臨床上用於高血壓管理和術後健康狀態監測。
- 實現最佳的臨床結果和個性化的藥物處方和健康計劃。



Website: www.sramekinsight.com

Email: sramekinsight@gmail.com

Telephone: +852 2488 8168

WhatsApp: +852 6769 1972

Address: Room 626, 17W West Avenue, Science Park, Shatin, N.T.



Rose Wang

Director
AIM-HI Accelerator Fund

Rose Wang is a serial entrepreneur who helps other individuals and teams—including female cancer researchers—start their own businesses and make them thrive.

Wang is the founder of Binary Group, a consulting and business solutions firm. She also currently serves as Executive Advisor to the AIM-HI Accelerator Fund, a cancer impact investment organization launched in 2019 by the National Foundation for Cancer Research (NFCR) that focuses on early stage cancer start-ups.



Shane Burgess

Chairman and Co-CEO
Treadwell Therapeutics

Dr. Shane Burgess is a Co-Founder, Chairman, and Co-CEO of Treadwell Therapeutics, headquartered in Hong Kong. In addition to co-founding several successful international companies, including FYiDoctors, Shane has held leadership roles in organizations ranging from seed-funded start-ups to leading global companies and has consistently built and led high performance teams to drive innovative product development, deliver entity-wide strategic and operational effectiveness, and achieve transformative corporate and business development results.



Dajun Yang 杨大俊

Chairman, Executive Director and CEO
Ascentage Pharma

Dajun Yang, Ph.D., is the Co-Founder, Chairman of the Board, and Chief Executive Officer of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential "First-in-class" or "Best-in-class" innovative drug candidates in Phase I/II clinical developments in China, the United States and Australia. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the "863 Program") and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 "Dushu Lake Prize" for the Most Influential Leader in Drug R&D, an award widely recognized in the field drug R&D. Dr. Yang was the president of Chinese Biopharmaceutical Association-USA from 2005 to 2006 and has concurrently served as professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, vice director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences.



Zane Yang

**Chief Medical Officer
ABM Therapeutics**

Dr. Zane Yang, a research physician with more than 20 years' experience in academic research and the pharmaceutical industry, is the Chief Medical Officer (CMO) of ABM Therapeutics.

Before joining ABM, Dr. Yang was CMO of Denovo Biopharma. During his tenure, he expended and improved company's clinical research and development capability including two global phase 3 pivotal trials of enzastraurin in patients with newly diagnosed diffuse large B-cell lymphoma or glioblastoma multiforme. Prior to Denovo, Dr. Yang was Senior Vice President and US General Manager of Innovent Biologics. He built the company's first US R&D center and established multiple clinical trials in the US to develop sintilimab and an anti-CD47 antibody (IBI-188). Before joining Innovent, he was Senior Vice President of Clinical Research and Development for Spectrum Pharmaceuticals, where he led the entire R&D organization with a focus on developing two late-stage investigational drugs, Rolvedon (now it is approved by the US FDA) and poztotinib. In his early career years for the industry, he was Vice President, Oncology Clinical Development of Inovio Pharmaceuticals for DNA based cancer vaccine and therapy development. He also worked for Janssen Biotech / J&J Pharmaceutical Company, Novartis and Merck & Co.

Dr. Yang graduated from Peking University Medical School. Before his industry career, he was associate professor at University of Virginia Medical Center.



BOOTH NO. 3D-C26

Zhejiang Difference Biological Technology is a world-class biopharmaceutical company based on recombinant virus vector technology platform, and is committed to R&D of mucosal immune vaccines, antiviral drugs high-throughput screening (HTS) system, virus vector, gene therapy, oncolytic viruses, etc.

At present, Difference is promoting 3 vaccines to IND stage - nasal influenza vaccine, nasal COVID-19 vaccine, and DIVA avian influenza vaccine. Most of the pipelines are mucosal immune vaccines, with the advantages of broad-spectrum, prevent infection for respiratory infectious diseases and more convenient to vaccination.

At the same time, Difference provides CRO services such as live imaging pharmacodynamic evaluation service, HTS system for antiviral drugs, vaccine/vector design services, IVD product development service, customized scientific research service, etc.

Company Honors : 23rd China Patent Excellence Award, National High-tech Enterprise, Hangzhou High tech Research and Development Center, Hangzhou Listed backup enterprises, Hangzhou 5050 plan

SGS Biosafety Solutions

Health Inspired, Quality Driven.

Our solutions

Our Center of Excellence for biosafety based in Glasgow provides:

- Electron microscopy
- GMP Sanger sequencing
- Viral vaccines Adventitious agents and species specific viruses
- Replication of competent vectors
- Retrovirus
- Process impurities
- Genetic stability
- Other microbial contaminants

Supporting a variety of molecules

Our team of experts can support manufacturers of:

- Monoclonal antibodies
- Recombinant proteins
- Viral vaccines
- Cell therapies
- Gene therapies

"Most notably, the Biosafety Center of Excellence in Glasgow has participated in the batch-testing and release of over 3 billion doses of COVID-19 vaccine, helping to increase vaccine access and bring the global population out of the pandemic."

Archie Lovatt

Site Manager & Scientific Director at SGS

Contact us

To discuss your biosafety requirements, contact us today.

☎ +44 141 952 0022

✉ healthscience@sgs.com

🌐 sgs.com/services/biosafety

🌐 sgs.com/linkedin

INNOVATION GALLERIA | 創新廊

Synthetic Biology, Cell/Gene Therapy, Globalization

Thursday, September 14 | 11:00 AM - 17:30 PM (GMT+8)

Potential of Synthetic Biology in Healthcare

11:00 - 12:00

Chair: Prof. Fei Sun, Hong Kong University of Science and Technology

Synthetic biology: its implications on science and biotech development in Hong Kong

Prof. Jian Dong Huang, University of Hong Kong

Antibody reactions and exosomes for immunotherapy and osteoarthritis treatment

Prof. Jiang Xia, Chinese University of Hong Kong

Precision engineering of the gut microbiome

Dr. Lei Dai, Shenzhen Institute of Advanced Technology

Rewrite Health with Cell/Gene Therapy

12:00 - 14:00

Comparison of rAAV vectors manufactured by large-scale suspension cultures of sf9 and HEK293 cells

Chair: Dr. Shengjiang Liu, Avirmax Biopharm Inc.

Chair: Prof. Xumu Zhang, Southern University of Sci&Tech

Regulatory T cell intravitreal delivery using hyaluronan methylcellulose hydrogel improves therapeutic efficacy in experimental autoimmune uveitis

Dr. Wai Po Chong, Hong Kong Baptist University

Driving the next breakthroughs in cancer immunotherapies

Dr. Darren Ji, Elpiscience Biopharma

Less is More: Efficient non-viral immune cell engineering by circular single-stranded DNA mediated precise genomic integration

Dr. Howard Wu, Full Circles Therapeutics

Chinese Pharma Going International: Opportunities and Challenges (FDA Expert Club)

14:00 - 15:30

Strategies of Global Collaboration and Licensing for Chinese Innovative Pharmaceutical Industry

Opening Speech: Dr. Angela (Yuxin) Men, CMO for Haichang Biotech; CEO for The WhiteOak Group Inc

Key Considerations for China Biotech's Global Collaboration

Dr. Ning Li, Junshi Biosciences

Oversea License-out strategy of Chinese Innovative Drug Candidate

Dr. Tao Du, Evergreen Therapeutics

Panelists:

Mr. Ming Tang*, Yunnan Baiyao Group

15:30 - 16:30

Strategies for Global Innovative Drug & Device Development

Moderator: Dr. Angela (Yuxin) Men, CMO for Haichang Biotech; CEO for The WhiteOak Group Inc

Leverage AI in clinical research for enhanced drug development (利用人工智能在临床研究中提高药物开发效率)

Dr. Changqing Li, Evergreen

U.S. regulatory policy trend and legal considerations: from FDA's perspective

Dr. Yuzhi Hu, Sidley Austin

Updates on the ICH Q1/Q6 guidelines by the ICH Quality Expert Working Group (EWG)

Dr. Xiaobin Zhao, Haichang Biotech

Accelerated programs for innovative medical devices: breakthrough device designation and safer technology program

Dr. Zhang Mingdong Suzhou SINUS MedTech

Panelists:

Dr. Jimmy Wei, Chime Biologics

Ms. Shouqun Wang, China Commercial Lam Lee Lai Lawyers

16:30 - 17:30

Domestic Companies Going Global

Clinical and Regulatory Considerations for Domestic Biotech Companies Go Overseas

Dr. Shen Xiao, 3D Medicines, Inc.

下一代靶向CLDN18.2的抗体药物的设计及全球开发

Dr. Xueming Qian Transcenta

Panelists:


Mr. Yongheng Huang, Guangdong Association for Standardization

Ms. Huifang Wang, Shenzhen Biotech & Industry Cleaning Association

*No biography or information was provided before September 11, 2023.

Innovation in Cancer Therapy

Radiopharmaceutical for Cancer



Radioisotope produced by our linear accelerator installed near you

- New and current types of radioisotopes
- Possibility for shorter half-life radioisotopes
- Lower production / installation costs
- Increased availability
- No need to rely on imports

Targeting Molecule

- Proven methodology to develop new molecules specific for different cancer
- Can also work with existing targeting molecules





Fei Sun 孫飛

Associate Professor

Department of Chemical and Biological Engineering, HKUST

Prof. Fei Sun is an Associate Professor at the Department of Chemical and Biological Engineering, HKUST. Before joining HKUST in 2014, he worked as a postdoctoral scholar at the Department of Chemical Engineering, Caltech (supervisor: Frances H. Arnold, 2018 Nobel Laureate in Chemistry). He obtained Ph.D. in Chemistry from the University of Chicago in 2012 (supervisor: Chuan He, 2022 Wolf Prize Laureate in Chemistry) and B.S. in Chemistry from Peking University in 2007. His research interests include materials synthetic biology, protein engineering, optogenetics, chemical biology, and regenerative medicine. He is the awardee of NSFC Excellent Young Scientists Scheme (2021) and the Hong Kong RGC Research Fellow (2023).



Jiandong Huang 黃建東

Chair Professor of Synthetic Biology

The University of Hong Kong

Prof. Huang earned his BS degree from Fudan University, Shanghai and went to the US through the CUSBEA program to pursue his PhD study in transcriptional regulation during fruit fly embryonic pattern formation. He earned his PhD degree from the University of California, Los Angeles. Thereafter, Prof. Huang received his postdoctoral training in mouse genetics at National Cancer Institute, NIH in the USA. During this period, Prof. Huang was the first to report that the two major intracellular transportation systems of mammalian cells, the microtubule- and actin-filament-based system directly interact with each other through their motor proteins, kinesin and myosin. Later, he established his own laboratory at the University of Hong Kong. Prof. Huang is now the Chair Professor of Synthetic Biology and the L & T Charitable Foundation Professor in Biomedical Sciences in the School of Biomedical Sciences, the University of Hong Kong.

Prof. Huang's current research focuses on two areas: synthetic biology and intracellular transportation. For intracellular transportation study, Prof. Huang has focused on illustrating the functions of a microtubule-based motor molecular, Kinesin-1, in different cell types, aiming at understanding its roles in different cell types in development and disease. For synthetic biology, Prof. Huang have created novel genetic circuits for the control of gene expression and hence biological behavior. One successful example is the design and assembly with his colleagues of a genetic circuit for the spatiotemporal control of cell distribution and function. This new circuit was used to reveal how repetitive biological structure could be generated and how the number of repeats in biological structures can be controlled. Most recently, his team further engineered the interactions among multiple cell types to generate biological structures. The abilities for spatiotemporal control of gene activities, cell-cell interactions, cell distribution and functions are very useful for future preventive and therapeutic medicine, which Prof. Huang is applying to vaccine development and cancer therapy.



Jiang Xia 夏江

Professor

Department of Chemistry, the Chinese University of Hong Kong

Prof. Jiang XIA is a professor in the Department of Chemistry at the Chinese University of Hong Kong, and a professor (by courtesy) in the School of Life Sciences. Xia Jiang, graduated from the Department of Intensification of Nanjing University with a Bachelor of Science in 1999, received a Master of Science from Nanjing University in 2002, graduated from Stanford University with a PhD in 2006, and completed a postdoctoral degree at the California Institute of Technology (concurrently employed by the Howard Hughes Medical Institute).



Lei Dai 戴磊

Director

Center for Synthetic Microbiome

Shenzhen Institute of Advanced Technology

Dr. Lei Dai is the Director of Center for Synthetic Microbiome at the Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences. Dr. Dai received B.S. in Physics at University of Science and Technology of China and Ph.D. in Physics at Massachusetts Institute of Technology. He was a Jane Coffin Childs postdoctoral fellow at UCLA School of Medicine. His research group at SIAT develops novel experimental and computational approaches to study the ecology of complex microbial communities and improve host health via precision microbiome engineering. His works have been published in *Science*, *Nature*, *Cell Host & Microbe*, *Nature Communications*, *PNAS*, etc. He is the recipient of MIT Technology Review 35 Innovators Under 35 in China.



Shengjiang Liu

President and CEO

Avirmax Biopharma Inc.

Dr. Liu is an experienced biotechnologist, biopharma scientist, entrepreneur and executive. After receiving his Ph.D. in biochemistry from Kansas State University and completing his post-doctoral training with Dr. Arthur Kornberg, Stanford University, he served as the group leader at Genentech Virology Research Lab. He discovered and characterized rabbit calicivirus (RCV) which caused rabbit hemorrhagic disease (RHDV) in 1984. He developed an inactivated RHDV vaccine and several fast detection methods that were effectively used for controlling and preventing RHD disease Worldwide. In 2000, he co-founded and acted as the president of Abmaxis Inc., which pioneered the breakthrough antibody engineering and production technology called Abmaxis In Silico Immunization (ASIMTM). Abmaxis Inc. was acquired by Merck Co. in 2006. Between 2006-2019, he was the Sr. Principal and Chief Scientist in Biological Development of Bayer Pharmaceuticals. He played important roles in the development and regulatory submission of 33 biologics during his biopharma career, including recombinant human factor VIII (rhuFVIII), Kovaltry®, long acting rhuFVIII-BDD (Jivi®), Rituxan® etc. Before joining Avirmax, he was actively involved in AAV-FVIII gene therapy development for hemophilia A. Now he is focusing primarily on AAV capsid & GOI engineering, payload innovation, development, and production for ocular disorders.



Xumu Zhang

Professor of Chemistry

Southern University of Sci & Tech

Professor Xumu Zhang has published more than 350 academic articles in academic journals including *Science*; *J. Am. Chem. Soc.*; *Angew. Chem.* His papers are cited more than 15,000 times, of which a single paper is cited more than 1300 times and his H index is over 75. Professor Zhang received the Arthur C. Cope Scholar Award from the American Chemical Society in 2002 and was the first mainland Chinese scientist to receive this award. The Zhang enyne cycloisomerization, a named reaction, developed by Professor Zhang is crowned with his last name because of its importance. At present, less than five Chinese in the world have this honor. Professor Zhang won the title of "Shenzhen Gentleman of the Year 2016" because of his contribution to the establishment of the first research institute named after the Nobel Prize winner in China, Shenzhen Grubbs Institute.

科学家 企业家 梦想家的创业家园

—— 多园联动 打造世界级生物医药产业集群 ——

独栋厂房现正租售中, 公寓火热预订

厂房 $1000-12000\text{m}^2$ 星级公寓 $46-60\text{m}^2$



广东医谷·南沙生命科技园

双园联动, 打造南沙生物医药前沿产业带

主导产业

高端医疗器械、生物科技、细胞治疗、体外诊断、疫苗、创新药、免疫治疗、基因治疗等

· 南沙区首个国家级科技企业孵化器 · 已入驻企业300多家

· 南沙一园总建面约18万 m^2 · 南沙二园总建面约13万 m^2



实景图



效果图



广东医谷·珠海生命科技园

广东省重点建设项目

主导产业

生物医药、高端医疗器械、生物技术等

· 一桥通深圳, 一桥通港澳 · 总建面约22万 m^2 · 配套星级公寓—云珠阁, 筑就塔尖圈层私属地



广东医谷·云东海生命科技园

广东省重点建设项目

主导产业

创新药、疫苗、高端医疗器械、免疫治疗等

· 佛北战新主园区 · 云东海生物医药产业园

· 一期占地113亩, 总建面约19万 m^2 , 预计2023年7月交付



效果图



广东医谷·中山生命科技园

大湾区生物医药产业创新中心

主导产业

重点引进生物药、细胞工程、基因治疗、免疫治疗、基因芯片、大型医疗设备、高值耗材、诊断试剂等细分领域龙头企业

· 总建面约60万 m^2 · 配备污水处理站和危险品仓库

· 预计2024年2月一期交付



效果图

☎ 400-876-1199

生物医药产业生态创领者



南沙生命科技园(一期): 广州市南沙区南江二路6号 南沙生命科技园(二期): 广州市南沙区黄旗二路北 珠海生命科技园: 珠海高新区永创路6号 云东海生命科技园: 佛山市三水区云东海大道48号 中山生命科技园: 中山市福泽路17号

官网: www.medv.com.cn 总部地址: 广州市天河区珠江新城珠江东路30号广州银行大厦七楼

免责声明: 本宣传材料属于要约邀请, 其中对项目周边环境、交通/公共设施、政府规划、商业配套、教育资源、发展前景、区位等的展示或介绍, 旨在提供相关信息参考, 开发商对此不作任何承诺, 买卖双方的权利义务以最终订立的合同约定为准 (制作时间2023年7月)。



Wai Po Chong 莊偉波

Associate Professor

**Chinese Medicine – Teaching and Research Division
Hong Kong Baptist University**

Dr. Chong obtained his MPhil and PhD in Immunology from the Department of Paediatrics and Adolescent Medicine at The University of Hong Kong. He received his postdoctoral training in immunology from the National Eye Institute at National Institutes of Health (NIH) in Bethesda, MD, USA. After that, he was appointed as the Associate Professor at the Key State Laboratory of Ophthalmology, Sun Yat-sen University in Guangzhou, China. He joined the School of Chinese Medicine, Hong Kong Baptist University, as the Associate Professor in 2022.

Dr. Chong's research centers on the cellular and molecular mechanism involved in immunoregulation and autoimmunity, and discovering novel therapeutic drug for autoimmune diseases. His works on autoimmunity have been well recognized and published in prestigious journals, including Immunity, Journal of Experimental Medicine, Journal of Autoimmunity, Hepatology and Journal of Infection.



Darren Ji

**Co-founder, Chairman and CEO
Elpiscience Biopharmaceuticals**

Darren is Co-founder, Chairman, and CEO of Elpiscience. Prior to co-founding Elpiscience, Darren served as Venture Partner of Lilly Asia Ventures (LAV). Before joining LAV, Darren served as the Global Head and Vice President for Asia and Emerging Markets of Roche Partnering, Roche's deal-making body that manages the company's business development. While at Roche, Darren was responsible for driving the strategy and execution of partnering activities in the territory of Asia and Emerging Markets encompassing over 100 countries. During his tenure, Darren also championed and oversaw the closing of many key transactions between Roche and partners worldwide. He managed a global team and established a strong business network in key countries like China, Japan, Korea, Australia/New Zealand, Russia, and Brazil.

An accomplished entrepreneur himself, Darren spent a long career at the Procter & Gamble Company with increasing responsibilities in drug R&D and business development. He co-founded and managed as CEO of PharmaLegacy Laboratories in Shanghai in 2008, which became a premium CRO providing high-quality drug discovery services to a global clientele. Darren has been a highly respected leader in global life sciences and a sought-after speaker in various business forums. He was also an avid community builder exemplified by one of the longest tenures as a board member of the BayHelix Group.

Darren received his medical training at China Medical University, a Ph.D. from the University of Sheffield in the UK, and an MBA from the University of Chicago.



Howard Wu

Co-founder and CEO/CSO
Full Circles Therapeutics

Dr. Howard (Hao) Wu has almost 20 years' experience in gene editing technology and new drug discovery. He is specialized in overseeing R&D programs, new lab and research team set up in the biotech start-ups.

Dr. Wu is the co-founder and CEO/CSO of Full Circles Therapeutics, where he is dedicated to developing curative gene editing based gene/cell therapy. He is responsible for generating revenue through collaboration with MNC and biotech partners. Before founding Full Circles Therapeutics, Dr. Wu was leading multiple discovery biology programs and disease prioritization in the genetic disease space at Fulcrum Therapeutics Inc. (NASDAQ:FULC), a Cambridge small molecule drug discovery biotech company. He had been with the company through the full development phases starting from the start-up, expansion, until post-IPO development, during which he led a cross-functional team for portfolio disease selection and prioritization of multiple disease programs including neuromuscular disease, cardiac disease, hematological and metabolic diseases, including two major partnership collaborations with MyoKardia and Acceleron.

Before joining Fulcrum, Dr. Wu was a senior research fellow at Whitehead Institute, MIT. His research focused on neurological disorders utilizing a combination of CRISPR/Cas9 mediated genomic and epigenomic editing technology and stem cell technology. He did his PhD in Biochemistry and Structural Biology at Hongkong University of Science and Technology (HKUST) and Bachelor's degree in Chemistry from Fudan University before he did his postdoctoral research at Johns Hopkins University School of Medicine and Howard Hughes Medical Institute. Dr. Wu has more than 30 journal publications, patents, and research and industry grants. For his work, he has received fellowship award from human frontier science program (HSFP) and NARSAD young investigator award. He was also awarded the Alfred Blalock Young Investigator Award from JHMI and President's award from Whitehead Institute, MIT.



Yuxin Men 门宇欣

Chief Medical Officer
Haichang Biotech

Dr. Men joined the U.S. Food and Drug Administration (FDA) in 2003, and has served as senior/master clinical pharmacology reviewer, and team leader in the Office of Clinical Pharmacology, Center for Drug Evaluation (CDER), mainly responsible for evaluation of oncology and neurological drugs IND/NDA/BLA. In her nearly 18 years of drug regulatory career, she has reviewed/approved more than 2,000 new drug applications. She has received more than 50 awards from FDA, including Distinguished Service Award, Excellent Mentor Award, Distinguished Leadership Award and Excellent Regulatory Science Award. She has led many research projects related to drug review, won 12 FDA research grants, and participated in leading the development of several FDA guidelines. In May 2022, Dr. Men was recommended by PhIRDA to become an expert in the working group of ICH E21: Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials guidelines.

Dr. Men is the vice president of the Chinese Biopharmaceutical Association – USA, the board member and vice president of the Chinese FDA Expert Association, and she is also the member of the Federal Asian Pacific American Committee (FAPAC) and the assistant chairman of the community outreach department. She hosted and served as the organizer or lecturer for many national and international conferences and made great contributions to building a communication bridge between China and the United States in biopharmaceutical field. Dr. Men graduated from Tianjin Medical University with a bachelor's degree in clinical medicine and obtained her Ph.D degree in pharmaceutical sciences from Virginia Commonwealth University. Since July 2021, she has served as the chief medical officer of Haichang Biotech. She has also served as the CEO of its subsidiary in US, The WhiteOak Inc. since early 2023.



GREEN LIFE TECHNOLOGY LTD.

PRESENTS

Official Distributor Hong Kong



HAB® HERRMANN - THE PIONEER IN MODERN OZONE-OXYGEN- & COLON-HYDRO-THERAPY.

Our certified medical devices set international standards. Since 1984.

AS THE MARKET LEADER, WE HAVE A HIGH RESPONSIBILITY.

HERRMANN Apparatebau GmbH (HAB®) can look back on 40 years of methodically acquired expertise in the development and manufacture of high-quality medical devices. Today, HAB® is the market leader in Ozone-Oxygen- and Colon-Hydro-Therapy. Worldwide.

What sets us apart are our constantly evolving innovations and the best possible implementation of the highest patient safety standards in our competence centre - for safe, economical and future-oriented therapies.

**PATIENT SAFETY AND COST-EFFECTIVENESS. MADE IN GERMANY.
EVERYTHING UNDER ONE ROOF. EVERYTHING FROM A SINGLE SOURCE.**



Hyper Medozon comfort

GREEN LIFE TECHNOLOGY LTD.

Room 917, Hewlett Centre, 54 Hoi Yuen Road,
Kwun Tong, Kowloon, Hong Kong
marketing@greenlifetechnology.com.hk
showroom appointment: + 852 6276 3745



**Colon
Hydromat** comfort



Tom Du 杜涛

Chairman
Evergreen Therapeutics Inc.

Dr. Tom Du graduated from Tianjin Medical University and received his PhD from McGill University in Canada. He received two years of post-doctoral training at Harvard University in the United States, under professor Frank Austen, member of the National Academy of Sciences. Since 1994, he has served as a new drug reviewer for FDA for 7 years. After joining FDA in late 2000, he served as the Director of The Registration Division of United Healthcare Corporation in the United States and senior Director of Clinical and Registration Division of Hutchison Whampoa Pharmaceuticals in Hong Kong. Since then, he has served as Humphrey's chief pharmaceutical development consultant in Humphrey Medical Consulting Co., LTD., leading a new drug development team from different countries, different cultural backgrounds and different specialties to successfully complete more than 100 new drug development and application work. He is currently a visiting professor of Peking Union Medical College, president of FDA Society and president of the Association of Regulations and Agreements.



Ning Li 李宁

CEO
Junshi Biosciences

Dr. Li is responsible for formulating business strategies and managing operation of the Junshi Biosciences.

From 1997 to 2010, Dr. Li worked at US Food and Drug Administration (FDA) as a regulatory reviewer and held various positions from Oncology drug team reviewer, senior reviewer/expert reviewer, senior GCP medical reviewer to team leader, branch chief with increasing responsibilities. Before he joined Junshi Biosciences, Dr. Li was appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He has extensive experience and expertise in clinical research and medical product evaluation.

Dr. Li obtained his bachelor's degree in public health from Shanghai Medical College of Fudan University, the PRC in July 1984 and his master's degree in medicine from Shanghai Medical College of Fudan University, the PRC in October 1987. He obtained his Ph.D. degree in preventive medicine from University of Iowa, the US in August 1994.



A4BEE

We deliver
digital innovation
for **biotech, pharma**
and **manufacturing**.

BOOTH NO. 3D-B18

Visit
our booth!
3D-B18

**Connectivity
& Integration**

**Modular
biotech smart
components**

**Lab retrofitting:
Edge and IoT
connectivity**

**Cloud
bioprocess
monitoring**

**AR / VR
solutions**

**End-2-End
software & platform
development**

**Manufacturing
& lab equipment**

**Control and
Automation
engineering**

\$10m

worth clients'
projects

80+

projects
in 4 years

85%

of clients return
with new
challenges

120+

talents
working
with us


**Curious?
Contact us!**

HELLO@A4BEE.COM
WWW.A4BEE.COM




MGI Tech Co., Ltd.

*As of December 31, 2022



DNBSEQ™ 核心技术
MGI Core Proprietary DNBSEQ™ Technology





Yuzhi Hu 胡育志

FDA Attorney
Sidley Austin LLP

Dr. Yuzhi Hu was a senior policy advisor at the U.S. Food and Drug Administration (FDA) from 2014 – 2022. As a pharmacist and epidemiologist by training and veteran FDA staff, Yuzhi focused on clinical trial evaluation and policy at the Center for Device and Radiological Health (CDRH). He led teams reviewing marketing application and postmarket oversight and compliance of devices in all therapeutical areas and submission types including PMA, 510(k), De Novo, HDE, PAS, and 522 mandated surveillance studies. Yuzhi led the CDRH-wide Real-World Evidence program and served as a voting member at the CDRH Policy and Process Governance Board. He was often consulted internally and externally on a wide range of subjects, including clinical trial design, data integrity, relevance, reliability, registry development, breakthrough designation, regulatory compliance strategy development, and more. Yuzhi also collaborated with and brought insights to international audiences, especially the regulators and regulated entities in China. He has provided training to FDA staff routinely regarding assessment of clinical evidence in regulatory decision-making.

During his time at the FDA, Yuzhi received numerous awards including most recently the 2021 “CDRH Honor Award” and “FDA Excellence Award.” Now, as a FDA attorney at Sidley Austin LLP, Yuzhi focuses his practice on various FDA regulatory, compliance, and enforcement issues. Yuzhi brings a combination of regulatory insight and scientific rigor into the complex issues that our clients face. Yuzhi helps lifescience companies, especially those with China background, navigate the intricacy of entering the US market.



Shen Xiao 肖申

Chief Medical Officer
3-D Medicines

20 years review experience at the US. Food and Drug Administration (FDA). At the FDA, he started as a Pharmacology/Toxicology reviewer, then became a Medical Officer after passing the US Medical Licensing Examination and was later promoted to Senior Medical Officer. He has provided non-clinical and clinical reviews for several hundred INDs including all the stages of the drug development process. He has also reviewed and approved more than ten NDAs/BLAs as a primary clinical reviewer and as a multi-discipline review team leader.

Prior to FDA, as an attending physician in Nephrology in China and research fellow in US, he had more than ten years of experience in clinical nephrology practices, studies in pharmacokinetics and dose regimens of various antibiotics in dialysis populations, and research in cellular signal transduction in various endothelial and epithelial cells under different human pathological conditions. He has received several scientific awards including the Excellence in Analytical Science Award by CDER/FDA, Hoechst Marion Roussel Excellence in Renal Research Award by the American Physiological Society, Young Investigator Award by Japan National Society of Dialysis and Artificial Organs, Young Investigator Travel Grant by International Society of Nephrology, China National Scientific and Technological Third Award, and more.

He obtained his PhD in Renal Physiology and Cell biology from West Virginia University Graduate School of Health Science Center. He had his postdoctoral training from Department of Nephrology, Johns Hopkins University, and the Department of Cardiology, University of North Carolina prior to joining in FDA.

生物谷

生物谷一直深耕于生物医药领域，在生物行业有着极高用户关注度与知名度。生物谷网站（www.bioon.com）资讯内容包括医药产业、制药、转化医学、生物产业、生物研究、医疗健康、医疗器械等热门主题。依托互联网，面向企业和研究机构，提供全面的咨询，行业分析服务，针对行业不同的人群进行服务细分，提供领先、精准、高效地服务体系 and 解决方案。

生物谷会议聚焦“新发现，新技术，新产业”。特别在转化医学方面，重点推动科研学术与临床应用结合，将最新的理论，医学手段与技术与临床实践结合。自成立以来，每年举办近百场转化医学领域的会议与培训，涉及肿瘤、心血管、内分泌代谢等领域。其中，率先在国内举办非编码RNA，生物标志物，肿瘤干细胞，下一代免疫治疗，细胞治疗，脑科学等前沿学术会议，推动相关创新性技术在临床和科研领域的普及与应用，助力中国科研与临床整体水平提升。此外，会议注重产业推进与合作交流，举办了分子诊断、生物制药、生物大分子论坛、大数据与人工智能，医用材料，健康管理等领域的盛会。

生物谷秉承专业、专注、独立的精神，以会议实际效果为根本出发点，客观、公正地推动新技术的学术研究与开放合作，在专家与业内均赢得广泛口碑与赞誉。至今已成功举办生物医药行业研讨会、论坛、峰会超过百场。干细胞研讨会、个体化用药前沿研讨会、POCT产业发展论坛、生物制药周、细胞治疗系列会议等已成为行业会议的标杆，为促进产学研交流合作，推动行业的发展起了重要的影响。





Changqing Li

Chief Medical Officer
Evergreen Therapeutics

Dr. Li graduated from the School of Medicine of Xi'an Jiaotong University, and received his master's degree in hospital management and his doctor's degree in public health from the University of Alabama at Birmingham, USA. He worked as a resident physician at the University of Chicago Medical Center for three years and was licensed as a physician in the United States and certified as a clinical pathologist. Dr. Li was a senior medical reviewer of the US Food and Drug Administration (FDA), and was the first person from mainland China who studied abroad to enter FDA clinical review as a doctor. He has experience in FDA drug review and has led the development of new drugs for a number of multinational pharmaceutical companies. Dr. Li has extensive experience developing new drugs in oncology, immunotherapy, anti-inflammatory, gastrointestinal and gynaecological diseases, and has extensive experience in Phase I to IV clinical trials worldwide. He has led hundreds of clinical trials and more than 30 new drug applications worldwide. In addition, he has extensive experience working with global drug regulatory agencies (FDA, EMEA, MHRA, Health Canada, PMDA, DCGI [India] and NMPA [China]).



Xiaobin Zhao 赵孝斌

Founder and CEO
Zhejiang Haichang Biotech Co., Ltd.

Ben Zhao is founder and CEO of Zhejiang Haichang Biotech Co., Ltd. (HCBio). Prior to HCBio, Dr. Zhao is a CMC reviewer and GMP inspector specialized in complex drugs at the US FDA. In 2014, he founded HCBio devoted to developing high-quality liposomal drugs with rational design. Previously, Dr. Zhao was a group leader in developing small interfering RNA (siRNA) at Abbott Laboratories. In China, he developed the first generic liposomal doxorubicin (Libaoduo®) in 2008. Dr. Zhao is an inventor of 12 patents and has published over twenty peer reviewed articles. He also serves as an Expert Working Group (EWG) member for ICH, and an Advisory Board member for the NSF Nanotechnology center. Dr. Zhao was trained as a medical doctor at Norman Bethune University of Medical Sciences and received a Ph.D. degree from the Ohio State University.



Mingdong Zhang 张明东

Chief Medical Advisor
Suzhou SINUS MedTech Co., Ltd

Dr. Mingdong Zhang is currently the Chief Medical Advisor for Suzhou SINUS MedTech Co., Ltd. Mingdong was the formal Chief Medical Officer and Vice President of Medical Affairs for Boston Scientific Asia Pacific, promoted from the position of Chief Medical Officer and Vice President of Medical and Regulatory Affairs for Boston Scientific Greater China in 2019. Mingdong was previously the Global Medical Director for Johnson & Johnson's electrophysiology business in Southern California. Mingdong was also a Medical Officer/Epidemiologist at the US FDA's Center for Devices and Radiological Health (CDRH) from 2007 to 2008. In his earlier career path, Mingdong spent eight years doing research at the US National Institutes of Health as a Research Fellow and Staff Scientist and the Medical School of the Chinese University of Hong Kong as a professor. During his service in CDRH/FDA, Mingdong provided medical reviews for multiple original PMAs and 510k submissions on medical devices including IVDs; led designs of post-approval studies; and performed risk assessment and health hazard evaluations of medical devices. Mingdong graduated from Shanghai Medical University with an MD and MPH in Epidemiology. He then earned his PhD in Molecular Virology from Baylor College of Medicine in Houston, Texas.



生物器材网

www.bio-equip.com

生物仪器、试剂、耗材和技术服务的专业信息平台



扫一扫关注微信号



服务领域

生命科学, 医学研究, 生物制药, 生物工程, 现代农业, 食品安全, 环境监测, 公安司法等



产品范围

仪器设备、试剂、耗材、实验动物、细胞株、生物技术服务



访客来源

大学、研究所、医院、制药厂、疾控中心、检验检疫、环保、食品检测、公安、仪器生产制造、销售、代理、经销商等机构和企业

BIOHK2023

Media Partners

为生命科学服务，为优质厂商服务

35000⁺
厂商用户

120 万⁺
产品信息

20 万⁺
在线询价



<https://www.bio-equip.com>



021-64166852



info@bio-equip.com



Xueming Qian 钱雪明

Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics.

Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).

Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder's Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR.



Jimmy Wei

President
Chime Biologics

Dr. Wei, President of Chime Biologics, is a healthcare and life sciences executive with over two decades of global experience. Prior to joining Chime Biologics, Dr. Wei has led the incubation and investments activities into multiple well-known biotech companies, including Zai Lab, I-Mab, XW Labs, CMAB and JHL Biotech.

Dr. Wei was a founding partner of Pivotal Capital and I-Bridge Capital, and a partner of KPCB China Fund. Before joining KPCB, Dr. Wei was Senior Vice President and Head of Business Development at Hutchison Medipharma, where he was responsible for establishing global partnerships with several multinational pharmaceutical companies, including AstraZeneca, Johnson & Johnson, Lilly etc.

Dr. Wei graduated from North Carolina State University with PhD in biochemistry. He also holds an MBA with honors from the Darden Business School, University of Virginia, and a Bachelor's degree in Biology from Wuhan University.



Yongheng Huang

Vice President
Guangdong Association for Standardization

Huang Yongheng is a professor-level senior engineer in standardization, vice president of Guangdong Association for Standardization, vice president of Shenzhen Standardization Association, professor of Guangdong Open University, visiting professor of Guilin Institute of Technology, and external tutor of Tsinghua University Shenzhen International Graduate School.



Shouqun Wang

Managing Partner

China Commercial Lam Lee Lai Lawyers

Shouqun Wang, Managing Partner of China Commercial Lam Lee Lai Lawyers. She is currently a member of the Standing Committee of the People's Congress of Pingshan District, Shenzhen, Vice President of the Shenzhen Corporate Compliance Association, Secretary General of the Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurs Alliance, Executive President of the Shenzhen Qianhai Hong Kong Chamber of Commerce, and Secretary of the Shenzhen Qianhai Belt and Road Legal Services Federation. Director, Shenzhen Pioneer Demonstration Zone International Group Expert, and President of Shenzhen Pingshan District Biomedical Industry Law Research Institute.

Lawyer Wang Shouqun has been engaged in legal work for more than 20 years and is proficient in the fields of corporate compliance, financial securities, cross-border mergers and acquisitions, investment and financing, government services and dispute resolution. Established China's first Guangdong-Hong Kong-Macao partnership law firm – Huashang Lin Lili (Qianhai) Joint Venture Law Firm, and promoted the National People's Congress and the Ministry of Justice to approve the establishment of the "Qianhai Belt and Road Legal Services Federation" in Qianhai, taking the lead. The "Shenzhen Qianhai Hong Kong Chamber of Commerce" and the "Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurs Alliance" were established, and the first "Shenzhen Pingshan District Biomedical Industry Law Research Institute" was established in the country. She has successively served as legal counsel to government departments and large state-owned enterprises such as Shenzhen Qianhai Administration Bureau, Shenzhen Pingshan District People's Congress, Shenzhen Investment Holding Co., Ltd., Shenzhen Metro Group Co., Ltd., Shenzhen Talent Housing Group, etc.



Huifang Wang

Secretary-General

Shenzhen Biotech & Industry Cleaning Association

Wang Huifang holds a PhD from the School of Basic Medicine (Pharmacy) at Guangzhou University of Chinese Medicine, an MBA from the School of Business Administration at Dalian University of Technology, a bachelor's degree in pharmacy from Henan University of Traditional Chinese Medicine, and a PHARMACY TECHNICIAN diploma from Auckland University of Technology in New Zealand.

She is currently a deputy to the Second People's Congress of Pingshan District, Shenzhen City, the Secretary-General of Shenzhen Biotech & Industry Cleaning Association, and the founding and current Secretary-General of Shenzhen Pingshan District High-Level Talents Association. She has successively served as the after-sales service manager of the marketing department of Shenzhen Joicare Group, the pharmaceutical sales manager of the marketing department of Sinopharm Shenzhen Zhijun Pharmaceutical Co., Ltd., the purchasing department manager of Sinopharm Shenzhen Jianfeng Pharmaceutical Company, the pharmacist assistant of NEW PHARMACY pharmacy in New Zealand, and the Shenzhen Enterprise Alliance Subsidiaries of the Association/Shenzhen Entrepreneurs Association: General Manager and Legal Person of Shenzhen Qilian Sanhui Economic and Trade Development Co., Ltd., Executive Deputy Secretary-General of Shenzhen Enterprise Federation/Shenzhen Entrepreneurs Association, China Joint Venture Company of Oxford University Science and Technology Innovation Center in the UK: Executive President of Shenzhen Zhongjin International Technology Transfer Center and Executive President of Shenzhen Pharmaceutical Industry Association.


Dr. Wang Huifang has worked in the pharmaceutical field for nearly 30 years and has been engaged in industry association services for nearly 10 years. She is familiar with high-level talent services in various fields. She has led the release of 5 industry group standards, including "Clean Engineering Project Quotas" and the supporting "Clean Engineering Projects" "Quota Supporting Pricing Software" has made great contributions to promoting the development of the clean industry; compiled the "Clean Industry Blue Book" to fill the gap in China; coordinated government functional departments, organized universities, law firms, and leading Chinese companies to promote the "Shenzhen Special Economic Zone" Legislate the Regulations on the Development of Clean Industry; cooperate with universities and relevant government departments of vocational education to promote the training and level evaluation of clean engineering technicians to help the high-quality development of China's clean industry; be familiar with GMP, GLP, GSP and other relevant laws and regulations in the pharmaceutical field, and specialize in medicine, Full-process project management of decoration and decoration of laboratories and factory clean rooms in food and other fields.

BOOTH NO. 3D-A26

Improving Lives Through Logistics



NAF Pharma is a GDP-certified logistics provider specializing in storage and shipping of pharmaceutical, biotechnology and life sciences products.



Our Services

We use a risk-based approach for every shipment and carry out industry best practices.

Thermal Packaging Solutions

Our active and passive packaging covers the following temperature ranges:

- ✓ -196°C Liquid Nitrogen (LN₂) /Dry Shipper
- ✓ -20°C frozen
- ✓ +2°C to +8°C refrigerated
- ✓ +15°C to +25°C controlled ambient
- ✓ Dry Ice



Cell and Gene Supply Chain



Clinical Trial Logistics



Pharmaceuticals and APIs



Biological and Infectious Substances



Biopharma and Medical Devices



Warehouse & Distribution

www.nafpharma.com

TECHNOLOGY HALL | 科技廳

Microbiome, Novel Methods, Chinese Medicine

Thursday, September 14 | 11:00 AM - 17:00 PM (GMT+8)

Understanding your Microbe Garden

11:00 - 12:00

A Journey from Microbiome Research to Probiotics Development
Prof. Stephen Tsui, The Chinese University of Hong Kong

WDCM serves as an information infrastructure for the exploration and utilization of microbe resources worldwide

Dr. Juncal Ma, Institute of Microbiology, CAS

Nano-Encapsulation and Healthy Microbiome

Dr. Joo Ann Ewe, Nano and Advanced Materials Institute (NAMI)

Explore Cutting Edge Approaches to Disease Treatment (Sponsored by Zein Biotechnology)

12:00 - 13:30

Development of Novel Drugs with Potential to Cure Type 2 Diabetes

Chair: Dr. Zhongmin Ma, Revivallon Biopharmaceutical

Compound to effectively decrease A β 42 and Tau deposition, and show multi-beneficial efficacies on treating Alzheimer's disease in mice and humans

Dr. Jinan Li, Talengen Institute of Life Sciences*

Novel Lipid Nanoparticles for Nucleic Acid Therapeutic Delivery

Dr. Robert Lee, Zhejiang Haichang Biotechnology

New orally administrable peptide for treatment of diabetes

Dr. Chi Ming Wong, Hong Kong Polytechnic University

Adoptive Cell Therapy for Pancreatic Cancer with KRAS Mutation Specific TCR

Dr. Hongming Hu, ImmuXell*

Chinese Medicine Special Program: From Farm to Pharm

12:00 - 17:00

Chair: Prof. Wendy Hsiao, Macau University of Science and Technology

Novel medicinal properties of a well-known herb *Andrographis paniculata* in esophageal cancer - supported by preclinical and clinical evidence

Keynote Speaker: Prof. Clara Lau, Chinese University of Hong Kong

The role gut microbiome in the cancer-preventive effect of *Gynostemma pentaphyllum*

Prof. Wendy Hsiao, Macau University of Science and Technology

From integrative medicine to new medicine by using advanced biotechnology

Prof. Aiping Lyu, Hong Kong Baptist University

Material Innovation for Chinese Medicine Modernization

Dr. Erik Ko, Nano and Advanced Materials Institute (NAMI)

*No biography was provided before September 11, 2023.

Promoting Healthy Living by Advanced Materials & Nanotechnologies

以先進材料及納米技術促進健康生活

Nano and Advanced Materials Institute (NAMI) has established several core platform technologies for the development of marketable products in four main areas: HomeCARE, PersonalCARE, MedicalCARE, and FoodCARE, to support the industry for the development of innovative products.

納米及先進材料研發院 (NAMI) 建立了多項核心平台技術並在四個主要領域：家居護理、個人護理、醫療護理和食品護理，開發可商品化的技術，支持業界推出創新產品。

**Ultra-Sensitive
Diagnosis Technology**
超靈敏診斷技術



**Healthcare
Nanofiber Technology**
醫療保健納米纖維

Tunable Hydrogel
特性可調水凝膠



**3D Printable
Formulations for
Texturized Food**
3D打印配方製作具質感的食品

**Encapsulated Probiotics
(Topical and Oral)**
包裹益生菌 (外用及口服)



**Highly Efficient
Extraction Technology**
高效萃取技術

Film-Forming Technology
薄膜形成技術



**Functional Surface
Treatment**
功能性表面處理

Antimicrobial Technologies
抗菌技術



**Sustainable Plastics &
Functional Elastomers**
可持續塑料、功能性彈性體





Stephen Tsui 徐國榮

Professor

School of Biomedical Sciences, The Chinese University of Hong Kong

TSUI Kwok-Wing Stephen is currently a Professor and the Associate Director (Research) in the School of Biomedical Sciences. He is also the Director of Hong Kong Bioinformatics Centre in the Chinese University of Hong Kong (CUHK). In 1995, he received his PhD degree in Biochemistry at CUHK. He was then appointed as an Assistant Professor in the Biochemistry Department in 1997 and promoted to the professorship in 2004. He was also a former member of the International HapMap Consortium and worked on the single nucleotide polymorphisms of human chromosome 3p. During the SARS outbreak in 2003, his team was one of the earliest teams that cracked the complete genome of the SARS-coronavirus and facilitated the emergence of real-time PCR assay for the virus. Totally, he has published more than 270 scientific papers in prestigious international journals, including Nature, Nature Machine Intelligence, New England Journal of Medicine, Lancet, Journal of Allergy and Clinical Immunology, Allergy, Nucleic Acids Research, Genome Biology and PNAS. His h-index is 45 and the citations of his publications are over 17,000. His major research interests are next generation sequencing, bioinformatics and metagenomics in human diseases. Recently, he finished many high-quality genomes of mites and cockroach. Moreover, larger number of novel allergens in these two groups of species is identified and characterized. In 2018, he found BioMed Technology Holdings Limited in the Hong Kong Science and Technology Park. This company focuses on microbiome testing and probiotics development.



Juncai Ma

Director, World Data Center of Micrororganisms

Institute of Microbiology, Chinese Academy of Sciences

Dr. Juncai Ma graduated from Biological Resource Department of Mie University, Japan in 2006, is the Assistant Director of Institute of Microbiology, CAS (IMCAS) and the Director of Information Network Center, IMCAS. He is also the Deputy Chairman of the Expert Committee on CAS Database, Director of Committee on Type Culture Collection, CAS, commissioner of CODATA Chinese National Committee, and executive of WFCC. Currently he is mainly engaged in the research work on bio-grid, parallel indexing, super large-scaled full-text retrieval technology, search engine of remote heterogeneous databases, Linux Cluster System, and comprehensive utilization of IT technology in the field of biology. Meanwhile, he is in charge of the implementation of such significant projects as China Microbial Resource Database, Information Network System of CAS Biology Specimen Museum, Microbial Information Gateway of National Scientific Digital Library, E-Science Bio-Grid, National Scientific Data Sharing Platform as well as Information Network of Chinese Biotechnology and Industry.



Ewe Joo Ann 尤茹艷

Technical Manager

Nano and Advanced Materials Institute (NAMI)

Dr. Joo Ann EWE has extensive research experience in probiotics and microbiome related health management. She advocates the importance of a balanced microbiome for overall gut and skin health; her research specializes in developing related functional foods and skin care products.



Zhongmin Ma 马忠民

**Founder and Chief Executive Officer
Revivallon Biopharmaceutical Co. Ltd.**

Dr. Zhongmin Ma is the founder and Chief Executive Officer of Revivallon Biopharmaceutical Co. Ltd, a company dedicated to the development of innovative drugs with potential to cure diabetes. He is also an Adjunct Investigator of Zhuhai Fudan Innovation Institute, Fudan University. Dr. Ma has more than 30 years' experience in diabetes research and drug development. Prior to founding Revivallon, he served as the Chief Scientific Officer of Diapin Therapeutics, USA, a company to develop innovative drugs to treat metabolic diseases. Before that, Dr. Ma was a professor at Mount Sinai School of Medicine (MSSM) in New York, where his laboratory made breakthrough discoveries in β -cell regeneration in vivo. This groundbreaking work paved the way for developing novel drugs with potential to cure diabetes. Dr. Ma was one of the founders of Chinese American Diabetes Association (CADA) and served as the President for one term. He got his Ph. D. degree in Biochemistry from St. Louis University School of Medicine and his B.S. degree in Biology from Fudan University, Shanghai, China.



Robert Lee

**Chief Scientific Officer
Zhejiang Haichang Biotechnology Co., Ltd.**

Dr. Robert Lee currently holds the position of Chief Scientific Officer (CSO) at Zhejiang Haichang Biotechnology Co., Ltd. Previously, he served as the Kimberly Chair Professor of Pharmacy at Ohio State University. Dr. Lee is widely recognized as a prominent authority in the field of drug targeting and drug delivery systems.



Chi Ming Wong 王志明

**Associate Professor
The Hong Kong Polytechnic University**

Dr Wong received his B.Sc. in Biochemistry at the Hong Kong University of Science & Technology in 1997 and at the University of Hong Kong in 2003, respectively. With the support of Croucher Fellowship for Postdoctoral Research, he obtained his postdoctoral training in the laboratory of Dr. Alan G. Hinnebusch (Head of the Program in Cellular Regulation and Metabolism) at National Institutes of Health working on the mechanism of eukaryotic transcription termination (Wong et al, 2007). In 2008, he rejoined his PhD supervisor Prof Dong-Yan Jin's group to explore the role of peroxiredoxin in oxidative defense and genomic stability (Tang et al, 2009; Tang et al 2015). In 2010, with the funding supports from NIH and NSFC, he studied the mechanism of eukaryotic transcription termination and its link in RNA surveillance (Wong et al 2010; Kong et al 2014). Dr Wong joined the Department of Medicine at HKU as Research Assistant Professor in 2011 and collaborated with Prof Aimin Xu (Director of State Key Lab of Pharmaceutical Biotechnology) to explore new metabolic hormones and factors (Wong et al 2014; Lee et al 2016; Huang et al 2017).


Dr Wong is now Assistant Professor at the Department of Health Technology and Informatics of The Hong Kong Polytechnic University.

About VectorBuilder

Overview


VectorBuilder is a global leader in gene delivery technologies. As a trusted partner for thousands of labs and biotech/pharma companies across the globe, VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside.

Research Vectors & Virus



Service Type	Turnaround
Vector cloning	Starting from 5 days
Plasmid DNA preparation	Starting from 1-2 days
Lentivirus	Starting from 8-16 days
Adeno-associated virus (AAV)	Starting from 8-16 days
Adenovirus	Starting from 27-39 days
MLLV & MSCV retrovirus	Starting from 8-16 days
Baculovirus	Starting from 15-22 days
Vesiculo Stomatitis virus (VSV)	Starting from 21-35 days
Herpes Simplex virus (HSV)	Starting from 28-35 days
Vaccinia virus (VACV)	Starting from 21-28 days

CRO Services



Service Type	Turnaround
AAV Capsid Evolution	Please inquire
Mutagenesis (for Vectors)	Please inquire
AAV Biodistribution Profiling	Please inquire
mRNA Gene Delivery Solutions	Please inquire
Pooled library construction	Starting from 9-15 weeks
BAC recombineering	Starting from 35-42 days
Stable cell line generation	Starting from 9-15 weeks

CDMO services



VectorBuilder is a full-service CDMO with extensive expertise in manufacturing GMP-grade gene therapy vectors. We support the full spectrum of vector design, production and QC needs along the entire gene therapy drug development pipeline. Our highly experienced team has worked with thousands of customers to create research-grade vectors for the early discovery stage, GMP-like vectors for the pre-clinical stage, and full GMP-grade vectors for the clinical stage.

Features Offerings



- CRISPR Genome Editing Solutions
- shRNA Gene Knockdown Solutions
- Inducible Gene Expression Solutions
- shRNA (3+1) Virus Packaging
- COVID-19 Coronavirus Solutions



Revolutionize Gene Delivery
from **Research to Therapy**



载体家



云舟生物

云舟生物科技（广州）股份有限公司

电话：020-28069042

邮箱：service@vectorbuilder.cn

网址：www.vectorbuilder.com

地址：广州市科学城掬泉路3号国际企业孵化器D区三层

LABWARE®

LIMS for the Modern Laboratory

Automate Your Laboratory
with the Global Leader for
LIMS and **ELN**



LabWare Pharmaceutical & Bio-Pharma Manufacturing Industry Solutions

- Comprehensive Lot QA/QC management.
- Sample, test and batch tracking with full traceability.
- Advanced Product Specification management. Automated labelling, worklists and CoA generation.
- Stability / Shelf Life studies and inventory control.
- Environmental Monitoring.
- Standards, Reagents and Consumables management.
- Instrument Calibration & Maintenance.
- Flexible integration including ERP/SAP, MES and document management systems.
- Advanced Instrument integration including seamless integration with Empower & other CDS systems.
- KPI's, Dashboards, trending and charting.
- IQ/OQ validation support.



WELCOME

HONG KONG HEXU LABEL CO., LTD.

香港和煦标签用品有限公司



ABOUT US

关于我们

Hong Kong Hexu label Co., Ltd. was established in November 2008. It has been dedicated to serving clients with high-end printing and packaging needs. After more than a decade of hard work and relentless efforts, Shenzhen now has a factory covering an area of over 3,000 square meters and employs over 100 staff members.

Hexu specializes in printing adhesive labels and stickers widely used in industries such as electronics, food, pharmaceuticals, clothing, and liquor. Since its establishment, our company has taken "integrity" and "quality" as the core of the enterprise, adhering to the belief of "being honest and doing things honestly". Looking forward to the future, our company will continue to adhere to the business philosophy of "quality, efficiency, integrity, and practicality", continuously improve ourselves, surpass ourselves, and provide customers with thoughtful, enthusiastic, and high-quality services!

香港和煦标签用品有限公司成立于2008年11月，一直致力服务需求高端印刷包装产品的客户，十余年的艰苦创业和不懈努力，深圳现拥有厂房面积三千多平方米，员工人数一百多人。

和煦专业印刷不干胶类标签贴纸广泛用于电子、食品、药品、服装、酒业等行业。本公司自成立以来，以“诚信”与“品质”作为企业核心，秉承着“诚信做人，实在做事”的信念。展望未来，本公司将继续以“优质，高效，诚信，务实”的经营理念，不断完善自身，超越自我，为客户提供周到、热情、优质的服务！

OUR CERTIFICATE

我们的证书

We have always adhered to the concept of environmental protection, low-carbon, and sustainability, and our production factories have obtained quality and environmental protection certificates such as ISO14001, ISO45001, ISO9001, and FCS.

我们始终坚持环保、低碳、可持续的理念，我们的生产工厂已获得ISO14001、ISO45001、ISO9001和FCS等质量和环保证书。



Contact Now: ☎ +86 15928735857

✉ lucy@hexuprt.cn

☎ +86 15928735857





Clara Lau 劉碧珊

**Associate Director, Institute of Chinese Medicine
The Chinese University of Hong Kong**

Prof. Clara Lau is currently the Associate Director of the Institute of Chinese Medicine and the State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants at The Chinese University of Hong Kong. Her main research areas include anti-cancer herbs/natural products, and the beneficial herb-drug combinations. She has published over 280 refereed journal articles (h-index=45), 11 book chapters, and as an editor of the book series "Natural Products Chemistry of Global Plants". She currently serves as member of ChP-USP Advisory Group on Monographs for TCM Ingredients and Products; President of GP-TCM RA; Acting Secretary-General of CGCM; Council member of MCMIA. She is also the Associate Editors of Journal of Ethnopharmacology, Journal of Traditional and Complementary Medicine (eJTCM), Consulting Editor of Pharmacological Research, and Editorial Board members of various journals related to TCM or natural products.



Wendy Hsiao 蕭文鸞

**Professor
State Key Laboratory of Quality Research in Chinese Medicine
Macau University of Science and Technology**

Professor Wendy Hsiao, obtained her Ph.D. Degree from Columbia University in 1985, is an expert in cancer molecular biology, Wnt and MAPK signaling, with recent research focus on anti-cancer, cancer preventive, anti-inflammatory and anti-hyperlipidemia herbal medicines. She has published more than 70 articles in major journals including Science, Nature, Cell, Molecular Cellular Biology, Oncogene, Cancer Research, Clinical Cancer Research, Carcinogenesis, J Pathology, J Natural Products.

Currently, Professor Hsiao is carrying out several major research projects in her laboratory that include a Collaborative Research Project on "Discovery and development of biomarkers for evidence-based Chinese medicines using the proteomic technology platform" and a General Research Grant working on the anticancer effects and the underlying mechanism of a medicinal herb, Jia-gu-lan. Prof. Hsiao holds patents in US, Europe and China. In addition to her effort in TCM research, she also devotes a major fraction of her time in promoting TCM education.



Aiping Lyu 吕爱平

**Vice-President (Research and Development)
Hong Kong Baptist University**

Professor Lyu Aiping is a world-leading scientist in system medicine and aptamer-based translational medicine and drug discovery. He is not only working on basic research that demonstrates novel precision medicine-based therapeutic strategies for rheumatic disease treatment, but also on translational research in collaboration with pharmaceutical industry for the development of novel therapeutic agents. He is the director of the first aptamer R&D platform in Guangdong-Hong Kong-Macao Greater Bay Area of China, which has attracted aptamer pharmaceutical industries to establish "Aptamer Drug Valley" in the Hong Kong Science Park. He has developed the world's first ever osteoblast-targeting nucleic acid aptamer. His first discovery of the therapeutic aptamer targeting Sclerostin loop3 has been granted Orphan Drug Designation by US FDA (DRU-2019-6966) for evaluating the therapeutic potential for promoting bone formation in osteogenesis imperfect. He has also developed the first aptamer-Paclitaxel conjugates, which showcased a precision medicine-based personalized Paclitaxel for targeting specific cancer types, which is currently being developed into anti-cancer therapeutics by a pharmaceutical company.

Professor Lyu initiated the idea of using systems biology approach to identify metabolite biomarkers for subtyping RA patients with distinct clinical manifestations. His clinical research has also underpinned the potent efficacy of Tripterygium wilfordii Hook F. based therapy for RA treatment, which is recommended by the Chinese Association of Integrative Medicine as the Evidence-based Clinical Practice Guidelines. Besides, Professor Lyu has established the China's largest biobank of rheumatic diseases in Shanghai Guanghua Hospital of Integrative Medicine. The biobank has facilitated his discovery of the molecular mechanism addressing the limited efficacy of Leflunomide on bone erosion in a subgroup of RA patients with elevated serum C-reactive protein.

Prof Lyu has more than 600 publications with Google Scholar H index 66, i10-index 370 and a total of over 18000 citations. Over the years, he obtained more than 60 patents from his research activities.

Being a renowned expert and academic in the field, Prof Lyu has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009. Besides, he also currently serves as Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he is the director of Chinese Medicine Standardization Office in State Administration of Traditional Chinese Medicine (SATCM), and the director of Chinese Medicine Standard Research Center in CACMS. Most recently, he has been elected Foreign Member of the Academia Europaea.

He was invited to serve as Visiting Scholar in a number of institutions including Lund University in Sweden, Ohio State University in the United States, Hong Kong Polytechnic University and Hong Kong University of Science and Technology. Based on his outstanding research achievement, Prof Lyu was invited as guest speakers in various international academic conferences.



Erik Ko 高俊熙

**Senior Technical Manager
Nano and Advanced Materials Institute (NAMI)**

Dr. KO leads an R&D team of ~20 researchers at NAMI, an applied R&D center funded by the Hong Kong Government. His research focuses on advancing the healthcare industry through R&D projects in natural ingredients-based formulations, cosmetics, and functional foods and beverages. He is dedicated to modernizing Chinese medicine and has invented a 1-minute herbal capsule as well as nanocarrier-based herbal skincare and haircare products, transforming advanced materials from laboratory to market.

BOOTH NO. 3D-A20



公司简介

东富龙生命科学事业部，聚焦于制药、医疗行业前端技术的研究和开发，形成仪器、设备、耗材（包括耗材、试剂、填料、过滤、包材等）多维一体的一站式服务。

- 在细胞治疗领域，为免疫细胞、干细胞、肿瘤细胞疫苗等制备生产提供整体解决方案；
- 在基因治疗领域，为核酸药物（mRNA/DNA）、病毒载体药物等研发及产业化提供整体解决方案；
- 在生物样本库领域，研发自动化样本存储存储管理系统，提供细胞、组织样本库整体解决方案；
- 在耗材领域，我们已经在一次性袋子（反应袋/配液袋/储液袋）、试剂（培养基/冻存保护液）、填料、过滤（微滤/深滤/超滤/纳滤）、硬质包材形成了完善的耗材方案；
- 在消毒领域，致力于空气物表消毒、感染控制、终末消毒及多重耐药菌消毒，提供环境消毒整体解决方案。

依托东富龙集团成熟的设计、制造、工程施工及覆盖全国的售后服务能力，东富龙生命科学事业部可更快速、专业的服务于生物制药行业。

产品展示



GMP细胞药物制备全站



SUR一次性生物摇摆器



SuBed-C mini一次性固定床生物反应器



BRG系列生物反应器



培养基



填料



一次性使用无菌袋



过滤器

LOCI SQUARE | 基因位點廣場

Thursday, September 14 | 11:00 AM - 17:30 PM (GMT+8)


IVD Cancer Screening (Sponsored by New Horizon Health)	
11:00 - 12:00	<p>The Path to Transform Cancer Screening in China Mr. Yeqing Zhu, New Horizon Health</p> <p>Reach the New Horizon of Cancer Screening - A R&D perspective Dr. Rita Shih, New Horizon Health*</p>
Innovative Healthcare	
12:00 - 13:00	<p>Development and Prospect of Intelligent Traditional Chinese Medicine Equipment 智慧中医装备的发展与展望 Chair: Prof. Cong Yan, Beijing University of Chinese Medicine</p> <p>Portable noninvasive cardiovascular analyzer Mr. Kin Ming Lam Sramek Insight Limited 肠道减重新疗法—胃转流支架的前世今生 Mr. Yuxing Zuo Tongee Medical LNP Formulation and Preclinical Studies of mRNA Vaccine Dr. Xudong Yuan ACON Pharmaceuticals Inc. 大健康投资必读:减脂减重控糖新药趋势和投资解读 Dr. Qiao Jiang (LeaderMed) Technologies that make lab of the future and drive collaborative innovation Klaudia Kozusznik A4BEE*</p>
Pitching Strategies and Company Pitching	
14:00 - 15:00	<p>Pitching Strategies for Biomedical Companies Mr. James Zhang, Porda Hovas International Finance Communications Group</p>
15:00 - 17:30	COMPANY PITCHING

*No biography or information was provided before September 11, 2023.

Sponsored by



Founded in 2015, New Horizon Health is the pioneer and market leader in China's cancer screening market focusing on early detection of high-incidence cancers. On February 18, 2021, New Horizon Health was successfully listed on the Stock Exchange of Hong Kong under the stock code of 6606.HK, becoming the "first cancer screening stock in China".





Yeqing Zhu

CEO

New Horizon health

With over 15 years of experience in various leadership positions, including ebusiness, IT, sourcing, and vendor management, Mr. Zhu have developed a strong expertise in IT and digital strategies. My focus has always been on leveraging technology to drive sales, enhance operational productivity, and streamline processes. As a member of the Committee of Experts for the Ministry of Science & Technology (MOST), Mr. Zhu has actively contributed to the advancement of IT service innovation. Additionally, he hold certifications as an IT advisor for the National Development Bank and the China Banking Regulatory Commission (CBRC), demonstrating my proficiency in advising on IT matters in the financial sector. He is recognized as a distinguished expert for the National Service Outsourcing Human Resources Institute.



Cong Yan 闫聪

Professor of Life Sciences

Beijing University of Chinese Medicine

Mr. Yan Cong, Professor of School of Life Sciences, Beijing University of Chinese Medicine (BUCM), Doctoral Supervisor, Member of Academic Committee of BUCM, Director of Weigao Research Institute of BUCM, Member of Editorial Board of TMR Journal of Modern Traditional Chinese Medicine, Journal of Practical Clinical Medicine and other journals and reviewer of journals, Vice President of Chinese Society of Ethnomedicine, Vice President of Chinese Medicines and Drugs Quantitative and Efficacy Research Branch of China Society of Ethnomedicine, and Standing Director of Evaluation and Promotion of Appropriate Chinese Medicine Technologies of World Federation of Chinese Medical Association.

He received his bachelor's degree from the School of Physics, Peking University, PhD from the Department of Physics and Astronomy, University of Nottingham, UK, and postdoctoral work at the Sorbonne University (formerly University of Paris VI), France. He was awarded the Marie Curie Youth Research Fellowship of the European Union, participated in and was in charge of the sub-projects of the Advanced Grant of the European Research Council (ERC), and the National Research Instrumentation Development Program, etc. He has published in Chemical Society Reviews, JACS, Advanced Materials, Nano Letters and other high-level journals. He has published in Chemical Society Reviews, JACS, Advanced Materials, Nano Letters and other high-level journals, with the highest single impact factor of 40.2.

Currently at the Beijing University of Chinese Medicine, he is engaged in the construction of Chinese medicine mathematical and physical system, intelligent Chinese medicine diagnosis and treatment technology research and development, from Chinese medicine micro-nano diagnostic and treatment system, Chinese medicine intelligent manufacturing, Chinese medicine intelligent scenario application, Chinese medicine digital twin, intelligent Chinese medicine diagnostic and treatment of clinical and other five directions to promote the modernization of the Chinese medicine science, as well as Chinese medicine digital health care of the combination of industry, academia, and research into the transformation.



Xudong Yuan 袁旭东

CEO

ACON Pharmaceuticals Inc.

Dr. Xudong Yuan is the founder and CEO of ACON Pharmaceuticals. Dr. Yuan obtained his PhD from the College of Pharmacy in University of Georgia. Dr. Yuan had been a professor at Nova Southern University and Long Island University doing research in siRNA and drug delivery systems. Then he transitioned from academia to the pharmaceutical industry and worked in J&J, GSK, and RB at different levels, participating in different product development. Dr. Yuan also worked in smaller biotech companies, such as NAL and iView as senior director and VP in charge of R&D, manufacturing, and clinical studies. Dr. Yuan founded ACON Pharmaceuticals in 2020, and focuses on developing siRNA, mRNA therapeutics and complex drug delivery systems, such as nanoparticles, nanocrystals, and microspheres.



Yuxing Zuo 左玉星

Chairman / CEO

Hangzhou Tongee Medical Technology

Yuxing Zuo, also known as 左玉星, is a highly accomplished individual with a diverse background in the medical and business sectors. He is the founder of Hangzhou Tongee Medical Technology Co. Ltd and has seven years of experience as a clinical doctor in the Gastroenterology Department. With sixteen years of expertise in sales and product management of internationally renowned endoscopic medical devices, Yuxing Zuo brings a wealth of knowledge to the industry. He is the inventor of the Chinese first Gastric Bypass Stent System and holds a bachelor's degree in Preventive Medicine from Baotou Medical College. Additionally, he has a Postgraduate Diploma in Managerial Psychology (MPSY) from the University of Hong Kong. Yuxing Zuo's entrepreneurial achievements and commitment to medical innovation highlight his dedication to improving patient care and driving advancements in gastroenterology.



***Kin Ming Lam* 林建明**

Founder and CEO
Sramek Insight Limited

Mr. Lam is the Group CEO of Sramek Group Inc, a premium member of the American Heart Association, a committee director of HKFSCI, a corporate member of HKBMIA and a member of HKMHDIA. He graduated from the Chinese University of Hong Kong.



***Jiang Qiao* 姜桥**

Founder & CEO, Leadermed Group

Jiang Qiao has 20+ years of industry experience and is an expert in global pharmaceutical R&D and new drug approval in China. She has multiple peer-reviewed publications, and US & China patents and is a member of the Senior Scholar -China Pharmaceutical Association. Positions held: Senior Director of Global R&D Bayer/ Sanofi US R&D Headquarters, Co-Founder ClinChoice (Fountain Medical), Board Member-ProTom.



James Chang

Founder and Chairman
Porda Havas International Finance Communications Group

Mr. Chang is the Founder and Chairman of Porda Havas International Finance Communications Group, as well as the Director-general of Hong Kong-Mainland International Investment Society, the Executive President of the Hong Kong-Shanghai Cultural Exchange Association Limited and the Chairman of Zhang Dingfu Foundation. As a renowned media and financial PR professional, with over 30 years of experience in the mass media across Hong Kong, China and Taiwan, he is an expert in large-scale listing promotions and activities. Mr. Chang has organized promotion and media planning for over 350 IPOs and is regarded as the pioneer of financial PR by the Hong Kong media. He has led communication and media relation projects for Chinese state-owned and private companies seeking listings in Hong Kong, creating good market records.

松山湖科学城发展集团

东莞松山湖科学城发展集团有限公司是经东莞市人民政府同意，于 2021 年 2 月成立的松山湖园区国有独资企业，注册资本金 20 亿元。

公司旨在打造松山湖科学城综合投资运营服务平台，推动科学城先进产业引育能力、高端人才承载能力、城市综合服务能力的全面提升。

松山湖科学智汇城

科学智汇城由东莞松山湖独有国资企业松山湖科学城发展集团规划建设，项目围绕建设高标准、高质量、高水平现代化产业园区，打造大湾区示范性园区典范，为企业的发展提供全方位的软硬件保障。

项目以发展生物医药和高端医疗器械为主，其他配套产业为补充。通过引育企业项目，吸引高层次技术人才，形成产业人才聚集的产业创新生态，构建具有影响力百亿级产业集群。



松山湖科学城发展集团
SONGSHAN LAKE SCIENCE CITY DEVELOPMENT GROUP

Let's talk business.

Let's talk Vienna.

BOOTH NO. 3E-A3



Health Metropolis Vienna

Vienna Startup Package

- 4-week program to identify business opportunities
- Travel expenses covered
- Individual business coachings

Find us at our stand: 3E-A3

vienna
business
agency

BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS
POTENTIAL OF HONG KONG'S
BIOTECH ECOSYSTEM

CONFERENCE

DAY THREE

Friday September 15

KEYNOTE ADDRESS

Friday, September 15 | 09:00 AM - 10:00 AM (GMT+8)

09:00 - 09:30

KEYNOTE SESSION: **PROF. HIDEYUKI OKANO**, CHAIR OF THE DEPARTMENT OF PHYSIOLOGY, KEIO UNIVERSITY SCHOOL OF MEDICINE
iPSCs-based Regenerative Medicine, Drug Development, and Clinical Trial for Neurological Disorders

09:30 - 10:00

KEYNOTE SESSION: **PROF. TAK WAH MAK**, DIRECTOR, CENTRE OF ONCOLOGY AND IMMUNOLOGY, THE UNIVERSITY OF HONG KONG
Beyond Immunotherapy for Cancer Treatment: Emerging Strategies

Sponsored by



BIOHK2023 PLATINUM SPONSOR

BOOTH NO. 3D-B4

海康生命科技

HAIKANGLIFE

BioRadar® System

Platform for comprehensive detection of invisible pathogens

系統臨床
產品管線



Infectious
Disease



Cancer



Pediatric
Disease



Orphan Disease

Hai Kang Life Corporation Limited (Headquarters)

Add: Units 601-605, 6/F, Biotech Centre One, Hong Kong Science Park, Shatin, New Territories, Hong Kong, P.R.China

Tel: +852 2111 2123 | Fax: +852 2111 9762 | Email: info@haikanglife.com



Hideyuki Okano 岡野栄之

Professor and Chair
Department of Physiology, Keio University School of Medicine

He received M.D. in Physiology from Keio University in 1983. After he obtained a Ph.D. degree in Molecular Biology of Myelin-related genes and myelin deficient mutant mice from Keio University in 1988, he held a post-doctoral position at Dr. Craig Montell's Lab at Johns Hopkins University School of Medicine. He was appointed full professor at Tsukuba University School of Medicine in 1994, Osaka University School of Medicine in 1997, and returned to Keio University Medical School in 2001 as a full professor of Physiology. He has been conducting basic research in the field of regenerative medicine including neural stem cells and iPS cells, spinal cord injury, developmental genetics, and RNA binding proteins. His lab was the first in the world to successfully generate transgenic marmosets with germline transmission. His gene modification techniques can be used in a variety of non-human primates.

He has been awarded a number of awards and honors including the Medal with Purple Ribbon in 2009, the first prize of the 51st Erwin von Bälz Prize in 2014, and the Uehara Prize in 2022. He aims to establish and provide patient-specific iPS cells and genetically modified non-human primate models for neuroscience research and to explore the pathogenic mechanisms of neurological/psychiatric disorders. Currently, he is the leader of the Brain Project in Japan (Brain/MINDS) and the President of the Japanese Society for Regenerative Medicine. In 2022, he joined the Faculty of Massachusetts Institute of Technology (MIT, McGovern Institute) as a Visiting Professor. He was elected as the Vice President of the ISSCR in 2023 and his term began on July 1, 2023.

深圳市生命科学行业协会 Shenzhen Life Science Industry Association

深圳市生命科学行业协会简介

深圳市生命科学行业协会（英文名：Shenzhen Life Sciences Industry Association，简称：SLSIA），是2016年由北科生物、华大基因、融汇仁和、泰康人寿、达实智能和爱视集团等多家行业领军企业，以及深圳大学生命科学与海洋研究院、北京先进院、深圳北大医院、深圳市第一人民医院等高校和医院联合发起的，是全国首家生命科学行业社团组织。

深圳市生命科学行业协会的目标，就是在生命科学领域树立协会的形象、扩大协会的影响、争夺协会的话语权，成为“立足深圳、引领全国、走向全球”的权威社会组织，团结和带领协会成员抱团发展，共同分享生命科学行业的风口机会和企业发展红利，为促进中国大健康产业做贡献。

联系人：韩聪
电话：+86 13027956297 +852 6501 3956

KOBAYASHI DENKI 小林電機

BIOHK2023
Supporting Organization



~ 創新技術 不傷人體 ~ 222nm波長遠紫外光消毒儀

- ✓ 創新技術不傷人體皮膚及眼睛，而傳統紫外線過量會傷害人體。
- ✓ 不傷人體，實現人機共存，使用者可受全天候保護。
- ✓ 使用者可如常在222nm紫外線下活動，毋須像傳統紫外線必須關掉才可進入。

查詢電話：+852 2764-9028 / 技術支援：+852 6371-1490

電郵：sales@kobayashi-denki.com.hk / hardy1.kobayashi@gmail.com



@kobayshi_denki_hk



小林電機 Kobayashi Denki HK



Tak Wah Mak 麦德华

Director, Campbell Family Institute for Breast Cancer Research
Princess Margaret Cancer Centre, University of Toronto

Tak W. Mak is internationally known for his pioneering work on the genetics and molecular biology of cancer and the immune system. His group was the first to clone the gene encoding the human T cell receptor, providing the basis for CAR-T and TCR-T treatments. His team also showed that CTLA4 negatively regulates T cell activation, paving the way for checkpoint inhibitor immunotherapy. Most recently, his team established that the brain communicates with the immune system via T and B cells producing acetylcholine.

In the biotech arena, Dr. Mak was the Vice President of Research at Amgen as well as co-founded several companies including Agios Pharmaceuticals and Treadwell Therapeutics. These companies specialize in developing first-in-class drugs delineating metabolic and immunological vulnerabilities in tumour cells that can be exploited as novel therapies. Two IDH inhibitors and one drug directed at PKR are now FDA-approved for AML treatment and anemia patients, respectively. At Treadwell, three first-in-class agents targeting aneuploidy and immunotherapy focused on advanced cancers are now in phase II clinical trials .

Dr. Mak has published 1000 peer-reviewed research papers, holds dozens of patents, won numerous scientific and medical awards and is a recipient of a dozen Honorary degrees in Europe, Asia and North America.

ROMEGA

BOOTH NO. XX

挪威鱼籽油

NATURE'S FINEST BEST ω-3 AVAILABLE

Arctic Bioscience公司介绍

欧洲上市医药公司（股票代码：ABS） Arctic Bioscience致力于鱼籽油创新医学药物研发和临床营养产品研究，传递挪威健康生活理念。ROMEGA是其旗下医学营养品牌，目前已开拓母婴健康、大脑健康、视觉健康等方面临床营养产品，满足人类全生命周期营养需求。

BIOHK AUDITORIUM | BIOHK 會堂

Immunotherapy, Neurology, Infectious Diseases

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Is CAR-T Therapy Finally Affordable?	
10:00 - 11:00	<p>Moderator: Ms. Diana Viola, PharmaBoardroom</p> <p>Panelists: Dr. Azucena Gonzalez, Hospital Clinic de Barcelona Dr. Lin Yang, PersonGen BioTherapeutics Dr. Stephen Liu, (ST PHI Therapeutics)*</p>
Exploring The Marvels of The Brain	
	<p>Chair: Dr. Charles Hu, Ryoden Medical Holdings Ltd.</p>
11:00 - 11:20	<p>Neurogenesis for Stroke, Spinal Cord Injury, and Cardiac Arrest Keynote Speaker: Prof. Wise Young, Mononuclear Therapeutics Limited</p>
11:20 - 11:40	<p>Targeting Receptors for Brain Diseases Prof. Wei Chen, Beijing Tiantan Hospital, Capital Medical University</p>
11:40 - 12:00	<p>How Does The Brain Regain Consciousness from Anaesthesia? Prof. Xuejun Song, Southern University of Science and Technology</p>
12:00 - 12:15	<p>A Breakthrough in Implantable Photo-medicine Dr. Percy Luu, Incando Therapeutics*</p>
12:15 - 12:30	<p>脑机接口-让大脑连接未来 Mr. Lei Peng, NeuroXess</p>
12:30 - 12:45	<p>POINT: Breakthrough Therapeutics for Brain Disorders Mr. Coach Wei, Neural Galaxy</p>
12:45 - 13:00	<p>基于脑机接口的神经调控技术及产业化 Mr. Peng Cao, Genlight*</p>
13:00 - 14:00	Lunch Break
Biotech Battle against Infectious Viruses	
14:00 - 14:20	<p>Hepatitis B Control: Illustrating the Impact of Collaboration Keynote Speaker: Prof. Pei-Jer Chen, National Taiwan University and Hospital</p>
14:20 - 14:40	<p>Diagnostic Stewardship: Strategies to Enhancing Antimicrobial Prescribing Chair: Prof. Margaret Ip, The Chinese University of Hong Kong</p>
14:40 - 17:00	<p>A Novel Urinary DNA Isolation Method to Improve HPV Detection and Genotyping Dr. Ricky Chiu, PHASE Scientific</p>
	<p>Long COVID-19 symptoms in cohort and case-control studies: a systematic review Dr. Dexing Zhang, The Chinese University of Hong Kong</p>
	<p>Data science approaches to infectious disease surveillance and control Dr. Qingpeng Zhang, The University of Hong Kong</p>
	<p>基于重组病毒载体技术的生物药开发研究 Dr. Jiasheng Song, Difference Biological Tech</p>
	<p>创新转化与新冠病毒的科学防治 Prof. Hongzhou Lu, Shenzhen Third People's Hospital</p>

*No biography or information was provided before September 11, 2023.

天坛生物是中国医药集团有限公司、
中国生物技术股份有限公司
旗下唯一**血液制品**专业公司

BOOTH NO. 3E-A19

拥有6家血液制品公司 100多家单采血浆站

Owning 6 blood product manufacturers and
more than 100 plasmapheresis centers


公司致力于为社会提供**更多品种、更多数量**
和更优质量的血液制品

Owning 6 blood product manufacturers and
more than 100 plasmapheresis centers

新产品介绍

New Products Introduction

注射用重组人凝血因子VIII

中国血液制品企业**首个**推出的重组人凝血因子VIII产品


努力成为**中国领先**，具有**国际影响力**，
受到社会尊重的血液制品公司

To be a Chinese leading blood product
company with international influences
and worldwide reputation

2023年入选国务院国资委

“**创建世界一流专业领军示范企业**”Selected by SASAC as a “Building
World-Class, Specialized, Refined, and
Innovative Demonstration Enterprises” in 2023

蓉生静丙®10%

中国**首个**第四代静丙（层析法）产品浓度高达10%

☎ 电话: 010-65777816

✉ 邮箱: btbp@sinopharm.com

📍 地址: 北京市朝阳区双桥路乙2号院

☎ Telephone: 010-65777816

✉ Email: btbp@sinopharm.com

📍 Address: Yard B2, Shuangqiao Road, Chaoyang District, Beijing, China

中肽生化有限公司

可信赖的全球一体化

多肽/核酸CRDMO合作伙伴



CHINESE PEPTIDE

BOOTH NO. 3D-D24

Location



中国总部和生产基地
Headquarter & Manufacturing Base



销售总部
Sales Office



美国制造基地
US-based Manufacturing Base



中国DR生产基地
Research and Manufacturing Base

END-TO-END CRDMO PLATFORM

Discovery Synthesis

- Provide peptide and oligonucleotide products for drug discovery research
- Offer numerous options for discovery scales, purity levels, modifications
- From simple to the most complex and challenging molecules

CMC Development

- Process development, pilot scale-up, process validation, api & advanced intermediate production
- Analytical method development, quality standard establishment, stability study
- Pre-formulation, formulation development and manufacturing
- CMC dossier preparation to support global regulatory filing

Commercial Manufacturing

- Manufacturing of active pharmaceutical ingredients (APIs) for both new chemical entities and generics
- Provide Follow Up Stability Studies (FUST) after commercialization



Official Accounts



Official Accounts



Business Consulting



+86 571 86737011



sales@chinesepeptide.com



www.chinesepeptide.com



Diana Viola

Chief Executive Officer
PharmaBoardroom

Diana Viola is CEO and cofounder of PharmaBoardroom.com, a global platform for high-level dialogue between government authorities and regulators, C-level industry executives, financial investors and other key stakeholders, as well as Healthcare and Life Sciences Review, comprehensive digital reports covering various healthcare markets and industry thematic. In total, both platforms reach over 53,000 global industry stakeholders across the entire value chain from R&D, manufacturing, and marketing and sales, to supply chain distribution, logistics and other services. Over the past 15 years, Diana has been committed to driving global engagement on relevant industry topics, trends and debates, sharing best practices across international markets, and advocating for collaboration and innovation within the healthcare and life sciences industry.



Lin Yang 杨林

Founder, Chairman and Chief Scientific Officer
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Dr. Lin Yang, Founder/Chairman/Chief Scientific Officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd.; Distinguished Professor of Soochow University. He was an adjunct professor at MD Anderson Cancer Research Center, and has won many honors, including the Highest Honor in the National Disruptive Technology Innovation Contest Finals of the Ministry of Science and Technology of PRC. Dr. Yang has published more than 100 peer reviewed articles, including Cancer Cell, Cancer Research, Clinical Cancer Research, etc., and has been leading PersonGen team to develop a number of breakthrough first-in-class CART drugs, including the world's first approved INDs of autologous CD7-CAR-T and B7-H3-CAR-T injections for T lymphocyte-derived malignancies and pediatric solid tumors, respectively. He also plays a critical role in building an internationally advanced industrialization base based on the fully automatic CART cell production process in China.



Azucena Gonzalez

Imunologist
Hospital Clínic of Barcelona

Dr Azucena Gonzalez has been an immunologist at the Hospital Clínic of Barcelona since 2015. After finishing her residency, she received the 'Josep Font' Research Award to complete her doctoral work. Since 2016, she has been a specialist in the immunotherapy (IT) department, focusing on the development of new cell therapies to bring them to the patient. Dr Gonzalez is currently responsible for the production of CAR-T and TIL therapies.

She is an R3A researcher in the group "Immunogenetics and immunotherapy in autoinflammatory and immune responses," working predominantly in the "Cellular and genetic immunotherapy for the treatment of cancer and other immune-mediated diseases" research line. Her research studies have focused on the function of T lymphocytes since the study of the role of HLA polymorphism in T function (infection and histocompatibility) and converging on the participation in the antitumor response through them.



Wise Young 杨咏威

**Chairman and Lab Director
Mononuclear Therapeutics Limited**

Dr. Wise Young, founding director of the W.M. Keck Center for Collaborative Neuroscience and a professor at Rutgers, The State University of New Jersey, is recognized as one of the world's outstanding neuroscientists. He obtained a bachelor of arts degree from Reed College, a doctorate from the University of Iowa and a medical degree from Stanford University. After a surgery internship at New York University and Bellevue Medical Center, he joined the neurosurgery department at NYU. In 1984, he became director of neurosurgery research. In 1997, as part of Rutgers' commitment to the future, Dr. Young was recruited to establish and direct a world-class center for collaborative neuroscience.

Dr. Young was part of the team that discovered and established high-dose methylprednisolone (MP) as the first effective therapy for spinal cord injuries. This 1990 work upended concepts that spinal cord injuries were permanent, refocused research, and opened new vistas of hope. This team also played a major role in Andy Blight's signal work on 4-aminopyridine (4-AP), which shows significant promise for increasing nerve conductivity.

Dr. Young developed the first standardized rat spinal cord injury model used worldwide for testing therapies, formed the first consortium funded by the National Institutes of Health (NIH) to test promising therapies, and helped establish several widely accepted clinical outcome measures in spinal cord injury research.

Dr. Young founded and served as editor-in-chief of the Journal of Neurotrauma. He organized the National and International Neurotrauma Societies as forums for scientists to share discoveries and collaborate on spinal cord injury and brain research. He serves or has served on advisory committees for the NIH, the National Academy of Sciences, and NICHD, and has served on advisory boards for many spinal cord injury organizations.

Well-known as a leader in spinal cord injury research, Dr. Young has appeared on "20/20" with Barbara Walters and Christopher Reeve, "48 Hours," "Today," "Eye-to-Eye," Fox News and CNN's news magazine with Jeff Greenfield. His work has been featured in a Life magazine special edition, USA Today, and innumerable other news, talk and print presentations throughout the world. His honors include: NIH Jacob Javits Neuroscience Award (1985-1992), Wakeman Award (1991), Tall Texan of the Year Award (1997), 'Cure' Award (1998), Trustees Award for Excellence in Research (2001), Asian American Achievement Award (2002), Douglass Medal for work with the advancement of young women in the sciences (2003), and Elizabeth M. Boggs Award for service to the disability community (2004). In August 2001, TIME Magazine named Dr. Young as 'America's Best' in the field of spinal cord injury research. In 2005 he was the first researcher elected to the Spinal Cord Injury Hall of Fame. Dr. Young was appointed to the Richard H. Schindell Chair in Neuroscience in 2006 by the Rutgers University Board of Governors.



NOVEL EFFECTIVE TREATMENT STRATEGY TO ALZHEIMER'S DISEASE HAS BEEN DEVELOPED

Talengen Institute of Life Sciences/Talengen International Limited is a fully private and independent R&D institute founded in 2015 by a group of dedicated, enthusiastic and professional scientists strived to understand the regulation of hemostasis and thrombolysis, and the functional impacts to the body. Currently, the organization focuses on research and develop novel therapeutical methods against a group of difficult-to-treat diseases, and several therapeutic molecules against a number of unmet medical needs are being developed.

In particular, Talengen has discovered novel treatment strategy and the corresponding compounds to treat Alzheimer's disease. In both pre-clinical and clinical studies, the compound TP02HN106 has shown significant improvement of memory and psychiatric functions within days of treatment. TP02HN106 also shows rapid crossing of the blood-brain barrier, fast decreasing of A β 42 peptide and Tau protein, and also significant improvements of ChAT levels and the lowering of AChE activity. Furthermore, TP02HN106 has demonstrated an excellent safety profile with no adverse events observed.

So far, about 800 patents have been applied for or approved globally, covering a large number of unmet medical needs, treatment methods and territories. The organization welcomes co-development opportunities with international pharmaceutical companies.

Please contact Dr. Li
Tel: +861381 085 0852
Email: jnl@talengen-pharma.com



Wei Chen 陈伟

Professor

**China National Clinical Research Center for Neurological Diseases
Capital Medical University**

Dr. Chen has led a comprehensive translational research team focusing on the molecular mechanism of G protein-coupled receptor regulation and the development of new drugs. He discovered novel mechanisms in the regulation of non-classical G protein-coupled receptors by β -arrestin and GRKs, including receptors such as Frizzled, Smoothened, and TGF β III. He established an image-based drug screening platform, aiming to discover new drugs for the treatment of brain and other diseases stemmed from his own discoveries. Thus far his research team has discovered 1) bioactive ingredients in FDA-approved glucocorticoid drugs and natural products promoting stem cell proliferation for regenerative medicine, 2) a new therapy for stroke, 3) effective inhibitors for the treatment of Hedgehog-dependent medulloblastoma, and 4) novel small molecules for the treatment of refractory epilepsy. He received the honor of "Scholar" from the V Foundation and the American Cancer Society. He has authored over 50 publications and 10 patents in the area of receptor biology and drug discovery.



Xuejun Song 宋學軍

Director

**SUSTech Center for Pain Medicine, Southern University of Science
and Technology (SUSTech)**

Xue-Jun Song, MD, PhD, is currently Professor of Neurobiology, Anesthesiology, and Oncology, Director of SUSTech Center for Pain Medicine, Southern University of Science and Technology (SUSTech), Shenzhen, and Executive Director of Center for Pain Medicine, Peking University Health Science Center, Beijing, China. Dr. Song received his MD from Xuzhou Medical University and PhD from the Institute of Neuroscience, Chinese Academy of Sciences. Dr. Song did his Postdoc at Yale University Medical School and then served as an assistant, associate and full professor and director in Parker University Research Institute, Dallas, Texas, for eighteen years. Dr. Song's research has been focusing on understanding the neural mechanisms of chronic pain after nerve injury, bone cancer, diabetes, and exploring molecular targets for treatment of neuropathic, cancer and diabetic pain. His research has resulted in several dozens of publications in the prestigious journals including Anesthesiology, Brain, Cancer Research, FASEB J, JCI, J Neurosci, Nat Neurosci, Pain, etc. patents for chronic pain treatment. Dr. Song also serves as president of CASP / China Chapter of IASP, vice chair of Chinese Physiological Society Pain Translational Research Subcommittee, standing member of committee of Chinese Pharmacological-Anesthetics Society, International Chinese Academy of Anesthesiology, etc. and board member/associate editor of PAIN Reports and chief editor for English of Chinese J Pain Medicine.



Hillgene
谱新生物

BOOTH NO. 3E-B22,
3E-C21

让细胞药物谱写生命新篇章
CELL THERAPY INNOVATION INSPIRED

聚焦細胞藥·一站式CDMO服務

A leading CDMO platform for cell-based therapeutics



Plasmid



mRNA



Lentivirus



CAR-T/TCR-T/
CAR-NK



Immune Cells



Stem Cells

- IIT服務
IIT Services
- 工藝優化及IND申報
Process optimization and IND application
- 註冊臨床及商業化生產
Registered Clinical and Commercial Manufacturing
- CQDMO服務模式
CQDMO Service Mode

8⁺

Direct/indirect successful
IND applications

2⁺

Registered clinical
preparation experience

20⁺

cooperated with more
than 20 hospitals

200⁺

GMP batches lentivirus
manufacturing

200⁺

prepared cells for clinical use

18000⁺

Cell Factory Area (m²)



Coach Wei

Co-founder and CEO
Neural Galaxy

Coach Wei is the Co-founder/CEO at NeuralGalaxy. Coach previously worked as the Chairman of Nexaweb Technologies, a Boston based company he founded in 2000 that pioneered Rich Internet Applications and enterprise web 2.0. He raised over \$20M in venture capital for Nexaweb, built a global team, grew the revenue from zero to multi-million dollar and achieved over 7,000 global deployments of the Nexaweb Platform. At Nexaweb, he served a variety of roles including CEO, VP Engineering, CTO and marketing from 2000 to 2008. Before Nexaweb, Coach designed software for managing storage networks at EMC Corporation.

Coach is a frequent speaker on technology, industry trends and startup ecosystems, and serves on advisory boards of several Boston-area startups. He has received awards for his work on Ajax, Rich Internet Application and Entrepreneurship, including the "Interactive Experience Award" in 2005 and "Boston Top 40 under 40" in 2007. Coach holds a master's degree from MIT, six patents and maintains a blog on startups, web 2.0 and entrepreneurship.



Phoenix Peng 彭雷

Founder and Chief Executive Officer
NeuroXess

A successful serial entrepreneur with ventures spanning across Local Services, SaaS, Data mining, CRM, SNS, and other various enterprise applications. Founder and CEO of Keruyun, which was acquired by Alibaba Group for nearly 1 billion CNY in 2019.

Co-founded NeuroXess in 2021 and is serving as its CEO. The company has raised nearly 100 million RMB since its establishment, led by Shanda and Sequoia Capital. In 2022, NeuroXess received hundreds of millions of RMB in Series A financing led by Zhongping Capital, which is the largest early-stage financing in this field in China.

Mr. Peng holds a M.S. degree from Hong Kong Polytechnic University and a B.S. degree from University of Science and Technology of China.



Pei-ger Chen 陳培哲

Professor
National Taiwan University and Hospital

Professor Chen was appointed Director of the Hepatitis Research Center at the National Taiwan University Hospital in Taipei in 2001-2003, and now the faculty for Graduate Institute of Clinical Medicine, National Taiwan University. He was the President of the Taiwan Association for Study of the Liver (TASL) from 2012 to 2013. He served as the President of Taiwan Society of Virology from 2016-2018.

Upon completing his doctorate, Chen returned to National Taiwan University as a postdoctoral researcher, later joining the faculty in 1987. He was elected a member of Academia Sinica in 2006, and into The World Academy of Sciences in 2011. Chen specializes in hepatitis research and helped treat patients during the 2003 SARS outbreak, and was invited to a SARS-related seminar hosted by the World Health Organization, but did not attend because he was unable to isolate sufficiently after treating SARS patients, per the regulations in force for that meeting. Chen was invited to the 2009 World Health Assembly as part of the Chinese Taipei delegation. During the COVID-19 pandemic in Taiwan, Chen served on the vaccine review committee until late May 2021.

His research interests cover on the molecular virology and immunology of hepatitis viruses, and the genetic and genomic study of hepatocellular carcinoma. Professor Chen’s clinical research include the natural history of chronic viral hepatitis and hepatocellular carcinoma, and also explores and conducts new therapies and trials for both diseases. He has published over 630 articles in the areas of hepatitis and hepatocellular carcinoma.

He served in the Editorial Board of Gastroenterology between 2017-2019. He was a was a member of the editorial board of the journal Hepatology from 2001 to 2006, 2010-2011, and 2019-2021. In 2000, Professor Chen was awarded the International Research Scholar in Infectious Diseases by the Howard Hughes Medical Institute for a period of five years. He has been elected into Academia Sinica in year 2006, and become the TAWS member in year 2011.



Hongzhou Lu 卢洪洲

President

The Third People's Hospital of Shenzhen

Prof. Hongzhou Lu is the President of Shenzhen Third People's Hospital. Prof. Lu received his M.D. and Ph.D. degrees from Shanghai Medical College of Fudan University in 1999. He is a leading HIV and influenza expert in China and has published over 70 refereed papers in international journals, including three original articles in New England Journal of Medicine as he was the physician who reported the first case of H7N9 avian influenza A virus infections in humans. He played an active role in clinical management, academic communications, and public education during the H7N9 avian influenza outbreak in China. Prof. Lu was also one of the first batch of Chinese public health experts who worked over 65 days in Sierra Leone to fight against Ebola. Prof. Lu currently serves on five editorial boards of international journals and several boards of major government and academic organizations in China. His awards include the Leading Figure in China's Combat with SARS and the Shanghai Science and Technology Progress Award.



Margaret Ip 葉碧瑤

**Professor and Chairman, Department of Microbiology
The Chinese University of Hong Kong**

Margaret Ip is Professor and Chairman at the Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, and Honorary Consultant at the New Territories East Cluster of Hospitals of Hospital Authority. She is a clinical microbiologist with over 25 years' experience in research on the epidemiology and antimicrobial resistance of clinically important bacterial pathogens, inc. MRSA, *Streptococcus pneumoniae*, *Streptococcus agalactiae* (Group B *Streptococcus*) and other multidrug-resistant organisms. She has published over 290 international peer-reviewed papers. She serves as an Advisor and Member in a number of Scientific Committees on antimicrobial resistance and infection control and in Expert groups on GBS with WHO and FAO. She has supervised 20 fulltime completed PhD/MPhil students. She is an Examiner for the Hong Kong College of Pathologists and of the College of Physicians (in Infectious Diseases), and an external examiner for Universities locally and overseas in Malaysia, Australia and United Kingdom.



Dexing Zhang 張德杏

**Research Assistant Professor
JCSPPHC, Faculty of Medicine
The Chinese University of Hong Kong (CUHK)**

Prof. Zhang obtained her Bachelor of Medicine (Preventive Medicine) and Master of Medicine (Social Medicine and Health Service Management) from School of Public Health, Xiangya Medical College, Central South University, China. She obtained her PhD in Public Health in 2013 at CUHK and worked as a postdoctoral fellow in the school afterward. During her PhD study, she received an award to go to the University of Bristol, UK for a three-month research visit. In the last five years, as a co-investigator, Prof. Zhang received 9 research grants (a total of more than HK\$5 million) from GRF, HMRF, RFCID, HCPS, NSFC, CUHK Direct Grant and Knowledge Transfer Project Fund, and Department of Health. The projects cover a range of populations from children to adults with different methodologies including cross-sectional and cohort study, RCT, systematic review and qualitative study, within the field of primary health care and mental health.



Ricky Chiu

Chairman and CEO
PHASE Scientific International Limited

Dr Ricky Chiu is the Founder, Chairman and CEO of PHASE Scientific International Limited, as well as the lead inventor of the Company's core technology. He has been awarded the Ten Outstanding Young Person of the World, the Ten Outstanding of Young Person in Hong Kong, the InnoStars Award, the Young Industrialist of Hong Kong, the Outstanding Leader – Young Entrepreneur and the HKSAR Chief Executive's Commendation for Community Service for his outstanding research achievements in biotechnology innovations and his notable contributions to the fight against COVID-19 pandemic. Dr Chiu is an adjunct associate professor at the School of Biomedical Sciences and the Member of Board of Trustee of the United College of The Chinese University of Hong Kong, as well as the Court Member of The Hong Kong Polytechnic University. He is fully committed to grooming young talents and firmly believes in empowering the next generation to create a positive impact on healthcare globally. Dr Chiu and the PHASE Scientific team are currently engaged in research and product development for the detection of cancer and infectious diseases



Qingpeng Zhang 张清鹏

Associate Professor
Department of Pharmacology and Pharmacy and the Musketeers Foundation
Institute of Data Science, The University of Hong Kong

Dr. Zhang Qingpeng is an Associate Professor at the Department of Pharmacology and Pharmacy and the Musketeers Foundation Institute of Data Science, The University of Hong Kong. Dr. Zhang has been dedicated to interdisciplinary research in artificial intelligence and medicine. His research results have been published in top journals such as Nature Human Behaviour, Nature Communications, PNAS, JAMIA, MIS Quarterly, and have been widely reported by media including The Washington Post, The New York Times, The Guardian, Radio-Canada, Ming Pao. He received The President's Award and Outstanding Research Award from CityU, and the Andrew P. Sage Best Transaction Award from IEEE. His collaborative research with the Chinese Academy of Sciences has been recognized as the Outstanding Group in the National Science and Technology System against the COVID-19 Epidemic.



Jiasheng Song

Founder
Difference Biological Technology Co, Ltd.

Dr. Jiasheng Song is the Founder of Zhejiang Difference biological Technology Co, Ltd. He received his Ph.D. from Chinese Academy of Agricultural Sciences in 2010. He performed his postdoc research in UW-Madison (Yoshihiro Kawaoka lab), UPMC and Emory University during 2010-2016. Dr Song is strong in molecular virology and the development of genetic engineering vaccines. Currently, there are two vaccine products that is in the process of industrialization.(1) A novel DIVA influenza vaccine ; (2)A recombinant NDV vector Covid-19 vaccine. Over the past years, he deeply involved in several national and international key projects including Global Health Grant (Number OPPGH5383, Bill & Melinda Gates Foundation, "High-throughput analysis of avian influenza variants for pandemic potential") and the National Basic Research Program of China (973 Program).

Currently, Dr. Song takes charge of the project "Hangzhou Hi-Tech Zone 5050 Plan"(the title is Development and implementation of a novel DIVA influenza vaccine). 3 National invention patents have been licensed and 9 International patents have been applied.

Centre for Immunology & Infection

Using novel technology platforms for biomarker discovery and the development of new vaccine and therapeutic strategies.

- ✓ C2i is composed of an international team that leverages a highly multi-disciplinary expertise
- ✓ 1,000m² facilities including state-of-the-art laboratories, an advanced insectarium unique in Hong Kong, and a dedicated research clinic established for cohort recruitment
- ✓ Fostering innovation and evolving in the multidisciplinary environment offered by Science Park (HKSTP)
- ✓ The most advanced equipment and technologies supporting cutting-edge research to push the boundaries and drive groundbreaking discoveries

Healthy Human Global Project - Hong Kong



Novel Vaccine Platforms for Influenza



Mosquito-borne Viruses Epidemiology, Pathogenesis and Interventions



Novel Platform of Human Respiratory Tract



C2i is the fruit of a long-standing partnership of more than 20 years between the **LKS Faculty of Medicine of the University of Hong Kong** and the **Institut Pasteur**, two major institutions combining their expertise to establish this centre of excellence.

Our work is centered around four major research programs to face public health challenges and make Hong Kong a global center of excellence for precision medicine population strategies and innovative interventions targeting emerging infectious diseases.

C2iTech

SPIN OFF COMPANY



INNOVATION GALLERIA | 創新廊

AI and Commercialising Research

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Artificial Intelligence in Healthcare (Sponsored by Huawei Cloud)	
10:00 - 11:30	<p>Keynote: Mr. Wei Sang (Huawei Cloud)*</p> <p>An Introduction of CP AI Biotech Works in Food, Health and Sustainability Mr. John Jiang, CP Group</p> <p>Future opportunities at the intersection of modelling, AI, supercomputing and clinical trials. Dr. Christopher Morten, ELEM Biotech</p> <p>How AI is Transforming Drug Discovery & Aging Research Dr. Frank Pun, Insilico Medicine</p> <p>Patient care through AI-powered predictive solutions Dr. Echo Si Chen, Luca Healthcare</p>
Innovative Biopharmaceutical Production	
11:30 - 12:15	<p>核酸疫苗/药物连续生产工艺实现及法规要求 Dr. Tao Kang, Medium Biomedicine</p> <p>CRO及CDMO赋能高特异性基因疗法的开发与生产 Dr. Cole Cheng, Vector Builder</p>
Clinical Trials in Hong Kong	
12:15 - 13:00	<p>Moderator: Ms. Diana Viola, PharmaBoardroom (see biography on p.130)</p> <p>Panelists: Mr. Henry Yau, HK Clinical Trials Center Dr. Karen Chu, Harvest Integrated Research Organisation Dr. Danny Yeung, Gilead Sciences*</p>
13:00 - 14:00	Lunch Break
From Lab to IPO (Sponsored by Jun He)	
14:00 - 15:00	<p>Ms. Lihua De, Jun He Mr. Xudong Tao, Jun He</p>
Biotech Capital Markets in HK and GBA	
15:00 - 16:00	<p>Chair: Mr. Vijay Karwal AffaMed Therapeutics</p> <p>Panelists: Mr. Samuel Thong, Goldman Sachs Mr. Andrew Ng, Private Equity at VMS Group (see biography on p.51) Mr. Sammi Wong, HKSTP Capital Ms. Helen Chen, LEK Consulting Dr. Dong Li, Hong Kong APX Capital</p>
16:00 - 17:00	<p>Chair: Mr. Yuyao Peng, China Renaissance Securities</p> <p>Panelists: Mr. Mikio Tanji, Defta Capital Mr. Adrian Lam, Bioworld Ventures Mr. Honggang Zuo, Genecast Biotechnology Mr. Jielun Zhu, Fapon Group Dr. Charles Hu, Cere Ventures Viva HE, Managing Director, AZ-CICC Venture Investment Fund*</p>

*No biography or information was provided before September 11, 2023.

Sponsored by

 JUNHE | 君合律师事务所



Unlock the Secrets to Your Better Health with Saliva



Innovative Saliva Test

- Innovative
- Painless
- Easy to Use
- Home-based
- Trend Monitoring
- AI-assisted Analysis

Know you Risk

Stress	Diabetes
Infection	Nutrition
Cardiac	Stroke





John Yue Jun Jiang

Chief Technical Officer
Charoen Pokphand Group

Dr Jiang had been leading digital transformation in CP Group, responsible for group cybersecurity, data privacy, cloud strategy, blockchain and AI. Since 2019, transitioning to Group CTO, supporting the CP Group CEO vision of best in class of applied technologies (in retail, healthcare, food as medicine, multiomics, microbiome, longevity, cancer vaccine, zero waste, carbon neutral, cleantech, alternative protein-materials-energy, green/torquoise hydrogen, battery, chip, satellite, quantum computing, biotech, nanotech, metaverse, web 3, generative AI, etc), tech leadership and centers of excellences.

President of iFree Group - a HK based unicorn conglomerate of real estate, restaurants, travel and smart city/retail digital technology group, spanning across Asia and Australia. Founding Board of blockchain based AI medical start up EVER (a rising unicorn) with millions of patient data and hundreds of hospitals for preventive health and drug discovery, 10s thousands of clinics for global medical tourism.



Christopher Morton

CEO
ELEM Biotech S.L

Specialized in emerging technology ventures and markets, Chris worked across mechanical industries (aero, auto, energy) before turning to health tech 4 years ago. With ELEM, Chris and his Co-Founder have taken up the challenge to deliver the most powerful and safe environment for medical trials by simulating human physiology on supercomputers. Prior to ELEM, Chris held executive roles at Atos and Sogeti HighTech (CapGemini), set up Altair France, founded and led Samtech UK until its acquisition by LMS, now Siemens. Chris has an international background, read Aeronautical Engineering at Imperial College and Business Studies at Hult IBS.



Frank Pun

Head Hong Kong Office
Insilico Medicine

Dr. Frank Pun is the Head of the Hong Kong Office at Insilico Medicine, where he leads a team of application scientists focused on the AI-driven biological target discovery platform, PandaOmics. His primary objective is to provide cutting-edge AI technology to scientists, medical professionals, biotechnology firms, and pharmaceutical companies worldwide, enabling them to identify actionable therapeutic targets and expedite the process of drug discovery and development. Frank received his Ph.D. in biochemistry from the Hong Kong University of Science and Technology in 2010. Following his graduation, he served as a visiting scholar, leading a team dedicated to studying human CNS diseases and cancer for several years. In 2019, he also obtained an MBA from Rutgers Business School in the United States. Throughout his career, Frank has made significant contributions to target discovery, publishing numerous impactful papers in the field. He is recognized as a key opinion leader in his respective domain.



Echo Chen

CEO
LUCA Healthcare

Dr. Chen received her PhD from the University of Cambridge with a major in biotechnology. During her time at Cambridge, she was involved in the development of biosensors and participated in the development of IVD technologies for AIDS, hepatitis B, and hepatitis C. She also participated in global support programs sponsored by the WHO and the Global Fund to help African governments fight infectious diseases. Currently, she serves as the CEO of LUCA Healthcare. With a mission to provide more affordable and accessible healthcare, LUCA Healthcare works with partners to build digital health solutions that diagnose, predict and manage patients for a healthier world.



Tao Kang 康涛

Vice President
Medium Biomedicine (Suzhou) Co., Ltd.

Dr Kang, vice president of The Medium Biomedicine (Suzhou) Co., Ltd., Ph.D. graduated from Wuhan Institute of Virology, Chinese Academy of Sciences, Master's degree from University of Texas Health Science Center at San Antonio. He formerly served as a Visiting researcher at the University of Texas, Guest professor of Southern Medical University at Guangzhou, Director of translational development at Ractigen Therapeutics Co., Ltd., Director of technology and strategic development of Jiangsu Yaohai Biopharmaceutical Co., Ltd., Director of R&D of Guangzhou Recomgen Biotech Co., Ltd. More than 10 years of experience in biopharmaceutical development, registration and R&D management.



Cole Cheng

CDMO Application Scientist
Vector Builder

Hoi Lok received his BEng of Applied Chemistry from Osaka University, Japan, and his PhD from the Faculty of Biomedical Engineering, NUS, Singapore. With many years of academic research training on organic chemistry and molecular biology, he later worked on several post-doctoral projects including artificial oligonucleotide xenobiology, small binding proteins, commercial neutralizing assay development etc. in A*STAR, Singapore and SMART, Singapore.

After joining the VectorBuilder team, Hoi Lok accumulated substantial expertise in CMC of plasmid DNAs and viral vectors, as well as in GMP and corresponding regulatory guidelines from global authorities. Having facilitated multiple IND-enabling projects, Hoi Lok is now responsible for VectorBuilder's CDMO R&D, technical support, business development, and project management.



Henry Yau

Managing Director
HKU Clinical Trials Centre

Henry Yau is managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong Kong and CEO of the Centre's mainland China arm. Mr. Yau explains how the clinical trials landscape has evolved in Hong Kong over the past five years, especially in relation to the COVID-19 pandemic. He also covers some hot-button issues in global clinical research and how they pertain to Hong Kong, including cohort diversity, digitalisation, and convergence with medicine regulation and approvals.



Karen Chu

Founder and CEO
Harvest Integrated Research Organization (HiRO)

Karen is the founder and CEO of Harvest Integrated Research Organization (HiRO). It is a global clinical research organization (CRO) stemming from Asia-Pacific and specializes in cross-border clinical research development. Prior to her role at HiRO, Karen was previously a Partner of Fontus Capital. She continues her role as Venture Partner in Fontus Capital as a member of the Investment Committee in evaluating and making decisions on investment opportunities. Currently, Karen is a board member for three US/EU Biotech companies in clinical stages. In her previous roles, she was the Corporate Vice President for Clinical Research Services at Parexel International. Karen led Parexel's global clinical operations, which was responsible for the operational delivery of Phase I-III clinical trials. The team of operations was ~6000 employees across 50+ countries. In addition to her extensive experience with clinical trials globally, she possesses a unique understanding of cross-border strategy and management. Karen holds Bachelor of Science and Doctor of Pharmacy degrees from Rutgers, The State University of New Jersey, College of Pharmacy.



Zhijin Zhang

Partner
Junhe LLP

Ms. Zhang joined JunHe in 2006, and she has worked in both our JunHe Shanghai office and Jun He New York office. She was relocated to JunHe Hong Kong office from New York in 2012 and has practiced in our Hong Kong office since then. Ms. Zhang specializes in offshore various fund formation and downstream investment transactions, out-bound investment and cross-border M&A transactions, asset management and wealth management companies' multi-faceted cross border investment, equity, debt or structured financing transactions. Ms. Zhang has represented many Chinese sponsors and institutional investors (including Ministry of Finance of the PRC) in their fund formation projects with various offshore fund structures. For outbound investment and international bidding acquisition projects, Ms. Zhang is well-versed in representing Chinese companies in their world-wide investments. She is not only profound and seasoned in Chinese culture but quite sophisticated with both HK and international business and trading rules and regulations. She has been fairly active and experienced in representing startups, entrepreneurs and pioneering VCs from the perspective of overall legal and business compliance in the field of new economy, new consumption, hardcore science, artificial intelligence and healthcare.





CDMO and Consultation Service

加速生物藥抗腫瘤 藥創新藥上市時間 *Accelerate Biopharmaceuticals, ADC, Innovative medicines to the market*

提升穩定性 *Enhance Stability*

拋除冷鏈運輸 *Eliminate Cold-chain Transportation*

延長貨價期 *Extend Shelf-Life and Values*



Process Optimization, Controlled Crystallization



- 樣品檢測分析**


 1. 樣品熱性能分析
 2. 關鍵溫度檢測分析
 3. 凍乾顯微鏡, DSC分析
- 配方優化**

 1. 凍乾配方審查調整
 2. 使用冷凍保護劑及凍乾保護劑
- 工藝驗證**

 1. 使用保守工藝
 2. 建立多個備選工藝
 3. 從中篩選進入優化與開發
- 工藝開發**

 1. 使用之前得到嘅最佳配方
 2. 之前得到嘅最佳工藝進一步優化, 接近邊界
- 工藝放大**

 1. 根據樣品性質及期望的生產規模, 將生產工藝調整到適合生產的參數
 2. 放大相關知識介紹



FREE SAMPLES
Register Now

Tegent Group

Tel: +852-3910 1500 Fax: +852-2758 3830 Email: tegent@tegent.com.hk

Address: Suite 3605, 36/F, AIA Kowloon Tower, Landmark East, No. 100 How Ming Road, Kwun Tong

Tegent 德祥
since 1992
Your Local Specialist

Beijing
Shanghai
Chengdu
Wuhan
Hangzhou
Shenzhen
Guangzhou
Hong Kong
Macau



Lihua De 德立华

Partner
JunHe LLP

Ms. Lihua De is a partner of JunHe LLP and a registered foreign lawyer in Hong Kong. She obtained a Bachelor's degree in Economic Law from Peking University in 1984, and became a practicing lawyer in China by passing the Chinese Bar Exam in 1987. From 1984 to 1986, she worked at the Ministry of Petroleum Industry of the People's Republic of China, and then practiced law at the Great Wall Foreign Economic Law Firm, a subsidiary of the Ministry of Foreign Economic Relations and Trade, from 1986 to 1992. From 1992 to 1993, Ms. De worked as a visiting lawyer at a British law firm and a British barrister's chambers, respectively, and from 1993 to 2006, she practiced law at two Hong Kong law firms before joining JunHe LLP in June 2006. In her more than 30 years of legal practice, Ms. De has accumulated extensive experience in various fields such as direct investment, mergers and acquisitions, securities markets, and antitrust. She provides various consulting services on direct investment, mergers and acquisitions, antitrust, and subsequent operations in China for clients from mainland China, Hong Kong, and overseas. Ms. De is also deeply committed to the issuance of domestic and overseas companies in China and Hong Kong, with services covering industries such as large-scale manufacturing, telecommunications, real estate, transportation, natural resources, e-commerce, and finance.

As a lawyer for more than 30 years, Ms. De has the rationality, integrity, and profound legal knowledge of a legal professional. She has been active in the front line of providing services to clients for many years, personally participating in numerous major projects, and striving to influence and drive lawyers to devote themselves to providing high-quality and efficient legal services with a good leadership image and exemplary role. She has served as a permanent legal advisor for companies such as China Shipbuilding Capital, COSCO Shipping, China Reinsurance (Hong Kong), China Merchants Group, and Huaneng. Since 2016, Ms. De has been a member of the Legal Professional Committee of the Hong Kong Chinese Enterprises Association, always providing multi-dimensional and thoughtful solutions for clients, and has been highly praised and trusted by the industry and clients.



Xudong Tao 陶旭东

Partner
Junhe LLP

Mr. Tao joined JunHe in 2001 and is a senior partner of their capital market practice. Mr. Tao focuses on initial public offering by Chinese companies in domestic and overseas capital markets and post-listing matters, including: (1) deal structuring; (2) pre-IPO transactions such as M&A, ESOP and PE financing; (3) IPO by Chinese companies in domestic and overseas markets; (4) post-listing securities compliance, employee equity incentive schemes; (5) restructuring, takeover, take-private or re-listing involving listed companies, etc.

In overseas capital market area, Mr. Tao's most recent deals include: (1) underwriter's PRC counsel to DPC Dash Ltd. in its HKEX listing in March 2023; (2) underwriter's PRC counsel to JF Wealth Holdings Ltd. in its HKEX listing in March, 2023; (3) underwriter's PRC counsel to AIM Vaccine Ltd. in its HKEX listing in 2022; (4) underwriter's PRC counsel to Microport Medbot Group in its HKEX listing in 2021; (5) underwriter's PRC counsel to Dingdong (Cayman) Limited in its NYSE listing in 2021; (6) underwriter's PRC counsel to New Horizon Bio in its HKEX listing in 2020; and (7) issuer's PRC counsel to Vivo Biotech in its HKEX listing in 2019. In domestic capital market area, Mr. Tao is the issuer's counsel to the following in their Scitech Board listing: (1) Baili Pharm, 2023; (2) Transwarp, 2022; (3) Hanova Pharma, 2022; (4) Chengdu HitGen, 2020; (5) Zelgen Pharma, 2020, and (6) Shanghai Amologic, 2019. Mr. Tao also acts as the underwriter's counsel to BeiGene Ltd in its Sci-tech Board listing in 2021 and issuer's counsel to Ecovacs Robotics in its listing on Main Board of Shanghai Stock Exchange in 2018.



精明知識產權策略 業務升級增值秘訣

免費知識產權諮詢服務



- ▶ 香港律師會的執業律師（顧問）提供一對一諮詢面談服務
- ▶ 協助香港中小企業加深對知識產權（IP）的認識，制訂有效的知識產權管理及商品化策略

諮詢範圍涵蓋：



IP註冊



IP管理



IP授權



IP盡職審查

立即申請：www.ip.gov.hk/ipcs



知識產權培訓課程

增加專業知識和技能，全面提升管理企業知識產權的能力

基本課程

- ▶ 知識產權基礎課程
- ▶ 內地的知識產權管理與保護
- ▶ 香港的知識產權註冊及申請程序
- ▶ 企業保護商業秘密的策略與方法
- ▶ 專利基礎課程
- ▶ 加密貨幣、非同質化代幣、元宇宙和知識產權



IP保護



IP註冊



IP管理



IP策略

進階課程

- ▶ 知識產權審核及盡職審查
- ▶ 專利商品化和技術轉移的管理及策略
- ▶ 知識產權管理人員實務工作坊

課程概覽及報名：www.ip.gov.hk/ipmtp



知識產權管理人員計劃

- ▶ 協助香港企業（特別是中小企業）建立知識產權方面的人力資源，把握知識產權貿易所帶來的機遇
- ▶ 提供內容深入的知識產權培訓課程，讓企業的知識產權管理人員更有系統地增加專業知識和技能
- ▶ 所有在香港註冊的企業均可免費參加

為何參加？



優先報讀培訓課程



尊享培訓優惠



獲發參加證書



掌握最新IP資訊

更多：

- ▶ 免費參加知識產權管理人員實務工作坊及獲贈實務指南
- ▶ 以特價參加「亞洲知識產權營商論壇」

費用全免 立即登記

www.ip.gov.hk/ipms



瀏覽www.ip.gov.hk
了解最新的知識產權貿易支援服務及資訊

查詢熱線：2961 6833



知識產權署



Vijay Karwal 偉績加

**Executive Director and Chief Financial Officer
AffaMed Therapeutics**

Vijay Karwal is an Executive Director and Chief Financial Officer of AffaMed Therapeutics, based in Hong Kong. He brings over 27 years of global financial management and advisory experience in the healthcare industry with extensive background in business development, M&A and capital raising gained in roles in industry and as a senior investment banker. He is also an Operating Partner at leading Asian healthcare investor CBC Group and serves as an Independent Director of Mega Lifesciences PCL, one of the largest pharmaceutical groups in Southeast Asia, exchange listed and headquartered in Bangkok, Thailand.

Vijay joined AffaMed from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the international provider of kidney care services. Vijay previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, as Head of Healthcare Banking in North America at ABN AMRO, and as a senior member of ABN AMRO Rothschild – the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector, gaining extensive global experience across postings in London, Chicago, New York, Singapore and Hong Kong.

A native of the Netherlands, Mr. Karwal was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charterholder.



Samuel Thong

**Chairman and Co-head
Healthcare Investment Banking, Asia Ex-Japan**

Sam is chairman and co-head of Healthcare Investment Banking in Asia Ex-Japan. Sam joined Goldman Sachs in 2019 as a managing director. Previously, he was a senior banker at Morgan Stanley for 12 years in Hong Kong, covering the Asian healthcare sector. Prior to that, Sam covered US healthcare companies at Merrill Lynch in New York for 11 years. He earned a BA in Philosophy, a Doctor of Medicine degree and an MBA, all from the University of Chicago.



Sammi Wong

**Founding Member and Leader
HKSTP Ventures**

Sammi is an experienced venture capitalist and serves as a proactive board member to advise the investees in corporate strategy, international business development, governance and finance. As an appointed mentor of Hong Kong Life Science Society, he enjoys mentoring students regarding entrepreneurship in the areas of biomedical and healthcare sectors. Besides, Sammi is a guest lecturer at the University of Hong Kong and Awaji Youth Federation (Japan), coaching and teaching students in new venture creation and venture capital investing.

Sammi is the Founding Member and Head of the Hong Kong-based HKSTP Ventures, the venture capital arm of Hong Kong Science and Technology Parks Corporation. He oversees all the transaction executions, portfolio strategy and strategic partnership development since the inception of HKSTP Ventures in September 2015. The AUM of HKSTP Ventures has grown by 12 times throughout Sammi's five-year tenure. The investment portfolios under HKSTP Ventures are deep-tech focused, including Artificial Intelligence, autonomous driving, biomedical technology, robotics and semiconductor, and material science. Half of the investment portfolios are originated outside Hong Kong with investees located in Silicon Valley, Canada, China, Taiwan and the UK. Notable portfolio companies: ACT Genomics, AutoX, Fano Labs, Huue (UC Berkeley spin-off), Precision Robotics (Imperial College London spin-off), LuxCreo and Zeek etc.

Prior to joining HKSTPC, Sammi led the Greater China Distressed Investment team at Credit Agricole Corporate and Investment Bank. Besides, he obtained solid corporate finance exposure from his previous investment banking experience at ABN AMRO and BNP Paribas. Sammi has over 10 years of direct investment experience across industrials, real estate and various technology sectors in Greater China, Southeast Asia, Silicon Valley and the UK. He is a graduate of Saïd Business School, Oxford University with distinction and obtained CFA Charterholder qualification.



Helen Chen

**Global Sector Co-Head for Healthcare
Greater China Managing Partner
L.E.K. Consulting**

Helen Chen is Global Sector Co-Head for Healthcare and a Greater China Managing Partner of L.E.K. Consulting based in Shanghai. Helen was a member of L.E.K.'s Global Leadership Team from 2012 to 2016. She is also a Director of the firm's Asia-Pacific Life Sciences Centre of Excellence. Helen was named one of Consulting magazine's Global Leaders in Consulting in 2019.

Helen has over 30 years of consulting and industry experience in the U.S. and Asia markets and has lived in China since 2000. She helps companies expand their presence in China and Asia, and leverages Asia's innovation to improve their global businesses. For companies anchored in China, Helen advises on their drive to innovation and globalization. Helen is a frequent speaker and author on the opportunities and issues in China's healthcare and life sciences sectors. Her expert commentary has appeared in Bloomberg, Financial Times, The Wall Street Journal, Forbes Asia and the South China Morning Post, and in several industry publications, including BioCentury, In Vivo, Script and BioWorld.

Prior to joining L.E.K., Helen held senior management roles at several technology companies in the U.S. and China. She was an associate director of finance at Genentech (now Roche) and a sales planner at Abbott Laboratories (now Abbvie). Helen has an honors B.A. degree in Applied Mathematics from Harvard University.



Within Private Equity,
our sector focus and expertise span:

Healthcare

**Technology
&
Consumer**

A Trusted Alternatives Specialist

VMS Group was founded in 2006, and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong.

Apart from managing over US\$4 billion across its three in-house strategies – Private Equity, Real Estate and Structured Finance, the Group has also seeded or accelerated other asset managers through strategic partnerships across Venture Capital and Hedge Fund strategies with another US\$6 billion under management.

10.3+ USD
billion

VMS Ecosystem
AUM[^]*

4.3+ USD
billion

AUM*

~400

Ecosystem
investments

80+

Professionals

[^] Comprising AUM from VMS Group, and its strategic partners.

* As of 30 April 2023.

Scan QR Code to follow our social media accounts

VMS Group Hong Kong | Beijing | Singapore

+852 2996 2100 | IR@vmsig.com | www.vmsam.com

LinkedIn



WeChat





Li Dong 董利

Partner
Hong Kong APX Capital

Hong Kong APX Capital Partner Ph.D from Heidelberg University, Germany and Post Doc in King's College London. Worked as chief medical investment officer in Shenzhen Investment Holdings Co. Ltd and JinDong Capital. She has 20 years of experience of the healthcare industry and extensive networks and partnerships with medical companies in the Great Bay Area.



Yuyao Peng

Head
Hong Kong Healthcare Investment Banking, China Renaissance Securities

Yuyao Peng has worked in investment banking for several prominent companies. Yuyao started their career at Citi in 2012 as an Investment Banking Analyst and later became an Investment Banking Associate. In 2016, they joined Goldman Sachs as an Investment Banking Associate before being promoted to Investment Banking Executive Director in 2019. In 2020, they took on the role of Head of Hong Kong Healthcare Investment Banking at China Renaissance Huaxing Capital. Yuyao Peng obtained a Bachelor of Arts degree in Economics from Tsinghua University, where they attended from 2008 to 2012.



Mikio Tanji

Board Director
DEFTA Capital

After graduating from the University of Tokyo Faculty of Law in 1977, he gained various experiences as a banker at Long-Term Credit Bank of Japan, including overseas postings. After joining the firm, he led the launch of Qualipse, Osaka University's first venture, and later successfully completed an investment from an operating company. He was involved in the initial fundraising for the fund for which we are currently the GP, and ultimately closed the fund with an investment of USD 62 million. He is currently the general manager and investment steering committee member of the fund, where he presides over the investment steering committee, reviews investments, and serves as a director and auditor of several portfolio companies in the US and Japan.

He also serves as a director and auditor for several of the fund's portfolio companies in Japan and the U.S. He is a JD, and his experience as a business manager allows him to provide management guidance and formulate business strategies for venture companies through the board of directors.



Honggang Zuo

Chief Financial Officer
Genecast Biotech


Dr. Honggang Zuo previously served as a member of the Board from September 2017 to February 2018. Mr. Zuo was an executive director of Asian Special Situations Group of Goldman Sachs. Prior to that, he worked as an investment executive of Intermediate Capital Group in China, vice president of GE Capital in the United States, and director of MasterCard in the United States. In his earlier career, Mr. Zuo worked for PricewaterhouseCoopers in China. Mr. Zuo received his bachelor's degree in international business from Shanghai Jiao Tong University in 1998 and his master's degree in business administration from MIT Sloan School of Management in 2004.



Adrian Lam

Managing Partner
Bioworld Ventures

Mr. Lam is an accomplished equity portfolio manager and investor-operator in the healthcare sector, specializing in medtech, biotech and life science tools space. With an in-depth foundation in financial markets and engineering, he incorporates scientific knowledge, fundamental research, analytical insight and risk management into portfolio management and corporate development geared at generating risk-adjusted returns and alpha for investors. He has ten years of equity research experience in public and private markets and seven years of experience in developing FDA-approved medical devices, leading R&D teams and scaling healthcare ventures. He has successfully delivered unique global and interdisciplinary insights to both investors and operators.



依诺生物是一家拥有全球领先 mRNA 技术和 mRNA 领域全要素研发平台的生物科技公司。公司拥有 mRNA 药物和核心原辅料 GMP 级生产线，并成功构建 mRNA 药物集成产品开发体系，专家服务团队具备 mRNA 药物成功开发经验，可根据用户需求高效持续地提供 mRNA 研究整体解决方案。

ENO BIO is the world leading Biotech company engaged in mRNA technology and mRNA research and development in comprehensive platform. The company is equipped with GMP grade production line for mRNA drugs and core raw materials and excipients, and have successfully constructed mRNA development system. The expert team has deep expertise in developing mRNA drugs and providing integrated solutions for mRNA research with quality and efficiency.



Jielun Zhu

**Chief Financial Officer. and Chief Investment Officer
Fapon Group**

Jielun Zhu is an expert in finance and investment in the life science and healthcare industry with over 16 years of professional experience in investment banking and strategy consulting. As the CFO & CIO of FAPON, Jielun ZHU is in charge of financial management, capital market planning and execution, M&A, corporate venture investing and incubation at FAPON. He was the Managing Director and Head of Healthcare Investment Banking for Asia at Jefferies and formerly held various senior positions at UBS and Deutsche Bank. Before joining FAPON, Jielun ZHU served as the CFO of I-MAB Biopharma and supported the company in achieving numerous significant business and capital milestones.



Charles Hu 胡正忠

**Founding Partner
Cere Ventures Ltd**

A translational biomedical engineer with a passion in business development and investments, Charles's vision is in bringing about a vibrant healthcare innovation and investment ecosystem in the HK Greater Bay Area.

Charles's scientific expertise interfaces across tissue engineering, regenerative medicine, interventional radiology, and materials science. He is experienced in research commercialization and pharmaceutical medical affairs. He co-founded Incando Therapeutics, a medical therapeutics company specializing in diseases of the brain and in bringing innovative technologies to the clinical stage.

On the business front, Charles heads Ryoden Medical where he oversees healthcare venture investments for his family office. He also advises angels, and is keen on working with universities and government-related bodies to inspire passion in and support for biomedical developments.

Charles is a member of the Hong Kong Professionals and Senior Executives Association, an Industrial Advisor of Biomedical Engineering and visiting Assistant Professor of Biomedical Sciences at City University of Hong Kong, board member of two biotechnology startups and other businesses. He received the Guangdong-HK-Macao Greater Bay Area Outstanding Young Entrepreneur and Best Technology Innovation Award in 2023.

TECHNOLOGY HALL | 科技廳

Hot Trends in Biotechnology

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Searching for the Next Life Science unicorn

10:00- 11:00

Chair: Dr. Da Liu CR-CP Life Science Fund (see biography on p.57)

Panelists:

Mr. Nigel Yip, Sirnaomics

Mr. Francis Cao, InxMed*

Mr. Simon Hua, China Finances Strategies Investment Holdings Ltd

Dr. Rita Shih, New Horizon Health

Mr. Martin Law, MiRXES Hong Kong Ltd*

Advances in Medical Biotechnology

11:00- 13:00

Recent R&D Trend of Cell Therapy Drugs

Chair: Prof. Dan Zhang, Jiangsu Hillgene Biopharma

中国无创肠癌筛查的现状思考

Dr. Hongzhi Zou, Creative Biosciences

BioRadar: The complete disease surveillance system starting with Pneumonia

Dr. Jiangshan Zhan, Haikang Life Corp.

Development of SERS-based CRISPR/CAS9 sensor for the comprehensive detection of cancer-associated cfDNA utilizing transcription mediated production of malachite green aptamer

Dr. Taejoon Kang, Korea Advanced Institute of Science and Technology

Breakthroughs in technologies for mRNA therapies and some considerations on mRNA industry (mRNA疗法全链条技术突破与行业生态思考)

Dr. Zhaoyu Hu, Rhegen Bio

Breakthrough the impossible- leveraging liver regeneration to fight cirrhosis

Dr. Kathy He, Cargene Biopharma

Landscape Overview of mRNA Therapeutics

Dr. Jijun Yuan, Abogen Biosciences

Hemoglobin Based Oxygen Carriers: a Review of its clinical trials status

Dr. Jinhai Shi, Bing Biotech

13:00 - 14:00

Lunch Break

Inflammatory Disease and Medicine

14:00 - 15:30

The JAK-STAT Pathway to Th-GM and Clinical Applications

Chair: Prof. Xinyuan Fu, West China Hospital. GenEros BioPharma

Dual Targeting Of Innate And Adaptive Immune Checkpoints With A Pd L1/Sirpalphab Bispecific Macrophage Engager (Bime) For The Treatment Of Solid Tumors

Dr. Hongtao Lu, Elpiscience Biopharma

Generative AI Empowered Drug Discovery for Inflammatory Bowel Disease (IBD)

Dr. Xiao Ding, Insilico Medicine

Dual Action Tumor Immune Agonists from Tyligand Bioscience

Dr. Tony Zhang, Tyligand Bioscience

The Precision Medicine Era

15:30- 17:00

Chair: Dr. Desmond Hau, Pangenia

Moderator: Dr. Jay Dong, UltraDx

Cancer screening by circulating DNA analysis

Keynote Speaker: Prof. Allen Chen, Center for Novostics, The Chinese University of Hong Kong

Multi-cancer early detection via protein tumor markers and artificial intelligence

Dr. Mao Mao SeekIn Inc.

CARDIYON – A Novel Biotech Solution to Reduce the Risk of Cardiovascular Diseases

Dr. Vince Gao Govita Tech Ltd

Followed by all speaker panel discussion

GENERATIVE AI

TO IMPROVE THE QUALITY AND PRODUCTIVITY OF PHARMACEUTICAL RESEARCH

31 PROGRAMS IN TOTAL

29 TARGETS COVERED

4 CLINICAL-STAGE PROGRAMS

BOOTH NO. 3D-B25

PHARMA.AI

FULLY-INTEGRATED END-TO-END
GENERATIVE AI AND ROBOTICS
DRUG DISCOVERY SYSTEM



Biology42




Chemistry42



Medicine42

THERAPEUTIC PROGRAMS AS OF AUGUST 2023




Fibrosis Oncology Immunology Others

GET FULL PRECLINICAL PACKAGE

ADJUST CLINICAL DEVELOPMENT STRATEGY TO YOUR PIPELINE

GAIN ACCESS TO ALL PHARMA.AI PLATFORM AI TOOLS TO INCREASE INTERNAL CAPABILITIES

USE INCLINICO TO OPTIMIZE CLINICAL DEVELOPMENT



Insilico Medicine

INSILICO.COM





Nigel Yip

Chief Financial Officer
Sirnaomics

Mr. Wing Kei Yip has 12+ years of transaction experience in merger & acquisitions, initial public offerings, and private equity. Prior to joining Sirnaomics, Mr. Yip worked at Credit Suisse (Hong Kong) Ltd. from 2015 to 2018 and successively serving as an associate in the firm's Investment Banking division and a vice president in the Ultra High Net Worth Entrepreneur Coverage department. In his current role, he manages the overall fundraising process for Sirnaomics and communication with the banking and investor communities.



Simon Hua

Chairman
China Finance Strategies Investment Holdings Limited

Mr. Hua is the Chairman and CEO of CFS. He joined BOCOMI in 2008 and headed its direct investment and investment banking businesses. He is a member of Investment Committee of BOCOMI funds that he raised and managed. Total capital under his management was USD\$1.5B. Prior to BOCOMI, he was the Managing Director of Investment Banking at CLSA and the Executive Director in China-Euro Securities Limited, an investment bank joint venture by CLSA in China. During his term, CLSA was awarded the best investment bank for medium-size enterprises in Asia. Prior to CLSA, Mr. Hua was General Manager of Corporate Finance of Cazenove Asia, and worked at ICEA, and Bank of America

From 2006 onwards, through his own private equity fund, Shanghai Shengya Investment and BOCOMI's direct investment funds, Mr. Hua made many private equity investments in China, including Guangxi Nanning Water Co. Ltd, Viva Biotech Limited, GCL Silicon Technology Holdings Inc, Bright Smart Securities, Sanjiang Chemical, Boshiwa, Sino Polymer, Topsec Holdings Ltd and Wison, etc.

Mr. Hua advised many China and Hong Kong enterprises, including PetroChina, Sinopec, Chinalco, China Telecom, Lenovo, TCL, China Insurance, Phoenix TV and Ctrip, etc. for their initial listings and refinancings. He also led many financial advisory projects, including the acquisition of Cntorch by Weichai Power and asset restructuring of Guangdong Investment, etc. In the past 18 years, he has completed about 200 listing and project financing projects and about 50 financial advisory projects. The total transaction amount is more than USD \$100B. Mr. Hua holds an MBA from International University of Japan.



Dan Zhang

**Co-founder and Co-chairman
Hillgene Biology**

- Foreign academician of Russian Academy of Engineering, co-founder and co-chairman of Hillgene Biology
- Doctor of Medicine, Peking Union Medical College; Master of Public Health, Harvard University; Master of Management, Wharton School, University of Pennsylvania
- Director of China Pharmaceutical Innovation Promotion Association, Vice Chairman of Innovation Research and Development Service Committee
- Responsible expert of the national "13th Five-Year Plan" major New drug development plan
- Head of ICHE19 IFPMA Expert Committee, expert of NMPA ICH Working Group.
- Chief scientist of Xingwan Biology, co-founder of Kunling Medicine, former first chairman of Quintiles Greater China, senior CRO industry entrepreneur and entrepreneur
- Successful approval of domestic and foreign innovative drugs leading dozens of innovative drugs



Hongzhi Zou

**Founder
Creative Biosciences (Guangzhou) Co., Ltd**

Dr. Zou Hongzhi is the primary inventor of noninvasive sDNA test for early detection of colorectal cancer in the world. He is a National Major Talents Project expert.

Dr. Zou has tremendous expertise in research and development of molecular diagnostic technology in cancer detection and its related products. He was once the Director of R&D department at Exact Sciences Corporation where he developed Cologuard® which was cleared by FDA in 2014.

In 2015, Dr. Zou founded Creative Biosciences (Guangzhou) Co., Ltd and developed Colosafe® which is noninvasive sDNA test kit for colorectal cancer. Colosafe® is the first NMPA approved sDNA test kit receiving approval on Nov 20 2018, in China. In 2019, Dr. Zou received First Prize of Science and Technology Progress of Guangdong Province. In 2020, Dr. Zou was honored with Second Prize of China Medical Science and Technology Award. In 2021, Dr. Zou won First Prize of Science and Technology Progress by Ministry of Education.



ZENXTAG

BOOTH NO. 3E-B6, 3E-B4, 3E-B2,
3E-C5, 3E-C3, 3E-C1

Smart food label

ZenxTag Technology Limited provides sensitive paper-based sensors, food label, for the food industry so that they can improve internal quality control in the chilled food industry and reduce food waste.

Fresh



... Consume soon



... Spoilage



Food Safety, We Care!!



LinkedIn Instagram Facebook Website

Email: admin@zenxtag.com



Jiangshan Zhan

Council Member, CSO
Hai Kang Life Corporation Limited

Jiangshan Zhan, graduated from the School of Basic Medical Sciences of Peking University in 2017, and was awarded the honorary title of Outstanding Graduate of Beijing and Outstanding Graduate of Peking University. He received his Ph.D. degree in Neuroimmunology from the University of Munich, Germany, in 2021, and was awarded the Summa Cum Lauda Score, and was selected for the introduction project of the Postdoctoral International Exchange Program in 2022, and is now working in the Postdoctoral Workstation of the Department of Medical Sciences of Peking University. Jiangshan Zhan is now working in the Postdoctoral Station of Peking University Medical School, mainly focusing on the research of oligodendrocytes in animal models of multiple sclerosis and the pathological features of clinical diseases. He has published 21 SCI articles, of which 11 are first author/corresponding author, and has co-authored 3 books.



Kathy He 何奇志

CEO
Lerna Biopharma Pte

Kathy He is the Chief Executive Officer of Lerna Biopharma Pte, an innovative biotech leveraging novel biology insights and proprietary siRNA platform to develop highly targeted and potent nucleic acid therapeutics for liver diseases. Ms. He has over 20 years of R&D and commercial experience from global pharma companies such as Abbott, Merck and Takeda, notably in building differentiated product portfolios, developing strategic opportunities, and successfully bringing innovative therapeutics to market.

Prior to joining Lerna, Ms. He was the Chief Business Officer (CBO) and General Manager at Kira Pharmaceuticals, where she led the closing of its \$60M Series B+ round of financing and built an operation in China to support Kira's global expansion. Before Kira, she was the CBO and Head of Corporate Development at Abbisko Therapeutics (HKEx stock code: 02256), where she led the raise of over \$100M and closed a series of cross-border strategic partnerships. In addition to her extensive operating experience, Kathy also worked as a Venture Partner and Managing Director at top tier investment firms in China.

Kathy received a BS degree in biology from Wuhan University, a MS in molecular biology from University of Illinois at Urbana-Champaign, and MBA from Kellogg School of Management at Northwestern University. She is currently a board member of Diagnostic Photonics, an innovative medical device company, a former trustee of Illinois Mathematics and Science Academy, and a past board member of the BayHelix Group, a non-profit professional organization for business leaders in life sciences and healthcare industries.



香港檢測和認證局
The Hong Kong Council for
Testing and Certification
www.hkctc.gov.hk



高度專業誠信
High Professional Integrity

完善的知識產權保障
Good Intellectual Property Protection

卓越技術水平
High Technical Competence

敏銳的市場觸覺
Quick Response to Market Needs

健全的認可制度，廣獲國際承認
Robust Accreditation System
Being Highly Regarded Internationally

作為自由港、擁有先進的物流支援
A Free Port with Excellent Logistics Support



使用獲香港認可處認可的機構所提供的檢測認證服務，可提高顧客對你的產品和服務的信心。

Using testing, certification and inspection services provided by Hong Kong Accreditation Service's accredited organisations could enhance customers' confidence in your products and services.



想找合適的獲認可機構，請瀏覽香港認可處網站：
To find a suitable accredited organisation, please visit the
website of Hong Kong Accreditation Service:

www.hkas.gov.hk





Jinhai Shi

Chief Medical Executive
Bing BioTech Limited

Dr. Shi worked for Amgen for more than a decade, with a variety of positions in drug development. His over 20-years' experience of clinical practices, drug development, multiple global project management in clinical study, health economics and drug safety made him as Product Team Leader for many products developed in Amgen. Since 2011, he has been Vice President of Tianjin International Joint Academy of Biomedicine in charge of innovative drug R&D, and actively participates in many China bio-industry policy studies. He is a co-founder and General Secretary of China Protein Drug Quality Alliance, adjunctive professors of Peking University & Tianjin University.



Zhaoyu Hu 胡昭宇

Vice President
Rhegen Bio

Dr. Zhaoyu HU, Vice President of Rhegen Bio, an expert in the fields of chemical biology and biomedicine, who has rich experience and achievements in research fields such as mRNA vaccines and drugs, glycoconjugated vaccine and drugs, antiviral drugs, nucleoside modifications, targeted delivery and etc. He has promoted the development and clinical transformation of multiple innovative drugs and vaccines.



***Xinyuan Fu* 傅新元**

Chair Professor, West China Hospital, Chengdu
Founder and CSO, GenEros BioPharma, Hangzhou, China

Xin-Yuan Fu received his PhD in molecular biology at Columbia University in 1988 (Mentor: James Manley); postdoctoral training in Rockefeller University with James Darnell (1988-1991). Dr Fu was an Assistant Professor in Mt Sinai School of Medicine NY (1992-1994); an Associate Professor at Yale University (1994-2003), a Full Professor at Indiana University (2004-2015). Prof. Fu was the founding director of Tsinghua Institute of Genome Research of Tsinghua University, China (2000-2006) and the Head of Department of Biochemistry of National University of Singapore (2008-2011), Principle scientist and Professor, Cancer Science Institute of Singapore (2008-2018). Recently Professor Fu is taking academic positions in China, and developing therapeutics against inflammatory diseases. Dr Fu and his colleagues discovered the STAT gene family and the JAK-STAT signaling Pathway (Fu and Darnell et al, PNAS 89:7840-7843, 1992; Fu, Cell, 70:323-335, 1992). He has made a number of seminal discoveries in molecular mechanisms of mammalian development, immunity and diseases in the past 30 years. Particularly, in the past 23 years since Dr Fu's original discovery, there are about 40,000 publications on the JAK-STAT pathway, and over five FDA approved drugs against the JAK-STAT. Recently, Fu laboratory is focusing on STAT's role in regulation of inflammation, development and cancer. GenEros BioPharma is a cutting-edge drug discovery company founded by Dr Xin-Yuan Fu in 2015. GenEros pipelines focus on precision of medicine across inflammatory diseases and cancer.



***Hongtao Lu* 卢宏韬**

Co-founder and Chief Scientific Officer
Elpiscience Biopharma

Dr. Hongtao Lu is co-founder and Chief Scientific Officer of Elpiscience Biopharma, a biotech company focusing on innovative medicine for immuno-oncology. Trained as an immunologist and as an industry veteran for more than 20 years, he has extensive drug discovery experience across several therapeutic areas (autoimmune diseases, oncology and neuroscience) utilizing different therapeutic modalities (small-molecule and biologicals). Prior to Elpiscience, he had spent four years with Zai Lab, a NASDAQ-listed company, as co-founder and executive vice president for Scientific Research. Before Zai Lab, he was with GlaxoSmithKline as the founding head of Neuroimmunology Discovery Performance Unit (NI-DPU), where he led about 70 biologists and chemists focusing on drug discovery in neuroinflammatory diseases and neurodegenerative diseases. Dr. Lu spent his early career with Berlex Biosciences and Bayer Schering Pharma, where he conducted target identification and validation in autoimmune inflammatory diseases and oncology. Dr. Lu holds a Ph.D. in Regulatory Biology and conducted his graduate research at the Cleveland Clinic Foundation followed by post-doctoral fellowship at Yale University School of Medicine under the guidance of Dr. Richard Flavell.



Xiao Ding

**Senior Director, Head Of Chemistry
Insillico Medicine**

Xiao Ding has extensive work experience in the pharmaceutical industry. They currently hold the position of Senior Director and Head of Chemistry at Insillico Medicine since May 2021. Prior to this, they worked at Luo Shi Pharmaceutical from November 2020 to April 2021, where they served as the Scientific Lead in the Roche Accelerator program and as a Senior Scientist. Before that, Xiao Ding was employed at GSK, where they worked as a Scientist in the ND DPU, R&D China division from October 2012 to October 2017. They also had an internship at GSK from April 2011 to April 2012, where they worked as an Intern in the AB DPU at the UP site. Xiao Ding pursued their education in the field of chemistry with a focus on medicinal and organic chemistry. Xiao completed their Bachelor's degree in Organic Chemistry from Anhui University, where they studied from 2002 to 2006. After that, they furthered their studies at Shanghai Institute of Materia Medica, where they obtained a PhD in Medicinal Chemistry, graduating in 2011.



Tony Zhang 张彦涛

**Co-founder and CEO
Tyligand Bioscience**

Tony Zhang is the cofounder and CEO of Tyligand Bioscience, a clinical stage biotech focusing on the discovery and development of cancer therapeutics to address drug resistance in tumors like NSCLC and TNBC. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has built a differentiated pipeline including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload development. Tony has a BS degree in chemistry from Shandong University and a PhD degree from Purdue University. Prior to founding Tyligand, he has served at Eli Lilly for 25 years with escalating responsibilities, including Senior Research Fellow of Small Molecular Design and Development, founding Managing Director of Eli Lilly China R&D; and Vice President of Lilly Global External R&D, Asia. Tony has led multi-disciplined teams in drug discovery and development across several therapeutic areas, and has published more than 60 articles and monographs in the fields of synthetic, medicinal and process chemistry, and pharmaceutical product design. He is the inventor for 30 patents and many commercial manufacturing processes. He has been recognized as a CGP fellow, a Purdue Distinguished Alumnus, and Eli Lilly's Chairman's Ovation Awardee. He has also served as the Chairman of BayHelix 2010-2011.



Desmond Hau

**Founder and CEO
Bio-Gene Technology Limited**

Dr. Desmond Hau is the founder and CEO of Bio-Gene Technology Limited, a leading distributor of laboratory instruments, reagents, and consumables in Hong Kong, Macao, and mainland China. With a background in biochemistry and a passion for shaping his own journey, he established Bio-Gene in 1993. Over the past 30 years, the company has evolved to become an authorized distributor for renowned manufacturers in the fields of analytical sciences, clinical diagnostics, food and pharmaceutical safety, and life sciences research. Desmond has successfully expanded the business into new areas, including laboratory design and setup services. With a strong focus on customer satisfaction and providing comprehensive support, he envisions further growth in the medical devices and pharmaceutical sectors. Desmond is also part of the Pangenia Group, where collaboration and synergy among the group's companies drive innovation and expansion in the healthcare industry.



展位号 Booth No.
3C-E2

BOOTH NO. 3D-C15

自主全產業鏈基因工廠

業務涵蓋合成基因組學產品及服務、生命科學原料及設備、生物製造CXO三大方向

Beijing Tsingke Biotech Co., Ltd. is a world leading gene manufacturer, equipped with state-of-the-art R&D facilities for synthetic instruments, chemical and molecular biology reagents. Tsingke's integrated production platforms enable us to deliver cutting edge synthetic genomics products and services, life science research equipment and raw materials.



Tel: 400-668-3730 Web: www.tsingke.com E-mail: market@tsingke.com.cn
Add: Building 3, Unit W, No. 105 Jinghai 3rd Road, Beijing E-Town 100176, China.



Allen Chan 陳君賜

Professor, Department of Chemical Pathology 化学病理学教授
The Chinese University of Hong Kong 香港中文大学

Professor Chan is currently appointed as Professor of Chemical Pathology of the Chinese University of Hong Kong. With Professor Dennis Lo and Rossa Chiu, he developed the noninvasive prenatal tests for detecting fetal Down syndrome and other chromosomal aneuploidies. The test has become a standard in prenatal testing and over ten million tests are performed each year across the world. Professor Chan pioneered the development of circulating DNA analysis for cancer detection and led the first large-scale prospective study to evaluate the use of "liquid biopsy" for cancer screening. Using nasopharyngeal cancer as a model, his team showed that plasma DNA analysis is able to detect early asymptomatic cancers and improve survival. This work was selected as one of the ten notable articles published in the New England Journal of Medicine in 2017. Allen is a co-inventor of over 90 patent families and was named one of the "Top 20 Translational Researchers of 2020" by the renowned scientific journal Nature Biotechnology.



Mao Mao 茅矛

Founder and Chief Executive Officer
Pangenia Inc

Dr. Mao Mao is Founder and Chief Executive Officer of SeekIn and TwixBio. He is Adjunct Professor of several universities in Asia. He was Chief Scientific Officer of BGI Genomics responsible for R&D pipeline and oncology business. He was Senior Vice President of Translational Bioscience and Diagnostics responsible for in vitro diagnostics (IVD) product development and clinical lab service at WuXi AppTec. He was President of Asian Cancer Research Group (ACRG), a not-for-profit pharmaceutical industry consortium established jointly by Eli Lilly, Merck and Pfizer to accelerate research and ultimately improve treatment for patients affected with the most commonly diagnosed cancers in Asia. As one of the most senior scientists in Pfizer, he led biomarker and molecular diagnostics efforts at Oncology Research Unit. He managed a lab conducting GCLP-compliant clinical assays and diagnostics research to support Pfizer oncology clinical trials and companion diagnostics. He also worked with the academic and industry partners to generate large scale cancer genomics data. He was Director of Molecular Profiling & Pharmacogenomics at Merck Research Laboratories. He worked on biomarker discovery and coordinating extensive collaborations with academic institutions and industry partners to promote personalized cancer therapy in Asia Pacific region. During his early years with Rosetta/Merck, he made significant contributions to the Ink Jet DNA microarray technology development and subsequent applications. He was one of the inventors of the breast cancer prognosis test (MammaPrint) for the 70 genes identified from the study with his colleagues at Rosetta and the Netherlands Cancer Institute, which became the world's first In Vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire market clearance from the US FDA in 2007. Prior to Rosetta, he was the youngest Associate Professor at Shanghai Second Medical University. As one of the founding members of the National Human Genome Center in Shanghai, he established the first high-throughput DNA sequencing facility and pioneered genome research in China. He was the principal investigator of two National Key Programs of the 9th Five Year Plan in China. He did his doctoral research in studying the mechanism of acute promyelocytic leukemia (APL) differentiation therapy at Shanghai Institute of Hematology under the supervision of Professors Zhu Chen and Zhenyi Wang. During his doctoral study he identified RIG-E, a gene induced by retinoid acid during leukemic cell differentiation, which was recognized as the first novel human gene cloned at a laboratory in China. He also practiced as obstetrician/gynecologist and genetic consultant. He published 100+ articles in the peer-reviewed journals including Nature, Cell, Nature Genetics, Nature Biotechnology and PNAS, and chapters of two books. He is a strong advocate of advancing equitable cancer care through innovation.



Vince Gao 高醇新

Founder, CEO and CSO
Govita

- Founder, CEO & CSO, Govita Tech Ltd, Hong Kong (2016 – current)

Established Biological Pathway Omics (BPO®) and apply it to the research and development of genetic and metabolic testing, AI algorithms for data association, and nutraceutical formulas. Provide healthy longevity products and services to healthcare organizations and people in need. Cultivate talents in biotechnology R&D and successfully commercialize company's products.

- Executive President and CSO, BGI Health, BGI, China (2012 – 15)

Developed multi omics (genetic, proteomic and metabolomic) detection technologies, health programs and intervention products serving life science and medical institutions. Successfully developed biotech R&D and service teams and lectured globally on the application of multi omics in healthcare and preventive medicine.

- APAC Sr. Director, China GM, Applied Biosystems | Life Technologies | Sciex, USA 1998 – 2012

Led the development and marketing of molecular assay technologies, reagents and instruments that successfully expanded the market for pharmaceutical research, healthcare and life sciences. Led the company to develop the molecular testing market in the Asia Pacific region, especially in China, with an annual revenue of more than US 100 million.

- R&D Scientist, Study Director of Drug Metabolism AstraZeneca, USA (1993 – 1998)

Responsible for the clinical and metabolism studies of a breast cancer drug Arimidex. The two year survival rate for patients taking the drug was 85.4%. The annual revenue of the drug reached \$2B.

- Regenerative Med R&D Scientist, HemaGen, USA (1991 – 1993)

Developed artificial blood products for organ transport, angioplasty, first aid and life support.



Jay Dong

Founder and CEO
UltraDx

Jay Dong has a proven track record of commercial success: having successfully built the China business of a US company from "scratch", to become "the golden standard" of the industry with exceptional revenue growth, AND customer and employee loyalty. Aim to take it to the next level with industry-leading initiatives. Having lived in three countries, the U.S., Singapore and China, Jay Dong is a passionate and humbled business leader with proven track records of delivering results and building teams in multiple global regions. He operates at both strategic and tactical levels and moves between the two objectively as needed.

Jay Dong was a founding general manager of CST (Shanghai) Biological Reagents Company, CST's wholly-owned subsidiary in China that he launched in 2008. CST is a leading life science research company in the areas of enabling biomarker discovery, precision medicine, and companion diagnostics. Previously, he was with Becton Dickinson and Company in the U.S. as a marketing manager and then in Singapore as a business manager. He also co-founded the Precision Medicine and Companion Diagnostic Professional Organization of the Chinese Society of Biotechnology, serving as Secretary General and VP. Jay Dong also served on the board of directors of the Sino-American Biotechnology and Pharmaceutical Professionals Association in San Diego, CST Japan, and the BayHelix Group, as well as a board trustee and Vice Chairman of the Board of the Shanghai American School and its Chair of HR committee and Vice Chair of Finance Committee. Board member of MIT Shanghai Alum.



美國發明專利

CARDIYON™ 倍心安

超早期心血管健康檢測


BOOTH NO. 3E-C18,
3E-C20




取樣方法



指尖血

基因型
(先天遺傳)

心血管健康

表型
(後天環境)

瞭解更多請掃二維碼
Scan QR code for
detailed information

- 預測/預防心血管疾病
- 大幅度降低死亡風險
- 改善心血管健康狀況

2021年全球每天> 56,000人死於心血管疾病
> 56,000 people died of CVDs everyday worldwide in 2021.

80%的心血管疾病若能早期發現，是可以預防疾病發生的
Up to 80% of CVDs are preventable if detected early

几滴血，超早期檢測心血管疾病潛在風險，預防疾病發生
CARDIYON™ Solution can predict and prevent CVDs occurrence

LOCI SQUARE | 基因位點廣場

Start-up Special

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Building an Innovative Ecosystem for International Start-ups (Sponsored by AstraZeneca)

10:00 - 11:30

How AstraZeneca Can Boost An Innovation Ecosystem in Hong Kong

Ms. Shan Wu, AstraZeneca

Capital Market Review and Healthcare Industry Opportunities

Ms. Rongrong Guo, CICC*

Ms. Carol Liu, HKSTP*

Ms. Michelle Kam, HSITP*

"TOP 5 TO WATCH" PITCHING COMPETITION

11:30- 17:00

Companies Enrolled in Pitching Competition [List is not in pitching order]

Incando therapeutics
neoX Biotech (HK) Limited 北京星亢原生物科技有限公司
Jiangsu Hillgene Biopharma Co.,Ltd 江苏谱新生物医药有限公司
A4BEE
Allegrow Biotech Ltd
十度生物科技有限公司
Cimple Biotechnology Limited
City University of Hong Kong
CREATIVE BIOSCIENCES (HONGKONG) 广州康立明
eNano Health
Filix Medtech Limited
Govita
Greater Bay Biotechnology Limited
Lucy Biotech
Insighta Limited
TCRCure Biopharma Technology
Jupiter Neurosciences, Inc
LabWare Singapore Pte. Ltd
META Pharmaceuticals
Neuropix
Provectus Therapeutics
Rapafusyn Pharmaceuticals
Axbio
Talengen Institute of Life Sciences
瑞健生命科学研究院
ROMEGA 挪威鱼籽油
TROMSO NUTRITION TECHNOLOGIES
TUNECT CRO
Syngular
ZenxTag Technology
DIFFERENCE BIOLOGICAL TECHNOLOGY CO.,LTD
浙江迪福润丝生物科技有限公司
Cargene Biopharma
Beijing Tsingke Biotech Co., Ltd.
北京擎科生物科技股份有限公司
株式会社ekei labs
MDCE - 希毅医学

*No biography or information was provided before September 11, 2023.

Pitching list was as of September 11, 2023

If you would like to contact these companies, please reach out to info@hkbio.org.hk

Sponsored by

AstraZeneca 



Shan Wu

**General Manager of Hong Kong and Macau
AstraZeneca China**

Shan Wu is a Chinese-born professional who has made significant contributions to the pharmaceutical industry, particularly in China and Hong Kong. With a background as an organic chemist, she began their career at Johnson & Johnson (J&J), where they gained experience in sales, marketing, and market access roles focused on oncology and haematology. After a successful tenure at J&J, she moved to Roche, further expanding their expertise in the oncology field and contributing to the commercialization of innovative cancer products.

She later returned to J&J during a time when the Chinese government was offering reimbursement for oncology medicines, playing a role in including J&J medicines in the national reimbursement list. With the acquisition of Actelion by J&J, Shan Wu became Actelion's general manager for China, overseeing the integration of the rare disease portfolio and achieving significant growth.


In 2021, she joined AstraZeneca as the manager of the breast cancer franchise in China, leading a team of over 400 professionals. Their leadership approach focused on motivation, direct communication, and clear goal setting. They later assumed the role of general manager for AstraZeneca Hong Kong, reporting directly to the China country manager.

Her contributions to AstraZeneca's success in Hong Kong include a strong portfolio, particularly in oncology, and partnerships that facilitate scientific knowledge transfer. They emphasize the importance of being a first-in-class oncology treatment to gain reimbursement and market access in Hong Kong.


Throughout her career, she has launched various products and has sought to shape the market and drive innovation. Her initiatives highlight the strategic importance of Hong Kong for AstraZeneca, aiming to collaborate with stakeholders, position it as an innovation hub, and act as a gateway between China and the Western world.

Nanobody Discovery & GPCR Service


Dedicated to Support Your Novel NanobodyVHH and GPCR-targeted Drug Development




- Alpaca Immunization
- Library Construction
- Library Screening
- Affinity Maturation
- Humanization



- Anti-Flag VHH Beads
- Anti-GFP VHH Beads
- Anti-MYC VHH Beads
- Anti-HA VHH Beads
- Anti-mCherry VHH Beads
- Anti-MBP VHH Beads
- Anti-GST VHH Beads



- Bacterial Expression
- Yeast Expression
- Insect Cell Expression
- Mammalian Cell Expression
- GPCR Drug R&D Service
- GPCR Drug Development Support



AlpalifeB Inc.

Toll-free Phone: 1-413-399-9518;

Fax 1-617-336-7451

Office Phone: 1-617-383-9901 Ext 800.

Email: info@alpalifebio.com

Website: www.alpalifebio.com

Address: 299A Washington Street, Woburn, MA 01801 USA



BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS
POTENTIAL OF HONG KONG'S
BIOTECH ECOSYSTEM

CONFERENCE

DAY FOUR

Saturday September 16

KEYNOTE ADDRESS

Saturday, September 16 | 09:00 AM - 10:40 AM (GMT+8)

09:00 - 09:05	WELCOME REMARKS CHRIS PANG, HONG KONG BIOTECHNOLOGY ORGANIZATION
09:05 - 09:35	KEYNOTE SESSION: PROF. GEORGE GAO FU , ACADEMICIAN, CHINESE ACADEMY OF SCIENCE **
09:35 - 10:05	KEYNOTE SESSION: PROF. TONY MOK , CHAIRMAN, DEPARTMENT OF CLINICAL ONCOLOGY, THE CHINESE UNIVERSITY OF HONG KONG Novel Biotechnology for Early Cancer Detection
10:05 - 10:35	KEYNOTE SESSION: PROF. IVAN HUNG , CHAIR OF INFECTIOUS DISEASES, THE UNIVERSITY OF HONG KONG From SARS to COVID, what have we learnt?

**COULD NOT ATTEND DUE TO UNFORESEEN CIRCUMSTANCES

Invest**HK**

BIOHK2023 SILVER SPONSOR

Hong Kong
Where
Business
Goes to
Grow





***Fu Gao* 高福**

Member of Chinese Academy of Sciences, China

Professor George F. Gao obtained his PhD (DPhil) degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). His research interests include enveloped viruses and molecular immunology. His group research is mainly focusing on the enveloped virus entry and release, esp. influenza virus interspecies transmission (host jump), structure-based drug-design and structural immunology. He is also interested in virus ecology, esp. the relationship between influenza virus and migratory birds or live poultry markets and the bat-derived virus ecology and molecular biology. He has published more than 500 refereed papers (Including papers in Cell, Nature, Science, The Lancet, New England Journal of Medicine, Proceedings of the National Academy of Sciences USA etc.), 10 books or book chapters and holds more than 25 UK, US and Chinese patents. His research has recently expanded on public health policy and global health strategy. He led the China CDC team in 2014 (From September to November, when the disease went to its sky-high level) to work in Sierra Leone for fighting against Ebola and his heroic role there has made a great deal for the field work. He works hard now for establishing an Africa-based center for pathogens and tropical diseases.

Gao is a member (academician) of Chinese Academy of Sciences (elected in 2013), a fellow of The Third World Academy of Sciences (TWAS, also known as The World Academy of Sciences) (elected in 2014), a fellow of American Academy of Microbiology (AAM, elected in 2015); an associate (foreign) member of EMBO (European Molecular Biology Organization) (elected in 2016), a fellow of AAAS (American Association for the Advancement of Science) (elected in 2016), a fellow of RSE (Royal Society of Edinburgh) (elected in 2017), a fellow of AAS (African Academy of Sciences) (elected in 2017), a member (academician) of International Eurasian Academy of Sciences.



Tony Mok 莫樹錦

**Chairman, Department of Clinical Oncology,
The Chinese University of Hong Kong**

Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international phase III studies including the FASTACT 2, PROFILE 1014, IMPRESS, ARCHER 1050, ALEX, AURA 3 and KEYNOTE 042. These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on oncogene driven lung cancer and immunotherapy. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.

Professor Mok has contributed to over 308 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. He served as an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. He is the Past President, Past Treasurer of the International Association for the Study of Lung Cancer (IASLC) and Past Board of Director for ASCO. He is a member of the Board of Directors for ACTG-Sanomics Group, AstraZeneca, Aurora Tele-Oncology, HutchMed (China) and St. Stephen's College & Preparatory School. He is active in international education activity and has made significant contributions to AACR, ASCO, CSCO and ESMO. His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul 2020, Jr Scientific Award in 2017, National Science and Technology Progress Award in 2017, CSCO Annual Achievement Award in 2017, ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care 2020 and SingTao Hong Kong Leader of the Year 2020 Award. His recent article in the New England Journal of Medicine has been selected as one of the most "Notable Articles in 2017". He is one of the "Highly Cited Researchers" by Clarivate Analytics for four consecutive years from 2018 to 2022. He was awarded with the Bronze Bauhinia Star (BBS) by the Government of Hong Kong Special Administrative Region in 2022 to recognize his dedicated service in public affairs.

BOOTH NO. 3E-B21



專註於AI多靶點抗衰

賽立復是專註AI多靶點抗衰的生物科技公司, 由全球頂尖高校的博士團隊打造, 圍繞衰老的九大機理, 依托AI多靶點抗衰研究院的衰老機製研究平臺、抗衰老物質研究平臺、先進製劑研發平臺、產品評價及臨床研究平臺等四大平臺, 提供衰老幹預的個性化解決方案。

CELFULL® is a biotechnology company dedicated to AI-driven multi-target anti-aging, Created by a team of top doctoral researchers from leading universities worldwide. Centered around fermentation of nine major crops, CELFULL utilizes four major platforms: the Fermentation Mechanism Research Platform of the AI Multi-Target Anti-Aging Research Institute, the Elderly Anti-Aging Biomaterial Research Platform, the Advanced Formulation Development Platform, and the Product Evaluation and Clinical Research Platform. These platforms collectively provide personalized solutions for aging-related issues in elderly individuals.

旗下品牌賽立復提供衰老及退行性疾病的個性化藥物和膳食補充劑解決方案。

The brand under its umbrella, CELFULL, offers personalized pharmaceutical and dietary supplement solutions for aging and degenerative diseases.

賽立復作為美國老年協會(ASA)成員一直致力於用科研助力全球健康老齡化

As a member of the American Society on Aging (ASA), CELFULL has been dedicated to using scientific research to promote global healthy aging.



1 衰老機製研究平臺

Mechanism of Aging Research Platform

中科賽立復分子網絡抗衰聯合實驗室
CAS&CELLFULL Molecular Network
Anti-aging Joint Laboratory

3 先進製劑研究平臺

Advanced Agents Research Platform

賽立復線粒體醫學實驗室
CELLFULL Mitochondria Medical Laboratory



2 抗衰老物質研究平臺

Anti-aging Substances Research Platform

計算機輔助營養物質設計平臺
Computer Aided Nutrients Design Platform

4 產品評價與臨床研究平臺

Product Evaluation and Clinical Research Platform

賽立復-綿儷功效與安全評價聯合實驗室
CELEULL-MANNAY Joint Laboratory Efficacy and Safety Evaluation
中科賽立復分子網絡抗衰聯合實驗室
CAS&CELLFULL Molecular Network Anti-aging Joint Laboratory



为 神经系统疾病 提供创新医疗器械解决方案

磁共振引导激光消融手术系统 LaserRO



多场景

双光源双波长, 满足更多消融场景

多形态


6 种规格光纤型号选择, 配合双波长, 可实现精准适形

安全

创新一体化水冷光纤导管系统, 安全可靠

可预见

集术前规划, 术中监控, 术后评估于一体的全流程软件系统



植入式闭环自响应神经刺激系统 Epilcure

创新

国内首款自主研发自反应神经刺激系统, 可实现对癫痫患者监测和刺激的闭环交互, 按需治疗

便捷


可实现全颅骨植入

精准

高灵敏度的局部场电位信号采集技术

安心

高效能低热耗的无线充电技术

预警脑电异常,
并及时干预治疗

关于佳量

佳量医疗成立于2020年, 是一家专注于脑科学和神经外科领域的高科技平台型企业。公司已构建脑机调控、医用激光以及脑机芯片三大技术平台, 为多种神经系统疾病提供创新解决方案, 部分产品已进入临床试验阶段。

Hangzhou GenLight MedTech Medical was founded in Hangzhou in 2020, and is a high-tech platform enterprise dedicated to commercializing cutting-edge technologies in the fields of neuroscience and neurosurgery.

The company has built advanced technology platforms in three areas: Innovative brain-computer interface, advanced medical laser, and brain-computer chip. They all offer innovative medical solutions for various neurological diseases. Some of the company's products have entered the clinical trial stage.

浙江省杭州市余杭区仓前街道仓兴街1390号9幢B座

TEL: 0571-88730192

E-MAIL: support@glightmed.com





Fan Ngai Hung 孔繁毅

**Ru Chien & Helen Lieh Professorship in Health Sciences
Pedagogy, HKUMed**

Professor Ivan Fan Ngai HUNG is currently Chair of Infectious Diseases, Ru Chien and Helen Lieh Endowed Professor in Health Sciences Pedagogy, Professor of Medicine and Assistant Dean (Admissions), Chief of the Division of Infectious Diseases, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, and Honorary Consultant in Queen Mary Hospital, Hong Kong. He is also Clinical Professor and Chief-of-Service of the Department of Infectious Diseases and Clinical Microbiology at the HKU-Shenzhen Hospital.

Professor Hung is a dual specialist in Infectious Disease and Gastroenterology & Hepatology. He obtained his medical degree from the University of Bristol Medical School, England in 1996. After working in the University of Cambridge Medical School and Charing Cross Hospital, London, he returned to Hong Kong in 1999 and joined the Department of Medicine, Queen Mary Hospital. He was awarded the Anti-SARS gold badge award by the Hospital Authority in 2003 for his role in combating SARS as frontline medical officer. He received the Sir Patrick Manson Gold Medal award for best M.D. thesis. He was awarded the Richard Yu Lectureship and medal in 2016 by the Hong Kong College of Physicians. He was awarded the prestigious Outstanding Researcher Award from the University of Hong Kong in 2019. He is the Fellow of Royal Colleges of Physicians of London and Edinburgh, and fellow of the Infectious Disease Society of America and Advisory Board Member of the Universal Scientific Education & Research Network (USERN). Professor Hung has published more than 340 international peer reviewed original articles, including research articles in the Lancet, Nature, the Lancet Infectious Diseases and the Clinical Infectious Diseases. His research interest includes influenza, SARS-CoV-2 and other respiratory virus antiviral treatment and vaccinology. He has pioneered the use of the triple combination of interferon beta-1b, lopinavir/ ritonavir and ribavirin in the treatment of hospitalized COVID-19 patients, resulting in significantly faster clinical alleviation and viral load suppression. He and his team also pioneered the application of topical imiquimod before intradermal influenza vaccination, which results in protection against heterologous non-vaccine and antigenically drifted viruses. He was also the first to prove convalescent plasma and H-IVIG reduced mortality in patients with severe influenza infection in prospective clinical trials. He is ranked as HKU Scholars in the world top 1% in 2013, 2018-2022 (H-index 63 with 20695 citations). He is the world-leading expert in the field of antiviral and vaccinology for influenza and COVID-19 infection. He is currently the Editorial Board member of the Vaccine and Diagnostics medical journals. As a clinician scientist, Professor Hung believes in innovation, team-work and clinical application of translational research in tackling threats from emerging infectious diseases.

BIOHK AUDITORIUM | BIOHK 會堂

Public Day: Share & Inspire

Saturday, September 16 | 10:40 AM - 16:00 PM (GMT+8)

Biosafety (Sponsored by CSBT and IMCAS)

10:30 - 11:30

Chair: Dr. Juncai Ma, Institute of Microbiology, Chinese Academy of Sciences

Rational vaccine design: from Zika to COVID-19

Dr. Lianpan Dai, Institute of Microbiology, Chinese Academy of Sciences

Target tumor microenvironment to rejuvenate T-cell immune response

Dr. Longchao Liu, Institute of Microbiology, Chinese Academy of Sciences

Rethinking Drugs Discovery and Drug Repurposing

11:30 - 13:00

Developing a First-In-Class Drug – ARD-101

Dr. Tien Lee, Aardvark Therapeutics

Rethinking Small-Molecule Drug Discovery

Prof. Billy Wai Lung Ng, The Chinese University of Hong Kong

Fast Forwarding Research: Exploiting Approved Drugs

Dr. Yu Wai Chen, Hong Kong Polytechnic University

AI-driven de novo protein design for therapeutics (人工智能和生成式算法驱动蛋白药物设计)

Dr. Fan Liu, neoX Biotech

13:00 - 14:00

Lunch Break

AI & Robotics in Healthcare (Sponsored by CAIR-HKISI-CAS)

14:00 - 16:00

Chair: Prof. Hongbin Liu, CAIR-HKISI, Chinese Academy of Sciences*

Robotic Neurosurgery in the era of AI

Keynote Speaker: Dr. Tat Ming Danny Chan, Chinese University of Hong Kong

Surgical motion generation and perception towards intelligent minimally invasive robotic procedures

智能微创机器人手术运动生成和感知

Dr. Hongliang Ren The Chinese University of Hong Kong

Drugcompass: AI-based exploration of drug interactions 基於人工智能的藥物交互作用探索

Dr. Qingpeng Zhang, The University of Hong Kong (see biography on p.138)

Digital twin for brain surgery training, planning and navigation. 用于脑外科手术培训, 规划和导航的数字孪生系统

Dr. Zhongkai Zhang CAIR-HKISI, Chinese Academy of Sciences*

Continuum Robots and Artificial Intelligence for use in Healthcare and General Applications 連續體機器人和人工智能用於醫療保健和一般應用

Dr. Kar Hang Henry Chu The Hong Kong Polytechnic University

*No biography or information was provided before September 11, 2023.

Sponsored by



中国生物工程学会
Chinese Society of Biotechnology



中国科学院微生物研究所
INSTITUTE OF MICROBIOLOGY
CHINESE ACADEMY OF SCIENCES



Lianpan Dai

Principal Investigator

The Institute of Microbiology, Chinese Academy of Sciences

Dr. Dai received his doctor's degree from Technical University of Munich (TUM), Germany. His research is mainly focused on the design and development of novel vaccines against major pathogens and the mechanism of protective immune response. Important research and translational achievements have been made in the research and development of vaccines against coronaviruses, Zika virus and other emerging infectious diseases, among which the recombinant protein subunit COVID-19 vaccine has been approved for use in many countries. The results are published as first/corresponding authors in the journals including Cell, The New England Journal of Medicine, Lancet, Nature Immunology, Nature Reviews Immunology, Cell Host & Microbe. He is supported by the National Science Fund for Excellent Young Scholars, and is the winner of VCANBIO Award for Biosciences and Medicine, excellent member of the Innovation Promotion Association of Chinese Academy of Sciences, and the Young Scholar Award of Chinese Society of Immunology.



Longchao Liu

Professor

Institute of Microbiology Chinese Academy of Sciences

From 2011 to 2016, Prof. Liu pursued a Ph.D. in Biochemistry and Molecular Biology at the University of Chinese Academy of Sciences. Prior to that, they obtained a Bachelor of Science degree in Biotechnology from Jilin University, completing their undergraduate studies from 2007 to 2011.

Following his Ph.D., Prof. Liu embarked on post-doctoral fellow training at Dr. Yang-Xin Fu's Lab in UT Southwestern Medical Center, located in Dallas, TX, USA. They dedicated their time to research and professional growth in this role from February 2017 to November 2022.

Currently, [Name] holds the position of Principal Investigator, Professor, and Ph.D. advisor at IMCAS since January 2023. Their contributions and expertise are invaluable in advancing their field of study.

Throughout their academic journey, Prof. Liu has been recognized for their achievements. In 2018, they received the AAI Trainee Poster Award from UT Southwestern Medical Center. Additionally, during their time at the University of Chinese Academy of Sciences, they were honored as The Merit Students in 2015. Furthermore, they received The First Prize Scholarship in 2011 and were recognized as The Excellent Student Cadre in the same year at Jilin University. In 2008, they were acknowledged as Excellent Student and were awarded the National Scholarship at Jilin University.



Tien Lee

**Chief Executive Officer
Aardvark Therapeutics**

Dr. Lee has 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. Since 2017, Dr Lee has been the founder/CEO of Aardvark Therapeutics, Inc. Prior to this, Dr. Lee joined Nantkwest in 2014 and served as its Chief Strategy Officer until March, 2017. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology, and infectious disease indications. Dr. Lee is also an inventor or co-inventor of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including Nantkwest, Sincere Pharmaceutical Group, Cellics Therapeutics, and Aardvark Therapeutics. Dr. Lee earned his M.D. degree from UC San Diego and his B.A. degree from UC Berkeley in Molecular Biology where he was also a Regents and Alumni Scholar. Dr. Lee received post-graduate training in Internal Medicine through UC Los Angeles and Physical Medicine and Rehabilitation at UC Irvine.



Wai Lung Ng

**Assistant Professor
The Chinese University of Hong Kong**

Professor Ng's research interests are chemical biology, drug discovery, and medicinal chemistry. The Ng lab uses chemical, biological, and bioinformatics tools to develop novel small molecules for the treatment of various diseases, including cancers, infectious and neurodegenerative diseases. He has co-authored more than 20 papers in prestigious journals such as Science, Nature Chemical Biology, Molecular Cell, J. Am. Chem. Soc., Angew. Chem. Int. Ed., and ACS Central Science and also serves as a reviewer for more than 20 journals including Science Translational Medicine, Nature Chemical Biology, and Nature Communications.

Professor Ng obtained his B.Sc. degree in Chemistry (1st Class Hons.) and Ph.D. in Organic Chemistry from the Chinese University of Hong Kong (CUHK). During his graduate study, he was a Fulbright Scholar at Massachusetts Institute of Technology (MIT), under the generous funding supports from the Lee Hysan Foundation and the Fulbright Program. From 2014 – 2016, he joined the University of Oxford as a Croucher Foundation Postdoctoral Fellow. He was then recruited to Harvard Medical School / Dana-Farber Cancer Institute as a research fellow from 2016 – 2019. He was honored as a Young Global Leader (2022) by the World Economic Forum.

一期辦公研發，2024年中竣工

二期廠房

東莞
生物技術產業

中心園區

為生技企業提供優質資源和卓越服務！

東莞市生物技術產業發展有限公司
松山湖生物技術產業綜合運營服務商

公司於2012年底經東莞市政府批准在松山湖正式設立，註冊資本13億元，為松山湖高新區管委會下屬國有獨資企業，是松山湖生物技術產業綜合運營服務商，全市唯一的國有生物技術產業專業平臺。公司圍繞生物技術產業，形成產業園開發和綜合運營、產業基金投資和產業創新服務等三大主營業務，從全產業鏈著手，整合政策、資金、項目和市場等資源，與合作夥伴協同互補，以融合發展的理念，促進產業的協同發展。

公司未來將逐步建成，以生物技術產業綜合運營服務為方向，以產城開發運營為主體，以產業研發、投資與服務為核心的綜合性大型新興產業集團。

▶ 產業園招引企業

生物
醫藥

醫療
器械


智能
穿戴

生物
服務

生物
信息

熱綫電話：
86-0769-22892820





Yu Wai Chen 陳友維

Senior Research Fellow
The Hong Kong Polytechnic University

YWC studied Chemistry and Biochemistry at the Imperial College London. He worked for a PhD at the MRC Centre for Protein Engineering, Cambridge, UK under the supervision of Kim Henrick and Sir Alan Fersht, and completed in 1994. He did postdoc with Gary Brayer (University of British Columbia); and subsequently John Collier (Harvard Medical School) from 1994 to 1997. Next, he moved back to Cambridge, UK and joined the late Max Perutz as a research associate until 2003; then with David Glover (Cambridge). He was a visiting professor of the Institute of Microbiology of the Chinese Academy of Sciences in 2005. From 2005 to 2015, he was a lecturer at the Randall Division of King's College London. Since 2016, he joined the Hong Kong Polytechnic University as a research staff.

YWC aspires to advance the molecular understanding of pathogens and diseases, in particular, polyglutamine expansion diseases. He is generally interested in the structural biology of proteins that have implications in human diseases: including bacterial and viral virulent factors, proteins implicated in cell cycle control, cytoskeletal components, etc.



Fan Liu

Co-founder and Chief Technology Officer
neoX

Dr. Fan Liu, co-founder and CTO, is an expert in new drug discovery and development and holds a PhD degree in computational chemistry from the California Institute of Technology. His research was focused on understanding the structure of proteins from the structures to dynamics. He was a scientist at the Institute for Systems Biology and served as a principal investigator at BeiGene. Dr. Liu led and participated in a number of translational research projects of novel drugs.



Danny Chan 陳達明

**Honorary Clinical Associate Professor, Department of Surgery
The Chinese University of Hong Kong**

Dr Danny Chan is currently a Consultant in the Division of Neurosurgery in the Prince of Wales Hospital, and Associate Director of the CUHK Otto Wong Brain Tumour Centre. Dr Chan graduated from the Chinese University of Hong Kong with MBChB in 1995, entered specialty training and subsequently obtained his FRCSEd(SN).

Dr Chan's research interests are in functional neurosurgery, deep brain stimulation and cortical mapping, with 78 relevant publications. Dr Chan is renowned for his research in the world's first intraoperative MRI-guided robot for bilateral stereotactic neurosurgery. This project explored the use of an MR-compatible teleoperation system in neurosurgery, which would represent a major step towards safer, more accurate and effective brain surgery. His research paper was conferred the Best Conference Paper Award in the IEEE International Conference on Robotics and Automation 2018.



Hongliang Ren

**Associate Professor
The Chinese university of Hong Kong**

Professor Hongliang Ren received his Ph.D. in Electronic Engineering (Specialized in Biomedical Engineering) from The Chinese University of Hong Kong (CUHK) in 2008. He has been navigating his academic journey through Chinese University of Hong Kong, UC Berkeley, Johns Hopkins University, Children's Hospital Boston, Harvard Medical School, Children's National Medical Center, United States, and National University of Singapore. He has served as an Associate Editor for IEEE Transactions on Automation Science & Engineering (T-ASE) and Medical & Biological Engineering & Computing (MBEC). He has served as an active organizer and contributor on the committees of numerous robotics conferences, including a variety of roles in the flagship IEEE Conf. on Robotics and Automation (ICRA), IEEE Conf. on Intelligent Robots and Systems (IROS), as well as other domain conferences such as MICCAI/ROBIO/BIOROB/ICIA/CVPR. He served as publicity chair for ICRA 2017, concurrently as Organizing Chair for ICRA 2017 workshop on Surgical Robots, and video chair for ICRA 2021. He has delivered numerous invited keynotes/talks at flagship conferences/workshops at ICRA/IROS/ROBIO/MICCAI/CVPR/ICIA. He is the recipient of IFMBE/IAMBE Early Career Award 2018, Interstellar Early Career Investigator Award 2018, Health Longevity Catalyst Award (2022 by NAM & RGC), NUS Engineering Young Researcher Award (2019), Interstellar Early Career Investigator Award (2018), ICBHI (Biomedical and Health Informatics) Young Investigator Award (2019), NUS Young Investigator Award (2013), EMedic Global Gold Medal (2017) and Silver Medal (2021), Best Paper Awards in IEEE-ROBIO (2019 & 2013), IEEE-RCAR2016, IEEE-CCECE2015, IEEE-Cyber2014 among 30+ others awards.

He frequently served as an expert reviewer/judge for international funding agencies (60+ proposal reviews) of 10+ countries/regions (including Switzerland, Belgium, UK, Kazakhstan, Poland, Hong Kong, Macau, Chilean, China, Singapore etc.) and manuscript peer-reviews 317+ times for journals, including Science Robotics, Nature Biomedical Engineering, Nature Communications among many other top-tier journals (Please refer to the [Web of Science Reviewer Recognition](#) for the service records).



Zhongkai Zhang

Associate Professor
CAIR-HKIS, Chinese Academy of Science

Dr. Zhang Zhongkai is an Associate Professor in the Medical Robotics team at the Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences. His research interests include computer graphics, robotics, AI, and their applications to healthcare.



Henry Chu 朱嘉行

Associate Professor, Department of Mechanical Engineering
The Hong Kong Polytechnic University

Dr Henry Chu received his Bachelor's degree in Mechanical Engineering (Mechatronics option) from the University of Waterloo, Canada, in 2005, and his MASc and PhD degrees in Mechanical and Industrial Engineering from the University of Toronto, Canada, in 2007 and 2011, respectively. He was the recipient of the top-ranked Canada Graduate Scholarship (CGS) (2009-2011) and the pre-approved candidate of the Industrial R&D Fellowships (IRDF) program (2012) from the Natural Sciences and Engineering Research Council of Canada (NSERC). Prior to joining the Hong Kong Polytechnic University (PolyU), he was a Postdoctoral Fellow at the City University of Hong Kong through the International Transition Team Scheme (Office of the Provost).

At PolyU, he has secured various multi-disciplinary funds including Early Career Scheme (ECS), General Research Fund (GRF), Environment and Conservation Funds (ECF), Large Equipment Fund for Teaching and collaborative projects from the industries to support his research and teaching. He has supervised/co-supervised students to participate in various competitions/schemes, and received many awards, including Feature Article, Best Conference Paper Finalist, ASM Technology Award, and Jetson Project of the Month.



Unlocking the Power of Life Sciences and Healthcare Innovations

全方位推動 生命科學 及 醫療創新

The Hong Kong Polytechnic University is committed to research excellence and addresses global challenges with innovation. Research and Innovation Office, as a forward-looking department in the University, is devoted to propelling the University's technology development and advances to benefit the society by providing all-rounded support to facilitate research endeavours within the PolyU community, and foster partnerships among universities, industries, governments, supranational bodies, and the public.

香港理工大學致力於卓越研究，並以創新應對全球挑戰。研究及創新事務處作為理大具前瞻性的部門，致力推動大學的科技發展和進步，為研究團隊提供全方位的支持；並建立和促進官、產、學、研以至大眾之間的合作夥伴關係。

Stay tuned with our
research updates:

關注我們：



@PolyURIO



INNOVATION GALLERIA | 創新廊

Public Day: Share & Inspire

Saturday, September 16 | 10:30 AM - 16:00 PM (GMT+8)

Health Benefits of Probiotics	
10:30 - 11:15	<p>Moderator: Mr. Edmond Lau, HK Business Angel Network</p> <p>Panelists: Dr. Matey Yordanov, The Matrix Cube Dr. Mikhail Bychov, Vim Vitae</p>
STEM Education and Biotechnology	
11:15 - 12:00	<p>Prof. Fei Sun, Hong Kong University Science and Technology (see biography on p.90)</p> <p>Prof. Jiguang Wang, Hong Kong University Science and Technology</p> <p>Dr. Zhaoshi Bao, Capital Medical University</p> <p>Mr. Dason Cheung, Joray International Group*</p>
12:00 - 13:00	<p>New Technology: One Minute to Check Your Retina Airdoc</p>
13:00 - 14:00	Lunch Break
Focus on the Loop (Part Two)	
14:00 - 16:00	<p>Prof. Albert Yu, HKBIO</p> <p>Prof. Yuk Lam Lo, HKBMIA (see biography on p.46)</p> <p>Dr. Sabrina Chan, HKAPL (see biography on p.46)</p>

TECHNOLOGY HALL | 科技廳

Public Day: Share & Inspire

Saturday, September 16 | 10:30 AM - 13:00 PM (GMT+8)

Get Published in Nature	
10:30 - 11:15	Symposium: Ms. Mimi Mononen, Nature Journal
Voice of GBA Scholars	
11:15 - 13:00	<p>Ubiquitin-mediated proteolysis in cancer development and therapy Prof. Hai Rao, Southern University of Science and Technology</p> <p>Gut microbes modulate systemic inflammation and behavior disorders in neurologic disease Prof. Wenjing Zhao, Sun Yat-sen University (Shenzhen)</p> <p>Bistable insulin response as the stability anchor governing body mass dynamics: weight stability, weight gain, and beyond Dr. Guanyu Wang The Chinese University of Hong Kong (Shenzhen) Dr. Lin Deng, Shenzhen Bay Laboratory* Dr. Shaohua Ma, Tsinghua Shenzhen International Graduate School*</p>

*No biography or information was provided before September 11, 2023.

LOCI SQUARE | 基因位點廣場

Public Day: Share & Inspire

Saturday, September 16 | 10:30 AM - 13:00 PM (GMT+8)

10:30 - 11:00	<p>Know Your Stress Levels With A Simple Test eNano Health</p>
11:00 - 11:30	<p>Selenium For Improved Immunity: Healthy Egg Rolls Phoenix Bakery</p>
11:30 - 12:00	<p>Can Diabetes Be Cured? Dr. Ma Zhongmin, Revivallon Biopharmaceutical (see biography on p.109)</p>
12:00 - 13:00	COMMUNITY EVENT



Edmond Lau

Director
Hong Kong Business Angel Network

Edmond Lau has 20 years of profound experience in investment, financing and business development. He was the Head of Investment and CFO of Babel Capital focusing on fintech and digital assets investments. He was also the Managing Director of Lingfeng Capital and Head of Innovative Incubation Centre/ Head of Merger & Integration in SFExpress responsible for fintech and logistic tech. Prior to that, he served as the Head of Investment in FIH Mobile and the Investment Director in CLSA Capital Partners focusing on artificial intelligence, mobile Internet, and water technologies. Edmond was previously a Vice President in Citigroup and a senior consultant in Accenture providing financing solutions and strategic advices to telecom, media and technology corporations. Edmond holds an MBA (distinction, Dean's list) from London Business School, a Bachelor of Information Engineering (first class) from Chinese University of Hong Kong, and a Bachelor of Laws from China University of Political Science and Law. Edmond is devoted to technology development and is often invited to be a guest speaker/ panelist at prominent tech functions, such as Hong Kong Fintech Week, Tencent Greater Bay Area Fintech Forum, CFA China Investment Summit, Fintech Forum at The Macao Institute of Financial Services, Singapore Fintech Festival, and Cyberport VC Forum. He is the founding board member of CFA Shenzhen Association, Co-President of Hong Kong Internet Finance Association, board member of Hong Kong Business Angel Network, and a former board member of Hong Kong Society of Financial Analysts. Edmond is a member of Entrepreneurship Committee Advisory Group of Hong Kong Cyberport, ESS Assessment Panel of Innovation and Technology Commission, and teaches tech and investment courses in Universities. Edmond is also a CFA, a FRM, and a Chevening scholar.



Matey Yordanov

CEO
The Matrix Cube

Matey Yordanov has established and developing multiple businesses in Hong Kong for the past 4 years. His company in the biomedical field, Vim Vitae Limited, develops bioavailability and permeability enhanced endogenous compounds to provide an effective treatment for a range of health conditions. By targeting the most fundamental level of energy production in the human body, the mitochondria, the developed therapeutics are able to protect these cell organelles from stressors and toxins, to enhance energy generation and increase the rate of mitochondrial biogenesis, achieving elevated levels of cellular energy in the body. Furthermore, these therapeutics enable the human organism to autonomously optimize vital biochemical processes in the brain which further augments their efficiency. Extensive human studies are being undertaken and promising preliminary data has been demonstrated.



Mikhail Bychkov

CTO
Vim Vitae Limited

Mikhail Bychkov, an accomplished expert, boasts extensive experience spanning enterprise, healthcare, multidisciplinary scientific research, and their transformation into highly successful corporate ventures. Renowned for his advisory role to investors and large-scale project planners, Mikhail specializes in technical and scientific endeavors valued in the hundreds of millions. His exceptional achievements center around AI, Biomedicine, Process Optimization, and Risk Management. Serving as CTO at Vim Vitae Limited, Mikhail champions the inception of pioneering business and research initiatives, focused on optimizing diverse industries and driving profound societal impact.



Jiguang Wang

Associate Professor
The Hong Kong University of Science and Technology

Prof. Wang received his Ph.D. in Applied Mathematics from Academy of Mathematics and Systems Science, Chinese Academy of Sciences (CAS), and won the Special Prize of President Scholarship and Excellent PhD thesis Award of CAS. Between 2011 and 2015, he was a Postdoctoral Research Scientist at Columbia University. From 2015, he was named as the Precision Medicine Fellow and promoted to an Associate Research Scientist. He established the Wang Genomics Laboratory @HKUST in 2016, focusing on the application of data science in biology and medicine. He has made substantial contributions to (1) characterization, modelling, and prediction of cancer evolution from genomics (Nat Genet 2016; Nat Genet 2017; Nat Commun 2021); (2) discovery, elucidation, and clinical application of MGMT fusion (Nat Genet 2016; Nat Commun 2020) and METex14 in adult gliomas (Nat Genet 2018; Cell 2018); (3) Discovery of MAP3K3-I441M in CCM (AJHG 2021) and elucidation of EndMT in bAVM (Circ Res 2021); (4) reconstruction of RNA Exosome-regulated non-coding transcriptomes (Nature 2014; Cell 2015). He won the Excellent Young Scientist Award of NSFC (2019), School of Engineering Young Investigator Research Award (2019), School of Science Research Award (2021), and the Zhong Nanshan Youth Science and Technology Innovation Award (2021).



Zhaoshi Bao

Postdoctoral Researcher
The Hong Kong University of Science and Technology

ZhaoShi Bao is a Postdoctoral Researcher at Jiguang Wang's Lab. He obtained his Bachelor and Master degrees in Clinical Medicine at the Capital Medical University in 2011. After three-year research at Beijing Tiantan Hospital, Capital Medical University, he earned his M.D. and Ph.D. degrees in Neurosurgery in 2014. He then joined in the Department of Neurosurgery at Beijing Tiantan Hospital in Aug 2014, where he was named as an attending doctor in Dec 2017. Now his major research interest is personalized medicine for patients with glioma.



Albert Yu

Chairman

Hong Kong Biotechnology Organization (HKBIO)

Professor Albert Yu is a renowned neuroscientist and bio-entrepreneur who has devoted over two decades in neuroscience and infectious disease research and had significant contributions to molecular neurobiology and molecular diagnosis. Professor Yu is the Vice-Director of the Neuroscience Research Institute, Professor of the Department of Neurobiology and also a Professor at the Infectious Disease Center at Peking University. He is also the Chairman & CEO of Hai Kang Life Corporation Limited (HKLife), a Hong Kong-based biotechnology company with operations in Hong Kong and Beijing and is specialized in the R&D and commercialization of clinical and veterinary molecular diagnostics, as well as various cutting-edge food testing technologies and their optimization into user-friendly, cost-effective mobile field units (MFUs). HKLife's core technology, EFADchip, has been recognized as a globally leading technology which will overcome bottlenecks in existing lab-on-a-chip technologies and is expected to revolutionize modern clinical diagnosis. The technology has been awarded the prestigious 2009 Asia Pacific Frost & Sullivan Product Differentiation Excellence Award for In-Vitro Diagnostics.

Under the leadership of Prof. Albert Yu, HKLife has also been fast and accurate in responding to global infectious disease outbreaks such as avian influenza, SARS, and the recent H1N1 influenza outbreak. The technology in avian influenza diagnosis has been awarded the 2004 Hong Kong Award for Industry – Technological Achievement, was recognized as Chinese National Standards, and is being recommended by FAO/OIE in its Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. It is the first and only product being approved by the Japan Ministry of Agriculture, Forestry and Fisheries (JMAFF). In recognition of his expertise, Prof. Yu has been invited by various industrial and academic organizations (e.g. WHO, US Air Force) to introduce the technological advances introduced by HKLife.

Prof. Yu received his BSc, MSc and PhD from the University of Saskatchewan, Canada and spent subsequent years in the Canada, United States, Hong Kong, and China. Prof. Yu's broad cross-cultural experience base and active involvement in both the academic and business environment has led to the strategic vision behind the success of the HKLife team. Also, with a global network and an expanding base of established contacts in China, Prof. Yu has been an important facilitator of dialogue regarding the development of biotechnology in Asia. Over his professional and entrepreneurial career, Prof. Yu has published several books and over 200 peer-reviewed scientific articles and conference papers. He is also the co-inventor of numerous technologies with patents granted in major countries.

BOOTH NO. 3D-A23

INTRA
LINKS

全球領先的**虛擬數據室 (VDR)** 供應商

The World's Leading **Virtual Data Room (VDR)** Provider

助力生物科技企业**各個研發和融資階段**

Facilitating biotech companies through **all stages of R&D and financing**



企業服務 Corporate Services

- 供應鏈管理
- 財務匯報
- 法務協作
- 合約管理
- Supply chain management
- Financial Reporting
- Legal collaboration
- Contract management



研發/臨床 R&D/Clinical Trials

- 合作研發
- 臨床端口
- 遠程監控
- 安全共享文件
- Research collaboration
- Clinical portal
- Remote monitoring
- Secured document exchange



商業拓展 Business Development

- 授權
- 聯盟管理
- 企業發展
- 融資
- IP licensing
- Alliance Management
- Corporate development
- Financing



了解更多**Intralinks**
Learn more about **Intralinks**



官方網站 | Website



微信 | WeChat

生工生物企業介紹

生工生物工程（上海）股份有限公司（簡稱：生工生物）是一家高新技術企業，隸屬於集團公司BBI LIFE SCIENCES。生工生物起源于王啓松先生于1995年創立的“上海生工生物技術服務有限公司”，2003年生工生物正式成立，並於2012年進行股改後改爲現用名。生工生物致力於爲生命科學研究領域提供產品及服務，並爲醫藥診斷等工業客戶提供引物探針、試劑原料、耗材及包材等上游原料。

全球排名前列的DNA合成供應商；

大型測序服務提供者，擁有30多個測序生產基地；

中國大規模的生命科學研究產品和服務供應商之一；

擁有完整的資訊化訂購平臺和數位化智慧製造；

與Thermo Fisher達成官方戰略合作，賦能基因科學創新服務；

入選《福布斯2023半年度全球新獨角獸榜》。

Introduction of Sangon Biotech

Sangon Biotech (Shanghai) Co., Ltd. (abbreviated as Sangon Biotech) is a high-tech company in China, affiliated with the group company BBI LIFE SCIENCES. It was established by the founder Qisong Wang in 1995. The name used at the beginning of the company's establishment was "Shanghai Sangon Bioengineering Technology Service Co., Ltd.". In 2003, Sangon Biotech was established and underwent a shareholding reform and was changed to its current name in 2012. Sangon Biotech is committed to providing products and services for the field of life science research and provides upstream raw materials such as primers and probes, reagent raw materials, labwares, and packaging materials for industrial customers such as medical diagnosis.

wWe ranked top DNA synthesis suppliers in the world.

wWe are a large-scale sequencing service provider with more than 30 sequencing manufacturing bases.

wWe are large-scale suppliers of life science research products and services in China.

wWe have a full information ordering platform and digital intelligent manufacturing.

wWe have reached an official strategic cooperation with Thermo Fisher to empower innovation services in genetic science.

wWe have been selected into the 'Forbes 2023 Semi-annual Global New Unicorns List'.



Mimmi Mononen

Associate Editor
Nature Journal

Mimmi joined Nature Communications in September 2022. She received her PhD from Karolinska Institutet, where she studied early human heart development using single-cell RNA sequencing. She continued using single-cell technologies during her postdoc at Shanghai Jiao Tong University, where she worked on cancer stem cells. Mimmi handles manuscripts relating to single-cell biology. She is based in the Shanghai office.



Hai Rao

Head, Department of Biochemistry
Southern University of Science and Technology

Dr. Rao earned a Bachelor of Science degree in Chemistry from Wuhan University between 1985 and 1989. They then pursued a Master of Science degree in Chemistry at Boston University from 1989 to 1991. Following this, they obtained a Ph.D. from the State University of New York at Stony Brook & Cold Spring Harbor Laboratory, completing their doctoral studies between 1991 and 1996.

Dr. Rao served as a Postdoctoral Fellow at the California Institute of Technology from 1997 to 2002, under the mentorship of Alex Varshavsky. From 2002 to 2008, they worked as an Assistant Professor in the Department of Molecular Medicine/Institute of Biotechnology at the University of Texas Health, San Antonio. They were then promoted to the position of Associate Professor with tenure, holding this role from 2008 to 2019. From 2019 to October 9, 2020, they served as a Professor with tenure in the Department of Molecular Medicine at the same institution. Since October 12, 2020, they have held the position of Professor with tenure in the Department of Biochemistry at the School of Medicine, the Southern University of Science and Technology.

Dr. Rao's notable accolades include receiving the American Association for Cancer Research Minority-Serving Institution Faculty Scholar Award in Cancer Research in 2006. They were also granted a Postdoctoral Scholarship by the Leukemia & Lymphoma Society of America from 1998 to 2001. In 1996, they were honored with the Graduate Research Award from the State University of New York at Stony Brook.



Wenjing Zhao

Professor

Sun-Yat-Sen University School of Medicine, China

Dr. Zhao obtained Ph.D. degree from University of Rhode Island, where she focused her studies on the discovery of novel probiotics and the characterization of its mechanisms. After that Dr. Zhao pursued post-doctoral training at the Department of Microbiology and Immunology, Harvard Medical School, by studying the interplays among harmful microbes, commensal microbes, and their host immunity. In 2018, Dr. Zhao joins Sun Yat-sen University and the research of her group is focused on the roles and mechanisms of microbiome in human disease and the development of microbiome-editing technologies. Zhao group's recent research has been published in Nature, Science, PNAS, Protein & Cell, ebiomedicine, and Synthetic and Systems Biotechnology.



Guanyu Wang

Associate Professor, School of Medicine

The Chinese University of Hong Kong (Shenzhen)

Prof. Guanyu Wang is an associate professor of MED|LHS of the Chinese University of Hong Kong (Shenzhen), a committee member of "The Molecular Systems Biology Specialized Committee" of the Chinese Society of Biochemistry and Molecular Biology, a council member of "The Computational Systems Biology Branch" of Chinese Operations Research Society, and is awarded the title of "Shenzhen Oversea Talents." He was a postdoc and then a research assistant professor of the University of Texas Health Science Center at Houston, a research assistant professor at George Washington University Physics Department, and an associate professor of Southern University of Science and Technology. Prof. Wang published as first or corresponding author more than 50 high-quality papers in journals such as iScience(2), Proc Nat Acad Sci USA, Phys Rev Letts, J Roy Soc Interface (2), IEEE Transactions (2), Trends Immunol, Sci Bull, Theranostics, in total more than 60 papers. He also published a monograph "Analysis of Complex Diseases: A Mathematical Perspective (CRC Press)."

Interdisciplinary research is the defining feature of Guanyu Wang's group, which is targeting fundamental problems in biology and medicine. Professor Wang engages in a research system that centers on biological experiments, with scientific computation, mathematical analysis, and physical thinking as characteristic ingredients.



構建萬物互聯的智能世界

華為雲EI醫療智能體

全棧、開放、專業的醫療AI研發平台



BIOHK2023
SILVER SPONSOR

華為雲醫療智能體（EIHealth）覆蓋基因組、臨床資料研究和藥物研發三個領域，以全民健康為中心，推進人工智能與醫療健康相結合，提升醫療健康的服務能力和普惠水準，以華為強大的算力、存儲和AI演算法，賦能基因產業、疾病診斷和製藥領域。



基因組自動建模工具AutoGenome

利用AutoML等技術對基因組學資料建模分析，僅需5行代碼就可以完成基因組資料建模、訓練、準確性評估、預測和模型解釋。



藥物虛擬篩選

可根據靶點蛋白和小分子藥物的3D結構，計算蛋白與藥物之間的結合能量，並且依託雲端大算力從成千上百萬的小分子庫中快速篩選出與蛋白結合最緊密的候選藥物。



技術受限

數字主權
完全控制



數年 > 1個月
先導藥研發週期



診療效率 > 30%



掃碼進入華為雲官網“EI醫療智能體”頁面
了解更多詳情，歡迎撥打銷售熱線：+852 5700 0516

華為雲 一切皆服務

Acknowledgements

BIOHK would like to express our sincere gratitude to all the **sponsors** and **supporting organizations** listed in the following pages who played a vital role in making the BIOHK2023 convention a resounding success.

Special mention is given here to the organizations who have greatly contributed to BIOHK2023 and who have committed to continued contributions to BIOHK2024:

Certizen
China Renaissance
VMS Group

We would also like to give special thanks to all session chairs. In particular, those who spent great efforts to organize their sessions:

Dr. Christine Huang (Healthy Aging and Longevity)
Dr. Sujuan Ba (Cancer Research and Therapeutics)
Dr. Patrick Lu (RNA Medicine)
Dr. Yuxin Men (Chinese Pharma Going International)
Ms. Diana Viola (CAR-T Therapy/Clinical Trials in HK)
Mr. Liu Da (Next Life Science Unicorn)

Lastly, we would like to thank all the individuals, volunteers, and staff members who dedicated their time and efforts to make this convention possible. Their hard work and commitment have been vital to its success. We would especially like to thank student ambassadors for their outstanding contributions.



Supporting Organizations

Organizers



中国生物工程学会
Chinese Society of Biotechnology



中国科学院微生物研究所
INSTITUTE OF MICROBIOLOGY
CHINESE ACADEMY OF SCIENCES

Co-organizers



东莞市生物技术行业协会
DONGGUAN BIOTECHNOLOGY INDUSTRY ASSOCIATION



上海生物医药基金



深圳市生物医药促进会
Shenzhen Biological Medicine Promotion Association



中国科学院东莞松山湖科学中心
中国科学院与机器人创新中心



Diamond Sponsors



Platinum Sponsors



Gold Sponsors



KeyMed Biosciences



上海生物医药基金



Supporting Organizations

Special Supporting Organizations



Supporting Organizations / Companies



Supporting Organizations

Global Partners



Knowledge Partners



Media Partners



Technology Support Consultant



Office News Distribution Partner



BIOHK2023 AT A GLANCE

200+

SPEAKERS

153

EXHIBITOR BOOTHS

25


COUNTRIES

8700+

VISITORS

525K+

ONLINE ATTENDEES

**INTERNATIONAL ONE2ONE
PARTNERING PLATFORM****24**

SYMPOSIUMS

11

ROUNDTABLES

4

FORUMS

3

WORKSHOPS

OPENING CEREMONY

The Opening Ceremony was held at 9.00am on 13 September 2023 where many honored guests took the stage to officiate the opening of the event. Among them were the three co-Presidents of BIOHK2022, **Professor Albert CY Yu**, **Dr. Yu Guoliang** and **Mr. Chen Ping**; Government officials, **Hon. CY Leung** and **Professor Sun Dong** and **Mr. Chen Jie**, **Nobel Laureate Dr. Bruce Beutler**, Nobel Sustainability Trust Founder **Dr. Michael Nobel** and Trust Chairman **Mr. Peter Nobel**, and representatives of our sponsor organizations. During the ceremony, Professor Albert Yu, Professor Sun Dong, Mr. Chen Jie and Mr. Peter Nobel give captivating speeches and tokens of appreciation were presented to the sponsor organizations.



KEYNOTE SESSIONS

The program included 14 keynote sessions. Keynote speakers included renowned Government representatives **Hon. C. Y. Leung** and **Ms. Lillian Cheong**, distinguished scientists **Dr. Bruce Beutler**, **Prof. Rao Yi**, **Prof. Wang Yu**, **Prof. Akihiko Kondo**, **Prof. Raju Rucherlapati**, **Prof. Hideyuki Okano**, **Prof. Mak Tak Wah**, **Prof. Tony Mok** and **Prof. Ivan Hung**, and top entrepreneurs **Ambassador George Hara**, **Sir Jonathon Symonds** and **Ms. Nisa Leung**. These sessions were very inspiring and the large audiences were very appreciative of the unique opportunity to listen first-hand to these leading experts.



CONFERENCE

This year we welcomed over 200 speakers over the 4-day program. The program consisted of 24 symposiums, 4 forums, 3 workshops and 11 roundtable discussions.

SYMPOSIUMS:

The science behind biotechnology advances was presented in these symposium sessions focusing on a variety of hot topics in the field including cancer, regenerative medicine, gene therapy, infectious diseases and Chinese medicine.

We were delighted also to have an associate editor of Nature to enlighten us on how to successfully publish in the journal.



FORUMS AND WORKSHOPS:

These consisted of both speaker presentations and panel discussions on specific topics. In particular, we had a forum sponsored by the HK Longevity Medical Center on Healthy Aging and Longevity and another on RNA medicine that was sponsored by Sirnaomics. Of immense local interest, we had two workshops discussing the policies for the development of a life science ecosystem with a focus on the Lok Ma Chau Loop. Excellent ideas and suggestions were disseminated as the panelists entered in-depth discussions.



ROUNDTABLES:

While we had panel discussions on the importance of ethics in biotech industry, on advances in CAR-T therapy and the situation of clinical trials in Hong Kong, many of the roundtables focused on biotech investment angles. As expected, there was high turn-out for all panel discussions and great interaction with the audience.



EXHIBITION

BIOHK2023 boasted a diverse array of more than 150 booths, attracting exhibitors from around the world eager to showcase their products and brands. Representing a kaleidoscope of ingenuity, the exhibitors at BIOHK2023 showcased a breathtaking tapestry of products and brands, each one a testament to boundless creativity and unwavering dedication. From breakthrough therapeutics and revolutionary medical devices to sustainable agricultural solutions and groundbreaking research tools, the exhibits spanned a vast spectrum of disciplines, pushing the boundaries of what is possible and offering a glimpse into the future of biotechnology.



GALA DINNER

The much-anticipated Gala Dinner took place on September 15th at the historic Tang Ancestral Hall in Yuen Long, offering a unique dining experience with traditional Chinese Poon Choi. Guests were captivated by the enchanting ambiance of the Tang Ancestral Hall, where centuries-old architectural splendor sets the stage for an extraordinary dining experience that celebrates the timeless allure of Chinese culinary traditions.



PUBLIC DAY

On Saturday, September 16th, BIOHK2023 open its doors, extending a warm invitation to all who were eager to delve into the captivating world of biotechnology. The event went beyond a mere gathering, actively fostering knowledge-sharing and education by organizing school trips, where young minds had the opportunity to learn directly from esteemed scientists from diverse corners of the globe. It was a remarkable platform that nurtured curiosity, inspiring the next generation to embrace the wonders of the biotechnology industry and paving the way for a future brimming with scientific innovation.

We had a number of product demonstration sessions where companies introduced their latest products to the public. These included eNano Health presenting their Cortisol test which can measure glucose level with a little saliva sample; Airdoc Technology presenting their retinol imaging technology which can give a health assessment in minutes; and Baking Atelier introducing the power of selenium added to their egg rolls. These remarkable biotechnology products attracted huge public interest.



PITCHING COMPETITION

BIOHK2023 welcomed over 50 innovative companies from across the globe to compete for the covenant title of ‘Top 5 to Watch’ in this year's pitching competition to present their revolutionary discoveries and cutting-edge products. These non-listed companies were pre-selected by the BIOHK2023 committee for their innovative products and company potential. With an esteemed panel of judges, each bringing their field of expertise to the table, the competition reached high levels of intensity and excitement, displaying groundbreaking technologies that pushed the boundaries of innovation.

We would like to express our sincere gratitude to the following notable panel of judges who dedicated their time and expertise to the BIOHK2023 pitching competition (in alphabetical order):

- **Mr. Gordon Cheng**, Vice Chairman of HKBIO
- **Mr. Fred Li**, Executive Director of GOBI Partners
- **Ms. Jennifer Lian**, Founding Partner of Longly Capital
- **Ms. Serena Shao**, Founder & Managing Partner of Ascendum Capital
- **Mr. Frank Su**, Founding and Managing Partner of Redhill Capital
- **Mr. Ying Wang**, Executive Director of CRCP Life Science Fund
- **Mr. Peter Zheng**, Founding Partner of Orion Technology Fund (Head Judge)



Through scoring the participating companies, our panel of judges identified the companies that had showed good performance, steady growth and great potential. It was with great enthusiasm that we announced the **Top 5 Winners** of the pitching competition (in alphabetical order):

- **Jiangsu Hillgene Biopharma Co. Ltd.**
- **Lerna Biopharma PTE. Ltd.**
- **neoX Biotech**
- **TCRCure Biopharma Ltd.**
- **Tsingke Biotech**

Winners were later presented with a Certificate to commemorate the occasion. We extend our heartfelt gratitude to all the participants of this year's pitching competition, as it was a thrilling and closely contested race.



Urinary Albumin Self-Test for Monitoring Chronic Kidney Disease



- Globally more than 10% of adults have chronic kidney disease (CKD).
- Early decline of kidney function is mostly asymptomatic: Screening before diagnosis
- CKD is self-perpetuating: Monitoring after diagnosis

Users can obtain results in three simple steps :

1. Place the urine sample in contact with the product sampling port
2. Position the product flat and wait for about 15 minutes
3. Read the result via the naked eye

35.5 million people




130 million people




High-demand and Sustainable Market

Key technologies



2 US patents granted
(4 submitted)



SCIENCE ADVANCES | RESEARCH ARTICLE

CORONAVIRUS

Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees

Minghui Wu¹, Siying Wu¹, Gaobo Wang¹, Wengang Liu¹, Lok Ting Chu¹, Tianyi Jiang¹, Hei Kwan Kwong¹, Hui Lam Chow¹, Iris Wai Sum Li², Ting-Hsuan Chen^{1,2*}

Various COVID-19 vaccines are currently deployed, but their immunization varies and decays with time. Antibody level is a potent correlate to immune protection, but its quantitation relies on intensive laboratory techniques. Here, we report a decentralized, instrument-free microfluidic device that directly visualizes SARS-CoV-2 antibody levels. Magnetic microparticles (MMPs) and polystyrene microparticles (PMPs) can bind to SARS-CoV-2 antibodies simultaneously. In a microfluidic chip, this binding reduces the incidence of free PMPs escaping from magnetic separation and shortens PMP accumulation length at a particle dam. This visual quantitative result enables use in either sensitive mode (limit of detection (LOD): 13.3 ng/ml; sample-to-answer time: 70 min) or rapid mode (LOD: 57.8 ng/ml; sample-to-answer time: 20 min) and closely agrees with the gold standard enzyme-linked immunosorbent assay. Trials on 91 vaccinees revealed higher antibody levels in mRNA vaccinees than in inactivated vaccinees and their decay in 45 days, demonstrating the need for point-of-care devices to monitor immune protection.

More than 15 papers published

Contact us:

Prof. CHEN Ting Hsuan

Phone: +852 3442 4114

Email:

- Screening and monitoring of CKD needs quantitative measurement of urinary albumin.
- Standard tests in hospital are expensive and time-consuming.
- No rapid test on the market provides quantitative measurement for screening and monitoring of CKD

MEDIA REPORTS

Press invitations were sent to most of the newspaper companies in Hong Kong prior to the convention, including Ming Pao and SCMP as well as digital media including HK01 and iFeng (凤凰网). Science magazine helped in our promotion and was our media sponsor. Media reports can be read on our website at <https://2023.bio-hk.com/category/news/>.



香港BIO盛大開幕！60億港幣、河套合作區 加速建構生技生態系

Global Bio & Investment



[香港01] 香港國際生物科技展閉幕 醫療科技走進會場服務社區

HK01



HKG Epitherapeutics CEO Delivered a Keynote Presentation at BIOHK2023


prnewswire.com



香港BIO圓滿閉幕！200家廠商、42場論壇助力生技邁向國際

Posted on 9月17, 2023
Read More

Global Bio & Investment



[HKUST] UNVEILING HKUST'S BIOTECH BREAKTHROUGHS: OKT LEADS SEVEN STARTUPS AND SOLUTIONS SHOWCASED AT BIOHK 2023

HKUST



Hong Kong will need 'proper strategy' for integrating health data for biomedical hub ambitions, pharma giant GSK chair says

SCMP



【生物科技盛會】香港國際生物科技展 BIOHK2023開幕 粵港官員及業界齊聚梁振英：把握《深圳灣區發展規劃》機遇 孫東：塑造生物科技行業未來

Chinanews.se



BIOHK2023 香港國際生物科技論壇暨展覽 內地互聯互通、全球數碼身份核証

Posted on 9月13, 2023
Read More

sina.com.hk



BIOHK2023香港國際生物科技論壇暨展覽 明日啟動 一連四日綻放「萬花筒」主題

Posted on 9月12, 2023
Read More

Ming Pao



BIOHK2023香港國際生物科技論壇暨展覽 展示生物科技创新「無限可能」

Posted on 9月8, 2023

Ming Pao



[Startmeup] Make your impression at BIOHK2023 – "Top 5 To Watch" Pitching Competition is open for applications!

startmeup



[凤凰网] BIOHK2023即将启幕·助力香港成为国际创科中心

Posted on 8月25, 2023

凤凰网

FOLLOW BIOHK ON SOCIAL MEDIA



Facebook



Linkedin



*WeChat:
hkbioevents*



Instagram

New Breakthrough: Heavy metal and radionuclide monitoring

Artificial Mussels


NerOcean

Nerve of Ocean

BOOTH NO. 3E-B6, 3E-B4, 3E-B2,
3E-C5, 3E-C3, 3E-C1

What is Artificial Mussels?


Artificial mussels (AM) were designed to mimic the natural filtration abilities of real mussels, known for their ability to filter water and remove pollutants. It is a straightforward and passive sampling method for monitoring heavy metals and radioactive substances in water.



Our Device

Perspex Tubing

Permeable Gel



Complex Resins

New materials to capture heavy metal and radionuclides in single run.



**ONLY
1USD
PER AM**

Features

- No pre-concentration required
reduce sampling cost: time and energy
- Can be used in different seawater or freshwater
- Provide bioavailability information
- Measure multiple heavy metals simultaneously



DANGER

Radionuclides:



About Us

NerOcean is an ocean technology company established in August 2021 and based in HKSTP.

We aim to develop new sensing technology for cost-effective and sustainable water quality monitoring and management solutions.

Collaboration



Contact

support@nerocean.co

m www.nerocean.com



Lab Bench 09, Unit 111-115 and 115, 1/F, Building 11W, No. 11 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, N.T.



Contact Person: Dr. Ron Ng

Exhibitor List

Exhibitor Name	Booth No.
A4BEE	3D-B18
Advantage Austria	3E-A3
AlpalifeBio 深圳康體生物醫藥科技有限公司	3D-A24
Alphahygienic Co., Limited	3E-A28,3E-A30,3E-A32
Arbele Limited	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
Arctic Bioscience, ROMEGA 挪威魚籽油	3D-C32
Asia Molecular Diagnostics Laboratory Limited亞洲分子診斷實驗室有限公司	3E-C22
Asian Fund for Cancer Research Limited 亞洲癌症基金會有限公司	3D-C5
Axbio (Shenzhen) Co., Limited	3E-D11
Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司	3D-B20
BeiJing TianTan Biological Products Co., LTD 北京天壇生物製品股份有限公司	3E-A19
Beijing Tsingke Biotech Co., Ltd. 北京擎科生物科技股份有限公司	3D-C15
BIOHK	3D-B6
C2i	3E-C27, 3E-C25
CELFULL賽立復-美國AI多靶點抗衰老品牌	3E-B21
Centre for Translational Stem Cell Biology	3E-C29
Certizen Technology Limited	3D-C1, 3D-C3
Chinese Peptide Company 中肽生化有限公司	3D-D24
Cimple Biotechnology Limited	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
City University of Hong Kong 香港城市大學	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
CL e-logistics Solutions Limited	3E-A25
CMB Wing Lung Bank 招商永隆銀行	3E-A23
Convergence Biomanufacturing Co., Ltd, 深圳康沃先進製造科技有限公司	3D-C8
CREATIVE BIOSCIENCES (HONGKONG) CO.,LIMITED	3E-B32
Dongguan Biotech Industry Development Co.,Ltd, 東莞市生物技術產業發展有限公司	3D-C12
E3A Healthcare Pte Limited 億杉醫療科技有限公司	3D-D16
EA Bio Health Commerce Association	3D-A25
eNano Health Limited 依納康科技有限公司	3D-D9, 3D-D11
GBABA粵港澳大灣區生物科技聯盟	3E-A26
GENE ONLINE	3D-A18
Genesense Hong Kong Limited 芯像香港有限公司	3E-B10
Goldland Care Limited 嘉樂康雅有限公司	3D-B8
GOOVISION Technology Company Limited	3E-C17
Govita Tech Limited 健科國際股份有限公司	3E-C18, 3E-C20
Greater Bay Biotechnology Limited 華港龍生物科技股份有限公司	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
Green Life Technology Ltd.	3E-C7
Greentech Bioscience Co., Ltd 四川格林泰科生物科技股份有限公司	3D-D6
Hai Kang Life Corporation Limited 海康科技生命有限公司	3E-C15
Hangzhou GenLight MedTech Co.,Ltd 杭州佳量醫療科技有限公司	3E-A24
Herbs Generation International Ltd 草姬國際有限公司	3D-B10
HK Bio-Med Innotech Association 香港生物醫藥創新協會	3D-B2
HK Council for Testing and Certification 香港檢測和認證局	3D-D1
HKG epiTherapeutics	3D-B23

Exhibitor Name	Booth No.
Hong Kong Cyberport Management Company Limited	3D-C4, 3D-C2
HONG KONG HEXU LABEL CO., LTD 香港和煦标签用品有限公司	3E-A12
HONGKUN Industrial Group 鴻坤產業集團	3E-A7,3E-A5
Huangpu District Guangzhou Development District 黃埔區廣州開發區	3E-B20
Innodraco Technology (HK) Limited 創博科技有限公司	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
Insighta Limited 明察健康有限公司	3D-C17
Insilico Medicine 英矽智能	3D-B25
Intellectual Property Department 知識產權署	3E-A1
Invest Hong Kong 投資推廣署	3D-D2
Jiangsu Hillgene Biopharma Co.,Ltd 江苏谱新生物医药有限公司	3E-B22, 3E-C21
Jotbody HK Limited	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
K-O-CRON (Crystal Peace Health Science Ltd.)	3E-C2
Koln 3D Technology (Medical) Limited 科能三維技術(醫療)有限公司	3D-C24
LabWare Singapore Pte Ltd	3D-B16
Lee's Pharmaceutical (HK) Limited 李氏大藥廠	3D-C18,3D-C16
Life Star Biotech 生命之星國際有限公司	3D-D10
Mattey Supply Company Ltd 美譽創健有限公司	3D-D26
META Pharmaceuticals	3D-D4
MGI International Sales Co., Limited 華大智造	3D-D22, 3D-D20
NAF Pharma Logistics Limited 擎天醫藥冷鏈物流有限公司	3D-A26
Nano and Advanced Materials Institute Limited 納米及先進材料研發院有限公司	3E-A6 / 3E-B5, 3E-A4 / 3E-B3, 3E-A2 / 3E-B1
neoX Biotech (HK) Limited 北京星亢原生物科技有限公司	3E-B17
NerOcean Limited	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
NHJK Holding Corporation Ltd 諾輝健康	3D-B12, 3D-C11
Phase Scientific International Ltd 相達生物科技國際有限公司	3E-B8
PHC Medical Diagnostic Centre Ltd 標準病理檢驗所有限公司	3E-D21
Phoenix Bakery Since 1806 鳳凰邨	3E-C4
Realmeta Technology (Guangzhou) Co., Ltd.	3E-D13
Sangon Biotech (Shanghai) Co., Ltd. 生工生物工程（上海）股份有限公司	3D-B24
SGS Vitrology	3D-C23
Shenzhen ENO Biotechnology Co.,Ltd 依諾（深圳）生物科技有限公司	3E-C31
Shenzhen Life Sciences Industry Association 深圳市生命科学行业协会	3E-B19
Sichuan Aupone Pharmaceutical Co., Ltd. 四川奧邦古得藥業有限公司	3E-A21
Songshan Lake Science City Development Group 东莞市松山湖科学城发展集团	3D-C10
Sramek Insight Limited 瑞脉科研有限公司	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1


Exhibitor Name	Booth No.
SS&C Intralinks	3D-A23
Sunrise Diagnostics Center Ltd. 華昇診斷中心有限公司	3D-B26
Syngular Technology Limited 雲合科技有限公司	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
T. Y. Chu & Co., Ltd. 德原包裝用品有限公司	3D-C25
Talengen Institute of Life Sciences 瑞健生命科學研究院	3D-D23
Talengen International Limited 里仁科學實驗室	3D-D23
Taoist Culture of Healthy Living Association Ltd. 中道養生醫術學會有限公司	3E-C6
TCM Biotech International Corp., Lt 泰宗生物科技股份有限公司	3E-B23
Tegent Technology Limited 德祥科技有限公司	3E-A14
The Chinese University of Hong Kong 香港中文大學	3D-A19, 3D-A17, 3D-A15
The Commercial Press (Hong Kong) Limited 商務印書館(香港)有限公司	3D-C34, 3D-D33
The Hong Kong Polytechnic University 香港理工大學	3E-A22, 3E-A20, 3E-A18, 3E-A16
The Hong Kong University of Science and Technology 香港科技大學	3D-D21, 3D-D19, 3D-D17, 3D-D15
The Matrix Cube	3E-C11
Vim Vitae	3E-C9
VMS Group 鼎珮集團	3D-B17, 3D-B19
WWC Professional Corporation Limited 黃黃張會計師事務所	3C-F26
YCSD可持續發展青年委員會 (中國)	3D-D18
Yunzhou Biosciences (Guangzhou) Co., Ltd. 云舟生物科技(廣州)股份有限公司	3D-D31
Zein Biotechnology Co., LTD. 植恩生物技術股份有限公司	3E-A10, 3E-A08, 3E-B9, 3E-B7
ZenxTag Technology Limited	3E-B6, 3E-C5, 3E-B4, 3E-C3, 3E-B2, 3E-C1
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.	3D-C20, 3D-C22
ZHEJIANG DIFFERENCE BIOLOGICAL TECHNOLOGY CO.,LTD 江迪福潤絲生物科技股份有限公司	3D-C26
ZSHK Laboratories Limited 滬港中科國際生物科技股份有限公司	3D-C19
东富龙生命科技有限公司	3D-A20
中國科學院香港創新研究院人工智能與機械人創新中心	3E-C28, 3E-C26, 3E-D27, 3E-D25
北京中醫藥大學	3E-A9, 3E-A11, 3D-D10, 3E-D12
北京益然生物技術有限公司	3E-C15
医康物联(北京)科技有限公司	3E-A15
医拓健康生物科技(深圳)有限公司	3E-C19
广东医谷产业园投资管理股份有限公司	3C-F24
廣州南沙新區香港服務中心	3D-D28, 3D-D30, 3D-D32, 3E-A27, 3E-A29, 3E-A31
深圳市前海香港商會	3E-A13
深圳市枣孖健康科技有限責任公司	3E-C19
深圳市英汉思動力科技有限公司	3E-A17

3/F

FLOOR PLAN



■ Main Theatres
 ■ Exhibitor Booths



View exhibitor list on pages 210 - 212 and program overview pages 17 - 20

SPEAKER INDEX

- A**
Asial Ignacio p.82
- B**
Ba Shusong p.50
Ba Sujuan 巴素娟 p.77
Bao Zhaoshi p.189
Beutler Bruce p.24
Burgess Shane p.85
Bychov Mikhail p.189
- C**
Chai Dajun 柴大军 p.34
Chan Allen 陳君賜 p.166
Chan Danny 陳達明 p.184
Chan Sabrina p.46
Chang James p.119
Chang Liu p.51
Cheah Kathryn 謝賞恩 p.64
Chen Echo p.143
Chen Gong 陳功 p.64
Chen Helen p.149
Chen Pei-je 陳培哲 p.136
Chen Wei 陳偉 p.133
Chen Yu Wai 陳友維 p.183
Cheng Cole p.143
Cheong Lillian p.71
Cheung Elizabeth p.42
Chew Thian p.37
Chiu Ricky p.138
Chong Wai po 莊偉波 p.93
Chu Henry 朱嘉行 p.185
Chu Karen p.144
- D**
Dai Lei 戴磊 p.91
Dai Lianpan p.180
Dai Xiaochang 戴晓畅 p.55
De Lihua 德立华 p.146
Ding Xiao p.164
Dong Dong 董咚 p.54
Dong Jay p.1167
Dong Li 董利 p.151
Du Tom 杜涛 p.96
- E**
Ewe Joo Ann 尤茹艷 p.108
- F**
Fang Joe 方舟 p.44
Finely Aaron p.43
Fu Xinyuan 傅新元 p.163
- G**
Gao Fu 福高 p.174
Gao Vince 高醇新 p.167
Gonzalez Azucena p.130
Gu Zhenglong 顾正龙 p.36
- H**
Han Jisheng p.26
Han Winnie p.50
Hara George 原丈人 p.25
Hau Desmond p.164
He Kathy 何奇志 p.160
Hitzel Julianne p.37
Hsiao Wendy 蕭文鸞 p.113
Hu Charles 胡正忠 p.154
Hu Yuzhi 胡育志 p.99
Hu Zhaoyu 胡昭宇 p.162
Hua Simon p.157
Huang Christine Yuan p.32
Huang Jiandong 黃建東 p.90
Huang Yongheng p.103
Hung Fanngai 孔繁毅 p.178
- I**
Ip Margaret 葉碧瑤 p.137
- J**
Jakimov Sergey p.38
Ji Darren p.93
Jiang John, Yue-Jun p.142
Jiang Ruhong p.xx
Johnson Bruce p.79
- K**
Kang Tao p.143
Karwal Vijay p.148
Kennedy Christopher p.60
Ko Erik p.114
Kondo Akihiko p.73
Kuang Ming p.81
Kucherlapati Raju p.74
Kwong Ava p.81
- L**
Lam Adrian p.152
Lam Kin Ming p.119
Lati Amir p.32
Lau Clara p.113
Lau Edmond p.188
Lebel Francois p.56
Lee Robert p.109
Lee Tien p.181
Leung Nisa p.72
Li Changqing p.101
Li Hongmei p.65
- Li** Ning p.96
Li Yuling p.60
Liu Da p.57
Liu Fan p.183
Liu Longchang p.180
Liu Shengjiang p.91
Lo YukLam p.46
Lu Hongtao p.163
Lu Hongzhou p.137
Lu Patrick p.55
Lyu Aiping p.114
- M**
Masuda Yoko p.36
Ma Juncai p.108
Ma Vincent p.45
Ma Zhongmin p.109
Mak TakWah p.126
Man Nancy p.57
Mao Mao p.166
Men Yuxin p.94
Mok Tony p.175
Mononen Mimmi p.193
Morton Christopher p.142
Moskalev Alexey p.33
- N**
Newman Phil p.38
Ng Andrew p.51
Ng Wai Lung p.181
- O**
Okano Hideyuki p.124
- P**
Peng Phoenix p.135
Peng Yuyao p.151
Pun Frank p.142
- Q**
Qian Xueming p.103
Qiao Jiang p.119
- R**
Rabinovici Jaron p.35
Rao Hai p.193
Ren Hongliang p.184


- S**
- Shen** Dong p.56
Shi Jinhai p.162
Song Jilasheng p.138
Song Xuejun p.133
Sugiyama Haruo p.78
Sun Fei p.90
Symonds Jonathan p.28
Szyf Moshe p.78
- T**
- Tang** Mark p.37
Tanji Mikio p.151
Tao Xudong p.146
Thong Samuel p.148
Ting Xie p.64
Tsang Arthur p.454
Tsang Conrad p.42
Tsui Stephen p.108
- U**
- Ung** Monin p.54
- V**
- Viola** Diana p.130
- X**
- Xia** Jiang p.90
Xiao Shen p.99
- W**
- Wang** Edward p.56
Wang Guanyu p.194
Wang Huifang p.104
Wang Jiguang p.189
Wang Rose p.85
Wang Shouqun p.104
Wang Xin p.33
Wang Yu p.70
Wei Coach p.135
Wei Jimmy p.103
Welch Richard p.61
Wong Chi Ming p.109
Wong Sammi p.149
Wong Stephen p.44
Wong Tony p.82
Wu Howard p.94
Wu Min p.57
Wu Shan p.170
Wuh Hank p.38
- Y**
- Yamada** Hidekazu p.36
Yan Cong p.117
Yang Dajun p.85
Yang Frank p.43
Yang Lin p.130
Yang Mengyang p.51
Yang Zane p.86
Yau Henry p.144
Yi Rao p.27
Yip Nigel p.157
Yip Raymond p.47
Yordanov Matey p.188
Yu Albert p.190
- Young** Wise p.131
Yu Guoliang p.47
Yuan Xudong p.118
- Z**
- Zhan** Jiangshan p.160
Zhang Dan p.158
Zhang Dexing p.137
Zhang Michael p.61
Zhang Mingdong p.101
Zhang Qingpeng p.138
Zhang Tony p.164
Zhang Xumu p.91
Zhang Yang p.35
Zhang Zhijin p.144
Zhang Zhongkai p.185
Zhao Wenjing p.194
Zhao Xiaobin p.101
Zheng Lei p.79
Zhou Zhongjun p.34
Zhu Jielun p.154
Zhu Yeqing p.117
Zou Hongzhi p.158
Zou Lily p.82
Zuo Honggang p.152
Zuo Yuxing p.118

創科無限 引領未來
VENTURE BEYOND BOUNDARIES

香港城市大學
City University of Hong Kong



**BOOTH NO. 3E-B6, 3E-B4, 3E-B2,
3E-C5, 3E-C3, 3E-C1**



HK Tech 300 – a large-scale flagship innovation and entrepreneurship programme with an allocation of HK\$600 million from CityU and over HK\$100 million from co-investors.

110+ start-ups have already received Angel Fund investment of up to HK\$1 million each.

8-week sponsored training programme
資助訓練課程



HK\$100,000
Seed Fund
10萬港元種子基金



HK\$1,000,000
Angel Fund
100萬港元天使基金



HK\$10,000,000
External Funds
1000萬港元其他外來基金



EARLY SCREENING EARLY PREVENTION

早篩查 早預防

COLORECTAL
DISCOMFORT
IS NOT TRIVIAL.
腸道不適 不是小事



香港康立明生物科技有限公司 Creative Biosciences (HongKong) CO., Ltd.

香港分公司地址：香港九龍觀塘敬業街55號皇廷廣場17樓F室

廣州總公司地址：廣州高新技術產業開發區科學城開源大道11號A2棟第2層

郵箱：chijunlin@creativebio.cn

網站：en.creativebio.cn

固話：(020)82510982 / +00852 36197467

BOOTH NO. 3E-B32

SPONSOR & EXHIBITOR INDEX

- A**
- A4BEE p.97
- Advantage Austria p.121
- AlpalifeBio 深圳康體生物醫藥科技有限公司 p.171
- Arbele Limited p.83
- Arctic Bioscience, ROMEA 挪威魚肝油 p.126
- AstraZeneca p.21
- Ausvic Capital Ltd p.23
- B**
- Beijing Tsingke Biotech Co., Ltd. p.165
- 北京擎科生物科技股份有限公司
- BeiJing TianTan Biological Products Co., LTD p.128
- 北京天壇生物製品股份有限公司
- Bio-Equip p.102
- Bioon.com 生物谷 p.100
- C**
- CELLFULL賽立復-美國AI多靶點抗衰品牌 p.176
- Centre for Immunology & Infection (C2i) p.139
- Chinese Peptide Company 中肽生化有限公司 p.129
- Cimple Biotechnology Limited p.206
- City University of Hong Kong香港城市大學 p.216
- CMB Wing Lung Bank 招商永隆銀行 p.39
- Creative Biosciences (Hong Kong) Co. Ltd. p.217
- D**
- DCH Auriga (Hong Kong) Limited p.31
- Dongguan Biotech Industry p.182
- Development Co.,Ltd, 東莞市生物技術產業發展有限公司
- E**
- eNano Health Limited 依納康科技有限公司 p.89, p.141
- G**
- GlaxoSmithKline Plc p.16
- Govita Tech Limited p.168
- Green Life Technology Ltd. p.95
- H**
- Hai Kang Life Corporation Limited p.123
- 海康科技生命有限公司
- Hangzhou GenLight MedTech Co.,Ltd 杭州佳量醫療科技有限公司 p.177
- Herbs Generation International Ltd p.48-49
- 草姬國際有限公司
- HK Council for Testing and Certification p.161
- 香港檢測和認證局
- HKG epiTherapeutics p.80
- HONG KONG HEXU LABEL CO., LTD p.112
- 香港和煦標籤用品有限公司
- Hong Kong-Shenzhen Innovation and Technology Park p.41
- HONGKUN Industrial Group 鴻坤產業集團 p.68
- I**
- Invest Hong Kong 投資推廣署 p.173
- Insilico Medicine 英矽智能 p.156
- Intellectual Property Department 知識產權署 p.147
- J**
- Jiangsu Hillgene Biopharma Co.,Ltd 江蘇譜新生物醫藥有限公司 p.134
- K**
- KeyMed Biosciences Inc p.29
- Kobayashi Denki p.125
- Koln 3D Technology (Medical) Limited 科能三維技術(醫療)有限公司 p.69
- L**
- LabWare Singapore Pte Ltd p.111
- M**
- Mattey Supply Company Ltd p.63
- 美譽創健有限公司
- MedV廣東醫谷產業園投資管理股份有限公司 p.92
- MGI International Sales Co., Limited 華大智造 p.98
- Moderna Inc p.66
- N**
- NAF Pharma Logistics Limited p.105
- 擎天醫藥冷鏈物流有限公司
- Nano and Advanced Materials Institute Limited 納米及先進材料研發院有限公司 p.107
- NerOcean Limited p.209

- S**
- Sangon Biotech (Shanghai) Co., Ltd. p.192
(生工生物工程(上海)股份有限公司)
- Science p.62
- SGS Vitrology p.87
- SHC上海生物医药基金 p.40
- Shenzhen ENO Biotechnology Co.,Ltd p.153
依诺(深圳)生物科技有限公司
- Shenzhen Life Sciences Industry Association p.124
深圳市生命科学行业协会
- Sirnaomics p.53
- SMARTCRRT p.76
- Songshan Lake Science City Development Group p.120
东莞市松山湖科学城发展集团
- Sramek Insight Limited 瑞脉科研有限公司 p.84
- SS&C Intralinks p.191
- T**
- Talengen Institute of Life Sciences 瑞健生命科学研究院 p.132
- Talengen International Limited 里仁科学实验室 p.132
- The Chinese University of Hong Kong 香港中文大學 p.59
- Tegent Technology Limited p.145
德祥科技有限公司
- The Commercial Press (Hong Kong) Limited 商務印書館(香港)有限公司 p.58
- The Hong Kong Polytechnic University p.186
香港理工大學
- Tofflon Science 东富龙生命科技有限公司 p.115
- V**
- VMS Group 鼎瑞集团 p.150
- Y**
- Yunzhou Biosciences (Guangzhou) Co., Ltd. p.110
云舟生物科技(广州)股份有限公司
- Z**
- Zein Biotechnology Co., LTD. p.6
植恩生物技术股份有限公司
- ZenxTag Technology Limited p.159
- ZHEJIANG DIFFERENCE BIOLOGICAL TECHNOLOGY CO.,LTD p.86
江迪福润丝生物科技有限公司



SEE YOU AT BIOHK2024

**11 - 14
SEPTEMBER
2024**

Address: Desk 37, Units 109B-113, Building 5W, Hong Kong Science Park, 5 Science Park West Avenue, Pak Shek Kok, N.T., Hong Kong

Website: www.bio-hk.com

Email: info@bio-hk.com

Tel: +852 2799 7688